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Abstract
Human T lymphotropic virus type I (HTLV-I) causes adult T cell leukaemia/lymphoma (ATL), 
a neoplasm of CD4* T cells. The related virus HTLV-II has been isolated from cases of CD8^ 
T cell variant hairy cell leukaemia but has not been definitively associated with neoplasia. 
Bovine leukaemia virus (BLV), which causes B cell leukaemia and lymphoma in cattle, 
belongs to the same group of retroviruses. The hypothesis tested in this study was that 
HTLV-I, HTLV-II or related viruses are associated with T cell leukaemias and lymphomas in 
the United Kingdom, particularly mycosis fungoides (MF) and Sézary syndrome (SS). A 
combination of cell and molecular biology techniques was used in an attempt to identify 
retroviruses in patients with these neoplasms.
Lymphocytes were cultivated from blood, skin and lymph nodes of patients with cutaneous 
lymphoid infiltrates to establish continuous T cell lines that might propagate HTLV-I, HTLV-II 
or related retroviruses. Techniques for the establishment of cultures included stimulation with 
mitogens, cytokines, conditioned medium and cocultivation. Cultured cells were examined 
for evidence of retroviruses by electron microscopy (EM), reverse transcriptase (RT) assay 
and the polymerase chain reaction (PGR). No retroviruses were isolated from 158 cultures 
initiated from 18 patients with cutaneous T cell lymphomas (predominantly MF and SS) and 
three patients with cutaneous B cell lymphomas (CBCLs). Four interleukin 2-dependent 
CD8* T cell lines derived from skin of three patients with MF were maintained in culture for 6 
to 8 months but no viruses were detected in these cultures by EM or PGR. One Epstein-Barr 
virus-infected B lymphoblastoid cell line was cultured for 5 months from a skin sample of a 
patient with GBGL. Supernatants tested from cell cultures derived from these and 10 other 
patients were negative for RT activity.
PGR was used to test for LTR, gag, pol, env and pX  sequences of HTLV-I or HTLV-I/II in 
clinical samples and cultured cells from 36 patients with cutaneous lymphoid infiltrates 
(predominantly MF and SS), six cases of large granular lymphocytic leukaemia and six 
cases of acute lymphoblastic leukaemia (ALL). Patients with ALL were tested by PGR for 
BLV infection since all were butchers from Gard iff with occupational exposure to cattle.
There was no definitive evidence of HTLV-I, HTLV-II or BLV infection.
The HTLV-I Tax protein has transforming properties in vitro and is important in HTLV-I 
leukaemogenesis. A model for Tax oncogenesis is c-Myc, which activates pathways leading 
to either proliferation or apoptosis, depending on the availability of survival factors. It was 
hypothesised that Tax or other p X  region proteins have anti-apoptotic properties, since 
several oncogenic viruses produce proteins that inhibit apoptosis. The p X  genes tax, rex, 
p30", p is " and p12  ^were cloned and expressed in Rati fibroblasts stably transfected 
with a gene encoding a chimaeric c-Myc-modified oestrogen (tamoxifen) receptor protein. 
The chimaeric protein translocates to the nucleus in the presence of 4-hydroxytamoxlfen, 
inducing apoptosis when Rati cells are deprived of serum. pX  gene products were tested for 
their ability to protect Rati cells from c-Myc-induced apoptosis in a low concentration of 
serum. It was demonstrated that Tax induces apoptosis in Rati cells deprived of serum but 
there was no inhibition of c-Myc or Tax-induced apoptosis by other p X  region gene products.
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Chapter 1
Literature Review: The Role of Retroviruses 
in Human T Cell Leukaemias and Lymphomas
1.1 Introduction
Neoplasms are abnormal proliferations of tissue, unresponsive to normai mechanisms for 
control of cell growth, differentiation and death. Viruses, particularly members of the Families 
Retroviridae, Herpesviridae, Papiiiomaviridae and Hepadnaviridae, have been implicated as 
aetiological agents in many neoplasms, including T and B cell leukaemias and lymphomas 
(Zur Hausen 1991). In leukaemias neoplastic cells of haematopoietic lineage circulate in the 
blood. Lymphomas are solid growths of neoplastic lymphoid cells. The association of human 
T iymphotropic virus type I (HTLV-I) with adult T cell leukaemia/lymphoma (ATL) has led to 
the hypothesis that HTLV-I or related retroviruses are involved in the aetiology of other T ceil 
neoplasms (Hall 1994, Lessin et a! 1994).
This thesis describes studies conducted at the Leukaemia Research Fund (LRF) Virus 
Centre using cell and molecular biology techniques to search for HTLV-I or related 
retroviruses in cutaneous T cell lymphomas (CTCLs), large granular lymphocytic (LGL) 
leukaemia and adult acute lymphoblastic leukaemia (ALL) in the United Kingdom (UK). It 
also describes experiments to investigate the role of HTLV-I pX  gene products in 
oncogenesis by studying their effects on apoptosis in cultured cells. This chapter reviews the 
biology of HTLV-I and related retroviruses, diseases associated with these viruses and the 
mechanisms of oncogenesis of HTLV-I. The classification and pathogenesis of CTCLs and 
LGL leukaemia are reviewed and evidence for the involvement of HTLV-I and related viruses 
in their aetiology is discussed.
1.2 Retroviruses
1.2.1 Classification o f retroviruses
Viruses in the family Retroviridae possess reverse transcriptase (RT), which transcribes viral 
RNA to DNA during the retroviral replication cycle (Baltimore 1970, Temin and Mizutani 
1970). Retroviruses have been categorised according to their biological behaviour into the 
oncornaviruses (oncogenic RNA viruses), lentiviruses (slow viruses) and spumaviruses 
(foamy viruses) (Teich 1985). A more recent classification is based on the structure of the 
retroviral genome (Van Regenmortel et a! 2000) (Table 1.1). Replication competent simple 
retroviruses contain gag (group antigen), pro (protease), po/(polymerase) and env 
(envelope) genes from 5’ to 3’, flanked by unique 5’ (U5) and 3’ (U3) sequences (Coffin et a! 
1997).
Table 1.1: Classification of Family Retroviridae (Van Regenmortel et al 2000),
Genus Species
Simple retroviruses
Alpharetrovirus Avian leucosis vIrus-RSA*
Rous sarcoma virus (Prague C)
Avian myeloblastosis virus (defective)
Avian myelocytomatosis virus 29 (defective)
Betaretrovirus Mouse mammary tumour virus* 
Mason-Pfizer monkey virus 
Jaagsiekte sheep retrovirus (ovine 
pulmonary adenocarcinoma virus) 
Squirrel monkey retrovirus
Gammaretro virus Murine leukaemia virus*
Abelson murine leukaemia virus 
Friend murine leukaemia virus 
Moloney murine leukaemia virus 
Feline leukaemia virus 
Gibbon ape leukaemia virus 
Viper retrovirus 
Reticuloendotheliosis virus
Complex retroviruses
Deltaretrovlrus Bovine leukaemia virus*
Human T lymphotropic virus type 1 
Human T lymphotropic virus type II 
Simian T lymphotropic virus type 1 
Simian T lymphotropic virus type II 
Simian T lymphotropic virus type III
Epsilonretrovirus Walleye dermal sarcoma virus* 
Snakehead retrovirus (tentative)
Lentlvirus Human immunodeficiency virus type 1* 
Human immunodeficiency virus type 2 
Simian immunodeficiency virus 
Bovine immunodeficiency virus 
Equine infectious anaemia virus 
Feline immunodeficiency virus 
Caprine arthritis encephalitis virus 
Maedi/visna virus
Spumavirus Chimpanzee (formerly human) foamy virus*
Bovine foamy virus
Feline foamy virus
Simian foamy virus 1
Simian foamy virus 3
* Type species
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Complex retroviruses, which include the lentiviruses (Genus Lentivirus), the HTLV/bovine 
leukaemia virus (BLV) group of viruses (Genus Deltaretrovlrus) and the foamy viruses 
(Genus Spumavirus), have an additional region, designated pX, which encodes regulatory 
proteins. Viruses in the HTLV/BLV group include HTLV-I, HTLV-II, simian T lymphotropic 
virus type I (STLV-I), STLV-II and BLV.
The recognised exogenous retroviruses of humans are HTLV-I (Miyoshi et al 1980, Poiesz et 
al 1980a), HTLV-II (Kalyanaraman et al 1982b), human immunodeficiency virus type 1 (HIV-
1) (Barré-Sinoussi et al 1983, Gallo et al 1984, Levy et al 1984, Popovic et al 1984) and HIV- 
2 (Clavel et al 1986). Humans can also be infected with non-human primate spumavlruses 
(simian foamy viruses) (Heneine et a /1998) and the previously designated human foamy 
virus is now thought to be of chimpanzee {Pan troglodytes) origin (Achong efa/1971, 
Herchenroder et a /1995, Meiering and Linial 2001). Many endogenous retroviruses and 
retrovirus-like elements are present in genomic DMA, including some with sequence 
similarity to HTLV-I (Mager and Freeman 1987, Perl et al 1989, Fujihara et al 1994).
1.2.2 Structure and organisation of retroviruses
Retrovirus virions are enveloped structures approximately 100 nm in diameter (Coffin et al 
1997). Proteins produced from the env gene are expressed on the envelope in the form of 
trimers. The conical nucleocapsid consists of two identical molecules of single stranded 
ribonucleic acid (RNA), three or four proteins cleaved from a polyprotein produced by the 
gag gene, a protease produced by the pro gene and an RT/integrase/ribonuclease (RNase)
H produced by the pol gene. Each viral RNA molecule is associated with a transfer RNA 
(tRNA) molecule of host origin.
1.2.3 Replication cycle of retroviruses
Infection by retroviruses is initiated by fusion of the retroviral envelope with the host cell 
membrane allowing entry of the nucleocapsid into the cytoplasm. Double-stranded 
complementary deoxyribonucleic acid (cDNA) is synthesised from the two single-stranded 
viral RNA templates by the viral RT (Coffin et a /1997). The associated tRNA molecules act 
as primers for synthesis of the minus strand by reverse transcription. The 5’ and 3' long 
terminal repeats (LTRs) of the provirus are formed by duplication of the U5 and U3 regions 
of the viral genome, with an intervening repeat (R) region. The cDNA translocates to the 
nucleus where it is integrated as a provirus into the DNA of the host cell by the viral 
integrase. Regulatory and structural messenger RNA (mRNA) transcripts are produced and 
virions are assembled from translated structural proteins and viral genomic RNA. Complete 
virions are released from the cell by budding through the plasma membrane to acquire a 
lipid envelope containing viral proteins. Most retroviruses, including the HTLVs, establish 
persistent, life-long infections in their hosts and production of infectious virions is not 
dependent on host cell lysis.
1.3 Human T lymphotropic viruses
1.3.1 Terminology
Human T lymphotropic virus type I (HTLV-I) has also been referred to as ATL-associated 
virus (ATLV), human T cell leukaemia virus type I and human T cell lymphoma/leukaemia 
virus type I (Poiesz et al 1980a, 1981, Yoshida et al 1982, Blattner et al 1983). HTLV-II is 
also known as human T cell lymphoma/leukaemia virus type II.
1.3.2 Propagation of human T lymphotropic viruses
1.3.2.1 Discovery of HTLV-I and HTLV-II
HTLV-I was first detected In CD4^ T cell lines established from lymph node cells and 
peripheral blood mononuclear cells (PBMCs) of a patient in the United States of America 
(USA) with a form of ATL initially diagnosed as mycosis fungoides (MF) (Gazdar et al 1980, 
Poiesz et al 1980a, b) (Sections 1.6.1.2 and 1.11.1.2). A second isolate was obtained from a 
CD4"‘ T cell line derived from PBMCs of a patient also with a form of ATL but initially 
diagnosed as having Sézary syndrome (SS) (Poiesz et al 1981). Serum from patients with 
ATL reacted with antigens expressed by a cell line producing retrovirus-like particles 
established from a case of ATL in Japan (Miyoshi et al 1980, Hinuma et al 1981 ). Retrovirus 
particles, initially designated ATLV but later shown to be identical to HTLV-I, were also 
detected in a cell line established by cocultivation of umbilical cord blood mononuclear cells 
(UCMCs) with PBMCs from a patient with ATL (Miyoshi et al 1981a, b). Subsequently, 
HTLV-I has been identified in numerous other T cell lines established from patients with ATL 
(Hinuma et al 1982a, Yoshida et a /1982, Hoshino et a /1983, Markham et al 1983) and 
HTLV-l-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) (Jacobson et al 
1988) (Section 1.6.3), as well as asymptomatic people (Gotoh et al 1982, Sugamura et al 
1984a). HTLV-II was first isolated from a CD8^ T cell line derived from a patient with a T cell 
variant of hairy cell leukaemia (HCL) (Saxon et al 1978b, Kalyanaraman et al 1982b) 
(Section 1.7.1).
1.3.2.2 Cellular tropism of HTLV-I and HTLV-II
HTLV-I establishes productive infection of activated CD4* T cells of both T helper (Th) 1 and 
2 phenotypes in vitro and in vivo (Merl et ai 1984, Richardson et al 1990, Fan et al 1992, 
Macchi et al 1998) (Section 1.10.1.3). CD8^ T cells and B cells are also susceptible to 
infection but have lower levels of viral transcriptional activity (Longo et al 1984, Mann et al 
1984, Franchini et al 1985, Koyanagi et al 1993). Natural killer (NK) cells can be infected 
with HTLV-I following activation but do not produce infectious virions (Macchi et al 1987, Lo 
et al 1992). A wide range of other cell types is susceptible to infection with HTLV-I, including 
monocytes, macrophages, microglial cells, dendritic cells, fibroblasts, epithelial cells 
including enterocytes and mammary epithelial cells, synoviocytes, endothelial cells and 
neurones, but the role of these cells in maintaining viral infection in vivo or in transmitting 
HTLV-I is uncertain (Hoxie et al 1984, Kitajima et al 1991, Fan et al 1992, Hoffman et al 
1992, Macatonia et al 1992, Zacharopoulos et al 1992, Ali et al 1993, De Revel et al 1993,
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Koyanagi et al 1993, Sakai et a l 1993, Lehky et al 1994, Southern and Southern 1998). The 
receptor for HTLV-I has not been identified but appears to be expressed by many types of 
cells (Gavalchin et al 1995). T cells from PBMCs, UCMCs or bone marrow can be infected 
with HTLV-I following cocultivation with lethally irradiated HTLV-l-infected cells, whereas the 
infectivlty of cell-free virus is low (Miyoshi et al 1981c, Yamamoto et al 1982b, De Rossi et al 
1985, Fan et al 1992). CD8^ T cells are the main cells infected by HTLV-II, although CD4^ T 
cells, B cells and other lymphoid cells are also susceptible to infection (Rosenblatt et al 
1988b, Ijichi et al 1992, Lai et al 1995).
1.3.2.3 Transformation of T cells by HTLV-I
In vitro transformation is the conversion of cells with a limited life span into immortalised cells 
(cells that are able to grow indefinitely) with an altered phenotype and often a reduced 
requirement for growth factors such as those present in serum. Upon transformation in 
culture, normally adherent cells such as fibroblasts exhibit focus formation (piling up due to 
loss of contact inhibition) and colony formation in soft agar or suspension cultures (due to 
loss of anchorage dependence). Transformed cells may also be tumorigenic in athymic 
(nude) mice or other animal systems. T cells are considered to be transformed when they 
are able to proliferate indefinitely in the absence of exogenous interleukin (IL) 2 (Grassmann 
et al 1994).
Normal human T cells can be transformed in vitro following infection with HTLV-I and HTLV- 
II (Miyoshi et al 1981c, Chen et a /1983, Markham et al 1983, Popovic et a /1983, Merl et al 
1984, Aboud et al 1987, Graziano et a /1987). T cells undergo polyclonal expansion 1 to 7 
weeks following cocultivation of recipient PBMCs or UCMCs with HTLV-l-infected cells 
(Lando et a /1983, Kimata and Ratner 1991). Eventually there Is selective outgrowth of one 
or a few dominant clones, usually CD4^ T cells although some may be CD8^, with oligoclonal 
integration of HTLV-I provirus (De Rossi et al 1985, Kimata and Ratner 1991). The efficiency 
of infection and transformation is increased if T cells have been activated but HTLV-I 
infection per se activates T cells (Merl et al 1984, Martin and Southern 1996, Hollsberg 
1999) (Section 1.8.8). HTLV-l-infected T cell clones derived from PBMCs have variable 
expression of HTLV-I mRNA; T cells with transcriptionally silent proviruses do not 
spontaneously proliferate (Richardson et al 1997). HTLV-l-infected T cell lines often have 
defective proviruses with preferential retention of the pX  region (Kobayashi et al 1984, Bhat 
ef a /1993) (Section 1.3.3).
Infection of T cells with HTLV-I is associated with increased expression of IL2 and IL2 
receptor (IL2R), as well as alterations in expression and function of many other cellular 
constituents (Section 1.8). HTLV-l-infected T cell lines may be IL2-dependent (immortalised) 
or IL2-independent (transformed) (Arima et al 1986, Katoh et al 1986, Arima et a /1987). 
HTLV-l-transformed T cells form colonies in soft agar in the absence of exogenous IL2 (Due 
Dodon and Gazzolo 1987). In most in vitro models of HTLV-I infection of T cells, there is an 
initial phase of IL2-dependent growth following which the cells become independent of 1L2, 
usually after 6 to 12 months (Markham et al 1983, Yssel et al 1989, Hollsberg et al 1992, 
Rohwer et a /1994). These results are consistent with a role for IL2 in proliferation of T cells 
in the early stages of HTLV-I infection and transformation, although some HTLV-l-infected T
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cell lines do not produce IL2 and do not require exogenous IL2 for survival (Markham et al 
1983, Arya et al 1984, Volkman et al 1985). Maintenance of IL2 production in vitro may 
depend on the presence of macrophages in primary cultures of PBMCs from ATL patients 
(Arima et al 1992). The roles of the HTLV-I Tax protein and IL2 in transformation of T cells 
by HTLV-I are discussed in Section 1.8. The use of cell culture for isolation and diagnosis of 
infection with HTLV-I and HTLV-II is discussed in Section 1.4.1.
1.3.3 Genomic structure of HTLV-I
The 9,068 nucleotide HTLV-I genome is organised from 5' to 3' into U5, gag, pol, env, pX  
and U3 regions (Seiki et al 1983, Gallo et al 1988, Myers e ta l 1991) (Figure 1.1). The 
genomic structures of HTLV-II, STLV-I, STLV-II and BLV are similar (Sagata et al 1985, 
Shimotohno et a/ 1985b, Watanabe et a /1985). HTLV-I gag encodes the group antigens 
p19®^^ p24^^^ and pi 5®^ ,^ which are capsid proteins, gag-po/encodes a protease, p i 4*^ ™, 
pol encodes the RT/integrase/RNase H p95*^ °' and env encodes the envelope glycoproteins 
gp46^"'' and gp21^"''. The p X  region encodes regulatory proteins (Section 1.3.4).
1.3.4 HTLV-I pX gene expression
The proteins p40'^ (Tax), p27"' (Rex), p2 l"’, p30" (Tof), p13" and p12* are encoded by the 
four main open reading frames (ORFs I, II, III and IV) in the p X region of HTLV-I (Kiyokawa 
et al 1984, Lee et al 1984, Slamon et al 1984, Kiyokawa et al 1985b, Shimotohno et al 
1985a, Ciminale et al 1992, Koralnik et al 1992) (Appendix 1). Tax (transactivator) and Rex 
(regulator of expression) are the major proteins expressed from pX, whereas p2l'", Tof, pi 3" 
and p12* are minor products derived by translation from alternatively spliced transcripts 
(Kiyokawa et al 1985b, Seiki et al 1985, Berneman et al 1992a, Ciminale et al 1992, Koralnik 
et al 1992). mRNAs expressed from the p X  region derive their initiation codons by splicing 
with short transcripts from the gag-env region using several donor and acceptor sites (Figure 
1.1). The 2 kb doubly spliced taxirex mRNA that encodes Tax, Rex and p2l"' consists of a 
non-coding exon (exon 1) from the 5' LTR (HTLV-I 1 to 119), a small first coding exon (exon
2) overlapping the 3' end of pol and the 5' end of env (containing the AUG initiation codons 
and using splice acceptor sites at HTLV-I 4641, 4685 or 4701 and a single splice donor site 
at HTLV-I 4831) and a large second coding exon (exon 3) In the distal portion of the pX  
region with a splice acceptor site at HTLV-I 6950 (Seiki et al 1983, Kiyokawa et al 1985b, 
Seiki et al 1985, Wachsman et a /1985, Nagashima et al 1986). Tof is encoded by a doubly 
spliced mRNA consisting of the same exon 1 from the 5' LTR, exon 2 from HTLV-I 4641 to 
4831 and exon 3 from the splice acceptor site HTLV-I 6478 in ORF II of the pX  region 
(Ciminale et a /1992, Koralnik et al 1992). pi 3" is encoded by a singly spliced mRNA 
consisting of exon 1 spliced to exon 2 at HTLV-I 6875 in ORF II of the pX region (Berneman 
et al 1992b). p12‘ can be encoded by singly or doubly spliced pX ORF I mRNA transcripts 
(Koralnik et al 1992). The singly spliced mRNA consists of exon 1 spliced to exon 2 at HTLV- 
I 6383 in pX ORF I. The doubly spliced mRNA consists of exon 1 spliced to exon 2 (HTLV-I 
4641 to 4831), with exon 3 starting from the splice acceptor site at HTLV-I 6383 in pX ORF I, 
as for the singly spliced mRNA. The initiation codons for both of the mRNA transcripts 
encoding p i2' are located In pXORF I.
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HTLV-II, STLV-I and BLV also make use of complex splicing for expression of pX products 
(Alexandersen et al 1993, Orita at al 1993b). Tax2 and Rexg are encoded by the pX region of 
HTLV-II (Rosenblatt at al 1988a). Taxsiv and Rbxblv are produced by BLV (Rice at al 1987) 
(Section 1.9.2.1).
In HTLV-l-infected T cells Tax and p i3" are predominantly localised in the nuclear matrix, 
Rex and Tof in the nucleolus, p2l'" in the cytoplasm and pi 2* in the endoplasmic reticulum 
and Golgi apparatus (Goh at al 1985, Slamon at al 1988, Nosaka at al 1989, Koralnik at al 
1993).
A 152 amino acid pX product pi 7' (Rof) has been identified in cells transfected with a 
molecular clone of HTLV-I, but has not been detected in naturally infected cells (Ciminale at 
al 1992). RNA transcripts arising from several ORFs on the negative strand of HTLV-I have 
been detected in Infected cells but their significance is unknown (Larocca at al 1989, Chou at 
al 1995). The pX ORFs I and II that encode Tof, pi 3" and pi 2' are not necessary for HTLV-I 
replication and immortalisation in cultured cells but may be necessary for efficient replication 
in vivo (Derse at al 1997, Collins at al 1998, Robek at al 1998, Albrecht at al 2000, Bartoe at 
a /2000).
1.3.5 Structure and function of HTLV-! pX gene products
1.3.5.1 Tax(p40''')
Tax is a 353 amino acid phosphoprotein translated from ORF IV of the doubly spliced tax/rax 
mRNA transcript (Kiyokawa at a /1984, Lee at al 1984, Slamon at al 1984, Kiyokawa at al 
1985a, Seiki e ta l 1985) (Section 1.3.4) (Appendix 1). Its main functions are to activate 
transcription from the HTLV-I LTR and control expression of cellular genes (Sodroski at al 
1984, Cann at al 1985). A zinc finger motif located in the amino (N) terminal region is 
responsible for dimérisation and localisation of Tax to the nucleus (Smith and Greene 1992). 
Separate regions in the N terminus mediate transactivation through the nuclear factor kB 
(NFkB) and cyclic adenosine monophosphate (cAMP) response element binding 
(CREB)/activating transcription factor (ATF) pathways (Wachsman at al 1987, Smith and 
Greene 1990, Semmes and Jeang 1992, Adya and Giam 1995). The carboxy (C) terminal 
region also interacts with transcription factors. The role of Tax in HTLV-I leukaemogenesis is 
discussed in Section 1.8.
1.3.5.2 Rex (p27"')
Rex is a 189 amino acid phosphoprotein expressed from a different reading frame (ORF III) 
of the same doubly spliced mRNA as Tax (Nagashima at a /1986, Adachi at a/ 1992a) 
(Appendix 1). A domain at amino acids 57 to 69 allows Rex to form multimers 
(Weichselbraun at al 1992). An N terminal nucleolar localisation signal (NLS) directs Rex to 
the nucleolus (Siomi at al 1988, Nosaka at al 1989). The NLS also binds to the HTLV-I Rex 
response element (RxRE), a sequence of approximately 254 base pairs (bp) that forms a 
stable stem loop structure in U3 of the full-length viral mRNA transcript, inhibiting production
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of the doubly spliced mRNA transcripts encoding Rex and Tax (Hidaka et al 1988, Ballaun et 
al 1991, Unge et al 1991, G rone et al 1994). A leucine motif/activation domain at amino 
acids 82 to 93 of Rex acts as a nuclear export signal (NES) by interacting with cellular 
proteins that export mRNA from the nucleus, allowing Rex to shuttle between the nucleus 
and the cytoplasm (Bogerd et al 1996, Kubota et al 1996a, Palmeri and Malim 1996). Rex 
promotes transport of unspliced (gag-pol) and singly spliced (env) viral mRNA transcripts 
from the nucleus to the cytoplasm Instead of doubly spliced (tax/rex) mRNA (Inoue et al 
1987, Hidaka et al 1988, Nosaka et al 1989). It thus acts as a switch from early expression 
of regulatory proteins (Tax, Rex) to late expression of structural proteins (Gag, Pol, Env). 
Virions are not produced in the absence of Rex. The function of Rex is modulated by 
phosphorylation and may be influenced by expression of p 2 l‘" (Adachi et al 1992a, Kubota 
et al 1996a) (Section 1.3.5.3).
1.3.5.3 p2l"'
The 111 amino acid p2 l"‘ is translated from an internal ribosomal entry site of ORF III of the 
doubly spliced tax/rex mRNA, as well as from an alternative singly spliced ORF III mRNA 
transcript (Kiyokawa et al 1985b, Nagashima et a /1986, Furukawa ef a /1991, Orita et al
1991, Kubota et al 1996a) (Appendix 1). It represents a truncated form of Rex (amino acids 
79 to 189) that lacks the NLS but retains the NES and may compete with Rex for cellular 
proteins that export mRNA (Kubota et al 1996a). This leads to retention of unspliced viral 
mRNAs in the nucleus. p 2 l‘" could thus have a role in reducing the expression of structural 
proteins, maintaining latency and minimising the host immune response. Although p 2 l ‘" 
mRNA has been detected by RT-PCR in PBMCs of HTLV-l-infected people, Orita et al 
(1993a) associated p2 l"‘ expression with defective proviral genomes in HTLV-l-infected T 
cell lines and its function in vivo has not been confirmed.
1.3.5.4 Tof (p30")
Tof is a protein of 241 amino acids derived from a doubly spliced ORF II mRNA transcript 
(Ciminale et ai 1992, Koralnik e ta l 1993) (Section 1.3.4) (Appendix 1). It has serine, arginine 
and threonine-rich regions with sequence similarity to activation domains of the POU family 
of transcription factors and interacts with CREB binding protein (CBP)/p300 (Ciminale et al
1992, Zhang et al 2001) (Section 1.8.2.3). Two arginine-rich regions act as a NLS by 
allowing Tof to bind to the RxRE and point towards a role for this protein in regulation of 
mRNA expression (D’Agostino et al 1997).
1.3.5.5 p13"
p i3" is a protein of 87 amino acids translated from an internal initiation codon in p X ORF II 
and derived from singly spliced and doubly spliced mRNAs (Berneman et al 1992a, Ciminale 
et a /1992, Koralnik et al 1992) (Section 1.3.4) (Appendix 1). pi 3" interacts with farnesyl 
pyrophosphate synthetase but its function is unknown (Lefèbvre et al 2002).
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1.3.5.6 p12'
p12% expressed from singly or doubly spliced pX  ORF I mRNA transcripts (Section 1.3.4), is 
a 99 amino acid hydrophobic protein with two predicted transmembrane domains, between 
which is a proline-rich region (Ciminale et al 1992, Koralnik et al 1992, 1993) (Appendix 1). It 
forms dimers and localises in the endoplasmic reticulum and Golgi apparatus in association 
with calreticulin and calnexin (Koralnik e ta l 1993, Trovato et al 1999, Ding ef a/2001). In 
these sites p i2* binds to major histocompatibility (MHC) class I molecules, preventing their 
association with Pz microglobulin and enhancing MHC-I degradation by the proteosome 
complex (Johnson et a /2001). This may prevent surface expression of MHC-I and interfere 
with presentation of antigens, allowing HTLV-I to escape immune recognition, pi 2' also 
binds to the 16 kOa vacuolar H"" adenosine triphosphatase (ATPase) and the p and yc chains 
of IL2R (Franchini et al 1993, Koralnik et al 1995, Mulloy et al 1996). A role for p i2* in 
oncogenesis may be to stimulate proliferation of T cells by binding to molecules involved in 
cell signalling pathways (Section 1.8.4).
1.3.6 Control of HTLV-f gene expression
Tax and Rex are the main proteins controlling HTLV-I gene expression (Green and Chen 
1990). Tax transactivates the HTLV-I promoter by interacting with cellular transcription 
factors that bind to Tax response elements (TREs) in the U3 region of the proviral LTR 
(Brady et al 1987, Rosen et al 1987, Fujisawa et al 1991, Zhao and Giam 1991, Seeler et al
1993). The TREs comprise three copies of a 21 bp imperfect repeat sequence TRE-1 and 
one copy of a 47 bp sequence TRE-2. Members of the CREB/ATF family, including CREB 
and ATF-1 homodimers, CREB-ATF-1 heterodimers, activating protein (AP) 1 (Jun-Fos) 
heterodimers and AP-2, bind to TRE-1 (Zhao and Giam 1992, Suzuki ef al 1993a, Fujii ef al 
1995, Mori and Prager 1996, Barnhart ef al 1997). Cellular proteins that bind to TRE-2 
include Tax interacting factor 1 (TIF-1), Sp1, Myb and Ets-1 (Bosselut ef a /1990, Marriott ef 
al 1990, Nyborg and Dynan 1990, Bosselut et a l 1992, Dasgupta et a l 1992).
Responsiveness to Tax requires two copies of TRE-1 or one copy each of TRE-1 and TRE-2 
(Shimotohno ef a /1986).
Each TRE-1 can be further divided into three elements (A, B and C) with different binding 
specificities for a variety of transcription factors (Montagne ef al 1990, Yoshimura ef al 1990, 
Tsujimoto ef al 1991, Muchardt et a l 1992, Morita ef al 1993, Nyunoya ef al 1993). Most of 
these factors bind to TRE-1 in the absence of Tax but their affinity for the HTLV-I LTR and 
thus transcriptional activation of the viral promoter is augmented by dimérisation in the 
presence of Tax (Matthews ef a /1992, Zhao and Giam 1992, Armstrong ef al 1993, Franklin 
et al 1993) (Section 1.8.2). Alternatively, Franklin and Nyborg (1995) have suggested that 
CREB/ATF proteins anchor Tax to the promoter site, allowing Tax to induce transcription 
from its own C terminal activation domain.
Repressive sequences in the U5 and R regions may also be involved In control of HTLV-I 
gene expression (Kashanchi ef al 1994, Xu ef al 1994, Okumura ef al 1997). Other 
mechanisms of transcriptional control include differential méthylation of the LTR, gag-pol-env
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and pX  regions (Clarke et al 1984, Kitamura et al 1985, Saggioro et al 1990, Ca(3ens et al
1994), phosphorylation of Tax (Green et al 1992b, Saggioro et al 1994a), c/s-acting inhibitory 
elements in the pol~env region (Saiga et al 1997) and sequestration of Tax by the NFkB2 
precursor Lyt-10 (Béraud et al 1994) (Section 1,8.2.1).
Whereas expression of HTLV-I mRNA and protein in leukaemic cells of ATL patients is low 
and selective (Section 1.6.1.6), there is upregulation of expression of HTLV-I genes when 
PBMCs from HTLV-l-infected people, including those with ATL, are cultivated in vitro (Poiesz 
et al 1980a, Hinuma et al 1982a, Hoshino et al 1983, Salahuddin et al 1983, Clarke et al 
1984, Setoyama et al 1992). Expression of HTLV-I genes is also Induced following activation 
with mitogens or through induction of the cellular stress (heat shock protein) response 
(Andrews et al 1995, Lin et al 1998). The effects of Tax on expression of cellular genes and 
mechanisms of regulation of these genes are described in Sections 1.8.1 and 1.8.2.
As discussed in Section 1.3.5.2, Rex and possibly p 2 l‘" are involved in post-transcriptional 
control of HTLV-I gene expression, increasing the expression of structural proteins by 
regulating mRNA processing and thus directing the production of virions (Inoue et al 1987, 
Hidaka et a /1988, Nosaka et al 1989). The roles of Tof, p i 3" and pi 2* in the control of 
HTLV-I gene expression are uncertain.
1.4 Detection of infection with human T lymphotropic viruses
The sensitivity and specificity of diagnostic tests for the detection of infection with HTLVs are 
critical in establishing associations between HTLV-I, HTLV-II or related viruses and disease 
entities. This section summarises the virological, serological and molecular assays 
commonly used for diagnosis of infection with HTLVs. Serological tests are used in the 
clinical diagnosis of HTLV infection.
1.4.1 Virus isolation
HTLV-I and HTLV-II are usually isolated by cultivating PBMCs from infected people and 
promoting the selective outgrowth of immortalised CD4^ or CD8^ T cell lines, respectively 
(Poiesz et al 1980a, Yoshida et al 1982, Rosenblatt ef al 1986) (Section 1.3.2). Conditioned 
medium (CM) or purified cytokine preparations, especially those containing IL2, are used to 
stimulate the proliferation of CD4^ T cells for isolation of HTLV-I (Chapter 2). UCMCs are 
used as recipient cells that become infected with HTLV-I and proliferate to form T cell lines 
when cocultivated with donor PBMCs from infected people (Miyoshi et al 1981a, b, Hjelle et 
a/1992b).
Virus particles in cultured T cells may be difficult to distinguish by electron microscopy (EM) 
from non-virus particles such as cell membrane blebs. Detection of RT activity in 
supernatants from infected cell lines is of diagnostic value, but HTLV-I or HTLV-Il-specific 
RT activity has to be distinguished from that produced by other exogenous and endogenous 
retroviruses and from non-specific RT activity. Stronger evidence for the presence of a 
retrovirus is obtained by density gradient centrifugation and association of RT activity with a
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particular density of particle. Virus-specific antigens can be demonstrated in infected cell 
cultures by immunofluorescence (IF) and other immunological techniques and viral genomes 
and transcripts can be detected by molecular methods (Section 1.4.3).
1.4.2 Serological assays
Strong humoral immune responses are mounted against HTLV-I Env (gp21^"'', gp46^"''), Gag 
(p i9°^^, p24^^^) and Tax (p40'^) antigens, whereas antibodies against Rex (p27'*')/p2l"‘, Tof 
(p30‘") and p12‘ are detected at lower titres or in only a small proportion of HTLV-l-infected 
people (Kamihira et al 1989, Dekaban et al 1994, Saiga et al 1996, Chen et al 1997,
Dekaban et al 2000). Immunological assays used for screening serum samples for 
antibodies against HTLV-I and HTLV-II include the enzyme-linked immunosorbent assay 
(ELISA) and particle agglutination (PA) assay (Beilke 1992). Supplemental tests for 
serological confirmation of HTLV-I and HTLV-II infection include the western blot (WB)
ELISA and radioimmunoprecipitation assay (RIPA) (Aboulafia et a /1992). Criteria for HTLV- 
l/ll seropositivity are repeated reactivity in the ELISA and reactivity against proteins from two 
genes, for example HTLV-I p i 9^ '^ '' and p24®^ ®, by WB ELISA or RIPA. Often both 
supplemental tests are required for comprehensive detection of reactivity against HTLVs, as 
reactivity tends to be stronger against HTLV Env proteins by WB ELISA and stronger 
against Gag proteins by RIPA. The delay between infection and seroconversion can result in 
false negative results (see Section 1.5.1.1). In people who become infected with HTLV-I 
following blood transfusions, antibodies against p24®^ ® are detectable earlier than antibodies 
against p i9^^ ,^ resulting in indeterminate seroreactivity in testing conducted during 
seroconversion (Manns et al 1991). A further problem with interpretation of serological 
results is that HTLV-I and HTLV-II could not be clearly distinguished using early tests (Lee et 
al 1989, Chen et al 1990, Wiktor ef al 1990, Hjelle ef al 1991a). Variations in pattern of 
seroreactivity and geographical clustering of seroindeterminate results have been suggested 
as evidence for the presence of variant HTLVs (Maruyama ef al 1989, Nerurkar ef al 1992, 
Madeleine ef al 1993, Re ef al 1993, Busch ef a /2000). Anti-Tax antibodies have been 
reported in 4% of intravenous drug users (IVDUs) negative for HTLV-I in standard 
serological assays (Ehrlich ef al 1989a) (Section 1.11.1.5). The sensitivity and specificity of 
the tests used and the method of sampling can affect estimates of prevalence and incidence 
of infection (Section 1.5.2).
1.4.3 Molecular assays
integrated HTLV-I and HTLV-II proviral DNA can be detected in infected patients by the 
polymerase chain reaction (PCR), Southern blot (SB) hybridisation and in situ hybridisation 
(ISH) (Beilke 1992) (Chapter 3). Viral RNA genomes and mRNA transcripts are detected by 
RT-PCR, northern blot hybridisation and DNA-RNA ISH. Selection of probes and control of 
the stringency of hybridisation is important in optimising the sensitivity and specificity of 
reactions in SB and northern blot hybridisation. PCR is highly sensitive but this sensitivity 
also introduces the risk of false positive results due to contamination. Most studies 
comparing PCR with serological assays have found few virus-positive antibody-negative 
people (Lee ef al 1989, Kinoshita ef al 1993, Miyata ef al 1995).
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1.5 Epidemiology of human T lymphotropic viruses
1.5.1 Transmission
1.5.1.1 HTLV-I
HTLV-I Is a cell-associated virus and transmission occurs more efficiently by transfer of 
intact Infected T cells than by cell-free fluids (Fan et al 1992). Transmission occurs through 
sexual intercourse, blood transfusions and other transfers of cellular blood products, sharing 
of needles by IVDUs and ingestion of breast milk by babies (Okochi et a /1984, Hino et al 
1985, Kajiyama et al 1986, Nakano et al 1986, Glaser et al 1988, Chen et a /1989, Lee et al 
1989, Khabbaz et al 1990, Kaplan et al 1996). Sexual and lactational transmission are the 
main modes of infection in endemic regions, whereas in non-endemic regions intravenous 
drug use accounts for a substantial proportion of transmission; transplacental and perinatal 
transmission are less important (Blattner et al 1983) (Section 1.5.2.1). Since the main 
vehicles for infectivlty during sexual intercourse are lymphocytes in semen, the rate of 
transmission is higher from male to female than from female to male (Kajiyama et al 1986). 
The proportion of people seroconverting after transfusion with HTLV-I infected blood 
constituents is 35 to 60% and occurs 20 to 90 days following transfusion (Manns ef al 1991).
1.5.1.2 HTLV-II
The main modes of transmission of HTLV-II appear to be through sharing of needles by 
IVDUs and, prior to the introduction of screening tests, through blood transfusions (Robert- 
Guroff et al 1986, Lee ef al 1989). HTLV-II is also transmitted by sexual intercourse and 
through breast milk, as for HTLV-I, and these appear to be the main modes of transmission 
in endemic populations (Hjelle ef al 1990).
1.5.2 Geographical distribution and high risk groups
1.5.2.1 HTLV-I
HTLV-I is distributed throughout the world, with endemic foci defined by geographical 
regions and ethnic groups. The virus is endemic (greater than 2% prevalence) in southern 
Japan, the Caribbean, central America, north eastern South America, central and southern 
Africa, Melanesia and Polynesia (Hinuma ef al 1982b, Levine ef al 1988a) (Figure 1.2).
Areas in which the prevalence of HTLV-I is less than 2% (non-endemic regions) include 
North America, Great Britain, Europe, the Mediterranean and the Middle East. The 
seroprevalences of infection reported among randomly selected donors in endemic regions 
tested by RIPA were 12% in Japan and 3.5% in the West Indies, compared to 1.5% in non­
endemic regions (Blattner et al 1983). The seroprevalence of HTLV-I in Japan ranges from 0 
to 35%, endemic regions being the islands of Kyushu, Shikoku and the Ryukyu chain, 
including Okinawa.
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HTLV-I seroprevalences of up to 14% have been detected in some populations in the 
Caribbean (Levine et al 1988a). Countries with high prevalences of HTLV-I seropositivity in 
this region include Jamaica, Trinidad and Tobago, Martinique, Guadeloupe, Barbados and 
Haiti. Countries of South America with foci of high prevalences of seropositivity for HTLV-I 
include Colombia, Brazil, Venezuela, Surinam and Guyana. HTLV-I is prevalent (3.7 to 
21.0% seropositivity by RIPA) in Africans from the Ivory Coast, Ghana, Nigeria, Zaire,
Kenya, Tanzania and South Africa (Saxinger et ai 1984, Biggar et al 1985, 1993). There is 
serological and virological evidence of infection with HTLV-I and related viruses in 
indigenous populations of Papua New Guinea, the south western Pacific islands and 
Australia (Kazura et al 1987, Asher et al 1988, May et al 1990, Yanagihara et al 1991). Foci 
of endemicity have also been reported in Italy (Manzari et al 1985).
In the UK the prevalence of HTLV-I infection is low, although certain ethnic groups derived 
from HTLV-I endemic regions have high prevalences of infection (Greaves et al 1984,
Tedder et al 1984, Mowbray et al 1989, Banatvala ef al 1990, Brennan ef al 1990, Salker ef 
al 1990, Tosswill et al 1990, Simms et al 1994, Hale et al 1997). In women attending 
antenatal clinics in England, antibodies were detected against HTLV-I by ELISA in 0.05% 
and against HTLV-II less than 0.01% (Ades ef a/2000). The seroprevalence of HTLV-I in 
Afro-Caribbean (0.97%) and African (0.26%) women was higher than in Caucasian women 
(0.03%). In north London 5.2% of IVDUs had antibodies against HTLV-I/II, whereas no 
antibodies against HTLV-I/II were detected in IVDUs in Scotland (The HTLV European 
Research Network 1996, McIntyre ef a/2001).
1.5.2.2 HTLV-II
HTLV-II is prevalent in some groups of American Indians and in IVDUs (Reeves ef a /1990, 
Maloney ef al 1992, Black ef al 1994). Endemic foci are located predominantly in South 
America. The prevalence is high in American Indians in Florida, New Mexico, Arizona and 
Panama. Cayapo and Kraho Indians of the Amazon Basin in Brazil have HTLV-II 
seroprevalences of 12 to 33%, whereas other tribes in the same region have low 
prevalences of infection (Maloney ef al 1992). High prevalences of HTLV-II infection (11 to 
18%) were reported among IVDUs in the USA using serological and molecular assays 
(Robert-Guroff ef al 1986, Ehrlich ef al 1989b, Lee ef al 1989, Kwok ef a /1990). Prevalences 
of HTLV-II infection in IVDUs were 2.6% in the UK and 1.5% in Italy (Tedder ef al 1984, Zella 
ef a/1990).
1.5.3 Molecular epidemiology
1.5,3.1 Subtypes of human T lymphotropic viruses
HTLV-I and HTLV-II have approximately 60% nucleotide sequence identity (Seiki ef al 1983, 
Shimotohno ef al 1985b, Kwok ef al 1988b, Lee ef a! 1993). HTLV-I has been classified into 
Cosmopolitan (U), Central African ( Ib ) ,  Melanesian (Ic) and Pigmy (b) subtypes (Mahieux ef 
al 1997). The prototype HTLV-U strain is the Japanese isolate HTLV-Utk-i and Cosmopolitan 
isolates from Japan, the Caribbean, North and South America and Africa have greater than 
or equal to 97% nucleotide sequence identity across the full-length genome. Melanesian
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strains have 92% identity with HTLV-Iatk-i (Gessain et al 1993). Three subtypes of HTLV-II 
have been identified; lU, Mb and lie (Switzer et al 1995, Biggar et al 1996).
1.5.3.2 Origins and global spread
STLV-I, which is closely related to HTLV-I, is present in Old World primates in Africa and 
Japan and it has been hypothesised that HTLV-I and STLV-I originated in Africa (Gallo et al 
1983b, Gessain et al 1992b). The viruses appear to have evolved in non-human primates 
with multiple independent events of transmission to humans accounting for different 
subtypes of HTLV-I (Koralnik et al 1994, Liu et a /1996). HTLV-I may have been spread to 
the Americas by infected Africans in more recent times. In Japan, HTLV-I appears to have 
been introduced to the Joman people between 300 and 100 BC, resulting in high 
prevalences of infection in their descendents, the Ainu and Ryukuans (Vidal et al 1994). The 
Melanesian subtype (HTLV-lc) appears to have evolved in relative isolation from other 
strains (Gessain et al 1993). Foci of HTLV-IU endemicity have been identified in American 
Indians, consistent with introduction of HTLV-II to the Americas at least 15,000 years ago 
(Biggar et al 1996). However, it is uncertain whether STLV-II is present in New World 
monkeys (Chen et al 1994). HTLV-I Ib has been identified in isolated populations of Pygmies 
in Africa and thus HTLV-II appears to be an ancient virus (Gessain et a /1995).
1.6 Diseases associated with HTLV-I
HTLV-I is aetiologically associated with ATL and HAM/TSP and has been implicated in other 
neoplastic or immune-mediated diseases, which are described in this section (Table 1.2). 
Evidence for the involvement of HTLV-I or related viruses in MF/SS, other CTCLs and LGL 
leukaemia is discussed in Section 1.11.
1.6.1 Adult T cell leukaemia/lymphoma
Adult T cell leukaemia/lymphoma (ATL) is an aggressive T cell neoplasm of adults caused 
by HTLV-I. It was first described in Japan and defined on the basis of distinctive 
ciinicopathological features and geographical distribution (Uchiyama et al 1977, Hanaoka et 
al 1979, Shimoyama et al 1991).
1.6.1.1 Epidemiology
Cases of ATL are clustered in regions reflecting the distribution of HTLV-I infection, 
particularly south western Japan and the Caribbean (Blattner et al 1982, 1983, Hinuma et al 
1982b, Robert-Guroff et al 1982) (Section 1.5.2.1). Sporadic cases occur in other parts of 
the world where HTLV-I infection is uncommon; many of these cases are in Japanese or 
Afro-Caribbean migrants from endemic regions (Greaves et al 1984, Wyld et al 1990, 
Pawson et al 1998a and b, Levine et al 1999). Over their life span, 1 to 5% of people 
infected with HTLV-I develop ATL (Kondo et al 1989, Murphy et al 1989, Tokudome et al 
1989, Tajima e ta l 1990).
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Table 1.2 Proposed association of human T lymphotropic virus type I
with human diseases.
Adult T cell leukaemia/lymphoma*
HTLV-l-associated myelopathy/tropical spastic paraparesis'
HTLV-l-associated myositis
HTLV-l-associated uveitis
HTLV-l-associated arthritis
HTLV-l-associated pneumonitis
Infective dermatitis
HTLV-l-associated lymphadenitis
Autoimmune thyroiditis
Autoimmune thrombocytopaenia
Systemic lupus erythematosus
Sjogren's syndrome
Multiple sclerosis
Chronic fatigue syndrome
B cell chronic lymphocytic leukaemia
B cell hairy cell leukaemia
B cell non-Hodgkin lymphoma
Acute and chronic myeloid leukaemia
Mycosis fungoides/Sézary syndrome
Lymphoproliferative disease of large granular lymphocytes
Aetiological role accepted
- I ' ' / '
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In Japan, 0.25 to 3.90 cases/100,000 people/year are diagnosed, although in some areas 
the rate may be substantially higher. The latent period between exposure to HTLV-I and 
occurrence of ATL is usually 20 years or more. Most ATL cases present from 25 years of 
age and the peak occurrence is at 50 to 55 years of age, although much younger cases 
have been reported (Murphy et a /1989, Tajima et al 1990, Pombo de Oliveira ef al 2002). 
Exposure to HTLV-I early in life, particularly through breast milk, is associated with a higher 
risk of development of ATL (Murphy et al 1989).
1.6.1.2 Clinical and pathological features
ATL usually presents as an acute form with leukaemia and neoplastic T cells infiltrating the 
lymph nodes, skin, liver, spleen and bone marrow (Uchiyama et al 1977, Blayney et al 
1983b, Jaffe et al 1984, Shimoyama et a /1991). This form is characterised clinically by 
enlargement of lymph nodes, nodular skin lesions, hypercalcaemia and lytic bone lesions. 
Among the less common variant ATL syndromes is a chronic form with erythaema but 
without hypercalcaemia or hepatosplenomegaly. A smouldering form with an indolent course 
involves the skin and is typified clinically by erythaema (Yamaguchi et al 1983). A 
lymphomatous form characterised by lymphadenopathy without leukaemia includes primary 
T cell lymphomas (TCLs) involving lymph nodes (Ohshima ef a/ 1998b). A variety of 
extranodal locations, including the gastrointestinal tract, may also be sites of primary 
lymphomas in ATL. Infection with secondary pathogens in ATL is associated with 
immunosuppression (White ef al 1995). Spontaneous remission of ATL is rare and the 
disease usually has an aggressive clinical course (Shimamoto ef a /1993). In patients with 
leukaemia, the circulating neoplastic lymphocytes are known as “flower” cells because of 
their lobulated nuclei (Jaffe ef al 1984). The neoplastic infiltrate in solid tumours consists of a 
mixture of small and large pleomorphic lymphocytes with lobulated nuclei, sometimes 
interspersed with multinucleated cells.
1.6.1.3 Immunology
The neoplastic cells in ATL are usually CD4^ T cells that are CD7", CD8' and CD25^ (IL2Ra^, 
Tac"") (Waldmann ef al 1984, Kamihira ef al 1992). In addition to CD25, markers of activation 
expressed by ATL cells include CD30, CD71, MHC-I I (HLA-DR), Ki67 and the lymphocyte 
common antigen (LCA) isoform CD45RA (Shirono ef al 1989). In functional studies, ATL 
cells exhibit T suppressor (Ts) activity (Tatsumi ef al 1980), whereas the pattern of cytokine 
secretion is variable (Tendler ef al 1994, Yamada ef al 1996). CD8’" and CD4^ cytotoxic T 
lymphocytes (CTLs) against HTLV-I gp21^"'', gp46^"'', pi 9®^ ,^ p24"^ ^^ , Tax and Rex antigens 
can be induced in vitro from PBMCs of patients with ATL, as well as asymptomatic carriers 
(Katahira ef al 1995). Fresh ATL cells have low susceptibility to lysis by Tax-specific CTLs 
due to reduced HTLV-I expression in vivo (Kozuru ef al 1989, Kannagi ef al 1993). NK cells 
are able to lyse HTLV-l-infected T cells that express viral antigens and evasion of NK cell- 
mediated destruction may be important in survival of neoplastic T cells (Feuer ef a /1995, 
Stewart ef al 1996). Plotnicky ef al (1994) noted that IL2-dependent HTLV-l-infected T cell 
lines are resistant to NK cell-mediated lysis, whereas IL2-independent cell lines are 
susceptible. An immunosuppressive effect of HTLV-I gp21^"'' has been demonstrated but its 
relevance to the pathogenesis of neoplasia is uncertain (Cianciolo ef al 1984).
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1.6.1.4 Molecular and genetic characteristics
HTLV-I proviruses are clonally integrated in neoplastic T cells in patients with ATL (Wong- 
Staal et al 1983, Seiki et al 1984, Yoshida et a /1984, Takahashi et al 1988) and ATL cells 
have clonal rearrangements of the T cell receptor (TCR) (3 genes (Jarrett et al 1986, 
Matsuoka et al 1988, Tanaka et a l 1989, Ohshima et al 1990, Kanekura et al 1993).
Although clonal numerical and structural chromosomal abnormalities are found in neoplastic 
T cells in a high proportion of patients, no common defects have been Identified (Kamada et 
al 1992, Ohshima et al 1998a). The TOR a locus may be involved in ATL cases, as well as 
HTLV-I negative T cell leukaemias, with breakpoints at chromosome 14q11 (Sadamori et al 
1986). As with many neoplasms, p53 mutations are frequent in leukaemic cells from ATL 
patients (Nagai et al 1991, Sugito et al 1991, Cesarman et al 1992, Sakashita et al 1992, 
Yamato et al 1993) (Section 1.8.5). Deletions are present in 10 to 56% of HTLV-I proviruses 
in neoplastic cells but there is preferential retention of the p X  region (Manzari et a /1983, 
Konishi et al 1984, Korber et al 1991, Ohshima et al 1991, Sakurai et al 1992a, Chou et al 
1995, Tamiya et al 1996). Mutations in p X  ORF II preventing expression of Tof and pi 3" 
have been identified in ATL cells in vivo indicating that these pX  proteins may not be 
essential for leukaemogenesis (Chou et al 1995).
The sites of integration of HTLV-I proviruses differ between patients with ATL and appear to 
be non-specific (Seiki et al 1984, Chou et al 1996, Ohshima et al 1998a). In some cases 
integration of HTLV-I adjacent to cellular genes such as IL2R has been demonstrated, but 
insertiona! mutagenesis is not considered to be the principal mode of oncogenesis (Okamoto 
et al 1986, Macera et a /1992, Nakamura et al 1994, Kubota et al 1996b, Chi et al 1997) 
(Section 1.8). A small number of patients with ATL-like leukaemia or lymphoma have anti- 
HTLV-I serum antibodies but no evidence of monoclonal integration of proviral DNA, 
suggesting that HTLV-I could induce leukaemia indirectly or by a hit-and-run mechanism 
(Yoshida et al 1989b, Fujiwara et al 2001 ). The rare occurrence of HTLV-l-negative cases of 
ATL-like neoplasia also supports the hypothesis that other molecular and cytogenetic events 
are important in the pathogenesis of ATL (Shimoyama et al 1987). ATL and HAM/TSP do 
not appear to be caused by different strains or molecular variants of HTLV-I, as the two 
diseases may develop in the same person or in members of the same family (Kawai ef al
1989, Uozumi et al 1991, Major e ta l 1993, Tamiya et al 1995). Sequence variations appear 
to be related to geographical origin of HTLV-I types rather than pathogenicity (Daenke ef al
1990, Kinoshita et al 1991, Komurian et a l 1991). It has also been shown that the HTLV-I 
LTR directs expression in a wide range of tissues independent of the source of virus 
(Gonzalez-Dunia ef a /1993).
1.6.1.5 Viral aetiology
The viral aetiology of ATL was established following the isolation of HTLV-I and its 
association with T cell leukaemias and lymphomas in Japan, the Caribbean and the USA 
(Blattner ef al 1982, Hinuma ef al 1982b, Blattner ef al 1983, Blayney ef al 1983a). Patients 
with ATL are almost invariably infected with HTLV-I and have serum antibodies against the 
virus (Posner ef al 1981, Kalyanaraman ef al 1982a, Robert-Guroff ef al 1982, Gallo ef al 
1983a). Infection precedes the development of ATL and HTLV-I genomes can be detected in
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leukaemic cells. Thus, although ATL develops in only a small proportion of HTLV-l-infected 
people after a long latent period, the evidence for an aetiological association is compelling. A 
small number of patients with ATL are negative in standard serological assays but have 
molecular evidence of HTLV-I infection; in some cases this may be due to the presence of 
defective HTLV-I (Korber et a /1991, Ohshima et a l 1991, Kubota et al 1995). ATL-like 
neoplasia has also been observed in a small number of patients without serological or 
molecular evidence of HTLV-I infection, but these cases appear to be exceptional 
(Shimoyama et al 1986).
1.6.1.6 Pathogenesis
HTLV-I does not possess a classical viral oncogene with homology to a cellular gene, as 
carried by acutely transforming simple retroviruses, and does not appear to induce neoplasia 
by insertional mutagenesis (Section 1.6.1.4). Instead, there is strong evidence that proteins 
encoded by the p X  region are responsible for oncogenicity (Section 1.3.5). Tax and Rex are 
essential for replication of HTLV-I (Chen et a l 1985) and Tax is the main HTLV-l-encoded 
protein implicated in leukaemogenesis (Nerenberg et al 1987, Tanaka et al 1990,
Grassmann et a l 1992) (Sections 1.8.1, 1.8.2 and 1.8.3). There is also evidence that p i 2’ 
has transforming properties (Section 1.8.4), but the oncogenic roles of Tof, p2l'" and pi 3" 
are uncertain (Chou et al 1995, Derse et al 1997, Robek et al 1998).
Most leukaemic cells from ATL patients do not express viral antigens detectable by methods 
of low sensitivity such as IF or WB immunoassay but viral antigens are readily detected 
following In vitro cultivation of PBMCs from these patients due to growth of HTLV-I in non- 
leukaemic cells (Poiesz et al 1980a, Hinuma et al 1982a, Hoshino et a l 1983, Salahuddin et 
al 1983). Similarly, HTLV-I mRNA cannot be detected in most leukaemic cells from ATL 
patients by northern blot hybridisation, whereas transcripts are readily detected by this 
method in cultured PBMCs (Clarke et a /1984, Franchini et al 1984) and ATL cells infiltrating 
skin (Setoyama et a /1992). Virus particles are produced in abundance in most HTLV-l- 
infected T cell lines, including ATL cells adapted to grow in culture (most of which are not 
derived from the leukaemic clone), whereas virus particles are rarely produced by ATL cells 
in vivo (Yoshida et al 1982, Vital et a l 1993). A low level of expression of HTLV-I mRNA and 
proteins in ATL patients could be a manifestation of viral latency due to regulation by viral or 
cellular gene products or by the immune system of the host (Section 1.3.6). Serum 
antibodies against HTLV-I suppress viral antigen expression in infected T cells in culture 
(Tochikura et al 1985). HTLV-I p24®^  ^can be detected more frequently in the serum of 
patients with acute or advanced ATL than in HTLV-I carriers or patients with chronic ATL 
(Ishibashi et al 1987). The host immune response may suppress populations of infected cells 
that express viral antigens until advanced stages of disease when the immune response is 
weakened. The increase in mRNA and protein expression in cultivated cells may result from 
activation of latent HTLV-I provirus in ATL cells. However, most HTLV-l-transformed cell 
lines that grow in culture from PBMCs of ATL patients are not derived from leukaemic clones 
(Yoshida et a /1982). Salahuddin et a /(1983) observed limited expression of HTLV-I 
antigens in UCMCs following HTLV-I infection. These results indicate that a high level of 
expression of viral antigens is not required for maintenance of the transformed phenotype in 
patients with ATL.
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Using more sensitive RT-PCR, HTLV-I genomic, env and pX  mRNA transcripts, including 
those encoding Tax, Rex, Tof, p2 l"’, p13" and p12', can be detected in uncultured PBMCs of 
most patients with ATL, as well as unaffected HTLV-I carriers, but levels are 10  ^to 10® times 
less than that in HTLV-l-infected T cell lines (Kinoshita et al 1989, Berneman et al 1992b, 
Ciminale et al 1992, Koralnik et al 1992). HTLV-I tax/rex mRNA transcripts were detected in 
0.001% of PBMCs in five of six ATL patients by RT-PCR (Kinoshita et al 1989). Setoyama et 
al (1994) detected tax/rex mRNA by the less sensitive ISH in 1 to 90% of leukaemic cells in 
peripheral blood of four patients with ATL and 1 to 50% of leukaemic cells infiltrating skin 
lesions in 10 patients. Ohshima e/a/(1996) detected tax/rex mRNA by RT-PCR-ISH in the 
cytoplasm of 10% of PBMCs containing HTLV-I proviruses from ATL patients. Mutations in 
pX  ORF II preventing expression of Tof and pi 3" have been identified in ATL cells in vivo 
(Chou et a /1995).
In asymptomatic people infected with HTLV-I there is polyclonal integration of provirus in 
CD4'" T cells (Yamaguchi et al 1988). With progression to ATL the proportion of circulating 
lymphocytes infected with HTLV-I increases and oligoclonal or monoclonal integration of 
provirus becomes detectable (Yoshida et al 1984, Kinoshita et al 1985, Leclercq et al 1998). 
HTLV-l-infected CD4^ T cell clones may persist for many years in carriers (Etoh et a /1997). 
In the preclinical stages of ATL there may be leucocytosis or the presence of abnormal 
lymphocytes in the peripheral blood (Kinoshita et a l 1985, Ikeda et al 1993). Some patients 
experience phases of smouldering or chronic ATL before the onset of acute ATL 
(Shimoyama et ai 1991). Upregulation of IL2 and IL2Ra (CD25) by Tax, generating an 
autocrine loop, is thought to be one of the mechanisms by which HTLV-I stimulates 
proliferation of T cells early in the course of infection (Arima et al 1986, Maeda et al 1987, 
Maruyama e ta l 1987, Siekevitz e ta l 1987) (Section 1.8.1.1). Many other biochemical 
pathways are altered in HTLV-l-infected T cells and could contribute to abnormal pre­
neoplastic proliferation or maintenance of the neoplastic phenotype. Accumulation of 
mutations in proliferating T cells leads to the emergence of neoplastic clones (Fukuhara et al 
1983, Sanada et al 1985, 1986, Mortreux et a /2001). The roles of Tax, p12‘, p53, c-Myc, 
apoptosis and Env in HTLV-I leukaemogeneis are discussed in Section 1.8.
1.6.2 HTLV-I and non-T cell neoplasia
Serological studies have associated HTLV-I with B cell, myeloid and other non-T cell 
neoplasia but an aetiological role is unconfirmed (Blomberg and Faldt 1985, Asou et al 
1986).
1.6.2.1 B cell neoplasia
A patient with B cell chronic lymphocytic leukaemia (CLL) had HTLV-I infection of T cells; 
leukaemic B cells were negative for HTLV-I but expressed immunoglobulins reactive with 
HTLV-I Gag and Env proteins (Mann et a /1987). HTLV-I infection of T cells may have 
resulted in chronic antigenic stimulation of B cells, promoting oncogenic events leading to 
leukaemia. HTLV tax sequences have also been amplified by PCR from PBMCs of other 
patients with B cell CLL, B cell HCL and B cell non-Hodgkin lymphoma, but there is 
insufficient evidence for an aetiological role in these neoplasms (Cardoso et al 1996).
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1.6.2.2 Myeloid neoplasia
HTLV-I/II seroreactivity has been detected in patients with acute and chronic myeloid 
leukaemia (Kalyanaraman et a/ 1982a, MostI et a l 1992). HTLV-l-related antigens, RT 
activity and retrovirus-like particles visible by EM were detected by Xu et al (1996a) in 
leukaemic PBMCs from patients with acute myeloid leukaemia. DNA from PBMCs of an 
HTLV-I seropositive patient with chronic myeloid leukaemia hybridised to a probe for the 
HTLV-I 3' LTR, but not to probes for other regions, suggesting the presence of variant or 
defective HTLV-I (Wong-Staal et a l 1983). However, there is insufficient evidence to 
incriminate HTLV-I in the aetiology of myeloid neoplasia.
1.6.3 HTLV-l-associated myelopathy/tropicai spastic paraparesis
HTLV-I has been aetiologically linked with HTLV-l-associated myelopathy (HAM) and tropical 
spastic paraparesis (TSP), which are considered to be identical syndromes (Gessain et al 
1985, Bartholomew ef al 1986, Osame et a l 1986, Roman and Osame et a l 1988).
1.6.3.1 Epidemiology
HAM/TSP occurs in areas endemic for HTLV-I (Levine ef al 1988a) (Section 1.5.2.1). 
Sporadic cases have been reported from non-endemic areas, mainly in immigrants from 
HTLV-I endemic areas (Sheremata ef al 1992). HAM/TSP develops in approximately 0.25% 
of people infected with HTLV-I over a lifetime of 75 years and the incidence in Japan is 3.1 
cases/100,000 HTLV-I infected people/year (Kaplan ef al 1990). Recipients of blood 
transfusions appear to be at higher risk of developing HAM/TSP, but infection by sexual 
intercourse is also a risk factor (Kramer ef al 1995). The latent period between exposure to 
HTLV-I and the development of disease is shorter for HAM/TSP than for ATL (Osame ef al
1986).
1.6.3.2 Clinical and pathological features
HAM/TSP is a chronic demyelinating disorder of the central nervous system (CNS) with a 
slowly progressive course characterised by weakness, spastic paraparesis or paraplegia 
(Gessain ef al 1985, Osame ef al 1986, Nakagawa ef al 1995). Atypical neurodegenerative 
disorders not matching the case definition for HAM/TSP have also been associated with 
HTLV-I (Kazadi ef al 1990, Hyer ef al 1991).
1.6.3.3 Molecular and genetic characteristics
integration of HTLV-I provirus in PBMCs of HAM/TSP patients is usually polyclonal or 
oligoclonal (Greenberg ef al 1989b, Gessain ef a/ 1990b, Furukawa ef al 1992). HTLV-I 
infects 3 to 30% of PBMCs and 15 to 18% of circulating T cells in HAM/TSP patients; most 
infected cells have a single integrated provirus (Richardson ef al 1997).
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1.6.3.4 Viral aetiology
Anti-HTLV-I antibodies are present in the serum and cerebrospinal fluid (CSF) of patients 
with HAM/TSP, supporting the viral aetiology of this disease (Gessain et al 1985, Osame et 
al 1987). HTLV-I sequences can be detected in PBMCs, CSF and CNS tissue (Bangham et 
al 1988, Bhagavati et al 1988, lannone et al 1992) and HTLV-l-infected T cell lines can be 
generated from PBMCs and CSF (Jacobson et a /1988).
1.6.3.5 Immunology and pathogenesis
HAM/TSP is thought to be an immune-mediated demyelinating disorder of the CNS with 
pathological changes induced by CTLs. Acute lesions in the CNS are infiltrated with 
activated CD4^ T cells, followed by accumulation of CD8'*' T cells and macrophages in the 
chronic stages (Umehara et al 1993). A strong humoral immune response is mounted 
against HTLV-I Env, Gag and Tax antigens (Dekaban et al 1994). CTL responses are 
directed predominantly against Tax (Jacobson et al 1990, Parker et al 1994). Most HTLV-l- 
infected T cells are transcriptionally silent in HAM/TSP patients; expression of tax/rex mRNA 
has been demonstrated in 0.001 to 1% of PBMCs (Beilke et al 1991, Gessain et al 1991). 
The quantity of provirus in the peripheral blood is usually higher in HAM/TSP patients than in 
HTLV-l-infected people without neurological disease and, paradoxically, the level and 
frequency of expression of tax in infected PBMCs may be higher than in ATL (Yoshida et al 
1989a, Gessain et a/ 1990b, Furukawa et al 1995). HAM/TSP patients may have a defective 
immune response to HTLV-I infection, permitting increased replication and expression of 
viral antigens coupled with development of autoimmunity. Certain MHC-I alleles, particularly 
HLA-A*02, are associated with reduced proviral load and reduced risk of HAM/TSP (Jeffery 
et al 1999). HTLV-I tax mRNA has also been detected by ISH in the CNS of HAM/TSP 
patients (Lehky et al 1995).
1.6.4 Other HTLV-f-associated immune-mediated diseases
HTLV-I has been associated with myositis, uveitis, arthritis, pneumonitis and several other 
apparently immune-mediated diseases. Attempts have been made to implicate HTLV-I in 
Sjogren's syndrome, multiple sclerosis (MS), systemic lupus erythematosus (SLE) and 
rheumatoid arthritis but the evidence for an association with these diseases is unconvincing.
1.6.4.1 HTLV-l-associated myositis
In Jamaica 11 of 13 patients with polymyositis had antibodies against HTLV-I (Morgan et a l
1989). HTLV-I sequences have been detected in muscle tissue of patients with polymyositis 
and antigens were localised immunohistochemically to mononuclear inflammatory cells 
(Sherman et al 1995). In contrast, only one of 54 Japanese patients with polymyositis was 
seropositive for HTLV-I (Nishikai et al 1991). Virus could not be detected by 
immunohistochemistry or ISH in muscle fibres of a series of HTLV-l-infected patients in 
Japan with polymyositis (Higuchi et al 1992). Thus, other factors may be involved in the 
pathogenesis of myositis in patients with HTLV-I infection in the Caribbean.
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1.6.4.2 HTLV-l-associated uveitis
Antibodies against HTLV-I were detected in a higher proportion of patients with idiopathic 
uveitis (35%) in Japan than patients with uveitis of defined aetiology (10%) or other ocular 
diseases (16%), compared to a seroprevalence of 11.5% in the local population (Mochizuki 
et al 1992). HTLV-I proviral sequences can be detected in the inflammatory exudate in the 
anterior chamber of patients with HTLV-l-associated uveitis.
1.6.4.3 HTLV-l-associated arthritis
HTLV-I is associated with arthritis and polyarthritis in endemic regions (Nishioka et al 1989, 
Sato et al 1991). Antibodies against HTLV-I are present and virus has been identified in the 
synovium and infiltrating T cells from joints of affected patients (Kitajima et al 1991, Eguchi 
et al 1992b). In contrast, no HTLV-I sequences were detected by PCR in one study of 
rheumatoid arthritis in a non-endemic region (Di Giovine et al 1994).
1.6.4.4 HTLV-l-associated pneumonitis
HTLV-l-associated pneumonitis, characterised by T lymphocytic alveolitis, has usually been 
observed in patients with other HTLV-l-related diseases (Sugimoto et al 1987, Vernant et al 
1988, Higashiyama et al 1994). Therefore, HTLV-l-associated pneumonitis may not be a 
distinct ciinicopathological entity.
1.6.4.5 Infective dermatitis
Infective dermatitis, a chronic dermatitis associated with Staphylococcus aureus or 
Streptococcus spp infection, has been associated with HTLV-I infection (LaGrenade et al 
1990). This may be a consequence of immunosuppression due to HTLV-I; similarly an 
increase in parasitic and bacterial diseases has been epidemiologically linked to HTLV-I 
infection (Nakada et al 1987, Murphy et al 1997). A lymphadenopathy characterised by 
infiltration of lymph nodes with polyclonal CD4^ T cells has also been attributed to immune 
dysfunction in HTLV-l-infected people (Ohshima et al 1992).
1.6.4.6 HTLV-I and other immune-mediated diseases
Serological and virological markers of HTLV-I infection have been identified in patients with 
several other immune-mediated diseases, including Sjogren's syndrome (Eguchi et al 1992a, 
Terada et a /1994), MS (Koprowski et al 1985), SLE (Olsen et al 1987, Lipka et a /1996), 
autoimmune thyroiditis (Kawai et al 1992), autoimmune thrombocytopaenia (Dixon et al
1989) and chronic fatigue syndrome (DePreitas et al 1991, Honda et al 1993), but evidence 
for an aetiological role in these conditions remains inconclusive.
Sjogren's syndrome and MS have been of particular interest because of their possible 
association with endogenous retroviruses that cross-react antigenically with HTLV-I. An 
apparent HTLV-I pi 9®®^ seroreactivity in some cases of Sjogren’s syndrome may be due to a 
cross-reactive antigen expressed in the salivary gland from the endogenous retroviral
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sequence HRES-1 (Banki et al 1992, Shattles et al 1992). Several groups have detected low 
copy numbers of HTLV-I tax sequences by PCR in labial salivary gland samples from some 
patients with Sjogren’s syndrome (Mizokami ef al 1998, Mariette et al 2000). It will be 
necessary to verify the methodology used in these studies and determine the pathogenetic 
role of the tax sequences before an aetiological link can be accepted.
HTLV-I sequences and antibodies have been identified in MS patients (Koprowski et al 1985, 
Greenberg ef al 1989a, Reddy ef al 1989) but an extensive series of follow-up studies failed 
to confirm the involvement of HTLV-I or related viruses in this disease (Ehrlich ef al 1991). 
mRNA transcripts of MS-associated retroviral element (MSRV), which belongs to the human 
endogenous retrovirus (HERV) family HERV-W, can be detected in retrovirus-like particles 
from cultured PBMCs of patients with MS, as well as in normal human placenta (Blond ef al 
1999). HERV-H sequences are also expressed in Epstein-Barr virus (EBV)-infected B 
lymphoblastoid cell lines (B-LCLs) established from MS patients (Haahr ef al 1994, 
Christensen ef al 2000). Further independent studies are necessary to determine if 
retroviruses are involved in MS.
1.7 Diseases associated with HTLV-II
The role of HTLV-II in the aetiology of disease is uncertain. The virus has been associated 
with CD8^ T cell lymphocytosis and leukaemia and chronic neurodegenerative disease 
resembling HAM/TSP but is not a cause of ATL (Kiyokawa ef al 1991) (Table 1.3). Kaplan et 
al (1991) identified a syndrome of severe skin disease, eosinophilia, and dermatopathic 
lymphadenopathy in patients with HTLV-II complicating HIV-1 infection. There is also 
evidence that HTLV-II is involved in immune-mediated diseases; HTLV-II po/and fax 
sequences were amplified from PBMCs of 52% of patients with Hashimoto’s thyroiditis and 
12% of patients with Graves’ disease compared to 2% of controls and 1% of blood donors in 
Japan, although all were seronegative for HTLV-II (Yokoi ef al 1995). Independent 
confirmation of this study is required. Evidence for the involvement of HTLV-II in MF/SS and 
LGL leukaemia is discussed in Section 1.11.
1.7.1 CDS* T cell lymphocytosis and leukaemia
Early isolates of HTLV-II were obtained from patients with T cell variants of HCL (atypical 
CD8^ T cell HCL) (Kalyanaraman ef al 1982b, Rosenblatt ef al 1986) and CD8^ T cell 
lymphocytosis in association with B cell HCL (Rosenblatt ef al 1988b). Sohn ef al (1986) 
detected antibodies against HTLV-I/II in two patients with T cell variants of HCL. Subsequent 
molecular and seroepidemiological studies have not established an association between 
HTLV-II and T or B cell forms of HCL (Rosenblatt ef al 1987, Lion ef al 1988, Hjelle ef al 
1991a).
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Table 1.3 Proposed association of human T lymphotropic virus type il
with human diseases.
CD8^ T cell lymphocytosis and leukaemia 
Chronic neurodegenerative disease 
Dermatopathic lymphadenopathy 
Autoimmune thyroiditis 
Mycosis fungoides
Lymphoproliferative disease of large granular lymphocytes
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1.7.2 Chronic neurodegenerative disease
Infection with HTLV-ll has been identified in patients with chronic neurodegenerative 
diseases resembling HAM/TSP (Hjelle et al 1992, Harrington et al 1993, Jacobson et al 
1993, Murphy et al 1993, Sheremata et al 1993). The virus has been isolated from PBMCs 
and detected by PCR in PBMCs but not CSF of patients with neurological disorders clinically 
indistinguishable from HAM/TSP (Jacobson et al 1993, Murphy et al 1993). HTLV-ll infection 
has also been demonstrated serologically and by PCR in four patients with tropical ataxic 
neuropathy, a neurological disorder characterised by ataxia, altered mental state, optic 
atrophy, deafness and peripheral neuropathy and described in Africa and the Caribbean 
(Sheremata et al 1993). However, HTLV-ll does not appear to be a common cause of 
chronic neurodegenerative disease.
1.8 Molecular mechanisms of HTLV-I leukaemogenesis
Tax is the main HTLV-l-encoded protein implicated in the pathogenesis of ATL (Franchini 
1995, Franklin and Nyborg 1995) (Section 1.6.1.6). This section discusses the mechanisms 
by which Tax modulates expression of cellular genes in HTLV-I-infected cells, the 
transforming properties of Tax, pi 2' and Env and the roles of p53, c-Myc and apoptosis in 
HTLV-I oncogenesis.
1.8.1 Effect of Tax on gene expression in HTLV-l-infected ceils
The expression of a wide variety of cellular genes is altered following infection by HTLV-I 
and this effect is mediated predominantly by Tax (Salahuddin et al 1984, Miyatake et al 
1988, Kelly et al 1992, Yoshida et al 1995) (Table 1.4). Differential regulation of cellular 
genes by Tax is hypothesised to be the main mechanism by which HTLV-I transforms T cells 
in vitro and initiates the oncogenic events leading to leukaemia in vivo. Many of the cellular 
genes transactivated by Tax are involved in activation, proliferation and differentiation of T 
cells, consistent with this protein having a direct leukaemogenic role in ATL (Wano et al 
1988, Marriott et al 1991, Hôlisberg 1999).
1.8.1.1 Cytokines and cytokine receptors
The high affinity IL2R is composed of a (CD25), common p (CD122, Pc) and common y 
(GDI32, Yc) chains (Taniguchi et al 1995). The pc and yc chains transduce signals resulting 
from binding of IL2 at the cell surface but their affinity for IL2 is increased substantially by 
inclusion of the a chain in the receptor complex. In activated T cells transduction of signals 
through the IL2R normally activates the Src family protein tyrosine kinases (PTKs) Lck and 
Fyn (Mills et al 1993). These in turn activate Ras, leading to up-regulation of the cellular 
oncogenes fos and jun. The 1L2 and IL2Ra genes are up-regulated by Tax and this effect is 
more pronounced in T cells than other cell types (Kronke et al 1985, Greene et al 1986, 
Inoue et al 1986, Waldmann 1986, Maruyama et al 1987, Siekevitz et ai 1987).
y .
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Table 1.4: Alteration of cellular gene expression by HTLV-i Tax,
Genes up-regulated through the NFkB pathway
Interleukins 1a, 2, 3, 4, 6, 8, 10 and 15 
Interleukin 2 receptor a and interleukin 15 receptor 
Tumour necrosis factors a (cachectin) and p (lymphotoxin) 
Granulocyte-macrophage colony stimulating factor 
Granulocyte colony stimulating factor 
CD106 (vascular cell adhesion molecule 1)
Bcl-xL
Genes up-regulated through CREB/ATF/AP1 pathways
Interleukin 5
Granulocyte-macrophage colony stimulating factor
Transforming growth factor p
Parathyroid hormone-related protein
p and G globin
Egr1 and Egr2
Fos and Fral
Nur77
Bcl-xL
Genes up-regulated through other pathways
Interleukin Ip  (NF-IL6, Spil)
Interleukin 2 (NFkB, NF-AT)
Interleukin 4 (NFkB, NF-AT, NF-IL6)
Interleukin 5 (GATA4, API)
Interleukin 2 receptor a (NFkB, SRF)
Platelet-derived growth factor receptor (Sis) (S p l, Egri ) 
Parathyroid hormone-related protein (GREB/ATF, SP1, EBS) 
Egri and Egr2 (GREB/ATF, SRE, EBS)
Fos (GREB/ATF, SRF, SIE, octanucleotide direct repeat)
Fral (Rb, API)
Genes down-regulated by Tax through CREB/ATF pathway
Cyciins A and D3 
DNA polymerase a
Genes down-regulated by Tax via bHLH proteins
Lck
p53
Neurofibromin (NF1)
Bax
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IL2 and IL2Ra are constitutively expressed in many T cell lines transformed by HTLV-I, 
although expression is not always maintained and HTLV-l-infected T cell lines may be IL2- 
dependent or IL2-independent (Arya et a! 1984, Wano et al 1984, Arima et al 1987, Kelly et 
al 1992) (Section 1.3.2.3). Expression of IL2Ra is Increased on the surface of PBMCs of 
HTLV-l-infected people in association with expression of tax/rex mRNA (Okayama et a!
1997). A Tax-mediated autocrine mechanism involving upregulation of IL2Ra expression and 
increased secretion of IL2 may thus be involved in maintenance of proliferation of T cells 
infected with HTLV-I in vivo (Arima et a! 1986, Maeda et al 1987, Maruyama et a /1987, 
Siekevitz e ta l 1987).
However, other pathways are almost certainly involved in stimulation of T cell growth by 
HTLV-I. Lck and Fyn are not necessary for IL2-mediated signal transduction in HTLV-l- 
infected cells, indicating the presence of alternative signalling pathways, for example 
activation of JAK/STAT through binding of p i 2' to yc (Mills et al 1992, Franchini et al 1993, 
Migone et al 1995) (Section 1.8.4). Lck is expressed in IL2-dependent but not IL2- 
independent HTLV-l-infected T cell lines, consistent with activation of alternative pathways in 
the process of transformation (Koga et al 1989) (Section 1.8.1.5). Human T cells expressing 
Tax proliferate in response to IL2 but can also be stimulated by anti-CD3 monoclonal 
antibodies (MAbs) through an IL2-independent pathway (Akagi and Shimotohno 1993) 
(Section 1.8.8). Many HTLV-l-infected T cells in short-term cultures from ATL patients do not 
proliferate in response to IL2, despite expressing IL2Ra and p (Uchiyama et al 1985, Katoh 
et al 1986, Noma e ta l 1989, Hôlisberg et al 1992). Furthermore, the IL2-dependence of T 
cell lines transformed by HTLV-I is unrelated to the level of expression of Tax (Katoh et al 
1986, Arima et al 1987) (Section 1.3.2.3). The yc component of the IL2R is shared with the 
receptors for IL4, IL7, IL9, IL13 and IL15 (Giri e ta l 1994, Kawahara et al 1994, Taniguchi et 
al 1995) and could be responsible for proliferation of ATL cells in response to exogenous 
IL2, IL4, IL7 and IL15 (Uchiyama et al 1988, Umadome et al 1988, Mori et al 1993b, Persaud 
et al 1995, Yamada et al 1998) (Section 2.2.1.2). The pc component of the IL2R is shared 
with the IL15 receptor.
The main mechanism by which Tax induces expression of IL2 and IL2Ra is through 
activation of the NFkB pathway (Ballard et a /1988, Leung and Nabel 1988, Ruben et al 
1988, Hoyos e ta l 1989, Crenon ef a/1993) (Section 1.8.2.1). The IL2 gene enhancer also 
has a response element for CD28RC, which is activated by members of the NF of activated 
T cells (NF-AT) family, themselves up-regulated by Tax in HTLV-I infected T cells (Curtiss et 
al 1996, Good et al 1996). As well as NFkB elements, the enhancer of the IL2Ra gene has a 
serum response element (SRE) transactivated by serum response factor (SRF) (Cross et al
1987) (Section 1.8.2.3).
Levels of the interleukins ILIaand p, IL3, IL5, IL6, IL8, IL10 and IL15 are also increased in 
HTLV-l-infected T cells and this increase is mediated by Tax (Miyatake et al 1988, Sawada 
et al 1992, Muraoka et al 1993, Wolin et al 1993, Mori et a/ 1994c, Yamashita et al 1994, 
Baba et al 1996). ILIa and p and the IL Ia  receptor are expressed by HTLV-l-infected T cell 
lines from ATL patients and the cells respond to IL Ia and p, consistent with a model of self­
stimulation similar to the IL2-IL2R autocrine loop (Wano et a /1987, Yamashita et al 1987,
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Shirakawa et al 1989, Mori et al 1994c). Tax up-regulaîes the ILIp gene promoter by 
interacting with the transcription factors NF-IL6 and Spil (Tsukada et al 1997).
In experimental models Tax increases expression of IL4 in T cells through NFkB, NF-AT and 
NF-IL6 sites in the IL4 promoter (Miyatake ef al 1988, Li-Weber et a /2001). ATL cells have 
increased expression of the IL4 receptor and have a proliferative response to IL4 (Uchiyama 
et a l 1988, Umadome et a l 1988, Mori ef al 1993b, 1996). However, Kodaka ef al (1989) and 
Mori ef al (1994b) were unable to demonstrate IL4 mRNA expression in leukaemic cells from 
ATL patients. Tax acts in synergism with GATA4 and API in transactivation of the IL5 gene 
and HTLV-l-infected T cell lines constitutively express this cytokine (Yamagata et a l 1997). T 
cells do not normally produce IL6 but production of this cytokine is induced following 
infection with HTLV-I (Sawada et al 1990, Lai and Rudolph 1991, Villiger et al 1991). Tax 
transactivates the IL6 and IL8 promoters through NFkB binding sites (Muraoka et a /1993, 
Mori ef al 1994d, Yamashita ef al 1994, Mori ef a/ 1995a).
IL10, IL15 and the IL15 receptor are also constitutively produced by ATL cells and HTLV-l- 
infected T cell lines through activation of the NFkB pathway (Azimi ef al 1998, Mori and 
Prager 1998, Mariner ef al 2001). IL15 may substitute for IL2 in activation of the JAK/STAT 
pathway In HTLV-l-infected T cell lines (Bamford ef al 1994, Burton ef al 1994, Migone ef al 
1995, Azimi ef a /1998, Yamada ef al 1998). ATL cells and HTLV-l-infected T cell lines 
express IL9 mRNA but this expression is independent of Tax and ATL cells do not proliferate 
in response to exogenous IL9 (Matsushita ef al 1997).
Tumour necrosis factors (TNF) a  and p are similarly increased in HTLV-l-lnfected T cells by 
Tax through the NFkB pathway (Tschachler ef al 1989, Paul ef al 1990, Albrecht ef al 1992, 
Nakajima ef al 1993). Macrophage inflammatory protein 1a is constitutively expressed in 
HTLV-l-infected T cells and induced by Tax (Kelly ef al 1992, Baba ef al 1996). HTLV-l- 
infected T cell lines also produce interferon (IFN) y (Sugamura ef al 1983). Levels of 
expression of granulocyte-macrophage colony stimulating factor (GMCSF), granulocyte 
colony stimulating factor (GCSF), macrophage activating factor and transforming growth 
factor (TGF) p are increased in HTLV-l-infected T cells by Tax (Jones ef al 1988, Niitsu ef al 
1988, Wano ef al 1988, Nimer ef al 1989, Kim ef al 1990, Sawada et al 1992, Himes ef al 
1993). Transactivation of the GMCSF promoter by Tax is mediated through a number of 
transcription sites including those binding NFkB and CREB/ATF (Nimer 1991, Himes ef al 
1993). NFKB-binding sites in the GCSF promoter are responsible for Tax-mediated 
transactivation of this gene (Himes ef a /1993). Expression of platelet-derived growth factor 
(PDGF) p and its receptor are increased in HTLV-l-infected T cells and the PDGFp receptor 
(c-s/s) promoter is up-regulated by interaction of Tax with the zinc finger transcription factors 
Spl and Egri (Goustin ef al 1990, Trejo ef al 1997). The PDGFp receptor mediates 
transformation by the bovine papillomavirus type 1 (BPV-1) E5 protein and could be one of 
the targets of HTLV-I p12‘ (Nilson and DiMaio 1993) (Section 1.8.4). HTLV-l-infected T cell 
lines also have increased expression of insulin-like growth factor (IGF) receptor type I and 
proliferate in response to IGF-I (Lai ef al 1993).
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1.8.1.2 Cell surface molecules
As well as the cytokine and growth factor receptors listed in Section 1.8.1.1, cell surface 
molecules up-regulated by Tax in HTLV-l-infected T cells include CD9, CD11, CD23 (FCg 
receptor II), CD21 (complement receptor 2), CD40, CD71 (transferrin receptor), CD80 (B7- 
1 ), MHC-I and GD2 ganglioside (Mann et al 1983, Nutman ef al 1987, Vidal ef al 1988, Yssel 
ef al 1989, Valle ef a /1990, Furukawa ef al 1993, McNearney et a l 1993, DezzuttI et a l 1996, 
Ohtsubo ef al 1997). CD54 (intercellular adhesion molecule 1, ICAM1) is expressed on 
uncultured leukaemic cells from ATL patients and levels of CD54 mRNA are increased in 
HTLV-l-infected T cell lines derived by transformation of cocultivated PBMCs or UCMGs 
(Fukudome ef al 1992, Dezzutti ef al 1995). However, GD54 and its ligand GD11 (Section 
1.10.1.5) may be down-regulated in HTLV-l-infected T cell lines derived directly from 
leukaemic cells of ATL patients (Fukudome ef al 1992, Tanaka ef al 1995). Thus, although 
Tax induces the GD54 promoter, its role in the regulation of GD54 expression in vivo is 
uncertain (Mori ef al 1994a, Tanaka ef al 1995). GD62 ligand (GD62L) is expressed on ATL 
cells and its promoter is transactivated by Tax, whereas this leucocyte adhesion molecule is 
down-regulated when normal T cells are activated (Tatewaki ef a /1995). GDI 06 (vascular 
cell adhesion molecule 1 ) is expressed at high levels on HTLV-l-infected T cells and 
transactivation of the GDI 06 gene by Tax is mediated through NFKB-binding sites (Valentin 
ef al 2001). Tax induces GDI 34 (0X40) and 0X40 ligand, the latter belonging to the TNF 
family, in HTLV-l-infected cells (Baum ef al 1994, Higashimura ef al 1996). Integrins a5pi 
and a4pi, which act as fibronectin receptors, are up-regulated on HTLV-l-infected T cells 
(Dhawan ef a /1993). GD151 (SFA-1, PETA-3), which associates with integrin a5pi and 
contributes to fibronectin adhesion, is also expressed on HTLV-l-transformed T cells and the 
GDI 51 gene is transactivated by Tax (Hasegawa ef a /1998).
1.8.1.3 Oncogenes, transcription factors, signalling pathways and cell cycle regulators
HTLV-l-infected T cell lines have increased concentrations of mRNAs for the API 
transcription factors Fos, Jun, JunB, JunD and Fral (Fujii ef al 1988, Nagata ef al 1989, 
Hooper ef al 1991, Tsuchiya ef a l 1993). Increased expression of Fos has been detected in 
PBMGs of patients with smouldering ATL (Iwahashi ef al 1994). Tax transactivates the fos 
promoter through four regulatory elements; a GREB/ATF-binding site, an SRE, a v-s/s 
conditioned medium inducible element and an octanucleotide direct repeat (Fujii ef al 1988, 
Alexandre and Verrier 1991). The fra1 promoter is transactivated by Tax through a site 
containing a retinoblastoma control element and two API-binding sites (Tsuchiya ef al 1993). 
Up-regulation of Egri and Egr2 by Tax in HTLV-l-infected T cell lines is mediated through 
GRE, Ets binding site and SRE sequences in the e g r i and egr2 enhancers (Wright e ta l 
1990, Alexandre ef al 1991, Fujii ef a /1991, Sakamoto ef al 1992). Nur77, which encodes a 
steroid receptor involved in TGR-mediated apoptosis, is constitutively expressed in HTLV-l- 
infected T cells and is up-regulated by Tax through the CREB/ATF pathway (Kelly ef al 1992, 
Liu ef a /1999). The anti-apoptotic gene bcl-xL is up-regulated by Tax through NFkB and 
CREB/ATF pathways (Mori ef al 2001 ). Tax also transactivates the proliferating cell nuclear 
antigen (PGNA) promoter (Ressler ef al 1997).
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The activities of a number of molecules involved in signal transduction pathways, including 
the PTKs Lyn and Fyn, protein kinase A and protein kinase C (PKC), are increased by Tax in 
HTLV-l-infected T cells (Koga et al 1989, Yamanashi et al 1989, Kadison et al 1990, Uchiumi 
et ai 1992, Lindholm et al 1996, Lemasson et al 1997, Weil et al 1999). Calpain II, a cysteine 
pro tea se that activates PKC, is increased by Tax in HTLV-l-infected T cells (Adachi et al 
1992b). In contrast, the activity of Lck is decreased (Koga et al 1989, Lemasson et al 1996) 
(Section 1.8.1.5). The JAK/STAT pathway is constitutively activated by tyrosine 
phosphorylation in uncultured leukaemic cells from ATL patients, IL2-independent HTLV-l- 
transformed T cell lines and Tax-expressing rodent fibroblast cell lines (Franchini et al 1993, 
Migone et al 1995, Xu et al 1996b, Takemoto et al 1997). This pathway may mediate 
transduction of signals through IL2R via p i2' (Section 1.8.4). HTLV-ll is able to transform T 
cells independently of JAK/STAT activation (Mulloy et al 1998b).
Tax interacts with the cyclin-dependent kinase (CDK) inhibitor p i 6"^ '^ '^ ®, releasing its 
repression of CDK4 and permitting the cell cycle to continue past the Gi/S arrest points 
(Suzuki et al 1996, Low e ta l 1997, Schmitt et al 1998), Deletions in which is a
tumour suppressor gene, have been reported in patients with ATL (Ogawa et al 1994, Hatta 
et al 1995). Hofmann et al (2001) demonstrated méthylation of p i6"^ '^ '^  ^and other genes 
involved in cell cycle control in a proportion of ATL patients. Tax also associates with cyclin 
D (Neuveut et al 1998) and the mitotic checkpoint protein MAD1 (Jin et al 1998).
1.8.1.4 Other proteins up-regulated by Tax
The parathyroid hormone-related protein (PTHRP) gene is transactivated by Tax through the 
CREB/ATF pathway and interactions with the transcription factors Etsi and Spl (Ikeda et al 
1993, Dittmer et al 1997). Elevated production of PTHRP by HTLV-l-infected cells may 
contribute to increased resorption of bone and retention of calcium by the kidneys in ATL 
patients (Fukumoto et al 1989, Watanabe et al 1990, Ejima et al 1993). ATL-derived factor 
(ADF)/thioredoxin-like protein is produced by HTLV-l-infected T cell lines but not uninfected 
T cell lines and the thioredoxin gene is transactivated by Tax (Wakasugi et al 1990,
Masutani et al 1996). AD F induces 1L2R and synergises with IL Ia  and p and IL2 in 
stimulating the growth of T cells, possibly through its effect on redox status (Wakasugi et al
1990). HTLV-l-infected T cell lines, as well as activated T cells, produce oncostatin M, a 
factor that stimulates growth of fibroblasts, but inhibits growth of melanoma cells (Nair et al 
1992). The lymphocyte chemoattactant stromal cell-derived factor 1 and its receptor CXCR4 
are preferentially expressed in HTLV-l-infected T cells and in T cells expressing Tax (Aral et 
al 1998b). Levels of expression of the cytoskeletal proteins vimentin and cytokeratin 7 are 
increased by Tax in HTLV-l-infected cells through the NFkB pathway (Lilienbaum et al
1990). Tax also transactivates several globin genes (Fox et a l 1989).
1.8.1.5 Proteins down-regulated by Tax
Tax down-regulates expression of Lck, the tumour suppressor proteins p53 and 
neurofibromin (NF1) and the apoptosis accelerator Bax (Ulttenbogaard et al 1995, 
Feigenbaum et a /1996, Brauweiler et al 1997, Lemasson et al 1997). Repression of these 
genes, mediated by the basic helix-loop-helix (bHLH) family of transcription factors
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(Ulttenbogaard et al 1995), may promote survival and proliferation of HTLV-l-infected T cells, 
contributing to oncogenesis. Although Lck and JAK/STAT are activated in some T cell 
neoplasms (Yu et al 1997) and IL2-dependent HTLV-l-infected T cell lines (Section 1.8.1.1), 
Lck is a regulator of apoptosis and therefore the ability of HTLV-l-infected cells to 
downregulate and bypass Lck may promote survival (Belka et al 2003). Repression of p 
polymerase by Tax may also contribute to oncogenicity by inhibiting repair of DNA, allowing 
mutations to accumulate (Jeang et al 1990). An increased frequency of random mutations 
has been observed in HTLV-l-infected and Tax-transfected cells (Majone et al 1993,
Saggioro et al 1994b, Miyake et al 1999). Tax represses cyclin A, cyclin D3 and DNA 
polymerase a by acting through CREB/ATF binding sites in the enhancers of these genes 
(Kibler and Jeang 2001). Expression of the TCR-CD3 complex is down-regulated by Tax in 
HTLV-l-infected T cell lines and leukaemic cells from patients with ATL (De Waal Malefyt et 
al 1990, Matsuda et al 1994).
1.8.1.6 Clinical relevance of alterations in cellular gene expression
It is difficult to ascribe specific clinicopathological correlates to the wide variety of cellular 
changes associated with HTLV-I infection in patients with ATL (Section 1.6.1.2). Over­
expression of receptor activator of NFkB (RANK) ligand (Nosaka et al 2002) and increased 
production of ILIa, TNFp and PTHRP by HTLV-l-infected T cells may induce 
hypercalcaemia and lytic bone lesions (Motokura et al 1989, Ishibashi et al 1991, Mori et al 
1994c). Upregulation of IL3, IL5 and GMCSF could contribute to granulocytosis and 
eosinophilia (Prin et a /1988). However, the clinical significance of many of the alterations in 
gene expression caused by Tax in HTLV-l-infected T cells is unknown. Since the level of 
expression of viral gene products in ATL cells in vivo may be low (Section 1.6.1.6), the 
effects of HTLV-I and Tax on cellular function in vitro cannot necessarily be extrapolated to 
ATL patients. Furthermore, it has been shown that clonaliy related ATL cells derived from 
the same patient may have different patterns of cytokine expression (Noma et al 1989).
1.8.2 Mechanisms o f reguiation o f cellular genes by HTLV-I Tax
Dysregulation of cellular functions by Tax is mediated through a variety of cellular 
transcription factors that attach to specific DNA sequences and activate or suppress 
cascades of genes. Tax does not bind directly to DNA but interacts with proteins in the NFkB 
and CREB/ATF families, increasing transcriptional activity by enhancing their dimérisation or 
by facilitating their translocation to the nucleus following dissociation or degradation of 
cytoplasmic inhibitors (Wagner and Green 1993, Kanno et a /1994, Baranger et al 1995, 
Franklin and Nyborg 1995, Yoshida et al 1995). Tax also activates transcription through 
pathways other than NFkB and CREB/ATF, such as SRF. The NFkB, CREB/ATF and SRF 
pathways appear to be important in transformation of cells by Tax (Smith and Greene 1991, 
Yamaoka et al 1996, Matsumoto et al 1997, Rosin et al 1998, Robek and Ratner 1999) 
(Section 1.8.3).
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1.8.2.1 NFkB
Members of the NFkB family are transcription factors that bind to consensus DNA 
sequences in the enhancers of many cellular genes. NFkB proteins include NFkBI (p50) 
derived from the precursor p i05, NFkB2 (p52) derived from the precursor Lyt-10 (p i00), Rel 
(p86), RelA (p65) and RelB (p50B) (Baeuerle and Henkel 1994). The NFkB pathway is 
involved in proliferation and differentiation of lymphocytes and is activated in T cells following 
stimulation through the TCR and by cytokines, mitogens and viral infection. HTLV-l-infected 
T cells constitutively express NFkB proteins and Tax specifically increases the functional 
activity of NFkBI, NFkB2, Rel and RelA in T cells (Lindholm ef a /1990, Arima et al 1991, Li 
et ai 1993, Lanoix et al 1994, Sun et al 1994). Elevated expression of NFkB1/p 105 and relA 
mRNA has been demonstrated in leukaemic cells from ATL patients (Inoue et al 1998). 
Cellular genes with NFKB-binding sites that are up-regulated by Tax include ILIa, IL2,
IL2Ra, IL6, IL15, IL15R, TNFa and (3, GMCSF and GCSF (Section 1.8.1).
There are at least three mechanisms by which Tax activates the NFkB pathway. The most 
important of these is by promoting release of NFkB dimers from inhibitors (IkBs) in the 
cytoplasm, allowing NFkB proteins to translocate to the nucleus and transcribe cellular 
genes (Karin 1999). IkBs include kBa, p, e, y (identical to the C terminal 607 amino acids of 
pi 05) and Bcl-3; Lyt-10 and p i 05 also have kB-like activity. Tax binds to MEKK1, resulting 
in activation of IkB kinases (Chu et al 1998, Geleziunas et al 1998, Yin et al 1998). IkB 
kinases phosphorylate IkBs, facilitating their degradation by the proteosome complex (Sun et 
a! 1994, Kanno et al 1995, Lacoste et al 1995, Maggirwar et al 1995, Good and Sun 1996). 
Released from IkBs in the cytoplasm, NFkB proteins translocate to the nucleus, where they 
activate cellular genes. Tax also binds to ankyrin repeat motifs in IkBs and this interaction 
further contributes to translocation of NFkB proteins to the nucleus by facilitating competitive 
dissociation of NFkB-IkB complexes (Watanabe et al 1993, Hiral et al 1994, Kanno et al 
1994, Munoz et al 1994, Suzuki et al 1995, Petropoulos ef al 1996, Petropoulos and Hiscott
1998).
Furthermore, Tax mediates transactivation of NFKB-binding sites by interacting with ankyrin 
repeat motifs in the Rel homology domains of NFkB proteins, promoting the formation of 
NFkB dimers, which bind to DNA (Lacoste et al 1991, Armstrong et al 1993, Suzuki et al 
1994, Hiscott et al 1995, Petropoulos et al 1996). NFKB-binding activity induced by Tax is 
thus initially due to translocation of NFkB dimers (especially NFKBI-RelA) from the 
cytoplasm to the nucleus and is later supplemented by complexes containing newly 
synthesised proteins as a result of transcriptional activation of NFkB promoters by Tax in a 
positive feedback loop (Li ef al 1993, Kanno ef al 1994, Sun ef al 1994). Conversely, 
sequestration of Tax in the cytoplasm by association with Lyt-10 (and to a lesser extent 
pi 05) could form part of a negative feedback loop leading to viral latency following activation 
of NFkB in HTLV-l-infected T cells (Béraud ef al 1994, Pepin ef al 1994) (Section 1.3.6).
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1.8.2.2 CREB/ATF
Proteins in the CREB/ATF and AP1 families are basic region leucine zipper (bZIP) proteins 
that bind to CREB response elements (CREs) in the enhancers of many genes (Lemaigre et 
al 1993, Karin et a l 1997). CREB, ATF1 and ATF2 up-regulate expression, whereas CRE 
modulator (CREM) down-regulates expression. The mechanism by which Tax activates 
transcription through CREB/ATF and API factors is by interaction of Tax dimers with the 
basic regions of these proteins, promoting dimérisation through their leucine zippers, which 
enhances their ability to bind to DNA (Zhao and Giam 1992, Wagner and Green 1993, 
Baranger et al 1995, Perini et al 1995, Kwok et al 1996). Cellular genes responsive to 
transactivation by Tax through CREB/ATF-binding sites include egr1, egr2, fos, GMCSF, 
PTHRP, Nur77, cyclin A and DNA polymerase a (Section 1.8.1).
1.8.2.3 Other mechanisms of activation by Tax
Tax interacts with SRF and enhances its binding to CArG elements in the SREs of egr1, 
egr2, fos and IL2Ra (Fujii et a l 1992, Armstrong et a /1993, Suzuki et a l 1993b) (Section 
1.8.1). Other mediators of transcriptional activation by Tax include CBP/p300 (Kwok et al 
1996, Bex et al 1998, Van Orden et al 1999), HEB1 (Béraud et al 1991), TATA box-binding 
protein (TBP) (Caron et a /1993), TFIIA (Clemens et al 1996) and NF-YB (Pise-Masison et al 
1997). Tax mutants that selectively activate the CREB/ATF pathway localise with CBP, 
whereas Tax mutants that selectively activate the NFkB pathway localise with p300 (Bex et 
al 1998). Tof also binds to CBP/p300 (Zhang ef a/2001) (Section 1.3.5.4). Repressive 
effects of Tax on cellular genes are mediated through CREB/ATF and bHLH pathways 
(Section 1.8.1.5). The enhancers of many genes have more than one site responsive to 
transactivation by Tax.
1.8.3 Transforming properties o f Tax
Tax is able to transform established rodent fibroblast cell lines, immortalise primary rat 
embryo fibroblasts (REFs) and immortalise human T cells (Grassmann ef al 1989, Pozzatti 
ef a /1990, Tanaka ef al 1990, Smith and Greene 1991, Grassmann ef a /1992). Tax 
cooperates with Ras in the transformation of primary REFs, but is unable to transform them 
when expressed alone (Pozzatti ef al 1990). Miyazaki ef a /(1996) demonstrated cooperation 
of Tax with c-Myc and Lck in the transformation of a B cell line to IL3-independence. 
Participation of Lck and Ras in Tax-mediated transformation in this model is consistent with 
involvement of the IL2R signalling pathway (Section 1.8.1.1). Primary human T cells 
Immortalised with Herpesvirus saimiri or retroviral vectors expressing Tax remained 
dependent on IL2 and had increased expression of IL2Ra (Grassmann ef al 1989, Akagi ef 
al 1,995). Mutational inactivation or deletion of tax from transformed, cells resulted in 
reversion of the transformed phenotype (Sakurai ef al 1992b, Yamaoka ef al 1992). An 
established rodent fibroblast cell line (Rat2 cells) transformed by Tax lost its transformed 
phenotype when fused with non-transformed human fibroblasts, even though expression of 
functional Tax was maintained in the hybrid cells, indicating that transformation by Tax is 
dependent on additional oncogenic events, particularly inactivation of tumour suppressor
■■
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function (Inoue et al 1994). Expression of Tax is maintained in T cell lines transformed by 
HTLV-I even though such cell lines may not express structural genes (Sodroski et al 1985). 
Tax2 is essential for transformation of human T cells by HTLV-ll (Ross et al 1996, Endo et al 
2002).
As discussed in Section 1.8.2, the NFkB, CREB/ATF and SRF pathways are involved in Tax- 
mediated transformation. Tax mutants that stimulate the GREB/ATF pathway but not the 
NFk B pathway are able to transform Rat2 cells (Smith and Greene 1991, Rosin et a l 1998).
In contrast, Yamaoka et al (1996) demonstrated that activation of NFkB was necessary for 
Tax-induced transformation of another established rodent fibroblast cell line (Rati cells). An 
IL2-dependent murine T cell line (CTLL-2) lost its dependence on IL2 for growth when 
transfected with a plasmid expressing Tax and this effect was mediated through the NFkB 
pathway rather than the CREB/ATF pathway (Iwanaga et al 1999). The same cell line 
required expression of Tax that transactivated both pathways in order to form colonies in soft 
agar in the absence of IL2 (Iwanaga et al 1999). Colony formation by fax-transfected Rati 
cells In soft agar was dependent on the NFkB pathway, whereas focus formation by primary 
REFs in cooperation with Ras was dependent on the SRF pathway (Matsumoto ef al 1994, 
1997). Immortalisation of primary human T cells (indefinite growth in the presence of (L2) 
was dependent on activation of the NFkB pathway by Tax but did not require an active 
CREB/ATF pathway (Robek and Ratner 1999). Similarly, activation of the NFkB pathway in 
fax-transfected human PBMCs conferred growth responsiveness to IL2, whereas clonal 
expansion of CD4'" T cells from this population was associated with activation of the 
CREB/ATF and SRF pathways (Akagi et al 1997a). In HTLV-l-infected T cells the IL2- 
dependent phase of growth is associated with activation of the NFkB pathway, whereas loss 
of dependency on IL2 is associated with activation of the CREB/ATF, SRF and JAK/STAT 
pathways (Migone ef al 1995) (Section 1.3.2.3). These results suggest that different 
signalling pathways are involved in distinct facets of the transformation process mediated by 
Tax.
1.8.4 Role o f p i  2! in HTLV-I oncogenesis
p12‘ has oncogenic properties and may play a role in HTLV-I leukaemogenesis. Although 
unable to induce transformed foci when transfected alone, pi 2' enhances transformation of 
murine Cl 27 fibroblasts when co-transfected with BPV-1 E5, a 44 amino acid oncoprotein 
implicated in the development of papillomas induced by BPV-1 in cattle (Schlegel ef al 1986, 
Franchini ef al 1993). Transformation of C l27 cells by E5 is mediated by the PDGFp 
receptor (Section 1.8.1.1); E5 transforms NIH 3T3 cells by interacting with the epidermal 
growth factor (EGF) receptor (Martin ef al 1989, Nilson and DiMaio 1993). p12‘ and E5 have 
structural similarities, both being hydrophobic proteins that localise in the endoplasmic 
reticulum and Golgi apparatus (Koralnik ef al 1993) (Section 1.3.5.6). The second of two 
putative transmembrane regions of p i2* (amino acids 39 to 62) has 59% amino acid identity 
with the single transmembrane region of E5 (amino acids 6 to 28), a common amino acid 
motif LFLL and a conserved Q residue (Franchini ef al 1993) (Appendices 1 and 2). p i2' and 
E5 both associate with 16 kDa vacuolar H  ^ATPase, a proton pump responsible for 
acidification of vesicles (Goldstein e ta l  1991) (Section 1.3.5.6). However, the sites of
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interaction of p12* and E5 with 16 kDa vacuolar H"' ATPase are different and the binding 
domain in p i 2* is not the same as the domain that mediates its ability to potentiate 
transformation (Koralnik et al 1995). BPV-1 E5 enhances the binding of 16 kDa vacuolar H'' 
ATPase to the PDGFp receptor and this may be the mechanism by which the PDGFp 
receptor is constitutively activated in transformed Cl 27 cells (Goldstein et al 1992). It is 
unknown whether p i2* has a similar mechanism of action.
pi 2' binds to the cytoplasmic portions of the Pc and Yc chains of the IL2R (Franchini et ai 
1993, Mulloy et a /1996) (Section 1.3.5.6). A proline-rich region between the two 
transmembrane domains of p12‘ Is Involved in binding to IL2Rp and also mediates 
interaction with 16 kDa vacuolar ATPase (Mulloy et a /1996). p12‘ binds to an acidic 
region in the cytoplasmic domain of IL2Rpc, which is the site of interaction with Lck and 
involved in recruitment of JAK1 to IL2Rpc and JAK3 to IL2Ryc following IL2 stimulation, 
resulting in activation of STAT5 (Migone et al 1995, Ni cot et a l 2001 ). p i 2' may thus bypass 
the requirement of proliferating T cells for IL2. A Tax-p12-based model for HTLV-l-induced 
transformation of T cells is for Tax to activate the IL2-IL2R autocrine loop early in the course 
of infection, with p12‘ maintaining proliferation or preventing apoptosis later in infection 
through ligand-independent stimulation of the IL2R signalling pathway.
1.8.5 Role o f p53 in HTLV-I oncogenesis
p53 is a tumour suppressor protein that induces cell cycle arrest and apoptosis in response 
to DNA damage (Liebermann et al 1995) (Section 1.8.7). Mutations resulting in inactivation 
of p53 are found in many neoplasms and have been identified in cases of ATL (Hollstein et 
al 1991, Newcomb 1995) (Section 1.6.1.4). Leukaemic T cells in nine (42%) of 21 cases of 
ATL had significant mutations in p53 (Nagai e i al 1991, Sugito et al 1991, Cesarman et al 
1992, Sakashita et al 1992, Yamato et al 1993). Nucleotide sequence changes identified 
were predicted to lead to amino acid substitution (seven cases), deletion (one) or premature 
termination (one) in the encoded protein. There was a corresponding loss of the opposite 
p53 allele (loss of heterozygosity) in four cases. Mutations in p53 were more frequent in 
acute than chronic ATL (Nagai et a l 1991, Sugito et a l 1991, Sakashita et al 1992, Nishimura 
et a /1995).
p53 and other tumour suppressor proteins are frequent targets of viral oncogenes (Hoppe- 
Seyler and Butz 1995). p53 is increased in HTLV-l-infected T cell lines but the protein is 
inactivated by phosphorylation and this effect is mediated by Tax (Koeffler et al 1986, Reid 
et a l 1993, Pise-Masison et al 2000). T cell lines immortalised by Tax also have increased 
expression of p53 (Akagi et a l 1997b). The increase in p53 is due to stabilisation of the 
protein (increased half life) rather than an increase in the amount of mRNA, since Tax down- 
regulates p53 through binding of bHLH transcription factors to an E box element in the p53 
enhancer (Lübbert et al 1989, Reid et al 1993, Uittenbogaard et al 1994) (Section 1.8.1.5). 
Tax does not bind to p53 but induces phosphorylation of this protein through the NFkB 
pathway (Pise-Masison et a /2000). Phosphorylation blocks the interaction of transcription 
factors such as TFIID and MDM2 with the N terminal activation domain of p53. As a 
consequence, p53-mediated responses to cell damage are impaired in HTLV-l-infected cell
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lines (Cereseto et al 1996, Pise-Masison et al 1998). Mulloy et al {1998a) found that the 
CREB/ATF domain of Tax was also important in inhibition of p53 transcriptional activity. An 
increase in the level of inactive p53 is correlated with loss of IL2 dependence of HTLV-l- 
infected T cell lines (Yamato et al 1993, Gartenhaus and Wang 1995, Cereseto ef al 1996). 
Levels of p53 were also increased in leukaemic T cells in eight of 14 cases of ATL (Nagai et 
al 1991, Sugito efa/1991, Cesarman et al 1992). p53 thus appears to be an important target 
of HTLV-I Tax in infected cells.
1.8.6 Role o f c-Myc in HTLV-I oncogenesis
The Myc family of proteins, c-Myc, N-Myc and L-Myc, are nuclear phosphoproteins with bZIP 
and bHLH domains that act as transcription factors with an important role in cell proliferation 
(Marcu ef al 1992, Lüscher and Larsson 1999). c-Myc dimerises with Max and is involved in 
transformation, cell cycle progression and apoptosis (Heikkila ef al 1987, Dang ef al 1989, 
Kato ef al 1990, Evan ef al 1992, Amati ef al 1993). It cooperates with Ras in transformation 
(Land ef al 1983, Strasser ef al 1990). Activation of c-Myc appears to prime cells for either 
proliferation or death by apoptosis, depending on whether conditions are permissive for 
survival (Evan ef al 1992) (Section 1.8.7). Survival signals that allow c-Myc to induce 
proliferation in different contexts include cytokines present in serum such as IL2, IL3, IGF-I 
and PDGFp and expression of apoptosis inhibitors such as Bcl-2 (Fanidi ef al 1992, 
Harrington ef al 1994a). c-myc is activated in a wide variety of neoplasms, including human, 
murine, feline and avian leukaemias and sarcomas (Cory ef a /1984).
HTLV-I appears to have a variety of disparate effects on c-Myc expression and function. No 
mutations in c-myc were detected in leukaemic T cells from 10 ATL patients (Cesarman ef al
1992) and c-myc mRNA could be detected by ISH In 25% of leukaemic cells (Moriuchi ef al
1988), The level of c-myc mRNA was increased in an HTLV-l-infected T cell line examined 
by Koizumi ef a/ (1989). Duyao ef al (1992) demonstrated transactivation of c-myc by Tax 
through NFicB-response elements, whereas In a study by Fujii ef al (1988) Tax failed to 
activate transcription from the c-myc promoter. Similarly, there was no upregulation of c-Myc 
in a T cell line transfected with tax (Nagata ef al 1989). Inhibition of c-myc expression in 
HTLV-l-infected T cell lines was correlated with inhibition of growth (Koizumi ef al 1989,
Fujita and Shiku 1993). Tax inhibits c-Myc function, including its transforming properties in 
Rati cells, through a post-translational mechanism involving the CREB/ATF pathway 
(Semmes ef al 1996). These differences probably reflect the complex pattern of regulation of 
expression and the diverse functions of c-Myc in cells. Experiments investigating the effects 
of HTLV-I p X  genes on apoptosis induced by c-Myc in rodent fibroblasts under conditions of 
serum deprivation are described in Chapter 4.
1.8.7 Role o f apoptosis in HTLV-I oncogenesis
1.8.7.1 Apoptosis and oncogenesis
Apoptosis is a mechanism of programmed cell death in response to pathological or 
physiological stimuli (Kerr ef al 1972). In the process of oncogenesis, cells have a
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requirement to switch on genes that promote growth, for example the oncogene c-myc 
(Section 1.8.6). However, c-myc-induced proliferation is automatically coupled to activation 
of an apoptosis pathway, allowing cells to respond to potentially oncogenic events by 
committing suicide (Evan e ta l 1992, Evan and Littlewood 1993). Therefore, additional 
events that prevent apoptosis In response to aberrant cell proliferation are required for 
oncogenesis, for example by activating the antl-apoptotic gene bcl-2 or Inactivating the 
tumour suppressor gene p53 (BIssonnette et al 1992, Fanldl et al 1992, Harrington et al 
1994b, Pan ef al 1997). Tax up-regulates the anti-apoptotIc protein Bcl-xL and down- 
regulates the tumour suppressor proteins p53 and NF1 and the pro-apoptotic protein Bax 
(Ulttenbogaard ef al 1995, Feigenbaum ef al 1996, Brauweiler ef al 1997, Mori ef al 2001 ) 
(Sections 1.8.1.3 and 1.8.1.5). Apoptosis induced by expression of c-Myc is mediated by p53 
(Hermeking and Eick 1994) (Section 1.8.6).
1.8.7.2 Survival signals
Suppression of apoptosis is important in maintaining survival of normal cells under 
physiological conditions. Cells that survive In the presence of growth factors, such as IL2 or 
IGF-I, may undergo apoptosis when these growth factors are withdrawn, for example by 
cultivation in low concentrations of serum (Evan ef al 1992, Harrington ef al 1994a, Kulkarni 
and McCulloch 1994, Preston et al 1994). IL2-dependent T cells undergo apoptosis when 
IL2 is withdrawn (Duke and Cohen 1986). IL2, IL4 and IL7 prevent apoptosis of quiescent T 
cells In response to y-irradlatlon (Boise ef al 1995). Similarly, apoptosis is the mechanism of 
death in IL3- and IL6-dependent haematopoietic cells deprived of these cytokines (Colotta ef 
al 1992, Gottlieb ef al 1994). A potential mechanism of HTLV-I leukaemogenesis would be to 
prevent apoptosis In T cells. However, PBMCs from patients with ATL undergo apoptosis 
when cultivated in serum-free medium, similar to PBMCs from normal people (Debatin ef al
1993). This effect is only partially inhibited by IL2, Indicating that other growth factors in 
serum are required to prevent apoptosis of ATL cells and normal PBMCs (Tsuda ef al 1993). 
The growth of IL2-dependent HTLV-l-lnfected T cell lines is arrested in early Gi (Go) after 
withdrawal of IL2, due to inhibition of the cyclin E-CDK2 complex by p27* '^^\ whereas cell 
cycle progression is maintained in IL2-independent T cell lines upon serum starvation 
(Cereseto ef al 1999).
1.8.7.3 CD95-mediated apoptosis
The CD95 (Fas, Apo-1 )-CD95 ligand (CD95L) system is one of the pathways mediating 
activation-induced death in T cells (Owen-Schaub ef a /1992, Klas ef al 1993, Wang ef al 
1994, Alderson ef al 1995, Brunner ef al 1995, Dhein ef al 1995, Ju ef al 1995). Binding of 
CD95L to CD95 by cell-cell contact activates an apoptosis cascade through interleukin 1 p- 
converting enzyme (ICE)-like proteases (Enari ef al 1995, Los ef al 1995). CD95 is 
expressed by leukaemic cells In most cases of ATL and by HTLV-l-infected T cell lines 
derived from ATL patients, but the level of expression is variable (Debatin ef al 1990, 1993, 
Kota ni ef al 1994, Sugahara ef al 1997, Tamiya ef al 1998). CD95 was expressed on 
leukaemic cells of 46 (98%) of 47 ATL cases examined by Tamiya ef a/ (1998). HTLV-l- 
infected T cell lines, short-term cultured PBMCs and fresh neoplastic cells from most ATL 
patients, all of which expressed CD95, were susceptible to apoptosis induced by antl-CD95
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MAbs (Debatin et a /1990, 1993, Kota ni et al 1994). In two CD95" ATL cases, leukaemic cells 
had mutations in both alleles of the CD95 gene and were resistant to apoptosis Induced by 
antl-CD95 MAbs (Tamiya et al 1998, Maeda et al 1999). Resistance to CD95-mediated 
apoptosis in other HTLV-l-infected T cell lines (especially long-term cell lines established by 
cocultivation and not derived from leukaemic clones) was associated with expression of Tax 
and/or Fas-associated phosphatase 1 (FAP1), which acts as a negative regulator of the 
CD95 apoptosis pathway (Copeland et al 1994, Sato et a /1995, Aral et al 1998a).
Expression of Tax reduced the susceptibility of uninfected CD4'" T cell lines to CD95- 
mediated apoptosis, provided the cells were cultivated in 5 to 10% serum (Copeland et al 
1994, Chlichlia et al 1995, Chen et al 1997, Chlichlia et al 1997, Aral et al 1998a). The effect 
of duration of cultivation on expression of Tax by T cells could account for differences in 
sensitivity to CD95-medlated apoptosis. Tax up-regulates CD95L on T cells through NFkB 
and CREB/ATF pathways and these cells have an increased rate of apoptosis through the 
CD95-CD95L autocrine cell suicide pathway (Chlichlia et al 1995, Chen et a /1997, Chlichlia 
et a l 1997). CD95-CD95L interactions are involved in physiological regulation of T cell 
responses, but it is uncertain whether this system plays a significant role in ATL (Alderson et 
al 1995, Dhein et a l 1995).
1.8.7.4 Tax and apoptosis
The response of cells expressing Tax to withdrawal of growth factors Is similar to that of cells 
expressing c-Myc. Established (immortalised) rodent fibroblast cell lines undergo growth 
arrest in Go but survive when serum is withdrawn. Expression of c-Myc in the presence of 
serum leads to uncontrolled proliferation (transformation), whereas expression of c-Myc 
under conditions of serum deprivation leads to a reduction in the rate of population increase 
because continued proliferation Is balanced by an Increased rate of apoptosis (Evan et al 
1992) (Sections 1.8.6 and 1.8.7.1). Rati cells transformed by Tax, as well as REFs and 3Y1 
rat fibroblasts expressing Tax, undergo apoptosis when deprived of serum (Sakurai et al 
1992b). This effect Is blocked by Bcl-2 (Yamada et al 1994). The proportion of Rati cells 
expressing Tax that remain in S phase is maintained upon serum deprivation, indicating that 
Tax promotes cell cycle progression in the absence of external growth factors (Yamada et al
1994). Fujita and Shiku (1995) also observed that Rati cells transformed by tax underwent 
apoptosis following deprivation of serum, although the degree of apoptosis was less than 
that observed in Rat1 cells transformed by c-myc or fos. In a manner similar to c-Myc, Tax 
may thus activate pathways leading to either proliferation or apoptosis, depending on the 
availability of survival signals (Section 1.8.7.2). Appropriate survival signals would include 
growth factors such as those present in serum or antl-apoptotic factors such as Bcl-2. 
Conversely, since Tax may up-regulate c-myc (via NFkB) there is a possibility that c-Myc 
could mediate the apoptotic effect of Tax (Koizumi et al 1989, Fujita and Shiku 1993) 
(Section 1.4.6). Fos also induces apoptosis under conditions of serum deprivation and up­
regulation of fos (via CREB/ATF or SRF) could be another indirect mechanism by which Tax 
activates this pathway (Alexandre and Verrier 1991, Colotta ef al 1992, Smeyne et al 1993, 
Preston ef al 1996). which induces apoptosis independent of p53 activity, is also
up-regulated by Tax via NFkB in HTLV-l-infected and Tax-transformed T cell lines (Akagi ef 
al 1996, Cereseto ef al 1996, Gartenhaus ef al 1996, Parker ef al 1996, Low ef al 1997).
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The roles of the CREB/ATF and NFkB pathways in Tax-mediated apoptosis are uncertain. 
Iwanaga et al (1999) provided evidence that the CREB/ATF pathway mediated Tax-induced 
apoptosis, whereas Tax inhibited apoptosis through the NFkB pathway. Tax reduced the rate 
of apoptosis of the IL2-dependent murine T cell line CTLL-2 in the absence of IL2 and this 
effect was maintained by Tax mutants defective for activation of the CREB/ATF pathway, 
whereas Tax mutants with an active CREB/ATF pathway, but defective NFkB pathway, 
accelerated the rate of apoptosis (Iwanaga et al 1999). In contrast, Rivera-Walsh et al 
(2001) showed that Tax-induced apoptosis was mediated by TNF-related apoptosis-inducing 
ligand (TRAIL) acting through the NFkB pathway and that Tax Induces expression of TRAIL 
mRNA. An understanding of the pathways involved in Tax-Induced apoptosis would allow the 
importance of this mechanism In HTLV-I leukaemogenesis to be better defined.
1.8.8 HTLV-I envelope
Proliferation of T cells is stimulated following infection with HTLV-I and also by contact with 
Inactivated virions (Gazzolo and Due Dodon 1987, Martin and Southern 1996, Hôlisberg
1999). Cytokine-receptor loops such as IL2-IL2R appear to be Important components in 
maintaining HTLV-l-induced T cell proliferation (Section 1.8.1.1) but initial activation of 
HTLV-l-infected T cells may be induced by viral gp46^™ and through cell-cell contact 
involving CD2-lymphocyte function-associated antigen (LFA) 3, CD54-LFA1 and CD3-TCR 
Interactions (Wucherpfennig et al 1992, Akagi and Shimotohno 1993, KImata et a /1993, 
Cassé et al 1994, Kim ata et al 1994a). Activation of T cells Increases their permissiveness 
for HTLV-I infection (Section 1.3.2.2). The C terminus of HTLV-I p21^"'' has sequence 
similarity to the EGF receptor but there is no evidence that it plays a role in virus-induced 
proliferation of T cells (Lai 1991).
1.9 Animal models of HTLV-I leukaemogenesis
Animal models used in attempts to understand the pathogenesis of ATL, HAM/TSP and 
other HTLV-l-associated diseases include fax-transgenic mice, natural infections of cattle 
with BLV, natural infections of primates with STLV-I and experimental infections of mice, 
rats, rabbits and primates with HTLV-I.
1.9.1 HTLV-I tax-transgenic mice
Mice transgenic for tax have developed LGL leukaemia, fibroproliferative lesions, epithelial 
neoplasms, Immune-mediated diseases and skeletal abnormalities (Hinrlchs ef al 1987, 
Nerenberg ef al 1987, Furuta ef al 1989, Green ef al 1989, Iwakura ef al 1991, Ruddle ef al 
1993, Grossman ef al 1995). However, T cell neoplasms similar to ATL (Section 1.6.1) have 
not been demonstrated and in some fax-transgenic models there is no increase in the 
frequency of neoplasia (Furuta ef al 1989). The observation of LGL leukaemia in fax- 
transgenic mice Is most significant, since HTLV-I has been associated with this 
lymphoproliferative disorder in humans (Sections 1.10.2 and 1.11.2). in this model, mice 
transgenic for fax under the control of the lymphocyte-specific granzyme B enhancer, 
targeting expression to T, NK and lymphoklne-actlvated killer (LAK) cells, developed LGL
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leukaemia and NK cell tumours of the extremities and lymph nodes (Grossman et al 1995). 
Transgenic mice expressing tax in a wide variety of tissues from the HTLV-I LTR, as well as 
mice with tax expression targeted to T cells by Thy1.2 or CD3-8, frequently develop 
fibroproliferative lesions at sites of trauma, mainly on the extremities (HInrichs et al 1987, 
Nerenberg et al 1987, Coscoy et ai 1998, Hall et al 1998). The lesions are associated with 
peripheral nerves but can be distinguished from neurofibromatosis. Increased frequencies of 
other mesenchymal tumours (fibrosarcomas and lipomas), adrenal adenomas, 
adenocarcinomas of the mammary glands, salivary glands and lungs and fibroproliferative 
lesions of the Iris and ciliary body have also been observed in HTLV-I LTR-fax-transgenic 
mice (Green et al 1992a, Iwakura et al 1994). Rats transgenic for the HTLV-I pX region 
developed mammary adenocarcinomas (Yamada et a /1995). Proliferating cells from LGL 
lymphomas, fibroproliferative lesions and epithelial neoplasms in transgenic mice have high 
levels of expression of Tax, supporting a role for this protein in oncogenesis. However, only 
LGL leukaemia has been associated with HTLV-I infection in humans.
Mice and rats transgenic for tax are also predisposed to development of Immune-mediated 
diseases, similar to conditions associated with HTLV-I Infection in humans (Section 1.6!4). 
Arthritis developed In mice transgenic for the pX region of HTLV-I under control of the HTLV- 
I LTR or the metallothionein promoter (Iwakura et al 1991, Yamamoto et al 1993, Kira et al 
1997, Saggioro et al 1997). Autoantibodies and CTL responses against Tax and Env in joints 
were demonstrated (Iwakura et al 1995, Fujisawa et al 1998). A condition resembling 
Sjogren's syndrome, with proliferation of ductal epithelial cells In salivary, lachrymal and 
Harderian glands In association with infiltration of lymphocytes and plasmacytes, has also 
been observed in HTLV-I LTR-fax-transgenic mice (Green et al 1989, Bieberich et al 1993) 
(Section 1.6.4.6). Lymph nodes adjacent to affected salivary glands were hyperplastic and 
occasionally had métastasés of salivary ductal epithelium (Green et al 1989). Rats 
transgenic for the HTLV-I LTR-env-pX region developed arthritis, polyarteritis, polymyositis, 
myocarditis, sialoadenltls and thymic atrophy, consistent with an immune-mediated 
multisystem disease process (Yamazaki et al 1995). Thymic atrophy and 
immunosuppression in fax-transgenic mice is associated with growth retardation and 
increased mortality from bacterial and parasitic diseases (Hinrichs ef a /1987, Nerenberg ef 
al 1987, Furuta et al 1989, Iwakura ef a /1991, Bieberich et al 1993, Hall et al 1998). Skeletal 
abnormalities In HTLV-I LTR-fax-transgenic mice were characterised by remodelling of bone 
and myelofibrosis due to increased activity of osteoclasts and osteoblasts (Ruddle ef al 
1993, Saggioro ef al 1997).
CD3^ CD4^ CD8" TCLs of the abdominal lymph nodes and CNS neoplasms resembling 
neuroblastomas developed rapidly in 100% of mice co-transgenic for HTLV-I LTR-fax and Ig- 
G-myc (Benvenisty ef al 1992). However, mice transgenic for c-myc alone under the 
Influence of the HTLV-I LTR also developed CD4^ CD8^ T cell or B cell lymphomas In the 
mesenteric lymph nodes. Since in these experiments c-myc expression was driven by the 
HTLV-I LTR, the activity of which is up-regulated In the presence of Tax, It was not possible 
to determine whether Tax cooperated with c-Myc Independently of Its action on the HTLV-I 
LTR.
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1.9.2 Natural animal models o f HTLV-I infection
1.9.2.1 Bovine leukaemia virus
BLV Is an exogenous retrovirus that Infects B cells and causes B cell lymphoma and 
leukaemia (enzootic bovine leucosis, EBL) in naturally infected cattle throughout the world 
(Miller et al 1969, Ferrer et al 1974, Callahan et al 1976, Kettmann et al 1976, Paul et al 
1977, Burny et al 1987). The virus is transmitted by transfer of Infected cells In blood and 
milk (Ferrer et al 1981 ). In Infected cattle polyclonal proliferation of B cells (persistent 
lymphocytosis) is induced in the early stages of infection, followed by oligoclonal or 
monoclonal expansion of neoplastic B cells (Kettmann et al 1980). B cell neoplasia develops 
in sheep infected with BLV experimentally (Kenyon et al 1981). Transformed B cell lines 
containing integrated BLV provirus can be established from infected cattle. BLV also infects 
and transforms fibroblasts (Onuma et a l 1981, Rhim et al 1983). Seroepidemlological and 
molecular studies have failed to confirm BLV Infection In humans or Implicate BLV in human 
neoplasia (Burridge 1981, Donham et al 1987, Bender et a! 1988, Maruyama et al 1989).
BLV is structurally similar to HTLV-I and contains genes in the pX  region that express Tbxblv 
and RexsLv. as well as accessory proteins R"‘ and (Sagata et al 1985, Rosen et al 1986, 
Willems et al 1987, Jensen e ta l 1991, Haas et al 1992, Alexandersen et al 1993, Willems et 
al 1994). Kettmann et al (1982) found that defective BLV proviruses were frequent In EBL, 
with preferential retention of the pX  region, similar to HTLV-I in ATL. Other studies have 
reported conservation of complete BLV provirus with infrequent occurrence of deletions 
(Tajima et al 1998). Taxeiv immortalises B cells and cooperates with Ras in transformation of 
primary REFs, although it may not be necessary for maintenance of the transformed 
phenotype (Willems et al 1990, 1992, Twizere et al 2000). G'^ also cooperates with Ras In 
transforming primary REFs and Inducing tumours In athymic mice (Kerkhofs et a /1998).
1.9.2.2 Simian T lymphotropic viruses
STLV-I has been serologically associated with lymphomas In a variety of species of non­
human primates (Homma et al 1984). ATL-like leukaemia with monoclonal Integration of 
STLV-I has been described in African green monkeys {Cercopithecus aethiops) (Tsujimoto 
et al 1987). In captive colonies of baboons {Papio hamadryas) there is a high prevalence of 
STLV-I infection and most animals with TCLs are seropositive for STLV-I (Moné et al 1992, 
Voevodin et al 1996). STLV-I I does not appear to be associated with T cell neoplasia in 
monkeys.
1.9.3 Experimental animal models o f HTLV-I infection
Animals susceptible to experimental Infection with HTLV-I include rabbits, rats, mice and 
primates (Miyoshi et al 1985, Suga et al 1991, Kazanji et al 1997b, Fang et al 1998). HTLV-I 
infects and transforms rabbit and non-human primate T cells, as well as a variety of different 
cell types from these and other species (Miyoshi et a /1982, 1983). Genetic background 
appears to be an important determinant of susceptibility to infection and disease (Kazanji et 
al 1997a). Among several strains of rats infected experimentally with HTLV-i, only those
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derived from the WKAH strain develop ATL-like or HAM/TSP-like disease (Ishiguro et al
1992, Oka et ai 1992, Kushida et al 1994). Mesenchymal tumours and polyarthritis have also 
been observed in experimentally infected rats (Kira e ta l 1997) (Sections 1.6.4.3 and 1.9.1). 
Rabbits infected with HTLV-I develop ATL-like T cell leukaemia and CTCL (Seto et ai 1988, 
Simpson et al 1996). A rhesus macaque {Macaca mulatta) developed polyarthritis, uveitis 
and polymyositis following infection with HTLV-I (Beilke et al 1996) (Section 1.6.4). However, 
HTLV-I infection of non-human primates is not a useful model for ATL, since neoplasia is 
likely to be an infrequent and delayed consequence of experimental exposure (Kazanji
2000). CD4^ TCLs of human origin can be established in severe combined 
immunodeficiency (SCID) mice by inoculation of PBMCs from ATL patients (Feuer et al
1993, Kondo efa/1993).
1.10 T cell and natural killer cell neoplasms
The International Lymphoma Study Group Revised European-American Lymphoma (REAL) 
classification is used in this thesis for terminology relating to T cell and natural killer (NK) cell 
neoplasms (Harris et al 1994), with reference to Willemze et a /(1997) for specific 
classification of cutaneous T cell lymphomas (CTCLs) (Table 1.5). HTLV-I and related 
retroviruses have been associated with ATL (Sections 1.6.1 and 1.11), CTCLs (particularly 
MF/SS, cutaneous CD30^ ALCL and angiocentric TCL) and LGL leukaemia. CTCLs are 
neoplasms of T cells that primarily involve the skin. The epidemiology, clinicopathological 
features and pathogenesis of these neoplasms will be described in this section. The biology 
of acute lymphoblastic leukaemia (ALL), small plaque parapsoriasis, Langerhans cell 
histiocytosis (LCH) and cutaneous B cell lymphoma (CBCL) will also be described. These 
entities are included in the differential diagnosis of ATL and CTCL and were among cases 
from which samples were received for laboratory examinations described in Chapters 2 and
3.
1.10.1 Mycosis fungoides/Sézary syndrome
Alibert (1806) introduced the term mycosis fungoides (MF) to describe a mushroom-shaped 
tumour of the skin that developed following a rash. MF is now established as a distinct 
clinicopathological entity. Sézary and Bouvrain (1938) described the syndrome of 
erythroderma, leukaemia and lymphadenopathy that has become known as Sézary 
syndrome (88) and is now considered to be the leukaemic form of MF (Edelson 1980).
1.10.1.1 Epidemiology
MF/88 occurs sporadically and there is limited evidence for case clustering or areas of 
endemicity. The incidence of reported cases of MF/88 per 100,000 population per year is
0.13 to 0.14 in Europe and Australia and 0.29 in the U8A (Weinstock and Horm 1988); 0.9 
cases per 100,000 per year were reported in a more intensive, localised study in Minnesota, 
U8A (Chuang et al 1990). About 15% of cases of MF/88 are classified as 88. The median 
age of onset of skin lesions is 51 years; only a small proportion of cases appear during 
childhood or in young adults (Zackheim et al 1997). The male:female adjusted ratio is 2:1 to 
3:1 (Weinstock and Horm 1988, Chuang et al 1990). A trend to increasing incidence of
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reported cases has been observed (Weinstock and Reynes 1999). MF and other lymphoid 
neoplasms have occasionally been observed in relatives of patients with MF/SS (Greene et 
al 1982). Cohen et al (1980) identified an increased risk for MF in people employed in the 
manufacturing or construction industries, especially in petrochemical, textile, metallurgical 
and mechanical occupations, whereas other studies have not confirmed these associations 
(Tuyp et a /1987, Whittemore et a /1989).
1.10.1.2 Clinical and pathological features
MF is a slowly growing neoplasm, usually affecting adults, characterised by infiltration of the 
skin with neoplastic T cells exhibiting marked epidermotropism. in the early stages of MF 
neoplastic T cells infiltrate the epidermis with a band pattern (lichenoid reaction, vacuolar 
interface dermatitis), sometimes forming intraepidermal clusters (Pautrier’s microabscesses) 
(Shapiro and Pinto 1994). Patches, plaques and nodules (tumours) are formed as the 
disease progresses and there is involvement of lymph nodes and viscera in the advanced 
stages (Vonderheid et al 1994). S3 is a leukaemia characterised by erythroderma, 
lymphadenopathy and leucocytosis, with neoplastic T cells circulating in the peripheral blood 
(Matutes ef al 1990). Neoplastic lymphocytes infiltrate the skin in SS but may have less 
marked epidermotropism than in MF (Trotter ef al 1997, Kamarashev ef al 1998). Clinical 
erythroderma without a histologically distinct neoplastic infiltrate often precedes MF (Bakels 
ef al 1991 ). A rare "tumeur d’emblée” form of MF presents as tumours with no apparent 
premycotic or plaque stages and has a rapidly progressive course (Blasik ef al 1982). Other 
variants of MF include spongiotic/vesicular, bullous, follicular/mucinous, pustular, 
granulomatous and verrucous forms, as well as cases with altered pigmentation of the skin 
(LeBoit 1991).
The neoplastic cells infiltrating the skin in MF, circulating in the peripheral blood in 88 and 
infiltrating lymph nodes in advanced forms of the disease are T cells that are similar 
morphologically and immunologically and are termed MF/Sézary cells (Zucker-Franklin ef al 
1974). These are round cells with highly convoluted (cerebriform) nuclear contours (Lutzner 
ef al 1971). Transformation of neoplastic T cells to a large cell morphology characteristic of 
anaplastic large cell lymphoma (ALCL) occurs in some late stage cases of MF and 88 
(Salhany ef al 1988, Wood et a l 1993) (Section 1.10.3).
1.10.1.3 Immunology
MF/8ézary cells usually have a committed memory helper-inducer phenotype: CD2'", CD3'", 
CD4^, CD5^, CD8', CD7', CD25', GD30' and GD49^, with expression of TGR a|3 or yô surface 
antigens and the LGA null isoform (GD45RO) (Waldmann ef al 1984, Nasu ef al 1985,
Michle ef al 1989, Wood ef al 1990a, Boehncke ef al 1993, Bagot ef al 1996, Barzilai ef al 
1996, Willemze ef a /1997). Gases of MF with GD8'' phenotype have been identified 
(Agnarsson ef al 1990). T cell markers may be lost with progression of MF/88. In functional 
studies, PBMGs from some MF/88 patients exhibit Th activity, whereas in other patients Ts 
activity is predominant or there is a lack of effector activity (Berger ef al 1979, Miedema ef al 
1984, Golstein ef a /1986).
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Table 1.5: Classification of T cell and natural killer cell neoplasms (Harris et al 1994).
Precursor T cell neoplasm
1. Precursor T-lymphoblastic lymphoma/leukaemia 
Peripheral T cell and natural killer cell neoplasms
1. T cell chronic lymphocytic leukaemia/prolymphocytic leukaemia
2. Large granular lymphocytic leukaemia
Large granular lymphocytic leukaemia, T cell type 
Large granular lymphocytic leukaemia, NK cell type
3. Mycosis fungoides/Sézary syndrome
4. Peripheral T cell lymphomas, unspecified 
Medium-sized cell peripheral T cell lymphoma*
Mixed medium-sized and large cell peripheral T cell lymphoma  ^
Large cell peripheral T cell lymphoma *
Lymphoepithelioid cell (Lennert’s lymphoma)*
Hepatosplenic yô T cell lymphoma*
Subcutaneous panniculitic T cell lymphoma*
5. Angioimmunoblastic T cell lymphoma
6. Angiocentric T cell lymphoma
7. Intestinal T cell lymphoma (+/- enteropathy associated)
8. Adult T cell lymphoma/leukaemia, HTLV-F
9. Anaplastic large cell lymphoma, CD30^
Anaplastic large cell lymphoma, T cell type 
Anaplastic large cell lymphoma. Null cell type
10. Anaplastic large cell lymphoma, Hodgkln’s-like*
* Provisional entities
• >
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It has been suggested that the cytokine profile of neoplastic T cells is predominantly Th1 in 
MF and Th2 in SS (Saed et al 1994, Lee et a /1999), but other studies support a Th2 profile 
in both MF and SS (Vowels efa/1992, Tendler ef a/1994, Vowels ef al 1994, Dummer ef al
1996). Naïve (ThO) CD4^ T cells are induced by IL12 to differentiate into Thi cells, which 
produce IFNy, or by IL4 to differentiate into Th2 cells, which produce IL4, IL5 and IL13 
(Abbas ef al 1996). Since these cells have different roles in the regulation of immune 
responses, hypotheses as to the pathogenesis of MF/SS are restricted by uncertainty about 
the functional categorisation of the neoplastic cells.
Immunological abnormalities observed in patients with advanced MF/SS include decreased 
responsiveness of T cells to antigens and mitogens, decreased NK cell activity, decreased 
LAK cell activity, eosinophilia and increased serum IgE and IgA (Wood ef al 1990b). In SS 
there is a marked reduction in the number of non-neoplastic T cells In the peripheral 
circulation (Heald ef al 1994) and an associated immune deficiency may be responsible for 
secondary infections in MF/SS patients (Axelrod ef al 1992). An MHC-l-restricted cell- 
mediated immune response against neoplastic T cells has been observed in MF/SS patients 
(Berger ef al 1996). An infiltrate of activated cytotoxic CD8^ and CD4^ T cells accompanies 
the neoplastic CD4^ infiltrate in the early stages of MF/SS but decreases with advancement 
of disease, as does the proportion of activated CD8^ T cells in the peripheral blood (Wood ef 
al 1994a, Asadullah ef al 1997). Some authors have reported restricted use of TCR Vp 
epitopes by neoplastic T cell clones in MF, suggesting that exposure to a common antigen, 
such as a bacterial superantigen or persistent viral antigen, could contribute to chronic T cell 
activation and proliferation in MF (Potoczna ef al 1996), but others have shown that a variety 
of Vp genes are used (Longley ef al 1995, Bigler ef al 1996).
1.10.1.4 Molecular and genetic characteristics
The neoplastic character of MF/SS has been confirmed by the detection of clonal TCR p or y 
gene rearrangements in skin, PBMCs and lymph nodes (Weiss ef al 1985b, Whittaker ef al
1991). Clonality in MF/SS has also been demonstrated by cytogenetic studies but no 
consistent karyotypic abnormalities have been identified (Edelson ef al 1979, Nowell ef al 
1982, Johnson ef al 1985). Mutations, rearrangements or deletions involving lyt~10, p53 or 
ta ll have been observed in some cases of MF/SS but their pathogenetic role is uncertain 
(Thakur ef al 1994, Neri ef al 1995). Mutations in p53 develop during neoplastic progression, 
being found in one third of patients with tumour stage MF but not in patients with plaque 
stage MF (McGregor ef al 1999).
1.10.1.5 Pathogenesis
In models of the development of MF/SS a multistage progression of oncogenic events has 
been hypothesised (Lessin ef a /1994). Acute to chronic dermatitis with recruitment of a 
polyclonal T cell infiltrate often precedes the development of MF/SS (Sigurdsson ef al 1997). 
The next stage is cutaneous lymphoid hyperplasia, with formation of preneoplastic patches 
in the skin containing polyclonal lymphocytes exhibiting nuclear atypia (Lange Wantzin et al 
1988). Primary neoplasia in the form of plaques is initially localised to the skin, then tumours
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develop in association with erythroderma and there is spread to lymph nodes, viscera and 
peripheral blood (Bunn et al 1980, Toback and Edelson 1985). Transformation of MF to 
ALCL is marked by development of aggressive disease (Wood et al 1993). MF/Sézary cells 
circulate between cutaneous and extracutaneous sites and systemic dissemination of 
neoplastic T cell clones can be demonstrated early in the development of the disease (Miller 
et al 1980, Veelken et al 1995, Muche et al 1997). MF/Sézary cells proliferate most rapidly in 
lymph nodes, with a lower rate of proliferation in the skin and limited proliferation in the 
peripheral blood (Shackney and Schuette 1983, Tu ef a /1994). As disease progresses the 
rate of proliferation increases, while the proportion of cells undergoing apoptosis decreases 
(Kikuchi and Nishikawa 1997). Expression of c-Myc, Ras, Jun, Fos, PCNA and p53 
increases with advancing stages of MF (Kanavaros ef al 1994, Tu ef a /1994, Beylot-Barry ef 
al 1995, Lauritzen ef al 1995, QIn ef al 1999).
Selective expression of adhesion molecules is responsible for the tropism of subsets of T 
cells for the skin, lymph nodes and other tissues and may explain the distribution of cellular 
infiltrates at different stages of MF/SS (Miller ef al 1980, Borowitz ef al 1993, Campbell and 
Butcher 2002). CD54, induced on kératinocytes and dermal endothelial cells by T cell- 
derived IFNy and TNFa, binds to CD11a/CD18 (LFA1) expressed by T cells, including those 
in MF (Vejtsgaard ef a /1989, I maya ma ef al 1992, Uccini ef al 1993). This interaction 
appears to be necessary but not sufficient for epidermotropic behaviour. Loss of CD54 
expression by kératinocytes due to reduced IFNy expression by neoplastic T cells may 
permit systemic dissemination in SS (Nickoloff ef al 1989). CD62E (E-selectin, endothelial 
leucocyte adhesion molecule 1, ELAM1), which is expressed by dermal endothelial cells, 
particularly in inflamed skin, is one of the ligands for cutaneous lymphocyte-associated 
antigen (CLA), a carbohydrate epitope induced on CD62P (P-selectin) glycoprotein ligand 1 
(PSGL1) in T cells, including those infiltrating the skin in MF (Fuhlbrigge ef al 1997, Tietz ef 
al 1998). CLA, which acts as a skin homing receptor, is expressed on CTCLs but is absent 
from nodal TCLs (Picker ef al 1990, Noorduyn ef al 1992). Similarly, integrins a3pi, a5pi 
and a (^37, which act as extracellular matrix receptors, are expressed by epidermotropic T 
cells in MF but are absent from circulating MF/Sézary cells in SS (Savoia ef al 1992, 
Simonitsch ef al 1994). Most cases of MF lack expression of CD62L (L-selectIn, peripheral 
lymph node homing receptor), whereas expression of CD62L has been associated with the 
involvement of lymph nodes by CTCL (Wood ef al 1990a, Borowitz ef al 1993). MHC-II, the 
ligand for CD4, is expressed by kératinocytes and other cells in lesional skin in MF/SS, but is 
not correlated with the presence of epidermal lymphocytes (Wood ef al 1994b). IFNy- and 
TNFa-inducible proteins (IPs) IP9, IP10 and monokine induced by IFNy (MIG), which are 
chemotactic for CD4"^  T cells, are expressed by epidermal kératinocytes in MF/SS lesions 
and may also contribute to the epidermotropism of MF/Sézary cells (Daliani ef a /1998, 
Tensen e ta l 1998).
Abnormal production of cytokines by MF/Sézary cells, kératinocytes or antigen presenting 
cells (APCs) may contribute to the proliferation and distribution of neoplastic T cells in 
MF/SS, Increased expression of IL1, IL5, IL6, GMCSF, IFNy, TNFa, TGFa and EGF have 
been detected in MF (Kupper ef al 1988, Lawlor ef al 1990, Hansen ef al 1991, Vowels ef al 
1992, Tendler ef a /1994, Dummer ef al 1996, Asadullah ef al 1998, Daliani ef al 1998,
' I
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Courville et al 1999). IL4, IL10 and IL15 expression may increase with progression of MF 
(Vowels et al 1994, Asadullah et al 1996a, 2000). The response of MF/Sézary cells to 
cytokines is discussed in Section 2. Little is known about the expression of receptors for 
these cytokines. Neoplastic T cells in MF express both CD28 and its ligand CD80, providing 
the opportunity for self-costimulation (Nickoloff et al 1994). Rook et al (1993) hypothesised 
that IFNy production by tumour infiltrating lymphocytes (TILs) responding to the neoplastic 
infiltrate exceeds IL4 production by MF/Sézary cells in the early stages of MF, decreasing 
the rate of expansion of the population of neoplastic cells and promoting epidermotropism 
through induction of CD54 on kératinocytes. Eventually the population of neoplastic cells 
reaches a size at which IL4 production counteracts the production and biological activity of 
IFNy, leading to reduced expression of CD54 by kératinocytes, loss of epidermotropism with 
systemic dissemination of neoplastic cells and reduced anti-neoplasm immunity.
Rowden and Lewis (1976) proposed that persistent antigenic stimulation was responsible for 
the abnormal T cell proliferation in MF/SS. APCs, including Langerhans cells and 
interdigitating cells, are present among the neoplastic T cell infiltrate (Tjernlund 1982). 
Langerhans cells have been shown to contribute to epidermotropism of T cells (Shiohara et 
al 1988). It has been hypothesised that retroviral infection of Langerhans cells leads to 
chemotaxis or retention of T cells in the epidermis (MacKie 1981, Slater et al 1985, Lessin et 
al 1994). Chronic stimulation of this population would eventually lead to the selective 
outgrowth of a neoplastic T cell clone. Alterations in the morphology of Langerhans cells and 
increased interactions between Langerhans cells and MF/Sézary cells have been described 
in MF (Rowden et al 1979, Füllbrandt et al 1983). In contrast, Bani et al (1990) observed that 
MF/Sézary cells were frequently associated with interdigitating cells in the epidermis, but 
rarely made contact with Langerhans cells. However, most evidence incriminating 
retroviruses in CTCLs is focussed on infection of neoplastic T cells by HTLV-I or related 
viruses and a direct involvement of such viruses in oncogenesis (Dosaka et al 1991, Hall et 
al 1991) (Section 1.11). In addition, the density of Langerhans cells is increased in the 
dermis and epidermis in plaque stage MF, but may decrease with progression to tumour 
stage lesions, indicating that Langerhans cells could play a role in suppression of CTCLs 
rather than facilitating progression (Igisu et a /1983, Meissner et a /1993).
1.10.2 Large granular lymphocytic leukaemia
Large granular lymphocytic (LGL) leukaemia is defined as a clonal increase in the number of 
circulating large granular lymphocytes (LGLs) and may be of T cell or NK cell phenotype 
(Loughran et al 1985, Chan et al 1986, Loughran 1993). A chronic proliferation of LGLs that 
cannot be proven to be clonal is referred to as lymphoproliferative disease of LGLs 
(LDLGLs) (Pandolfi et al 1990, Scott et al 1993, Semenzato et al 1997). Synonyms for LGL 
leukaemia include chronic T cell lymphocytosis with neutropaenia, T cell CLL and Ty 
lymphocytosis/lymphoproliferative disorder (Brouet et al 1975, Aisenberg et al 1981, 
Reynolds and Foon 1984). Hypotheses regarding the aetiology of CD3^ and CDS' LGL 
leukaemia have included infection by retroviruses, activation by antigens, stimulation by 
cytokines and accumulation of mutations (Loughran 1993). Evidence for the involvement of 
viruses in LGL leukaemia is discussed in Section 1.11.
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1.10.2.1 Large granular lymphocytic leukaemia, T cell type
T cell LGL leukaemia is a clonal disorder of CD3^ cells with LGL morphology and is 
associated with chronic neutropaenia, anaemia, splenomegaly, recurrent bacterial infections 
and rheumatoid arthritis or other autoimmune diseases (Loughran et al 1985, Loughran 
1993, Scott efa/1993). Neoplastic lymphocytes have abundant, pale blue cytoplasm, 
azurophilic granules, an eccentric nucleus with moderately condensed chromatin and an 
inconspicuous nucleolus. The immunophenotype is usually CD2"', CDS’", CD4‘, CD7', CDS'", 
CDie"", CD25" and CD56", although CD4" CD8‘ and CD4'" phenotypes have been
observed (Pandolfi ef al 1991, Richards ef al 1992). Most cases are TCR ap"" but TCR yô”" 
expression has been reported (Foroni ef al 1988, Loughran ef al 1988a). Clonality has been 
demonstrated by cytogenetic studies (Loughran ef al 1985, McKenna ef al 1985) and 
detection of clonal rearrangements of the TCR p or y genes (Pelicci ef al 1987, Pandolfi ef al 
1991, Scott ef a /1993).
1.10.2.2 Large granular lymphocytic leukaemia, natural killer cell type
The clinical features of NK cell LGL leukaemia, a clonal disorder of CD3" CD56^ cells, are 
hepatomegaly, splenomegaly, anaemia and thrombocytopaenia, along with fever, night 
sweats and/or weight loss (B symptoms) (Sheridan ef al 1988, SIvakumaran ef al 1996). The 
immunophenotype is usually CD2"^ , CD3', CD4", CD8", CD16^, CD56^ and CD57'. NK activity 
has been demonstrated in leukaemic cells (Loughran ef al 1987). There is no expression or 
rearrangement of the TCR or immunoglobulin genes (McKenna ef al 1985, Loughran ef al 
1988a, Biondi e ta l 1989). Clonality has been confirmed in some cases by demonstration of 
clonal cytogenetic abnormalities or clonal X-linked inactivation of the phosphoglycerate 
kinase gene (Sheridan ef al 1988, Tanlwaki ef al 1990, Nash ef al 1993, Kelly ef al 1994). 
Cases of CD3' CD56^ LDLGLs in which clonality cannot be demonstrated usually have a less 
aggressive clinical course.
1.10.3 CD30* anaplastic large cell lymphoma
CD30'" anaplastic large cell lymphomas (ALCLs) are aggressive solitary or multiple tumours 
that In the primary systemic form have a bimodal age distribution and involve lymph nodes, 
skin, bone or soft tissues (Agnarsson and Kadin 1988, Kaudewitz ef al 1989, Paulli ef al
1995). Primary cutaneous CD30^ ALCLs, although indolent, limited to the skin and 
occasionally spontaneously regressing, paradoxically are often difficult to treat (Beljaards ef 
al 1993, Paulli ef a /1995, Willemze et al 1997). Secondary CD30^ ALCLs appear to be 
derived following transformation of MF, other TCLs or Hodgkin’s disease (Salhany ef al 
1988, Wood ef al 1993) (Section 1.10.1.2). In a patient with MF and cutaneous ALCL, CD30"  ^
T cells in spontaneously regressing tumours were derived from the same clone as 
MF/Sézary cells in patch stage MF lesions (Woodrow ef al 1996). CD30^ ALCLs are 
composed of large pleomorphic lymphoid cells with abundant cytoplasm and horseshoe­
shaped or wreath-like nuclei with prominent nucleoli, along with multinucleated Reed- 
Stern berg-like cells. Inflammatory leucocytes may infiltrate the involved tissue. CD30 is a 
marker of activation and CD30^ ALCLs variably express other activation markers such as
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CD25, MHC-II and CDw70 (Kaudewitz et a l 1989). The origin of the neoplastic cell is 
uncertain, since CD30^ ALCLs have been classified as having T cell, B cell or immature 
phenotype. Most cases of primary cutaneous CD30"' ALCL appear to be of T cell origin; 95% 
or more are CD4'" and 5% or less are CD8^, with variable expression of pan T cell antigens 
(CD2, CD3, CD5) (Kaudewitz e ta l 1989, Beljaards e ta l 1993, Willemze et al 1997). Primary 
systemic CD30'" ALCLs often express epithelial membrane antigen (EMA) and are negative 
for CLA, whereas most cases of primary cutaneous CD30'" ALCL are CLA^ and EMA" (De 
Bruin et al 1993). Clonal rearrangements of TCR genes are found in 50 to 60% of primary 
systemic CD30^ ALCLs; most cases of primary cutaneous CDOO”" ALCL also have clonal 
TCR gene rearrangements (Herbst et al 1989, Banerjee et a /1991 ). Many T cell and null cell 
primary systemic CD30^ ALCLs have the chromosomal translocation t(2;5)(p23;q35), which 
conjoins the nucleophosmin (A/PM) and anaplastic lymphoma kinase (ALK) genes (Morris et 
al 1994). This translocation does not appear to be present in most primary cutaneous CD30^ 
ALCLs (De Coteau et a /1996, Li et al 1997). The role of EBV in the aetiology of CD30^
ALCL is described in Section 1.11.3.1 and evidence for the involvement of HTLV-I in this 
entity is described in Section 1.11.1.7.
1.10.4 Angiocentric T cell lymphoma
Angiocentric TCLs are extranodal T cell neoplasms associated with blood vessels that 
frequently involve the nasopharyngeal region, lung and skin (Lipford et al 1988, Kanavaros 
et al 1993, Kato et al 1999). The nasopharyngeal/sinonasal form is also known as lethal 
midline granuloma or polymorphic reticulosis (Gaulard et al 1988, Strickler et al 1994). Blood 
vessels are surrounded and invaded by pleomorphic neoplastic lymphocytes, sometimes 
with a predominance of large cells, and frequently there is an associated inflammatory 
infiltrate, along with ischaemic necrosis. The immunophenotype is CD2‘", with variable 
expression of CD3, CD4, CD5, CD7 and CD8, indicating a T cell origin; however the 
neoplasms can also be CD3" CD56^, consistent with a NK cell phenotype. TCR p gene 
rearrangements have been detected in angiocentric TCLs of T cell type (Gaulard et al 1988). 
There are usually no clonal rearrangements or expression of TCR or immunoglobulin genes 
in the NK cell type, but clonality has been confirmed by karyotypic studies (Emile et al 1996, 
Tien et al 1997). EBV has been aetiologically associated with the nasopharyngeal/sinonasal 
form of angiocentric TCL (Section 1.11.3.1) and some groups have associated limited 
numbers of cases of angiocentric TCL with HTLV-I infection (Section 1.11.1.7). The 
neoplastic infiltrate in cutaneous ATL may have an angiocentric distribution with necrotising 
vasculitis (Haynes et al 1983, Manabe et al 1988).
Lymphomatoid granulomatosis is also an angiocentric immunoproiiferative condition that 
may involve the lungs or skin and in most cases appears to be a form of angiocentric TCL 
(James et al 1981, Kessler et al 1981, Gaulard et al 1988, Whittaker et al 1988). However, 
some pulmonary cases express B cell antigens, have clonal immunoglobulin gene 
rearrangements and contain EBV genomes, so represent proliferations of EBV-infected B 
cells (Nicholson et al 1996).
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1.10.5 Acute lymphoblastic leukaemia
Acute lymphoblastic leukaemias (ALLs) are aggressive clonal proliferations of T or B cell 
lineage lymphoid cells with heterogeneous morphological, immunophenotypic and 
cytogenetic characteristics (Harris et a! 1994, Copelan and McGuire 1995, Kersey 1997). 
Neoplastic lymphoid cells circulate in the blood and infiltrate tissues. ALL is over-represented 
as a neoplasm of childhood, with a peak in incidence at 2 to 5 years of age. The incidence in 
children under 15 years of age in the USA is approximately 30 cases/million/year (Young et 
al 1986). The incidence in adults is one third of this figure but exhibits a second peak at 50 
years of age followed by an increasing incidence with age. In paediatric and adult ALL, 
approximately 85% of cases are of precursor-B (pre-B) or B cell type and 15% of T cell type 
(Copelan and McGuire 1995, Kersey 1997, Khalidi e ta ! 1999). B cell ALLs express surface 
GDI 9 and include B-precursor (early pre-B) ALL (expressing cytoplasmic GD22 and nuclear 
terminal deoxynucleotidyl transferase), common ALL (expressing surface GD10), pre-B ALL 
(expressing cytoplasmic immunoglobulin heavy chains) and B-ALL (expressing surface 
immunoglobulin) (Janossy et a! 1989, Copelan and McGuire 1995) (Table 1.6). T cell ALLs 
have cytoplasmic expression of CDS and include precursor-T (pre-T) ALL (GD7"‘) and T-ALL 
(GD7^, GD2'"). Null ALL predominates in infants (less than 1 year of age), common ALL is 
predominant in children 1 to 7 years of age and T cell ALL is proportionally high in 
adolescents and young adults (McKinney et a! 1993).
Glonality in ALL has been demonstrated by cytogenetic analysis, X-linked inactivation of 
glucose-6-phosphate dehydrogenase and analysis of immunoglobulin and TGR gene 
rearrangements (Williams et a! 1985, Dow et a /1985, Khalidi et a /1999). The earlier stage B 
and T cell ALLs have partial or incomplete rearrangements of immunoglobulin receptor and 
TGR genes, respectively. Up to 5% of children and approximately 30% of adults with ALL 
have a Philadelphia chromosome (shortened chromosome 22) due to a t(9;22)(q34;q11) 
translocation that results in production of abnormal proteins, p190^ '^^ "'^ '^ or p210^ "^^ "*^ ', with 
increased PTK activity (Chan et a! 1987, Kurzrock et a! 1987, Faded et a! 1998). Most 
Philadelphia positive cases have the phenotype of B cell ALL, but appear to be derived from 
a pluripotential stem cell; mixed lineage leukaemia may occur (Secker-Walker et a! 1991, 
Gopelan and McGuire 1995, Schenk et a! 1998). A wide range of other numerical and 
structural chromosomal abnormalities have been observed (Faded et a! 1998, Kersey 1997). 
Translocations frequently generate oncogenic fusion proteins or result in deregulated 
expression of transcription factors. These include immunoglobulin H, k  or X-c-myc and TEL- 
AML1 in B cell ALL and TGR ^-T A L I or TGR a-c~myc in T cell ALL (Groce and Nowell 1985, 
Nakamura et a! 1993, Kersey 1997, Wiemels and Greaves 1999). The translocation 
t(4;11)(q21;q23) conjoining MLL and AF-4 occurs in approximately 60% of infants with ALL, 
as well as in 2% of older children and 3 to 6% of adults (Pul et a! 1991, Biondi et a! 2000). 
Some cases of childhood ALL are initiated in utero (Wiemels et a! 1999). Patients with ataxia 
telangiectasia have an increased risk of developing T cell ALL (Toledano and Lange 1980).
Geographical and temporal clustering of childhood ALL cases in the UK and elsewhere has 
been suggested as evidence for an infectious cause (Kinlen 1988, Gartwright et a! 1990, 
Kinlen et a! 1990, Alexander 1992, Alexander 1993, Gilman et a! 1999, Birch et a! 2000).
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Table 1.6: Immunophenotypes of acute lymphoblastic leukaemias
(Copelan and McGuire 1995).
Leukaemia Surface 
type markers
Cytoplasmic
markers
Nuclear
markers
B cell acute lymphoblastic leukaemia
Early Pre-B ALL GDI9 GD22 TdT
Common ALL GDI 9, GD10 GD22 TdT
Pre-B ALL GD19 Ig TdT
B-ALL GDI 9, GD22, ig - -
T cell acute lymphoblastic leukaemia
Pre-T GD7 CDS TdT
T-ALL GDI, GD2, GD3,
GD4, GD7, GD8
TdT
ALL Acute lymphoblastic leukaemia
CD Cluster of differentiation
Ig Immunoglobulin
TdT Terminal deoxynucleotidyl transferase
Pre Precursor
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Studies using PGR with specific, consensus or degenerate primers have so far failed to 
implicate herpesviruses, polyomaviruses or parvovirus B19 as the cause of common ALL in 
children (Luka et al 1991, Gentile et al 1999, Heegaard et al 1999, MacKenzie et al 1999, 
Smith et al 1999, MacKenzie et a /2001). ATL can be distinguished from T cell ALL on the 
basis of clinlcopathological features, particularly the presence of hypercalcaemia and lytic 
bone lesions, and the presence of HTLV-I infection.
1.10.6 Small plaque parapsoriasis
Small plaque parapsoriasis is a chronic dermatosis characterized by patches on the trunk 
and extremities that often resolve spontaneously (Harris et al 1994, Haeffner et al 1995). 
Histopathological examination reveals a mild superficial perivascular lymphocytic infiltrate 
composed of GD4'' T cells admixed with GD8’" T cells, Langerhans cells/indeterminate cells 
and macrophages, associated with mild spongiosis and parakeratosis. Both dominant clonal 
and polyclonal T cell populations have been demonstrated (Haeffner et al 1995).
1.10.7 Langerhans cell histiocytosis
Langerhans cell histiocytosis (LGH, histiocytosis X) is characterised by cutaneous 
infiltrations of Langerhans cells that contain Birbeck granules, express S-100 and GD1a and 
may have aberrant expression of GD2, GD3, GD54 and GD58 (LFA-3), consistent with an 
activated state (Ben-Ezra and Koo 1993, Hage et a /1993, De Graaf et al 1994, Emile et al 
1994). As well as cells with histiocytic morphology, lesions contain giant cells, macrophages, 
neutrophils, eosinophils, lymphocytes, plasma cells and occasional mast cells. Using PGR 
and ISH, 56 cases of LGH in the USA were negative for HTLV-I, HTLV-I I, HIV-1, EBV, 
herpes simplex virus (HSV) type 1, HHV-6, cytomegalovirus, adenovirus and parvovirus 
(McGlain et al 1994). Infiltrating histiocytic cells lack TGR gene rearrangements but clonality 
has been determined by X-linked inactivation studies of the androgen receptor gene and 
with X-linked polymorphic DNA probes, consistent with LGH being a neoplastic proliferation 
(Willman e ta l 1994, Yu efa/1994, Yu and Ghu 1995).
1.10.8 Cutaneous B cell lymphoma
Gutaneous B cell lymphomas (GBGLs) are described here because they represent one of 
the differential diagnoses of GTGL, being characterised by infiltrations of neoplastic B cells in 
the skin (Harris et al 1994, Rijaarsdam and Willemze 1994). They frequently have a follicular 
pattern with formation of nodules but neoplastic B cells may be distributed diffusely through 
the dermis and occasionally exhibit epidermotropism. Immunoglobulin gene rearrangements 
can be detected in most cases (Ghild et a /2001). A small proportion of cases have 
rearrangements in bcl-1, bcl-2, bcl-6 and lyt-10 genes (Neri et al 1995).
Herpesviruses have been excluded as likely aetiological agents in primary GBGL in 
immunocompetent patients (Dupin e ta l 1997, Nagore ef a/2000), although GBGLs in 
acquired immune deficiency syndrome (AIDS) patients may be associated with EBV (Beylot- 
Barry et al 1999), An association between Lyme disease and GBGL has been hypothesised 
(Gerroni et a l 1997); Borrella burgdorferi sequences were detected by PGR in DNA from
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seven (35%) of 20 lesions in Scotland (Goodlad et al 2000). However, further studies are 
required to confirm this relationship. Evidence for the involvement of HTLV-I in B cell 
lymphomas is discussed in Section 1.6.2.1.
1.11 Viral aetiology of cutaneous T cell lymphomas and large granular lymphocytic 
leukaemia
The possibility that HTLV-I or related retroviruses are involved in the aetiology and 
pathogenesis of CTCLs and LGL leukaemia is the main theme of this thesis. This section 
discusses the evidence for retroviral involvement in the aetiology of MF/SS, cutaneous 
CD30^ ALCL, angiocentric TGL and LGL leukaemia.
1.11.1 Human T lymphotropic viruses and cutaneous T ceii lymphomas
1.11.1.1 Epidemiology
The sporadic occurrence and other epidemiological features of MF/SS do not immediately 
support an infectious aetiology (Section 1.10.1.1). ATL and HTLV-I have distinct distributions 
by geographical area and population groups, whereas cases of MF/SS do not exhibit 
clustering and are mostly reported from Europe and the USA, which are not HTLV-I endemic 
regions (Weinstock and Horm 1988). Hjelle et al (1991b) found no difference in the 
incidences of MF between three ethnic groups in the USA with differences in the prevalence 
of HTLV-I I infection. There is little evidence that MF/SS is transmissible (Stratton 1948, 
Grossman and Duvic 1993).
1.11.1.2 Glinicopathological features
The similarity of clinlcopathological features of MF/SS and some forms of ATL is the main 
basis for attempts to search for HTLV-l-related viruses in GTGLs. As discussed in Section 
1.6.1.5, HTLV-I is the cause of ATL. MF/SS and ATL are both GD4^ T cell neoplasms that 
can involve the skin, lymph nodes, viscera and peripheral blood (Nagatani et al 1990). 
Gutaneous involvement occurs in 43 to 72% of patients with ATL and usually takes the form 
of rapid onset, generalised papules with erythaema (Ghan et al 1985, Gibbs et al 1987, 
Maeda and Takahashi 1989, Johno et al 1992). Smouldering ATL is a distinct cutaneous 
form that usually develops slowly, with systemic involvement and leukaemia being a late 
event, similar to most cases of progressive MF (Yamaguchi et al 1983, Jaffe et al 1984, 
Ghan et al 1985, Aral et al 1991, Shimoyama et al 1991). The acute and lymphomatous 
forms of ATL are aggressive diseases; likewise the rare “tumeur d’emblee” form of MF has 
no premycotic phase and has a rapidly progressive course (Blasik et al 1982). The 
hypercalcaemia and lytic bone marrow lesions characteristic of ATL are not observed in 
MF/SS (Nagatani et al 1990).
Whereas MF/SS is epidermotropic, the cutaneous infiltrate in acute ATL primarily involves 
the dermis and subcutaneous tissues, often consists of highly pleiomorphic cells with few 
reactive cells and is sometimes associated with vascular lesions (Hasui et al 1987, Maeda 
and Takahashi 1989, Nagatani et al 1990). However, the pattern of lymphocyte infiltration in
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ATL and MF can be very similar and Pautrier’s microabscesses can be observed in both 
conditions (Nagatani et al 1990, Johno et al 1992). Neoplastic T cells in ATL have 
moderately indented (lobulated) nuclei, whereas MF/Sézary cells have highly indented 
(cerebriform) nuclei (Hasui et al 1987, Maeda and Takahashi 1989, Nagatani et al 1990).
The neoplastic cells in both conditions are usually CD4^ CD7' T cells (Hanaoka 1984, Nasu 
et al 1985, Kamihira et al 1992), although Nagatani et al (1990) observed higher expression 
of CD7 by ATL cells than MF/Sézary cells. In unaffected people approximately 9% of normal 
T cells have a CD7‘ phenotype (Reinhold et al 1993). MF/Sézary cells rarely express CD25 
(or other activation markers) whereas CD25, CD30, CD71, Ki67 and MHC-II are usually 
expressed by ATL cells (Waldmann et al 1984, Maeda and Takahashi 1989, Oishi et al
1994). Transformation of MF to ALCL is also associated with acquisition of CD25, CD30, 
CD71, Ki67 and MHC-II expression (Gerroni et al 1992). ATL and MF/SS share expression 
of cell adhesion molecules, some of which are up-regulated by Tax in HTLV-l-infected T 
cells (Sections 1.6.1.3, 1.8.1.2 and 1.10.1.5). ATL cells exhibit Ts activity (Tendler et al 
1994, Yamada et al 1996), whereas MF/Sézary cells exhibit Th or Ts activity, as discussed in 
Section 1.10.1.3 (Berger et al 1979, Miedema et al 1984, Golstein et al 1986). Immortalised 
and transformed T cell lines infected with HTLV-I can be readily established from ATL cells 
in vitro, usually following the addition of IL2 or GM, whereas MF/Sézary cells, with few 
exceptions, do not proliferate readily under these conditions (Waldmann et al 1984, Abrams 
et al 1991 b, Zucker-Franklin efa/1991) (Chapter 2).
It has been possible to distinguish most cases of MF/SS from ATL using a combination of 
Glinicopathological criteria and the presence or absence of HTLV-I infection (Yamaguchi et al 
1984, Levine et al 1994a). Numerous cases initially classified as MF/SS were reclassified as 
forms of ATL following the discovery of HTLV-I (Poiesz et al 1980a, 1981, Blattner et al 
1982, Blayney et al 1983b, D'Incan et al 1995). Most cases of HTLV-l-associated GTGLs in 
HTLV-I endemic regions such as Japan probably represent cutaneous forms of ATL 
(Amagasaki e ta l 1984, Nakamura e ta l 1993). HTLV-l-infected patients with MF/SS-like 
diseases in non-endemic regions have subsequently developed ATL-like leukaemia, 
supporting an aetiopathological classification as ATL (Bunker et a /1990, Whittaker et al
1993, Fujihara et a /1997). Infiltrating neoplastic T cells in the cutaneous form of ATL contain 
monoclonally integrated HTLV-I provirus and thus may be distinguished from HTLV-I 
negative MF/SS (Takahashi et al 1988, Yamada et al 1989b, Dosaka et al 1991, Arai e ta l
1994, Fouchard et al 1998, Setoyama et al 1998). In some cases of smouldering ATL, clonal 
integration of HTLV-I and rearrangement of the TGR genes may only be found in T cells 
infiltrating the skin, with no evidence of a neoplastic clone in the peripheral blood (Dosaka et 
al 1991, Hamada et al 1992). Rare cases of ATL-like leukaemia do not have evidence of 
HTLV-I infection (Shimoyama et al 1986). Most peripheral T cell and NK cell neoplasms in 
non-endemic regions are not HTLV-l-associated (Henni et al 1990). However, HTLV-I and 
HTLV-I I have still been implicated in a number of cases that conform to the case definition of 
classical MF/SS (Kaplanski et al 1986, Zucker-Franklin et al 1991, 1992, Bazarbachi et al 
1994, Manca et al 1994).
In several early studies retrovirus-like particles were observed by EM and RT activity was 
detected in skin lesions and blood of patients with MF/SS, but it is uncertain if these are 
representative of true retroviruses (Van der Loo 1979, FCillbrandt et al 1983, Slater et al
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1985). Positive immunostaining for HTLV-I pi 9°^^ has been detected in involved skin and 
lymph nodes of patients with CTCL but the specificity of this reactivity is uncertain (Turbitt 
and MacKie 1985).
1.11.1.3 Serology
There is conflicting serological evidence that HTLV-I, HTLV-I I or related viruses are involved 
in MF/SS in non-endemic regions. Although some studies have reported ELISA 
seroreactivities as less than 1% (Posner et al 1981, Gallo et al 1983a), others have reported 
reactivities of 11% (Lange WantzIn et al 1986) and 24% (Srivastava et al 1990). Reactivities 
against HTLV-I by WB ELISA have been reported as 15% (Srivastava et al 1990) and 86% 
(Ranki et al 1990). Interpretation of these results is confounded by the unknown specificity of 
the serological assays used, including their ability to discriminate HTLV-I and HTLV-I I 
(Section 1.4.2). One group reported antibodies against HTLV-I Tax in 10% of MF/SS 
patients who were seronegative for HTLV-I/II structural proteins (Gag and Env) in standard 
serological assays (Pancake ef a /1995) (Section 1.11.1.5).
1.11.1.4 Cell culture
Retrovirus-like particles have been detected by EM and RT activity demonstrated In T cell 
lines propagated from patients with MF/SS (Kaltoft ef al 1984, 1987, Saal ef al 1989, Zucker- 
Franklin et al 1991, Bazarbachi ef al 1994). Reactivity with antiserum against HTLV-I p19®^ ® 
was detected in T cell cultures established from involved skin or lymph nodes of three 
patients with MF using CM and depletion of CD8^ TILs (Kaltoft ef al 1984). Extracellular C- 
type retrovirus-like particles could be induced by withdrawal of serum from a T cell line, Se- 
Ax, derived from a patient with SS, although no budding particles were observed and little or 
no RT activity was demonstrable in cell culture supernatants (Kaltoft ef al 1987). There was 
no evidence of HTLV-I by SB hybridisation (Kaltoft ef al 1988). C-type retrovirus-like particles 
were also observed by EM in cultured PBMCs from a French patient with SS and RT activity 
was detected in culture supernatants (Saal ef al 1989). The patient did not have detectable 
serum antibodies against HTLV-I and DNA from PBMCs was negative for HTLV-I by SB 
hybridisation.
Retrovirus-like particles were detected by EM in 18 cell lines established from PBMCs of 17 
patients with MF and one patient with SS using GMCSF and IL2 as growth stimulants 
(Zucker-Franklin ef al 1991). Molecular evidence suggested that incomplete or variant HTLV- 
I was integrated in four cell lines and HTLV-I I was integrated in one (Zucker-Franklin ef al
1992) (Section 1.11.1.5). However, the viral nature of the observed particles was not 
confirmed, they were not purified and characterised, their infectlvity was not demonstrated 
and RT activity was not reported. HTLV-I tax sequences were also detected by PGR in 20 
(80%) of 25 T cell lines established from PBMGs of SS patients in the USA, whereas all were 
negative for HTLV-I gag (Abrams ef a /1991 b, Ghosh et al 1994) (Section 1.11.1.5).
Retrovirus particles were detected by EM in PBMGs from a SS patient after four months in 
culture and weak RT activity was detected in culture supernatants, but no HTLV-l-related 
antigens could be detected (Bazarbachi ef al 1994). PBMGs from 19 patients with MF/SS
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were grown in culture for approximately three months using phytohaemagglutinin (PHA) and 
IL2 (Capésius et al 1991). No retrovirus particles or budding forms were detected in cultured 
cells by EM and only transient RT activity was detected in culture supernatants, mainly from 
degenerating cultures. No specific HTLV-I products were amplified by PCR from PBMCs 
using primers and probes for HTLV-I gag and pel.
In comparison with the use of molecular techniques on uncultured clinical samples (skin, 
PBMCs and lymph nodes), there have been fewer indications of the presence of retroviruses 
in cultured T cells from patients with MF/SS (Section 1.11.1.5). Only two groups have 
demonstrated the presence of HTLV-I or HTLV-I I sequences in cultured T cells from patients 
with MF/SS (Zucker-Franklin et a l 1992, Ghosh et al 1994).
1.11.1.5 Molecular techniques
HTLV-I or HTLV-I I sequences have been identified in DNA from PBMCs, skin and lymph 
nodes of patients with MF/SS from non-endemic regions and low prevalence populations 
using PCR, SB hybridisation and ISH (Hall et al 1991, Chan et a /1993). The proportion of 
MF/SS cases reported as positive for HTLV-I on the basis of PCR results has been 0% 
(Capésius ef a /1991, Lisby ef al 1992, Bazarbachi ef al 1993), 1 to 2% (D'Incan ef al 1992, 
Lapis ef al 1992), 7.5% (Whittaker and Luzatto 1993), 34% (Manca ef al 1994), 45% (Chan 
ef al 1993) and 92% (Pancake ef al 1995). It is difficult to reconcile these widely differing 
percentages; selected results are detailed here to illustrate the differences among groups 
working in this field.
Hall ef al (1991) detected HTLV-I proviral DNA by PCR in cutaneous lesions of five HTLV-I- 
seronegative Swedish patients with MF using primers for the LTR, gag, pel, env, and pX  
regions. Sequences from all regions were amplified from both PBMCs and cutaneous 
lesions in one patient with leukaemic stage MF, whereas incomplete provirus was identified 
in cutaneous lesions in the other four patients with non-leukaemic MF; one had gag, pel, env 
and pX, one had LTR and gag, one had gag and p X  and one had p X  only.
Zucker-Franklin ef al (1991, 1992) provided evidence for the presence of HTLV-l-related 
viruses in cultured PBMCs from HTLV-I/II seronegative patients with MF in the USA. PCR 
and SB hybridisation results suggested that incomplete or variant HTLV-I proviruses were 
integrated in cultured cells of four of 20 patients with MF (HTLV-I pel or env sequences 
amplified by PCR) and HTLV-I I was integrated in cultured cells of one case (HTLV-I I pel 
sequences amplified) (Section 1.11.1.4). The same group detected HTLV-I tax sequences 
by PCR and RT-PCR in PBMCs from 46 (92%) of 50 MF patients (Pancake et a l 1995). 
These patients were seronegative for HTLV-I/II Gag and Env in standard serological assays 
but five (10%) had antibodies against HTLV-I Tax (Section 1.11.1.3). Two AIDS patients with 
MF also had HTLV-I tax and pe l sequences amplifiable by PCR from PBMCs and skin 
(Zucker-Franklin ef al 1994).
HTLV-I tax sequences were amplified by PCR from PBMCs of 18 (72%) of 25 SS patients 
and three (30%) of 10 skin lesions of MF patients in the USA, whereas no HTLV-I gag or 
HTLV-I I gag or tax sequences were detected (Ghosh ef al 1994).
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HTLV-I gag and pXPCR products of identical sequence to a reference strain of HTLV-I were 
amplified from PBMCs of three of four HTLV-I ELISA positive patients with MF/SS in the 
USA (Srivastava et al 1992). Manca et al (1994) detected HTLV-I pel and tax sequences by 
PCR in 10 (34%) of 29 patients with MF from Italy, confirming these results in a double blind 
trial after a 6 month interval. HTLV-I pel, env and tax sequences were detected by PCR in 
one (2%) of 51 HTLV-I/II seronegative patients with CTCL from France (D'Incan et al 1992) 
and HTLV-I tax sequences were amplified by PCR from one (5%) of 20 patients with MF In 
the USA (Lapis et al 1992).
The wide range of reported frequencies of detection of HTLV-l-related sequences by PCR in 
patients with MF/SS suggests that there are differences in methods between groups and 
possible methodological problems such as PCR contamination. There might also be 
differences In case definitions and selection of cases for inclusion in different studies. If a 
retrovirus is involved in CTCL, it might be distantly related to HTLV-I or HTLV-I I, there might 
be deletions or mutations, it might be present in the skin in quantities below the detection 
limit of PCR or it might have been eliminated from the skin before clinical lesions develop 
(hit-and-run hypothesis) (Lisby et al 1992, Lessin et al 1994).
1.11.1.6 Defective viruses
Incomplete or variant HTLV-l-related viruses have been identified in patients with MF/SS on 
the basis of PCR, variant restriction endonuclease (RE) patterns on SB hybridisation and 
sequencing (Hall ef a/1991, Zucker-Franklin e ta l 1991, Srivastava e ta l 1992, Kiss et al 
1993, Whittaker and Luzzato 1993, Bazarbachi et al 1994, Ghosh et al 1994, Pancake et al
1995). The basis for declaration of incomplete or variant HTLV in samples analysed by PCR 
has been the amplification of HTLV-I or HTLV-I I sequences from some regions of the 
genome, with other regions of the genome being negative (Section 1.11.1.5). The p X  region 
appears to be retained preferentially and tax sequences have been detected more frequently 
than sequences of other genes (Hall et al 1991, Zucker-Franklin et al 1991, Srivastava et al 
1992, Ghosh et a /1994, Pancake et al 1995).
Monoclonally integrated HTLV-l-related proviral sequences were detected by SB 
hybridisation in DNA from PBMCs of an HTLV-I seronegative patient with SS from France 
(Kaplanski et al 1986). After digestion of DNA with EcoRI, which does not cleave within the 
provirus, RE-digested fragments were smaller (7.5 kb) than expected (9.0 kb) using a full- 
length HTLV-I probe, indicating integration of incomplete or variant HTLV-I. Seven 
Hungarian patients with MF had evidence of infection with HTLV-l-related viruses by SB 
hybridisation and serology (Kiss et a /1993). RE digestion suggested differences In the gag 
region of the integrated pro virus compared with a reference strain of HTLV-I. A full-length 
HTLV-I probe hybridised to SBs of DNA from PBMCs of an HTLV-I seronegative French 
patient with SS had a RE pattern distinct from that of HTLV-I (Bazarbachi et al 1994). HTLV-I 
pel and env sequences could not be detected by PCR.
Sequences with homology to HTLV-I were identified in DNA from PBMCs and cutaneous 
lesions of three of 40 HTLV-l-seronegative West Indian patients with MF in the UK by SB
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hybridisation using a full-length HTLV-I probe under conditions of high stringency (Whittaker 
and Luzzato 1993). After EcoRI digestion the HTLV-I probe hybridised to an 8 kb DNA 
fragment in one patient, indicating the presence of incomplete provirus. A 119 bp product 
amplified from the DNA of this patient by PCR using primers specific for the pol region of 
HTLV-I differed in sequence from the prototype HTLV-I in only one base. HTLV-I could not 
be detected by PCR in the other two patients using the same HTLV-I poZ-specific primers. 
After H/ndlll digestion of DNA from both of these patients, a 3 kb fragment was observed in 
addition to the expected 2 kb fragment when hybridised to the full-length HTLV-I probe. 
Whittaker and Luzzato (1993) suggested that these three patients had monoclonally 
integrated defective HTLV-I provirus.
Monoclonally integrated HTLV-I with a 5.5 kb deletion involving the entire pol gene and large 
portions of gag and env was demonstrated by hybridisation, RE analysis, cloning and 
sequencing in an EBV-infected B-LCL established from PBMCs of an HTLV-l-seronegative 
American patient with SS, as well as in uncultured PBMCs (Hall et al 1991). Since the 
defective virus could not be demonstrated in neoplastic T cells, its pathogenetic role in the 
patient is uncertain.
Monoclonally integrated HTLV-l-related sequences were identified by SB hybridisation in 
DNA from a skin lesion of an Italian patient with CTCL (Manzari et al 1984). Although a 
single fragment of approximately 16 kb was detected by SB hybridisation after EcoRI 
digestion, BamH\ digestion did not reveal an expected internal 1 kb fragment, suggesting 
that the provirus differed from a reference strain of HTLV-I by the absence of this restriction 
site. A putative HTLV-l-related virus, designated HTLV-V, was subsequently identified in 
eight of 150 patients with MF/SS and one patient with acute T cell leukaemia from Italy 
whose sera had weak reactivity for HTLV-I by ELISA (Manzari et al 1987). A 5 kb probe used 
in this study was cloned from a continuous B cell line established from the patient with acute 
T cell leukaemia and may not represent a relevant viral sequence, since no sequence data 
have been published. Therefore, the authenticity of HTLV-V is questionable.
Evidence from a number of groups thus indicates that defective genomes of HTLV-I and 
possibly related viruses are sometimes present in patients with CTCL (Hall et al 1991, 
Whittaker and Luzzato 1993, Pancake et al 1995). Preferential retention of the pX  region in 
these defective HTLV-I proviruses is evidence that pX  genes might have a role in the 
pathogenesis of MF/SS (Hall et al 1991, Pancake et a l 1995). As discussed in Section 
1.6.1.4, defective HTLV-I proviruses have been detected in a small proportion of patients 
with ATL (Konishi et al 1984, Korber e ta l 1991, Ohshima ef a /1991, Kubota ef a /1995). 
Infection by HTLV-I or a related virus may be necessary to initiate oncogenesis but there 
may not be a need to maintain the complete viral genome for maintenance of the 
transformed phenotype. When defective viruses have been identified in both ATL and HTLV- 
associated MF/SS there is preferential retention of pX sequences, suggesting that continued 
expression of genes from this region of the virus may be necessary for oncogenesis. 
Defective BLV pro viruses with preferential retention of the pX region are also found in 
leukaemic B cells from cattle with EBL (Kettmann ef al 1982) (Section 1.9.2.1).
.'A
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It is possible that recombination and complementation could occur between defective HTLV- 
l-related retroviral genomes and other exogenous viruses, endogenous retrovirus-like 
elements or cellular genes. Recombination and complementation leading to enhanced 
oncogenicity have been demonstrated in avian, feline and murine retroviruses (Weiss et al 
1973, Hayward and Hanafusa 1975, Stewart et al 1986, Stoye et al 1991, Sheets et al 1993, 
Golovkina et al 1997). HERV sequences with similarity to HTLV-I genes and thus potential 
for recombination have been identified (Mager and Freeman 1987, Perl et al 1989, Fujihara 
et al 1994). HERV-K sequences, although not homologous to HTLVs, express full-length and 
spliced mRNA transcripts and form virus particles in human germ cell and trophoblastic 
neoplasms, indicating that not all endogenous retroviral elements are transcriptionally 
quiescent (Lower et a l 1993, Herbst et al 1996).
1.11.1.7 Detection of human T lymphotropic viruses In other cutaneous T cell lymphomas
Anagnostopoulos et al (1990) detected HTLV-I by PCR using pol region primers in five 
patients with cutaneous CD30'' ALCL from Germany and one patient from Iran. SB 
hybridisation demonstrated monoclonal integration of HTLV-I in cutaneous lesions in five 
patients and incomplete provirus in four (Anagnostopoulos et al 1990, Detmar et al 1991). 
The Iranian patient was subsequently reclassified as a case of classical MF (Detmar et al 
1991). Conversely, in 24 patients with cutaneous CD30^ ALCL from Europe and Japan there 
was no evidence of HTLV-I infection by SB hybridisation or PCR using p X  primers 
(MacGrogan et al 1996, Wood et al 1997). Serum antibodies against HTLV-I have been 
reported in three patients with angiocentric TCL and HTLV-I gag and p X  sequences were 
amplified by PCR from lesional DNA of one (McNutt et al 1990, Shimokawa et al 1993). 
Insufficient studies have been done to determine whether HTLV-I or related viruses might be 
involved in cutaneous CD30^ ALCL or angiocentric TCL.
1.11.2 Human T lymphotropic viruses and large granular lymphocytic leukaemia
There is evidence that HTLV-I and HTLV-I I are involved in a small proportion of cases of 
LGL leukaemia. Seroreactivity against HTLV-I/II has been detected in patients with CD3* 
LGL leukaemia (Sohn et al 1986, Pandolfi et al 1987, Starkebaum et al 1987, Levitt et al 
1988, Loughran et al 1994a). Familial cases of CD3* LGL leukaemia have been reported 
and one case had antibodies against HTLV-I/II Gag but not HTLV-I p21^"'' (Loughran et al 
1994a). HTLV-II infection has been demonstrated by PCR in a small proportion of cases 
(Loughran et al 1992, 1994b). Some patients with CD3" LGL leukaemia have serological 
cross-reactivity with epitopes of HTLV-I p21^"'' (Loughran et al 1997b, 1998). HTLV-I or 
HTLV-II have been isolated or detected by PCR in a small proportion of cases of CD3‘ LGL 
leukaemia, although not necessarily in the leukaemic cells (Martin et al 1993, Henelne et al 
1994, Loughran et a /1998). A case of CD2^ CD3" CD4^ CD5^ CD7" CD8‘ CD16' CD25^ 
CD56" CD57' leukaemia with LGL morphology (“atypical ATL") and monoclonal integration of 
HTLV-I has been described (Sakamoto et al 1994). Other studies have not demonstrated 
any association between LGL leukaemia and HTLV-I or HTLV-II (Imamura et ai 1988, 
Woessner et al 1994, Zambello et al 1995). A model for LGL leukaemia in HTLV-I fax- 
transgenic mice is discussed in Section 1.9.1.
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1.11.3 Other viruses associated with cutaneous T cell lymphomas and large granular 
lymphocytic leukaemia
1.11.3.1 Herpesviruses
Epsteln-Barr virus (EBV) is able to infect and transform T cells in addition to B cells and 
epithelial cells, since all these cell types can express the EBV receptor CR2 (CD21) 
(Stevenson et al 1986, Fingeroth et al 1988, Watry et al 1991). EBV appears to be 
aetiologically involved in most cases of nasopharyngeal/sinonasal angiocentric T cell 
lymphoma (lethal midline granuloma) (Harabuchi ef al 1990, Kanavaros ef al 1993). An EBV- 
related virus, HVmne, has been detected in T cell lines and cutaneous lymphoid infiltrates of a 
non-human primate, the pig-tailed macaque {Macaca nemestrina), with MF (Rivadeneira ef 
al 1999). Although antibodies against EBV-associated nuclear antigen (EBNA) have been 
detected at increased frequency in patients with MF/SS, EBV genomes are rarely detected in 
neoplastic cells and the evidence for an aetiological role for EBV in most primary CTCLs, 
including MF/SS, is doubtful (Lee et al 1990, Dreno ef al 1994, Kanavaros ef al 1994, 
Anagnostopoulos ef al 1996, Angel ef a /1996, Jumbou ef a /1997). Similarly, most primary 
cutaneous CD30^ ALCLs are negative for EBV, although EBV is associated with some cases 
of primary systemic CD30^ ALCL (Anagnostopoulos ef al 1989, Hamilton-Dutoit and Pallesen 
1992, Kanavaros ef al 1992, Peris ef al 1995, Anagnostopoulos ef al 1996, Herbst ef al
1997). There is little indication that EBV has an aetiological role in angioimmunoblastic TCL, 
Lennert’s lymphoma, lymphomatoid papulosis or intestinal TCL (Weiss ef a /1992, Kadin ef 
al 1993, Khan ef al 1993, Pan ef al 1993, Anagnostopoulos ef al 1994).
Patients with LGL leukaemia usually have antibodies against EBV (Loughran ef al 1993). 
EBV in clonal episomal form has been demonstrated In leukaemic cells in some cases of 
CD3^ and CD3' LGL leukaemia (Kawa-Ha ef al 1989, Chan ef al 1992, Hart ef a /1992). 
However, other molecular studies have not confirmed an aetiological relationship between 
EBV and LGL leukaemia (Loughran ef al 1993, Pellenz ef al 1996).
Although human herpesvirus (HHV) 7 is a T lymphotropic virus, it has not been definitively 
associated with neoplasia (Berneman ef al 1992, 1998). HHV-6 was detected by PCR in skin 
biopsies of one of 30 patients with CTCL, whereas all samples were negative by PCR for 
EBV, HSV-1 and HSV-2 (Brice ef al 1993). Skin biopsies from patients with CTCL and 
PBMCs from patients with T cell LGL leukaemia were also negative for HHV-8 (KS- 
associated herpesvirus) by PCR (Dupin ef al 1997, Henghold ef al 1997, Loughran ef al 
1997a). Thus, there is insufficient evidence to incriminate herpesviruses other than EBV in 
TCLs (Nagore ef al 2000).
1.11.3.2 Human immunodeficiency virus type 1
T cell neoplasms, including MF, have been observed in HIV-1-infected people with AIDS 
(Crane ef al 1991, Nahass ef al 1991, Kerschmann ef al 1995, Munoz-Perez ef al 1999). 
Most are CD8^, possibly a consequence of depletion of the CD4* T cell population in AIDS. 
EBV may be involved in the development of cutaneous CD30^ ALCLs in AIDS patients 
(Dreno ef al 1993). A T  cell lymphoma with monoclonal integration of HIV-1 in neoplastic
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cells has been described in an AIDS patient (Herndier et a l 1992), but most AIDS-associated 
TCLs can be attributed to immunosuppression.
1.11.3.3 Hepatitis viruses
In an Italian study, some patients with CDS' LGL leukaemia had serum antibodies against 
hepatitis B (HBV) and C (HCV) viruses (Zambello et al 1995). HCV was not associated with 
lymphoproliferative disease in humans in France (Hausfater et a/2001). A patient with 
polyclonal proliferation of CDS"^  CD8* LGLs directed against HBV-infected CD4^ T cells has 
been reported, supporting the hypothesis that LGLs may be proliferating In response to 
chronic stimulation by viral antigens (Agostini et al 1989).
1.12 Associations between viruses and neoplasia
1.12.1 Viruses and human neoplasia
It has been difficult to establish aetiological associations between viruses and neoplasia in 
humans (Evans and Mueller 1990, Zur Hausen 1991). The identification of EBV as the cause 
of Burkitt’s lymphoma was the first such association to be established (Henie et al 1968).
The process of discovery leading to the identification of HTLV-I as the cause of ATL (Section 
1.6.1.5) further illustrates the difficulties in confirming causality. Only a small proportion of 
infected people develop ATL and there is a prolonged phase of induction between infection 
and the occurrence of disease. The process of oncogenesis in ATL appears to be complex, 
with multiple stages influenced by viral gene expression (Section 1.8) and host factors such 
as immune status and point mutations or chromosomal translocations involving oncogenes 
(Section 1.6). Neoplasms such as CTCLs with similar clinlcopathological features to ATL 
may develop in people that do not appear to be infected with HTLV-I. In other neoplasms of 
humans, for example carcinomas caused by papillomaviruses, different strains of viruses 
may have different oncogenic potential (Walboomers et al 1999). Cofactors are often 
required for oncogenic progression in virus-induced neoplasia, for example aflatoxins and 
alcohol in hepatocellular carcinoma caused by HBV (Monto and Wright 2001) and 
nitrosamines in nasopharyngeal carcinoma caused by EBV (Liebowitz 1994).
1.12.2 Criteria for establishing aetiological associations
The Henle-Koch postulates provide a clear but limited set of criteria for determining whether 
an infectious agent is the cause of a disease (Rivers 1936). The agent should be found in all 
cases of the disease and its location in tissues should correspond with the distribution of 
lesions. The agent should be isolated from lesions and cultivated to purity outside the host; 
when inoculated back into the host, the cultivated agent should produce identical disease. 
However, these criteria cannot be applied to viruses causing human neoplasia. Since viruses 
are propagated in cell cultures, it is difficult to ensure that inocula are free of other agents 
that could be alternative sole or cooperating causes of neoplasia. In particular, 
contamination of cell cultures with non-human viruses has been a major source of confusion 
in the search for viruses involved in human neoplasia (Reitz et al 1976, Smith et al 1979, 
Popovic et al 1982). The problem of ensuring purity of viruses has only been overcome by
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the use of infectious full-length molecular clones (Kimata et al 1994b, Zhao et a l 1995, Derse 
et al 1997, Robek and Ratner 1999).
An alternative set of criteria for the association of viruses with neoplasia was proposed by 
Evans (1976) and are developed here. Evidence of exposure to the virus should be 
demonstrated by detection of infection using virus isolation, molecular assays, antigen 
assays or tests for other viral markers including serological or cell-mediated immune 
responses (Section 1.4). The association of a particular virus with a specific neoplasm 
should be consistent and repeatable by different researchers in different places at different 
times. Infection should precede the development of neoplasia. However, initial infections with 
many oncogenic viruses are subclinical and therefore the time of exposure may be difficult to 
establish. There may be a dose response, with an increased frequency or earlier onset of 
neoplasia associated with higher levels of infection. Viral markers should be more prominent 
(higher antibody titres, higher concentration of circulating virus or higher antigenaemia) in 
cases with neoplasia than in matched controls. It should be possible to demonstrate infection 
in the neoplasm by virus isolation or molecular, immunological or ultrastructural techniques. 
However, not all viruses that initiate neoplasia may remain in the affected tissue (hit-and-run 
mechanism of viral oncogenesis) (Skinner 1976, Smith and Campo 1988, Shen et a l 1997, 
Nevels et al 2001) or viruses may induce neoplasia indirectly, for example lymphoid 
neoplasia associated with HlV-1-induced immunosuppression in AIDS patients (Cremer et al 
1990, Schulz et al 1996, Demario and Liebowitz 1998, Smith et al 1998).
An apparent association between a virus and a neoplasm would be considered more 
biologically plausible if the virus is from a taxonomic group that has previously been 
associated with a similar type of neoplasm in the same or related species (Fredricks and 
Reiman 1996). Oncogenic viruses isolated from humans with neoplasia should be able to 
transform cells in vitro. They may have the capacity to induce comparable neoplasms when 
inoculated into susceptible non-human animals. Experimental manipulation of the virus or its 
host may alter the expression of transforming properties. However, suitable In vitro and non- 
human animal models are not always available because of the difficulty in reproducing 
neoplasia in alternative hosts with human viruses (Section 1.9). Prevention of infection with a 
candidate oncogenic virus by vaccination or other prophylactic interventions should be 
associated with a decrease in the incidence of the neoplasm. T cell neoplasia in domestic 
fowl caused by Marek’s disease virus (MDV) can be prevented by vaccination with 
herpesvirus of turkeys or low virulence strains of MDV (Churchill et al 1969, Okazaki et al 
1970). Anti-viral therapy might increase the frequency or time to development of neoplasia in 
infected people or cause regression of neoplasms that have already developed.
Many human oncogenic viruses, for example HTLV-I, HHV-8, HBV, HCV and the human 
papillomaviruses (HPVs), proved difficult to isolate until the development of specialised cell 
culture systems and there are likely to be other human viruses that have not been identified. 
Increasingly, viruses are being identified and characterised by molecular techniques before 
they have been cultivated in vitro (Fredricks and Reiman 1996, Gao and Moore 1996). A X 
bacteriophage cDNA expression library was screened with antiserum from patients with non- 
A, non-B hepatitis to detect sequences of HCV, an RNA virus associated with hepatocellular 
carcinoma (Young and Davis 1983, Choo et al 1989). HHV-8 was discovered by
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amplification of viral sequences from KS, a skin tumour associated with AIDS, using 
representational difference analysis (RDA) (Lisitsyn et al 1993, Chang et al 1994). 
Consensus PCR using group-specific primers has been used to amplify sequences of 
previously unknown HPV genotypes from patients with cervical neoplasia (Van den Brule et 
al 1992). Novel herpesviruses have been detected by degenerate and consensus PCR in B 
cell lymphomas of common marmosets {Callithrix jacchus) (Ramer ef al 2000), 
fibropapillomas of green turtles {Chelonia mydas) (Quackenbush ef al 1998) and genital 
carcinomas of California sea lions {Zalophus californlanus) (Lipscomb ef al 2000).
Fredricks and Reiman (1996) outlined guidelines for establishing an aetiological association 
between a microorganism and disease based on molecular evidence in the absence of 
cultivation of the putative pathogen. These guidelines can be applied to novel virus-like 
sequences and neoplasia. Specific putative viral nucleic acid sequences should be present 
in neoplastic cells, although this may not apply to hit-and-run agents or those that act 
indirectly. There should be a lower frequency of detection, a lower copy number or absence 
of the specific virus-like sequences in unaffected tissues or in regressing neoplasms. 
Sequences might be detectable in samples that precede the development of neoplasia, 
indicating prior infection. The taxonomic group to which the putative virus belongs, inferred 
by sequence analysis, should be one that has known oncogenic members. The type of 
neoplasm being associated with specific novel virus-like sequences should be consistent 
with the known biological properties of members of that group. When assessing the 
significance of retroviral sequences detected in neoplasia, the potential for amplification of 
endogenous retrovirus-like sequences should be considered, particularly when using primers 
from regions such as po/where there is a high degree of similarity between endogenous and 
exogenous sequences. In neoplasia induced by retroviruses, each neoplastic cell would be 
expected to carry at least one integrated provirus but there is also the possibility that cells 
might lose part or all of the provirus following neoplastic transformation.
1.12.3 Epidemiological studies
Epidemiological criteria are also important in determining whether associations between 
viruses and neoplasia are likely to be causal (Evans 1976). The geographical distribution of 
infection with a virus should be similar to that of the neoplasm with which it is associated, 
adjusting for age of infection and presence of cofactors. The correlation between the 
distribution of HTLV-I infection and the occurrence of ATL was the most important factor in 
identifying a causal association. Even when a virus and a neoplasm have a similar 
geographical distribution, there is still a need for well-designed epidemiological studies. Not 
all infected people may develop the neoplasm; with viruses such as HTLV-I neoplasia may 
develop in only a small proportion of infected people and there may be a long delay between 
infection and development of the neoplasm. Viruses may not be responsible for all cases of 
a particular neoplasm if there is multifactorial causation. In these cases, it is necessary to 
study the degree of association between disease and hypothesised causal factors by 
measuring relative risks or odds ratios in cross-sectional, case-control and cohort studies. A 
significantly higher proportion of people infected with a candidate oncogenic virus or with 
specific viral markers (Section 1.4) should develop neoplasia than uninfected people or 
those without such markers.
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1.12.4 Involvement o f HTLV-I in cutaneous T cell lymphomas and targe granular 
lymphocytic leukaemia
Evidence for the involvement of HTLV-I or related viruses in MF/SS, other CTCLs and LGL 
leukaemia is presented in Section 1.11. Seropositivity for HTLV-I structural and regulatory 
proteins has been demonstrated in many cases. A number of studies have reported 
detection of HTLV-I sequences by PCR and SB hybridisation in PBMCs, neoplastic infiltrates 
and cell lines derived from affected patients. There is some evidence that defective HTLV-I 
or HTLV-II or variant proviruses are integrated in neoplastic cells of some cases of MF/SS 
and other CTCLs, with preferential retention of the pX region. However, the discrepancy in 
reported frequencies of detection of HTLV-I or HTLV-II markers in patients with these 
neoplasms must result in serious doubts as to the veracity of many studies. Methodological 
problems such as PCR contamination have to be excluded before positive results can be 
accepted. Concerns about previous studies have highlighted the need to establish stringent 
criteria for determining whether HTLV-I, HTLV-II or related viruses are aetiologically involved 
in CTCLs and LGL leukaemia.
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Clear case definitions for MF/SS and other CTCLs must be established in order to 
distinguish these T cell neoplasms from ATL and similarly the diagnostic criteria for LGL 
leukaemia must be well-defined. It is then necessary to obtain unambiguous evidence that 
patients with non-ATL CTCLs and LGL leukaemia are infected with HTLV-I, HTLV-II or 
related retroviruses. Isolation and propagation of infectious virus from affected patients 
would be the most definitive form of evidence, particularly if the virus is shown to be a new 
species of retrovirus or a distinct strain of HTLV-I or HTLV-II based on sequence information 
and detailed virus characterisation. Since retroviruses establish persistent infections, 
patients with neoplasms caused by defective integrated proviruses would be expected to be 
CO-infected with intact infectious virus that can be isolated from PBMCs or other non­
neoplastic cells. It is conceivable that cells containing intact proviruses could be eliminated 
by the host immune response, leaving only cells infected by defective viruses that fail to 
express antigens. In these cases It would be necessary to rely on molecular techniques that 
detect the remnant sequences. Stringent precautions would have to be taken to eliminate 
contamination by PCR products. The sequences of amplified products would have to be 
determined. An additional level of proof would be to accept results only when sequences of 
PCR products differ by statistically significant percentages from prototypical strains of HTLV- 
I and HTLV-II, particularly strains that might be handled by the same group in the same 
laboratory and used as positive controls. Since the level of sequence variation among HTLV- 
I isolates is low, criteria for interpretation of sequence results might be different to that of 
more variable viruses such as HIV-1. Sequences should be reproducible when obtained from 
different PCR products from the same and possibly different patients at different times. Only 
the study by Manca et a/ (1994) has so far met these criteria for MF/SS.
Studies conducted at the LRF Virus Centre from 1992 to 1995 to search for HTLV-l-related 
viruses in MF/SS, LGL leukaemia and other neoplasms are described in Chapters 2 to 4 of 
this thesis. The results of this work are discussed in Chapter 5 and compared with the 
findings of other studies.
Chapter 2
Detection of Retroviruses in Human T Cell Leukaemias 
and Lymphomas by Cell Culture
2.1 Introduction
2.1.1 Approach to isolation of retroviruses from T cell neoplasms
2.1.1.1 Role of human T lymphotropic retroviruses in T cell neoplasia
Human T lymphotropic virus type I (HTLV-I) is the cause of adult T cell leukaemia/lymphoma 
(ATL), a neoplasm of CD4^ T cells (Section 1.6.1). HTLV-II has been isolated from cases of 
CDS’" T cell variant hairy cell leukaemia (HCL) but has not been definitively associated with 
neoplasia (Section 1.7.1). The related retrovirus bovine leukaemia virus (BLV) causes B cell 
leukaemia and lymphoma in cattle (Section 1.9.2.1). Retroviral aetiologies have been 
proposed for a variety of diseases of humans for which the cause is currently unknown, 
including T and B cell lymphoid neoplasms (Sections 1.10.5 and 1.11) and autoimmune 
diseases (Section 1.6.4). The hypothesis tested in this study was that HTLV-I, HTLV-II, BLV 
or related viruses are associated with other T cell leukaemias and lymphomas. Combinations 
of cell and molecular biology techniques were used to search for retroviruses in patients with 
these neoplasms.
2.1.1.2 Spectrum of clinical diseases investigated
The emphasis in this study was on cutaneous T cell lymphomas (CTCLs), including mycosis 
fungoides (MF) and its leukaemic variant Sézary syndrome (SS). These neoplasms have 
similar clinlcopathological features to some forms of ATL and have been the subject of 
investigations by many groups in an attempt to confirm a retroviral aetiology (Section
1.11.1). Cases of large granular lymphocytic (LGL) leukaemia were examined for the 
presence of HTLV-related retroviruses because of reports associating this T or natural killer 
(NK) cell lymphoproliferative disorder with HTLV-I and HTLV-II (Section 1.11.2). Samples 
from a cluster of adult acute lymphoblastic leukaemia (ALL) cases in butchers and abattoir 
workers were also examined for the presence of HTLV-I, HTLV-II and BLV, the latter virus 
because of occupational exposure to cattle (Whittaker 1991) (Sections 1.9.2.1 and 1.10.5).
2.1.1.3 Outline of cell culture approach
The aim of the cell biology section of this project was to isolate retroviruses from human T 
cell neoplasms by cultivating T cells from peripheral blood mononuclear cells (PBMCs), skin 
and lymph nodes of affected patients. Cultivated T cells would act as host cells for the 
propagation of T lymphotropic retroviruses. Protocols for the long-term cultivation of T cells 
from patients with T cell neoplasia and patients with retroviral infections were designed.
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Techniques for the establishment of cultures included stimulation with concanavaiin A 
(ConA) or phytohaemagglutinin (PHA) then interleukin (IL) 2 (Gazdar et a /1980, Poiesz et al 
1980b, Ho et al 1990), IL2 alone, IL2 in combination with IL4 (Uchiyama et al 1988, Kaltoft et 
al 1992, Mori et al 1993b), IL7 (Dalloul et al 1992) and granulocyte-macrophage colony 
stimulating factor (GMCSF) (Zucker-Franklin et al 1991). Conditioned medium (CM) was 
prepared by collecting cell culture supernatants from PHA-stimulated umbilical cord blood 
mononuclear cells (UCMCs), providing a source of T cell growth factor (TCGF) (Poiesz et al 
1980a, Hoshino et al 1983). TCGF is an heterogeneous medium containing IL2 and other 
soluble growth factors (Morgan et al 1976, Ruscetti et al 1977, Gazdar et a /1979, 1980, Mier 
and Gallo 1980). In addition, CM was prepared by ConA stimulation of PBMCs from a patient 
with SS, producing Sézary T cell activating factor (SAP) CM (Abrams et al 1991a, b).
Lymphocytes from patients with T cell neoplasia were also cocultivated with UCMCs that 
would act as recipients for infection with retroviruses released from primary neoplastic cells 
or other infected cells from the same patient (Miyoshi et al 1981 b, Markham et al 1983, 
Popovic et al 1983). Cultured cells were examined for evidence of retroviruses by electron 
microscopy (EM) and cell pellets were collected for analysis by the polymerase chain 
reaction (PCR) (Chapter 3). Culture supernatants were collected for detection of reverse 
transcriptase (RT) activity. The immunophenotypes of cells from long-term cultures were 
determined by flow cytometry.
In this chapter the origins and properties of T cell lines established from patients with ATL 
(Section 2.1.2) and CTCLs (Section 2.1.3) are reviewed to provide a background to the 
approaches used at the Leukaemia Research Fund (LRF) Virus Centre to establish similar 
continuous T cell lines. The sources of clinical samples are described in Section 2.2. 
Techniques for the cultivation of lymphocytes from clinical samples are described in Section
2.3.5 and 2.3.6. All methods relating to collection of samples for subsequent molecular 
studies are also included in this chapter. The results of investigations for evidence of 
retroviruses in cultured T cells are described in Section 2.4.
2.1.2 Establishment of adult T cell leukaemia/lymphoma cell lines
2.1.2.1 ATL cell lines and isolation of HTLV-I and HTLV-II
The discovery of HTLV-I and HTLV-II is described in Section 1.3.2.1. HTLV-I (type isolate 
HTLVcr) was first detected in two CD4^ T cell lines established from a patient with a form of 
ATL initially diagnosed as MF (Gazdar et al 1979, 1980, Poiesz ef al 1980a, b). These cell 
lines were HUT102, derived from lymph node cells, and CTCL-3, established from PBMCs.
A second isolate (HTLV^b) was obtained from a CD4^ T cell line (CTCL-2) derived from 
PBMGs of another patient with a form of ATL initially diagnosed as SS (Poiesz ef al 1981). 
HTLV-I (ATLV) was also identified in CD4^ T cell lines established from patients with ATL in 
Japan by direct cultivation of PBMCs (cell line MT1) (Miyoshi ef al 1979a, 1980, Hinuma et al 
1981) and by cocultivation of UCMCs with ATL cells (cell line MT2) (Miyoshi ef al 1981a, b). 
Numerous other CD4"’ T cell lines have been established subsequently from ATL patients 
(Gootenberg ef a /1981, Hinuma ef al 1982a, Yoshida ef al 1982, Hoshino ef al 1983, 
Markham ef al 1983, Sugamura ef al 1984a) (Sections 1.3.2 and 1.4.1).
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In most cases the cell lines established from PBMCs of patients with ATL are not derived 
from the neoplastic clone but represent non-leukaemic cells infected in vitro (Miyoshi et ai 
1981a, Nowell et ai 1984, Maeda et al 1985, 1987). HTLV-II (HTLV^o) was first isolated from 
a CD8"^  T cell line derived from a patient with a T cell variant of HCL (Saxon et al 1978a, b, 
Kalyanaraman e ta l 1982b). The key to identifying these viruses was the establishment of 
CD4"' or CD8'" T cell lines from patients with neoplasia and such an approach continues to be 
important in attempts to isolate new human T lymphotropic viruses.
2.1.2.2 Methods for establishing HTLV-l-infected T cell lines from ATL patients
HTLV-l-infected T cell lines have been established from ATL patients by stimulation of 
PBMCs with ConA or PHA and continued cultivation in the presence of CM (TCGF) or IL2 
(Gazdar et al 1979, 1980, Poiesz et al 1980a, b, Gootenberg ef a /1981, Poiesz ef al 1981, 
Hinuma ef al 1982a, Hoshino ef al 1983, Sugamura ef al 1984a, Maeda ef al 1987).
Activation of T cells by ConA or PHA increases the efficiency of infection and transformation 
(Merl ef al 1984). CM and IL2 may be withdrawn as cell lines attain IL2 independence 
(Markham ef al 1983, Yssel ef al 1989, Hollsberg ef al 1992, Rohwer ef al 1994) (Section
1.3.2.3). Cultured neoplastic T cells containing integrated defective HTLV-I from a patient 
with CD8^ ATL also proliferated in response to IL2; these cells were shown to express the 
IL2 receptor (IL2R) (Matsushita ef al 1994).
Occasionally, HTLV-l-infected T cell lines have been established from ATL patients without 
the use of stimulants (Katoh ef al 1986). Cocultivation of PBMCs from ATL patients with 
UCMCs is a frequently used method for establishing HTLV-l-infected T cell lines (Miyoshi ef 
al 1981a, b, Yoshida et al 1982, Markham ef a /1983, Popovic e ta l 1983, Hjelle e ta l 1992b).
2.1.2.3 Proliferative responses of ATL cells
ATL-derived neoplastic T cells proliferate in response to IL2, IL4, IL7 and IL15 (Uchiyama ef 
al 1988, Umadome ef al 1988, Mori ef al 1993b, Persaud ef al 1995, Yamada ef al 1998).
The receptors for these cytokines share the common y (yc) chain and this component may be 
a mutual element in the signalling pathway for stimulation of HTLV-l-infected T cells by these 
exogenous cytokines during the process of transformation (Persaud ef al 1995) (Section
1.8.1.1). IL4 and IL7 can substitute for 1L2 in immortalising some HTLV-l-infected T cells 
(Uchiyama ef al 1988, Umadome ef al 1988, Mori ef al 1993b, Persaud ef al 1995, Asadullah 
ef al 1996b, Mastino ef al 1997).
ATL cells also proliferate in response to GMCSF (Matsushita ef a /1997). The receptors for 
GMCSF, IL3 and IL5 share a common (3 (Pc) receptor but the responses of ATL cells to IL3 
and IL5 have not been studied in detail (Guthridge ef al 1998).
70
2.1.2.4 Infection of T and B cell lines with HTLV-I and herpesviruses
Epstein-Barr virus (EBV)-infected B lymphoblastoid cell lines (B-LCLs) coinfected with HTLV- 
I are occasionally established from patients with ATL (Yamamoto et al 1982a, Hi rose et al 
1984, Koyanagi et al 1984). These cell lines express IL2R and proliferate in response to IL2 
(Sugamura et a/ 1984b). Since HTLV-I Tax up-regulates complement receptor 2 (CD21), the 
receptor for EBV (Section 1.8.1.2), HTLV-l-infected T cell lines established from patients with 
ATL could also be susceptible to coinfection with EBV (Koizumi et al 1992, Kuraya et al 
1995, Ohtsubo et al 1997). However, this appears to be an infrequent event (Ohtsubo et al 
1997, 1999).
2.1.2.5 Infection of T cell lines with other T lymphotropic retroviruses
Cultivation of T cells from patients with T cell neoplasia might occasionally result in 
propagation of other human T lymphotropic viruses, such as HIV-1, HIV-2, human 
herpesvirus (HHV) 6 and HHV-7 (Barré-SInoussi et al 1983, Levy et al 1984, Popovic et al 
1984, Clavel et al 1986, Salahuddin e ta l 1986, Downing et al 1987, Tedder e ta l 1987, 
Frenkel et al 1990, Berneman et al 1992a, Zhou et al 1999).
2.1.3 Cultivation of T ceils from patients with cutaneous T cell lymphomas
2.1.3.1 T cell lines established from patients with mycosis fungoides/Sézary syndrome
The growth requirements of representative MF/Sézary T cell lines are summarised in Table 
2.1. MF/SS-derived CD4^ T cell lines that do not require stimulants for growth include Hut78 
(Gazdar et al 1980, Poiesz et al 1980a, b), HH (Starkebaum et al 1991) and L-726A (Crae et 
al 1991 ). L-726A was established at the LRF Virus Centre from skin lesions of a patient with 
SS. TCGF (IL2)-dependent CD4^ MF/Sézary T cell lines include two cell lines from skin and 
one from a lymph node of patients with MF (Kaltoft et al 1984), the Se-Ax cell line cultivated 
from PBMCs of a patient with SS (Kaltoft et al 1987), a T cell line from PBMCs of a patient 
with CTCL established by Kadin et al (1988), nine MF/Sézary cell lines (SZ series) from 
PBMCs of patients with SS (Abrams et al 1991a, b) and a T cell line from a patient with 
CTCL established by Boehncke et al (1993). The CD4^ T cell line My-La, from the skin of a 
patient with MF (Kaltoft et al 1992), and two T cell lines established from patients with CTCL 
by Boehncke et al (1993) required IL2 and IL4. Another T cell line established from a CTCL 
patient by Boehncke et al (1993) was dependent on IL4 alone. Three IL7-dependent T cell 
lines (CHA, BEL and RIC) were established from MF/SS patients by Dalloul et al (1992).
In most cases T cell clones cultured from MF lesions are not derived from neoplastic 
MF/Sézary cells but arise from tumour infiltrating lymphocytes (TILs) (Ho et al 1990, Harwix 
ef a/2001).
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Table 2.1: Growth requirements of representative HTLV-I and HTLV-ll-negative CD4^ T 
cell lines established from patients with mycosis fungoides/Sézary syndrome.
Cell line T cell neoplasm Source of cells Reference
Independent of exogenous growth stimulants
Hut78 CTCL PBMCs Gazdar et al 1980
L-726A SS Skin Crae et a /1991
HH CTCL PBMCs Starkebaum et al 1991
Interleukin 2-dependent
Se-Ax SS PBMCs Kaltoft ef al 1987
SZ-4 SS PBMCs Abrams ef al 1991a, b
Interleukin 2 and interleukin 4-dependent
My-La MF Skin Kaltoft ef al 1992
Interleukin 7-dependent
CHA SS PBMCs Dalloul ef a /1992
CTCL Cutaneous T cell lymphoma
MF Mycosis fungoides
SS Sézary syndrome
PBMCs Peripheral blood mononuclear cells
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2.1.3.2 T cell lines established from patients with other T cell lymphomas
Selected CD4^ T cell lines established from patients with T cell lymphomas (TCLs) other 
than MF/SS are listed in Table 2.2. These cell lines are not dependent on growth factors and 
do not appear to be infected with HTLV-I or HTLV-II. As discussed above, a number of T cell 
lines established from patients initially diagnosed with MF or SS (for example HUT102, 
CTCL-2, CTC-16 and Sez 627), were found to be infected with HTLV-I and these patients 
would be regarded as having ATL (Poiesz et al 1980b, Uchiyama et al 1980, Poiesz et al 
1981, Reitz et al 1983, Namiuchi et al 1986, Detmar et al 1991 ). Zucker-Franklin et al (1991 ) 
provided equivocal evidence for HTLV-related viruses in cell lines established from PBMCs 
of 17 patients with MF and one patient with SS using GMCSF and IL2 as growth stimulants 
(Section 1.11.1.4). An IL2-dependent CD4^ T cell line WHN2 has been established from a 
patient with HTLV-l-negative leukaemia resembling ATL (Kagami et al 1993).
2.1.3.3 Methods for establishing T cell lines from patients with mycosis fungoides/Sézary 
syndrome
CD4'' T cell lines have been established from patients with MF/SS and other CTCLs by in 
vitro propagation of lymphocytes extracted from skin, lymph nodes or blood. To establish 
these cell lines, growth of T cells has been stimulated with mitogens such as ConA or PHA, 
along with various combinations of IL2, IL4, IL7 and GMCSF (Gazdar ef al 1980, Ho ef al 
1990, Abrams ef al 1991 a, Starkebaum ef al 1991, Zucker-Franklin ef al 1991, Dalloul ef al 
1992, Kaltoft ef al 1992, Boehncke ef al 1993).
CM prepared from PHA-stimulated PBMCs or UCMCs has been used to provide a source of 
TCGF (Mier and Gallo 1980, Poiesz ef a/ 1980b, Kaltoft ef a /1984, 1987). SAF CM produced 
by ConA-stimulated PBMCs from a patient with SS was used to establish T cell lines from 
other patients with MF/SS (Abrams ef a/ 1991a, b). MF/SS patient-derived lymphocytes have 
also been cocultivated with UCMCs and other cells (Detmar ef al 1991). Kaltoft ef al (1984) 
found that depletion of CD8^ T cells (TILs) permitted outgrowth of neoplastic CD4"’ T cell 
clones from skin-derived lymphocyte cultures. Adaptations of these methods to the cell 
culture studies at the LRF Virus Centre are described in more detail in Section 2.3.6.
2.1.3.4 Proliferative responses of mycosis fungoides/Sézary cells
The in vitro proliferative responses of PBMCs and skin-derived lymphocytes to mitogens are 
reduced in most patients with MF/SS (Burg ef al 1978, Golstein ef al 1986, Ho ef al 1990, 
Wood e ta l 1990b) (Section 1.10.1.3). Although MF/Sézary cells usually express the T cell 
receptor (TCR)/CD3 complex, they can more readily be activated through antigen- 
independent pathways such as those involving CDw60, CD2, and CD28 (Hansen ef a /1993). 
Proliferative responses have been demonstrated to IL2 alone or in combination with IL4, IL7 
and GMCSF (Kaltoft ef al 1987, Zucker-Franklin ef a /1991, Dalloul ef al 1992, Kaltoft ef al 
1992, Foss ef a /1994), as well as to CM (TCGF) with IL2 activity (Poiesz ef al 1980a, Kaltoft 
ef al 1984, Abrams ef al 1991b, 1993). In some studies MF/Sézary cells have proliferated 
strongly in response to IL7 and IL15 and less strongly to IL2 and IL4 (Kaltoft ef al 1987, 
Dalloul ef al 1992, Kaltoft ef al 1992, Foss ef a /1994, Dobbeling ef a /1998).
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Table 2.2: HTLV-I and HTLV-ll-negative CD4^ T cell lines established from patients with  
T cell leukaemias and lymphomas other than mycosis fungoides/Sézary syndrome.
Cell line T cell neoplasm Reference
CCRF-CEM T cell ALL Foley et al 1965
MOLT-3 T cell ALL Minowada et al 1972
MOLT-4 T cell ALL Minowada et al 1972
H-SB2 T cell ALL Royston et a /1974
JURKAT(JM) T cell ALL Schneider et al 1977
RPMI 8402 T cell ALL Srivastava et al 1975
TALL-1 T cell ALL Hiraki et al 1978
HPB-ALL T cell ALL Morikawa et al 1978
SUP-T3 T cell ALL Smith et al 1984
Kit 225 T cell CLL Hori ef a /1987
HPB-MLT T cell lymphoma Morikawa ef a /1978
SUP-T1 T cell lymphoma Smith ef al 1984
lARC 301 T cell lymphoma Duprez ef al 1985
HPB-MLp-W T cell lymphoma Morikawa ef al 1991
ALL Acute lymphoblastic leukaemia
CLL Chronic lymphoblastic leukaemia
74
Cytokines produced by MF/Sézary cells and other cells in MF lesions are listed in Section 
1.10.1.5. Although many MF/SS-derived T cell lines express IL2Ra (CD25) and require IL2 
for growth, most MF/Sézary cells in lesions do not express CD25 (Boehnke et al 1993) 
(Section 1.10.1.3). Therefore, any response to IL2 in vivo is likely to be mediated by a less 
strongly responsive receptor complex composed of the pc (CD122) and yc (CD132) subunits 
of the IL2R.
The use of TCGF and IL2 for cultivation of primary T cells from skin lesions or PBMCs of 
patients with MF/SS could select for T cells that express the high affinity IL2R but are not 
derived from the neoplastic clone. Mitogen-activated PBMCs from SS patients produce SAF, 
a 28 kDa protein that induces IL2Ra on MF/Sézary cells, rendering them responsive to IL2 
(Abrams et al 1993). This autocrine loop of stimulation could account for the successful 
propagation of the SZ series of T cell clones from patients with SS by Abrams et al (1991b).
As discussed above, some MF/SS-derived T cell lines require IL4 alone or in combination 
with IL2 for growth (Kaltoft et al 1992, Boehncke et al 1993). IL4 expression is low in early 
MF lesions, although it may increase in later stage MF (Vowels et al 1994, Asadullah et al 
1996a).
IL7 and IL7 receptor (IL7R) a (CD127) are expressed by a proportion of MF/Sézary cells in 
cutaneous lesions (Foss et al 1994, Asadullah et al 1996b, Bagot et al 1996, Dobbeling et al 
1998). IL7 produced by kératinocytes or MF/Sézary cells could act in an autocrine or 
paracrine fashion to induce expression of IL7Ra and IL2Ra on MF/Sézary cells (Dalloul et al 
1992, Heufler et al 1993, Foss et al 1994, Bagot et al 1996). The presence of such a 
stimulatory pathway would be consistent with the establishment of IL7-dependent T cell lines 
from some MF/SS patients (Dalloul et al 1992, Foss et al 1994, Dobbeling ef al 1998). 
However, it has been difficult to demonstrate a role for IL7 in maintaining proliferation of 
MF/Sézary cells in vivo (Asadullah et al 1996b).
IL15 prolongs the survival of MF/Sézary cells and is a growth factor for some MF/SS cell 
lines; IL15 mRNA is expressed by PBMGs, basal cell layer kératinocytes and T cells 
infiltrating the skin in MF/SS patients (Dobbeling ef al 1998). These observations strengthen 
the premise that the yc chain of the receptors for IL2, IL4, IL7 and IL15 plays an important 
role in maintaining proliferation of MF/Sézary cells in vivo.
2.1.4 Cell lines derived from patients with LGL leukaemia
Although no fresh PBMGs were submitted for culture from patients with LGL leukaemia in 
this study, a brief description of established NK or T cell lines derived from affected patients 
is given here. Five GD3"^  GD8'", one GD3^ GD8‘ and one GD3 GD8 lL2-dependent LGL cell 
lines were established using PHA and IL2 as growth stimulants (Pistoia ef a l 1986). Three 
GD3^ GD8^ LGL cell lines were established using IL2 (Loughran ef a/ 1988b). TKS-1, a GD3' 
GD56' cell line with LGL morphology, was derived from a patient with GD3' GD56^ LGL 
leukaemia using IL2 (Kojima ef al 1994). NK-92 is an IL2-dependent GD3" GD7^ GD56^ NK 
LGL cell line that expresses the lL2Ra (GD25) (Gong ef al 1994).
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Neoplastic LGL cells proliferate in response to IL2 in vitro (Koizumi et ai 1986). NK-YS is an 
EBV-infected NK cell line established from a nasal angiocentric NK cell lymphoma with LGL 
morphology by cocultivation with a murine stromal cell line in the presence of IL9 
(Tsuchiyama et al 1998). The requirements for establishment of T cell LGL cell lines thus 
appear to be similar to those for other T cell lines.
2.1.5 Proliferation of normal T cells in culture
2.1.5.1 In vitro activation and proliferation of normal T cells
T cells are normally activated through binding of specific antigens to the TCR (Minden and 
Mak 1986, Davis and Bjorkman 1988). The lectins ConA and PHA are non-specific 
(polyclonal) activators of T cells that bind to the TCR-CD3 complex (Palacios 1982, Chilson 
and Kelly-Chilson 1989). Monoclonal antibodies (MAbs) against accessory cell surface 
molecules such as CD2, CD3, CD28 and CDw60 will also activate T cells (Meuer et al 1984, 
Hansen et al 1993). T cells from healthy people will not respond to IL2 unless activated. 
Resting T cells express the low affinity pc and yc subunits of the 1L2R but have limited 
expression of the high affinity a subunit (CD25) (Minami et al 1993). In addition, the amount 
of IL2 secreted by resting T cells is very low. Following activation, T cells transiently produce 
IL2 and express higher levels of IL2Ra, which combines with the pc and yc subunits to form 
the high affinity IL2R complex, allowing the cells to respond strongly to IL2. Activated T cells 
will proliferate for 1 to 2 days by this 1L2-1L2R autocrine mechanism but will not usually 
persist in culture, even in the continued presence of exogenous IL2, and rarely become 
immortalised spontaneously (Section 2.1.5.2). In contrast, T cells from patients with some T 
cell leukaemias and lymphomas, including HTLV-I infected patients with ATL, often respond 
directly to IL2 and are more readily immortalised (Section 2.1.2.3). There are differences in 
the in vitro proliferative properties of helper (Th) and suppressor (Ts) T cells (Taylor et al 
1987). Th cells are able to produce IL2 whereas Ts cells require an exogenous source to 
maintain viability.
The use of cytokines such as IL2, IL4, IL7 and IL15 to stimulate the growth of MF/Sézary 
cells in culture has been described in Section 2.1.3.2. These four cytokines are important in 
preventing the death of activated normal T cells in vitro, similar to their effects on MF/Sézary 
cells, although IL4 and IL15 are more effective than IL2 or IL7 (Kaltoft 1998, Vella et al 
1998). Many other cytokines, such as IL6, IL9, IL12 and interferon (IFN) y, are involved in 
growth and differentiation of normal T cells (Lanzavecchia and Sallusto 2000).
2.1.5.2 Longevity of normal T cells in vitro
The longevity of normal human T cells in culture is limited but varies according to the type of 
medium and conditions of cultivation (Perillo et al 1989). In standard cell cultures, 
unstimulated primary T cells derived from PBMCs usually survive for 20 to 30 days in the 
absence of exogenous growth stimulants before undergoing death by apoptosis. Activated T 
cells proliferate more strongly and will persist in culture for longer; death of most or all 
members of the popCilation (“crisis”) usually occurs at 30 to 60 days. Under such conditions.
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normal human T cells are able to undergo 50 ± 10 population doublings before their 
proliferative capacity is lost, similar to human fibroblasts (Hayflick 1965, Houck ef a /1971,
Perillo et al 1989, Goletz et al 1994).
2.1.5.3 Role of the cellular environment in maintaining proliferation of T cells
The compartments of the body in which neoplastic cells proliferate in MF/SS are complex
and dynamic microenvironments. Cutaneous lesions in MF contain a diverse range of cells,
including kératinocytes, fibroblasts, Langerhan’s cells, interdigitating cells, melanocytes and
TILs, in addition to MF/Sézary cells. Cell-cell contact and secretion of cytokines by these ;l
cells is likely to be important in maintaining survival and growth of neoplastic T cells (Section
1.10.1.5). Antigen presenting cells (APCs) are particularly important in activating T cells in
vivo (Johnson and Jenkins 1993). T cell-T cell interactions are also significant and can result
in activation through costimulatory pathways such as those mediated by CD28-B7 and
CD40-CD40 ligand (Grewal and Flavell 1996, Greenfield et al 1998). However, the limited
lifespan of T cells in vitro suggests that these interactions cannot maintain the viability of T
cell populations in the absence of other proliferative signals. Maintaining the survival of T
cells in vitro in the absence of these supporting elements is one of the challenges in
attempts to establish continuous T cell lines.
The presence of mixed cell populations In cultures of lymphocytes from skin lesions, PBMCs 
and lymph nodes could maintain the survival of MF/Sézary cells and promote the outgrowth 
of continuous T cell lines derived from neoplastic clones. Cultures of adherent cells derived ij
from the peripheral blood were able to support the growth of normal CD4^ and CD8^ T cells 
in the absence of exogenous cytokines for up to 3 months (Sutkowski et al 1995). Apoptosis 
that follows withdrawal of IL2 from activated normal T cells can be prevented by cultivation in 
the presence of fibroblasts (Scott et a l 1990) (Section 1.8.7.2). These stromal cells produce 
growth factors and could have an effect similar to that of exogenous CM.
2.1.6 Detection of retroviral infection in cultured cells
Methods for detecting infection with HTLV-I and HTLV-II in cultured T cells are described in 
Section 1.4.1. With varying degrees of specificity, these methods are applicable to the 
detection of other retroviruses, including novel T lymphotropic retroviruses. Virions can be 
visualised by EM in most productive retroviral infections and RT activity is detectable in 
culture supernatants, but these assays do not permit specific identification. Budding 
retroviruses in cultured T cells may be difficult to distinguish from cell membrane blebs. The 
RTs of HTLV-I, HTLV-II and BLV have stronger activity with magnesium (Mg^ "^ ) than with 
manganese (Mn^^) as cofactors (Gilden et al 1975, Graves et al 1977, Poiesz et a/ 1980a,
Rho et al 1981, Kalyanaraman e ta l 1982b, Hoffman et al 1985). Similarly, HIV-1 and HIV-2 
exhibit Mg^^-dependent RT activity (Barré-Sinoussi e ta l 1983, Popovic e ta l  1984). RT 
activity due to the presence of an exogenous retrovirus has to be distinguished from that 
produced by endogenous retroviruses and from non-specific cellular RT activity. Density 
gradient centrifugation can be used to associate RT activity with a particular density of 
particle.
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The use of immunological techniques for detection of virus-specific antigens is usuaiiy based 
on prior knowledge and isolation of the virus of interest or closeiy related viruses in order to 
generate specific reagents. Sera from patients with ATL were used to detect immunoiogicai 
reactivity in T cell lines infected with HTLV-I before a retrovirus had been identified in these 
cuitures (Miyoshi et al 1980, Hinuma et al 1981). Cross-reactivity between antibodies to virus 
structural group antigens (Gag) has been a useful technique for detecting novel retroviral 
infections in cuitivated ceils. The use of molecular techniques can be highly specific, for 
example using unique primers for amplification of HTLV-I sequences by PGR. Alternatively, 
group-specific consensus and degenerate primers can be used to ampiify retroviral 
sequences from a number of related viruses, as well as potentially from novel viruses 
(Chapter 3). In this study EM, RT assays and PCR were used in attempts to identify 
retroviruses in T cells cultured from patients with T cell neoplasia. A wide range of 
serological reactivity against HTLV-l/ll has been reported in MF/SS patients by different 
groups (Section 1.11.1.3). Serological testing conducted previously at the LRF Virus Centre 
had demonstrated that most patients with MF/SS were negative for HTLV-l/ll by ELISA and 
WB ELISA, with only a few patients exhibiting seroindeterminate reactivities. Therefore, 
serological testing was not performed routinely on samples from MF/SS patients in this 
study.
2.2 Sources of clinical samples
Samples for testing in this project were obtained from patients with MF/SS and other 
cutaneous lymphoid infiitrates, LGL ieukaemia and ALL in the United Kingdom (UK).
2.2.1 Cutaneous T cell lymphomas and other cutaneous lymphoid infiltrates
To study the involvement of retroviruses in CTCLs, sampies of skin, lymph nodes and blood 
were collected from patients with cutaneous lymphoid infiltrates in the West of Scotland and 
other parts of the UK. Most samples were submitted by Dr D Tillman, Western Infirmary and 
Department of Dermatology, University of Glasgow Medical School. Other samples were 
submitted by Professor R Mackie and Dr D Bilsland, Western Infirmary and Department of 
Dermatology, University of Glasgow Medical School, Dr D Ellis, Inverclyde Royal Hospital, 
Greenock, Dr J Norris, Dumfries and Galloway Royal Infirmary. Dumfries, Dr E Spilg,
Victoria Royal Infirmary, Glasgow, Dr F Humphreys, Dr J Hunter and Dr M Tidman, 
Department of Pathology, University Medical School, Edinburgh, and Dr N Kirkham, 
Department of Histopathology, Royal Sussex County Hospital, Brighton.
Samples were received from 36 patients with cutaneous lymphoid infiltrates during the 
period 1987 to 1995. Patients in this study were 20 to 91 years of age (mean 58 years, 
median 61 years). Histological, haematological and immunohistochemical examinations 
demonstrated that most cases were MF or SS but there were also cases of cutaneous 
(peripheral) T cell lymphoma (CTCL), angiocentric T cell lymphoma, small plaque 
parapsoriasis, Langerhan’s ceii histiocytosis (LCH) and CBCL (Table 2.3).
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The clinicopathological features of these cutaneous lymphoproliferative disorders are 
described in Section 1.10. Most patients with MF/SS conformed to the case definitions for 
these diseases and the neopiastic population in all cases consisted of CD4* T cells. One 
patient with SS (patient 1198) had a marked CD3* CD4^ lymphocytosis with aberrant 
expression of CD25 (Section 1.11.1.2). Samples of whole blood (10 ml) were diluted with an 
equal volume of transport medium containing heparin without preservative (Appendix 4: 
A4.2.2) and transported chilled to the LRF Virus Centre. Samples of fresh tissues (skin or 
lymph nodes) were placed in 10 ml of transport medium also containing heparin without 
preservative and transported similariy.
2.2.2 Large granular lymphocytic leukaemia
Samples of blood from six patients with LGL leukaemia in England were submitted by Dr M 
Bhavnani, Department of Haematology, Royal Albert Edward Infirmary, Wigan. Patients 
were 67 to 81 years of age and had CD3^ CD8^ LGL leukaemia (Table 2.4). T cell receptor 
(TCR) rearrangements were detected in one of four patients tested by SB hybridisation. 
Whoie biood (10 mi) was diluted with an equal volume of transport medium containing 
heparin without preservative and transported chiiied to the LRF Virus Centre.
2.2.3 Adult acute lymphoblastic leukaemia in butchers from Cardiff
PBMCs and bone marrow from five patients with ALL were kindly provided by Dr J Whittaker, 
Department of Haematology, University Hospital of Wales, Heath Park, Cardiff (Whittaker 
1991). All patients were male butchers from Cardiff, 21 to 31 years of age (age of one 
patient unknown). They had ALL of common, pre-B ceii or T cell type (Section 1.10.5) (Tabie
2.5). PBMCs had been harvested from heparinised blood samples at the University Hospital 
of Wales by Ficoll density gradient centrifugation (Section 2.2.2) and pellets of 1 x lO f cells 
stored frozen at -80°C. Bone marrow had also been stored frozen at -80°C. PBMCs and 
bone marrow were packed with solid COg (dry ice) pellets for transportation to the LRF Virus 
Centre.
2.2.4 Samples from people without neoplasia
Umbilical cord biood was collected at the Southern General Hospital, Glasgow, and Royal 
Alexandria Hospital, Paisley. The blood was mixed with an equal volume of transport 
medium with heparin at the time of collection and transported chilled to the LRF Virus 
Centre. These samples were not screened for viruses but the population was considered to 
be at low risk for infection with HTLV-I or HTLV-I I, since Scotland is not an endemic region 
for these viruses. UCMCs were used for cocultivation with cells derived from patients with 
neoplasia and as a source of CM for ceii cuitures (Section 2.3.6.10). Samples of human 
placenta were also obtained from the same sources for extraction of DNA. Peripheral blood 
was collected by venipuncture from adults working in the Department of Veterinary 
Pathology, University of Glasgow Veterinary Schooi, and placed in transport medium with 
heparin. PBMCs from aduit peripheral blood were used as negative control samples for 
PCRs.
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2.3 Materials and methods
2.3.1 Containment facilities for handling clinical samples
2.3.1.1 Level II containment facility
Containers with clinical samples were opened in class II microbiological safety cabinets 
(MSCs) In the level II containment facility at the LRF Virus Centre. The containment facility 
operated under negative pressure. Air extracted from MSCs and from the main containment 
room passed through independent high efficiency particulate air (HEPA) filters. Clean 
laboratory coats and surgical gowns were worn. MSCs and the main containment room were 
disinfected with formaldehyde gas every 6 months. Laboratory personnel were routinely 
vaccinated against hepatitis B virus (HBV) and tuberculosis. Samples entering the laboratory 
were assigned unique patient and sample identifying numbers. Accompanying documents 
were filed in the laboratory and sample details recorded in a computerised database.
2.3.1.2 Microbiological safety cabinets
Handling procedures and the laminar flow of air in the class II MSCs prevented cross­
contamination of samples and reduced the risk of infection of personnel. Two latex gloves 
were worn on each hand when working in MSCs. The outer gloves were discarded and 
replaced every time hands were withdrawn from the operating environment. Sample 
containers and the interiors of MSCs were sprayed with 1% Virkon-S or 70% ethanol before 
and after samples were handled. Disinfection was maintained for at least 15 minutes 
between uses of MSCs by different operators or for different purposes. Disposable plastic 
pipettes, sample containers, bottles for solutions and media, centrifuge tubes and tissue 
culture flasks were used for most work. The use of glass was minimised. Sterile round-nosed 
scissors and rats-toothed forceps were used for manipulation of tissues, including cutting 
tissues into pieces for extraction of DNA. Solutions were transferred by pipette using battery- 
operated devices. Components of pipetting devices potentially in contact with tissue culture 
fluids were dismantled and soaked in 1% Virkon-S between uses and filters were changed.
The three MSCs in the level II containment facility were used for handling different material. 
MSC 1 was used for handling known HTLV-I, BLV, EBV, human herpesvirus (HHV) 6 or 
HHV-7-infected cell lines. MSC 2 was used for handling clinical specimens and tissue 
cultures derived from those specimens. MSC 3 was used for preparing sterile medium and 
solutions and for handling cell cultures demonstrated to be free of specified exogenous 
retrovirus or herpesvirus infections. Viable cells were stored in liquid nitrogen (-195.8°C). 
Samples of serum and cells and tissue samples for DNA extraction were stored at -80°C in 
freezers in a room adjacent to the containment laboratory. Handling of potentially infectious 
material outside MSCs was undertaken with appropriate precautions. Cell culture flasks were 
sealed when in incubators and during handling in the main containment room. Cells were 
inactivated before removal from MSCs for quantification by haemocytometer counts (Section
2.3.3.3). During centrifugation tubes were placed in sealed screw-top cannisters (Aerosolve, 
Beckman).
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2.3.1.3 Disposal of waste
Used plasticware and glass heparin containers were soaked in 2% Virkon-S in trays for 1 
hour before the trays were placed in plastic autoclave bags and autoclaved at 121°C for 1 
hour. Discarded samples, solutions and tissue culture media were diluted with at least an 
equal volume of 2% Virkon-S in screw-top plastic containers and subjected to the same 
autoclave protocol. All other laboratory waste was placed in double autoclave bags and 
autoclaved at 121 °C for 1 hour before removal from the laboratory and disposal by 
incineration.
2.3.2 Materials
The sources of frequently used materials are listed in Appendix 3 and the compositions of 
routinely used solutions for cell biology are listed in Appendix 4. Additional reagents and 
buffers are specified in individual sections.
2.3.2.1 Cell culture
Cells were cultivated in 50 cm^ offset screw-top tissue culture flasks containing 5 to 10 ml 
medium (Costar) or in 250 cm^ flasks containing 25 to 50 ml medium (Appendix 4: A4.1). 
Some cultures were performed in 96-well microtitre plates containing 50 to 200 pi medium 
per well or 12-welt tissue culture plates containing 1 to 2 ml medium per well.
2.3.2.2 Materials for manipulation of fluids
Disposable pipettes (Costar) suitable for handling 1, 5, 10 and 25 ml volumes were used for 
transferring fluids (Appendix 4: A4.1). Blood samples, cell culture media and other fluids 
were centrifuged in 15 and 50 ml screw-top polypropylene centrifuge tubes (Falcon, Becton 
Dickinson and Sterilin, J Bibby). These tubes, as well as 5 ml screw-top polycarbonate bijous 
and 20 ml Universal tubes, were used for storing fluids and tissues. Small quantities of 
media and additives for cell culture were sterilised by filtration through 0.2 and 0.45 pm 
cellulose acetate filters (Acrodisc, Gelman Sciences) attached to syringes. Larger volumes 
were sterilised by vacuum filtration using 250 and 500 ml bottles with 0.2 or 0.45 pm 
cellulose acetate filters (Costar).
2.3.2.3 Centrifuges
The main centrifuge used for cell culture work was the GPR bench centrifuge (Beckman) 
with a GH 3.7 swinging bucket rotor. This held 15 and 50 ml screw-top polypropylene 
centrifuge tubes in racks inside screw-top cannisters (Aerosolve). Microtitre (96-well) plates 
were centrifuged using microplate carriers. A bench microcentrifuge (Micro Centaur, MSE) 
was used for centrifuging 0.6 ml flip-top PCR tubes and 1.5 ml flip-top and screw-top 
prolypropylene microcentrifuge tubes.
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2.3.2.4 Cell culture medium
Standard tissue culture medium consisted of RPMI 1640 medium nominally containing 10 or 
20% foetal bovine serum heat-inactivated at 56°C (hi-FBS), 400 mg/ml streptomycin, 400 
U/ml penicillin and 2 mM L-glutamine (RPMI 1640 + 10 or 20% hi-FBS + 2-ME) (Moore et al 
1967) (Appendix 4: A4.2.1). Medium with 10% hi-FBS was used for most established cell 
lines and medium with 20% hi-FBS for cultivation of cells derived from clinical samples. 
Phenol red was included as an Indicator of changes in pH. Gentamicin was sometimes 
added at a final concentration of 50 to 70 pg/ml if bacterial contamination developed. 
Amphotericin B was added to cultures at risk of fungal contamination at a final concentration 
of 1 pg/ml. However, cultures that developed fungal growth were discarded without opening 
the contaminated flasks.
2.3.3 Manipulation o f cells
2.3.3.1 Standard procedure for cultivation of eucaryotic cells
Established cell lines were usually split at a ratio of 1:4 to 1:6 twice weekly to densities 
ranging from 5 x 10'^  to 5 x 10  ^cells/ml. The tissue culture flasks were aerated with filtered 
5% CO2 in air for 30 sec then sealed and incubated at 37°C. Cells in suspension were 
diluted with an appropriate quantity of standard tissue culture medium and unwanted cells 
and medium were discarded by dilution with at least an equal volume of 2% Virkon-S.
Cells that formed adherent monolayers, including BLV-FLK and fibroblast cultures derived 
from skin samples of patients, were separated from the plastic of the tissue culture flasks by 
incubation with trypsin or dispase (Appendix 4: A4.2.5). For trypsinisation, the cell culture 
medium was removed and replaced with 1.5 to 3 ml 0.25% crude trypsin in 1 M 
ethylenediaminetetraacetic acid (EDTA) (trypsin-EDTA). The flask was incubated at 37°C for 
5 to 15 min with occasional gentle tilting. When most cells appeared separated by light 
microscopy, the flask was tapped firmly to dislodge remaining adherent cells. Alternatively, 
the fluid was flushed up and down several times using a pipette. Tissue culture medium 
containing 20% hi-FBS (10 ml) was added to the flask and mixed to dilute and Inactivate the 
trypsin. The cells were then centrifuged at 270 g (1,000 rpm) for 5 min and the supernatant 
was discarded. The cell pellet was resuspended in an appropriate volume of tissue culture 
medium, returned to a tissue culture flask and aerated with 5% CO2 in air before incubation. 
Dispase was used at a concentration of 1 U/ml for passaging cultures of skin from clinical 
samples that had adherent fibroblasts underlying lymphocytes in suspension.
When the quantity of cells extracted from a clinical sample was low, 12-well plates or 96-well 
microtitre plates were used to maintain the density of cells in culture. Cells in 96-well 
microtitre plates were usually cultured at 1 x 10® to 3 x 10® cells/ml in 200 pi medium. N-2- 
hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES) buffer, gentamicin and 
amphotericin B were added to the standard tissue culture medium. Approximately 200 pi of 
autoclaved ultrapure water were added to unused wells to maintain humidity. The lids were 
secured with tape.
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2.3.3.2 Light microscopy
An inverted light microscope (Labovert, Leitz) was used for examination of cells in culture 
flasks and for haemocytometer counts at powers of 40x, 100x or 200x.
2.3.3.3 Quantification of cells
The concentrations of PBMCs, UCMCs and cultured cells were determined by counting cells 
in known volumes using an improved Neubauer haemocytometer chamber (Fisons). Cells in 
even suspension (50 pL) were stained with 0.1% crystal violet in 1% acetic acid (50 pi) for 3 
to 5 min in a 5 ml screw-top polycarbonate bijou. Erythrocytes in preparations of PBMCs 
were lysed by the acetic acid. The stained cells were pipetted under the coverslip of the 
haemocytometer chamber and the numbers of viable cells were counted in each of four 1 
mm X 1 mm x 0.1 mm (0.1 mm®) chambers. The concentration of cells in the original volume 
was calculated by multiplying the total number of viable cells by 1 x 10"^ . The 
haemocytometer chamber and glass cover slips were stored in 1% Virkon-S between uses.
2.3.3.4 Cryopreservation of viable cells and cell cultures
Viable cells for cryopreservation were suspended at a density of 1 x 10® to 1 x 10  ^cells/ml in 
tissue culture medium containing 20 to 50% hi-FBS and 10% dimethyl sulphoxide (DMSO). 
Alternatively, cells were suspended in hi-FBS containing 8% DMSO. Aliquots of 1 ml were 
transferred to screw-top polypropylene low temperature storage vials (Cryotube, Nunc). 
These were placed In a freezing container (Nalgene) filled with isopropanol and held at - 
80‘^ C for 4 hours for a controlled decrease (1°C/min) in temperature. The vials were then 
transferred to a liquid nitrogen (liqNa) container for storage at ~195.8°C.
2.3.3.5 Cultivation of cryopreserved cells
Cryopreservation tubes were removed from liquid nitrogen and placed in a screw-top metal 
cannister to prevent dissemination of contents should the tubes explode as they thawed. The 
metal cannister was placed in a MSC for 5 min until the contents were thawed. The cryotube 
was removed from the cannister, opened and the contents were pipetted drop by drop into a 
15 ml screw-top polypropylene centrifuge tube containing 5 ml of the appropriate tissue 
culture medium. The 15 ml tube was centrifuged at 270 g for 5 min and the supernatant was 
discarded. The cell pellet was resuspended in 2 to 5 ml of standard tissue culture medium 
and the concentration of viable cells was determined (Section 2.3.3.3). Cells were diluted to 
5 X 10® to 5 X 10® cells/ml In appropriate tissue culture medium, aerated with 5% CO2 in air 
and incubated at 37°C. Cells were examined daily and subcultured as required, if many cells 
died in the first week of culture, these were removed by centrifuging through a Ficoll gradient 
(Section 2.3.5.1). The purified viable cells were washed by centrifuging and discarding the 
supernatant, then were resuspended in fresh medium, aerated with 5% CO2 in air and 
returned to cultivation.
i
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2.3.3.6 Collection of cell culture supernatants
Supernatants were collected from selected cell cultures for use as CM and for assay of RT 
activity after centrifuging at 270 g for 5 min.
V 2.3.3.7 Cytospins for Epstein-Barr virus latent membrane protein staining
Cultured cells for cytospin preparations for EBV latent membrane protein (LMP) 1 staining 
were centrifuged to remove the medium and washed three times in PBS 1x. After counting 
using an haemocytometer (Section 2.3.3.3), cells were resuspended at a concentration of 1 
X 10® cells/ml. Volumes of 100 pi containing 1x10® cells were centrifuged onto 3- 
aminopropyltriethoxysilane (APES)-coated glass cytospin slides (Fisons) at 400 rpm in a 
cytospin centrifuge (Shandon Cytospin 2) for 5 min. The cytopsin preparations were air 
dried, fixed in ice-cold acetone or methanol for 30 min and stored at -20°C. Staining for EBV 
LMP-1 with MAbs CS1-4 was performed by Dr A Armstrong at the LRF Virus Centre using 
techniques established in the laboratory (Armstrong et a l 1992).
2.3.3.8 Testing for mycoplasma contamination
1 Testing for contamination with mycoplasma was performed by June Freeland and Linda
Andrew at the LRF Virus Centre. Sub-confluent normal rat kidney (NRK) cells were grown 
with 0.5 ml test culture supernatant in slide flasks (Nunclon, Nunc) for 3 days at 37°C. The 
cells were fixed with ice cold methanohglacial acetic acid (3:1), washed twice with distilled 
water, then stained with 50 ng/ml Hoescht 33258 (Sigma) for 10 min at room temperature 
(Appendix 4: A4.7). Stained cells were washed with distilled water and examined under a 
wet-mounted cover slip using a fluorescent microscope (Laborlux K, Leitz). Mycoplasma 
typing was performed using a commercial PCR kit (Boehringer-Mannheim).
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2.3.4 Established ceil lines>
2.3.4.1 C8166
C8166 (C81-66-45) is an HTLV-l-infected human CD4^ T cell line derived from the 
 ^ productive HTLV-l-infected cell line HUT102 (Salahuddin et al 1983). HUT102 (ATCC TIB
162) was the first HTLV-l-infected cell line established (HTLV-I type strain H T L V c r) and was 
derived from lymph node cells of a patient in the USA with cutaneous ATL resembling MF 
‘ (Gazdar ef a /1979, 1980, Poiesz ef a/1980a, b. Hay ef a /1988) (Section 1.3.2.1). C8166
contains one full length defective and two incomplete integrated HTLV-I proviruses, the 
incomplete proviruses having deletions of most of their regions from gag to env (Bhat et al 
1993). All three proviruses are transcriptionally active and C8166 expresses Tax and p2 l"’ 
but has no expression of Rex, Gag or Env, no detectable RT activity and no production of 
virions (Salahuddin et al 1983, Bhat et al 1993). It is thus a suitable cell line for handling at 
containment level II. DNA and cell pellets derived from C8166 were used as positive controls 
for HTLV-I and HTLV-l/ll PCR analyses.
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2.5.4.2 J.JHAN
J.JHAN is a derivative of the human CD4^ T cell line Jurkat (JM) (ATCC TIB-152), cultured 
from neoplastic T cells of a child with ALL and not known to be infected with any exogenous 
retrovirus (Schneider et al 1977, Gillis and Watson 1980, Hay et al 1988). It was provided to 
the LRF Virus Centre by Dr M Steele, Western General Hospital, Edinburgh. DNA and cell 
pellets from this cell line were used as negative controls for HTLV-I and HTLV-l/ll PCR 
analyses and culture supernatants were collected for use in the RT assay.
2.3.4.3 L-726A
L-726A is an IL2~independent CD4^ T cell line established at the LRF Virus Centre from skin 
lesions of a patient with SS (Crae et al 1991) (Section 2.1.3.1). No viruses have been 
demonstrated in this cell line. DNA and cell pellets from L-726A were tested for HTLV-I and 
HTLV-l/ll by PCR and culture supernatants were tested for evidence of RT activity.
2.3.4.4 HH
HH Is an IL2-independent CD4'' T cell line derived from PBMCs of a patient with CTCL and 
was kindly provided by Dr G Starkebaum, Department of Medicine, Seattle Veterans Affairs 
Medical Center, Seattle, Washington, USA (Starkebaum e ta l 1991) (Section 2.1.3.1). This 
cell line is not known to be infected with HTLV-I. DNA and cell pellets from HH were tested 
for HTLV-I and HTLV-l/ll by PCR and culture supernatants were tested for evidence of RT 
activity.
2.3.4.5 My-La and My-La MC
My-La is an IL2 and IL4-dependent CD4"' T cell line established from the skin of a patient 
with MF (Kaitoft et al 1992) (Section 2.1.3.1). My-La marker chromosomes (MC) is a 
derivative of My-La with a 46XY= karyotype. These cell lines were kindly provided by Dr K 
Kaitoft, Department of Medicine, Institute of Human Genetics, Aarhus University, Denmark. 
They were grown in standard tissue culture medium containing 10% hi-FBS, 50 U/ml IL2 and 
30 U/ml IL4. DNA and cell pellets were tested for HTLV-I and HTLV-l/ll by PCR and culture 
supernatants were tested for evidence of RT activity.
2.3.4.6 BLV-FLK
BLV-FLK is a BLV-infected foetal lamb kidney (FLK) fibroblast cell line (Astier et al 1978, 
Onuma et ai 1981, Rhim et al 1983, Hay et al 1988). It has one or a few intact copies of the 
BLV provirus and produces infectious virions (Marbaix e ta l 1981). Cell culture supernatants 
from this cell line were used as positive controls in RT assays and DNA and cell pellets were 
used as positive controls in BLV PCR analyses (Chapter 3).
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2.3.4.7 FLK
FLK is an ovine fibroblast cell line not known to be infected with exogenous retroviruses 
(Astier et al 1978). Infection of this cell line with BLV resulted in the persistently infected cell 
line BLV-FLK described above. Cells obtained from this cell line were used as negative 
controls in BLV PCR analyses.
2.3.5 Processing o f clinical samples
2.3.5.1 Purification of mononuclear cells from peripheral blood
Blood samples had been diluted with an equal volume of heparinised transport medium at 
the time of collection (Section 2.2.1) (Appendix 4: A4.2.2). On receipt at the LRF Virus 
Centre they were diluted with an equal volume of Hanks’ balanced salt solution (HBSS + 2% 
hi-FBS) to one quarter of their original concentration. The diluted blood (20 to 25 ml) was 
carefully layered with a pipette over 15 ml of metrizoate-Ficoll (Ficol 400 solution, Ficoll- 
Paque, Pharmacia LKB or J.Prep, J.Bio), an aqueous solution of density 1.077 g/ml 
containing polymerised sucrose and sodium metrizoate/diatrizoate, in each of two 50 ml 
screw-top polypropylene centrifuge tubes (Falcon). The gradient was centrifuged at 1,500 g 
for 20 to 30 min at 18°C with no braking. Erythrocytes passed through the layer of Ficoll to 
sediment in the bottom. PBMCs remained at the interface with the Ficoll layer. PBMCs were 
removed with a polypropylene bulb pipette, transferred to a 50 ml centrifuge tube containing 
30 ml HBSS + 2% hi-FBS and centrifuged at 270 g for 5 min. The PBMCs, forming a pellet 
at the bottom of the centrifuge tube, were retained and the supernatant was discarded. If the 
supernatant was red due to lysed erythrocytes, the washing step was repeated by 
resuspending the cells in 30 ml HBSS and centrifuging. The pelleted PBMCs were 
resuspended in 10 ml medium and centrifuged again. The final cell pellet was resuspended 
in 1 to 3 ml medium and the concentration of cells was determined using an 
haemocytometer (Section 2.3.3.3). PBMCs were diluted to 1 x 10® to 2.5 x 10® cells/ml in 
appropriate medium with selected stimulants for cultivation of T cells (Section 2.3.6).
Volumes containing 1 x 10® to 1 x 10® PBMCs in PBS 1x were transferred to 15 ml screw-top 
polypropylene centrifuge tubes to prepare cell pellets for DNA extraction (Section 3.3.5.1). 
Cell pellets for PCR were prepared with 1x10® PBMCs In PBS 1x in 0.6 ml flip-top PCR 
tubes (Section 3.3.5.1).
2.3.5.2 Processing of tissue samples
Tissue samples (skin, lymph nodes and human placenta) were processed on the day of 
receipt for tissue culture and storage at -80°C for later DNA extraction. Tissues were 
dissected into pieces approximately 1 mm® in sterile plastic Petri dishes using sterile round­
nosed scissors and rats-toothed forceps. Approximately 1 ml of standard tissue culture 
medium was added to prevent desiccation. Half of each tissue was stored frozen at -80°C for 
DNA extraction and half was cultivated in an attempt to establish T cell lines (Section 2.3.6). 
Dispase II was added to the medium at a concentration of 1 U/ml and incubated at 37°C for 
10 to 15 min to assist in the dissociation of cells from samples of skin and lymph nodes.
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2.3.6 Cultivation o f lymphocytes from clinical samples
PBMCs and cells from skin and lymph nodes of patients with MF/SS and other cutaneous 
lymphoid infiltrates were cultivated in an attempt to establish T cell lines. Cells and tissues 
were suspended in standard tissue culture medium (RPMI 1640 + 20% hi-FBS + 2-ME) 
containing selected exogenous cytokines (Appendix 4: A4.2.6), CM or no stimulants, or were 
cocultivated with UCMCs. Specific protocols were adapted from those used by other groups 
to establish CD4"' cell lines from patients with MF/SS (Sections 2.1.3.3 and 2.1.3.4) (Table
2.6). Once or twice weekly cells were centrifuged and resuspended in fresh medium 
according to the selected protocol.
2.3.6.1 Unstimulated cultures
Cells harvested from blood, skin and lymph nodes were cultivated in flasks at a density of 1 x 
10® cells/ml. Half of the culture volume was removed and centrifuged at 270 g for 5 min once 
weekly or as required. The cells were resuspended in an equal volume of fresh medium and 
returned to the same flask. The remaining supernatant was stored for assay of RT activity, 
as were supernatants collected from other cultures (Section 2.3.3.6).
2.3.6.2 Phytohaemagglutinin and interleukin 2
Cells were cultivated at a density of 1 x 10® cells/ml with 5 pg/ml PHA-P for 48 to 72 hours. 
The medium was then replaced with medium containing 50 U/ml IL2.
2.3.6.3 Concanavalin A and interleukin 2
Cells were cultivated at a density of 1 x 10® cells/ml with 5 pg/ml ConA for 48 to 72 hours. 
This was replaced with medium containing 50 U/ml IL2.
2.3.6.4 Interleukin 2
Cells were cultivated at a density of 1 x 10® cells/ml with 50 U/ml 1L2.
2.3.6.5 Interleukin 7
The protocol for use of IL7 for cultivation of T cells from patients with MF/SS was adapted 
from Dalloul at al (1992) and Foss et a /(1994). Cells were cultivated at a density of 1 x 10® 
cells/ml with 10 ng/ml IL7.
2.3.6.6 Interleukin 2 and interleukin 7
Cells were cultivated at a density of 1 x 10® cells/ml with 50 U/ml IL2 and 10 ng/ml IL7.
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Table 2.6: Protocols for cultivation of T cells from  
cutaneous T cell lymphoma patients.
PHA IL2 5 pg/ml phytohaemagglutinin then 50 U/ml interleukin 2
ConA IL2 2 pg/ml concanavalin A then 50 U/ml interleukin 2
1L2 50 U/ml interleukin 2
IL2 + GMCSF 10 U/ml interleukin 2 + 100 U/ml granulocyte macrophage colony stimulating factor
IL2 + IL4 50 U/ml interleukin 2 + 30 U/ml interleukin 4
IL2 + IL7 50 U/ml interleukin 2 + 10 ng/ml interleukin 7
IL7 10 ng/ml interleukin 7
UCMC CM 25% umbilical cord blood mononuclear cell conditioned medium
IL2 + SAP CM 15 U/ml interleukin 2 + 0.2% Sezary activating factor conditioned medium
Cocultivation Cocultivation with umbilical cord blood mononuclear cells
Unstimulated No exogenous growth factors
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2.3.6.7 Interleukin 2 and interleukin 4
The protocol for use of IL2 and IL4 to stimulate MF/Sézary cells was adapted from Kaitoft et 
al (1992). Cells were cultivated at 1 x 10® cells/ml with 50 U/ml IL2 and 30 U/ml IL4.
2.3.6.8 Interleukin 2 and granulocyte-macrophage colony stimulating factor
GMCSF was used according to the method described by Zucker-Franklin et a/ (1991). Cells 
were cultivated at a density of 2.5 x 10® cells/ml with 10 U/ml IL2 and 100 U/ml GMCSF.
2.3.6.9 Interleukin 2 and Sezary T cell activating factor conditioned medium
SAF CM was prepared according to the method described by Abrams et al (1991b, 1993). 
PBMCs from a patient with SS (patient 1198) were cultivated at 4 x 10® cells/ml with 2 pg/ml 
ConA for 48 hours. The supernatant was harvested by centrifugation at 270 g  for 5 min. 
Residual ConA was inactivated with 1 mg/ml a-methyl mannoside and the supernatant was 
filtered into a 20 ml screw-top Universal container through a 0.45 pm cellulose acetate filter 
(Acrodisc, Gelman Sciences) attached to a syringe. This supernatant, designated SAF CM, 
was stored at ~20°C until required. Cultures were initiated from other patients with MF/SS at 
densities of 1 x 10® cells/ml with 0.2% SAF CM and 15 U/ml IL2 for 3 days. The cultures 
were then maintained with 15 U/ml IL2 (without SAF CM), medium being replaced two to 
three times per week. After 6 weeks, cultures were re-stimulated with 0.2% SAF CM and 15 
U/ml IL2 for 3 days before reverting to 15 U/ml IL2 alone.
2.3.6.10 Umbilical cord blood mononuclear cell conditioned medium
UCMC CM, an unmodified culture supernatant also known as lymphocyte conditioned 
medium, was prepared from UCMCs stimulated with PHA-P. UCMCs were cultivated at a 
density of 1 x 10® to 2.5 x 10® cells/ml with 5 pg/ml PHA-P for 48 hours. The supernatant was 
harvested after 3 days by centrifuging the cells at 270 g for 5 min and stored at -20°C.
UCMC CM was added at a concentration of 25% to cultures of cells from clinical samples 
containing 1x10® cells/ml that had been stimulated with 5 pg/ml PHA-P for 48 hours. The 
supernatant was replaced with a mixture of 75% medium and 25% UCMC CM once per 
week.
2.3.6.11 Cocultivation with umbilical cord blood mononuclear cells
UCMCs were cocultivated with cells from patients with neoplasia to act as recipient cells for 
infection with retroviruses released from patient cells and to produce growth stimulants that 
might promote outgrowth of continuous T cell lines. UCMCs were cultivated at 1 x 10® 
cells/ml with 5 pg/ml PHA-P for 48 to 72 hours. These cells were centrifuged then 
resuspended at 2 x 10® cells/ml. Fresh or cultured cells (donor cells) from patients with 
neoplasia were suspended at a density of 2 x 10® cells/ml. Equal volumes of suspensions of 
donor and recipient cells were mixed in the same flask and cultivated with 50 U/ml IL2. A 
control flask containing 2x10® UCMCs/ml in the same medium was maintained in parallel. A
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different sex was chosen for recipient UCMCs and donor cells from the patient with 
neoplasia so that any cell line established from cocultures could be karyotyped to determine 
the origin of the cells.
2.3.7 Immunophenotyping o f cultured lymphocytes by flow cytometry
The immunophenotypes of cultured lymphocytes were determined by flow cytometry using 
an EPICS Elite II (Coulter). Cells were labelled with MAbs to determine the expression of 
surface antigens with specificity for different cell types (Table 2.7) (Appendix 4: A4.3.2).
Cells removed from cultures were centrifuged in 15 ml screw-top polypropylene tubes at 270 
g for 5 min. The supernatant was discarded and the cells were resuspended in 5 ml HBSS + 
2% hi-FBS. After counting using an haemocytometer (Section 2.3.3.3), aliquots of 1 x 10® 
cells were transferred to 5 ml polypropylene cytometer tubes (Sarstedt) and centrifuged 
again at 270 g  for 5 min. The supernatant was removed and the cells were resuspended in 
PBS 1x containing 0.1% sodium azide and 2% bovine serum albumin (PAB). The tubes were 
centrifuged and the supernatant was removed. The cells were resuspended in 50 pi PAB 
containing 20% rabbit serum and held on ice for 30 to 60 min to block non-specific binding 
sites on cells. The cells were again washed with 1 ml PAB, centrifuged and the supernatant 
discarded. This solution was replaced with 10 pi of a solution containing 20% rabbit serum in 
PAB and 5 pl/ml fluorescein isothlocyanate (FITC) or R-phycoerythrin (RPE)-conjugated 
murine MAbs against CD2, CD4, CDS, GDI 5, GDI 9, GD30, GD33 or GD45. FITG and RPE- 
conjugated murine MAbs against Asperg///t/s n/ger glucose oxidase were used as negative 
controls. Cells were double-labelled with anti-GD2-FITG + anti-GD19-RPE and anti-GD8- 
FITG + anti-GD4-RPE for two-colour EPICS analysis. Binding of MAbs to cells was allowed 
to proceed for 20 to 30 min on ice. Unbound MAbs were removed by centrifuging three times 
at 270 g for 5 min, the supernatant being removed and the cell pellets resuspended in 1 ml 
PAB each time. After the last wash step, the cells were fixed by adding 1 ml 1% 
paraformaldehyde In PBS 1x and held at 4°C until analysed by flow cytometry. EPICS 
analysis was performed by Linda Andrew in the LRF Virus Centre.
2.3.8 Electron microscopy
Cells from four long-term cultures of T cells (> 6 months) established from three patients with 
MF, as well as lymphocytes from five other patients with MF or SS after 21 to 50 days in 
culture, were processed for electron microscopy (EM) in an attempt to observe intracellular 
and budding retrovirus particles. After determining the density of cells by counting using an 
haemocytometer (Section 2.3.3.3), aliquots of 5 x 10® cells were placed in 15 ml screw-top 
polypropylene centrifuge tubes. The tubes were centrifuged at 270 g for 5 min and the 
supernatant was discarded. Cell pellets were resuspended In 5 ml of 2% glutaraldehyde in 
0.05 M sodium cacodylate pH 7.2 to 7.3 and the tubes were centrifuged at 900 g (2,000 
rpm). The supernatant was removed and carefully replaced with 1 ml glutaraldehyde 
solution. Glutaraldehyde-fixed cell pellets were submitted to the EM unit in the Department of 
Veterinary Pathology for post-fixing, epoxy embedding and examination by thin section 
transmission EM (Zeiss 109). Processing and examination of EM samples were performed 
by Ross Blackley, with additional interpretation by Dr Helen Laird.
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Table 2.7: Specificity of selected haematopoietic cell surface markers.
Cell surface markers are indicated by their cluster of differentiation (CD) nomenclature.
Surface marker Predominant cell types
CD45 Haematopoietic cells
CD2 T cell
CD19 B cell
CD3 Mature T cell
CD4 CD4^ helper/inducer T cell
CDS CD8^ cytotoxic/suppressor T cell
CD15 Myeloid lineage cells
CD33 Myeloid lineage cells
CD30 Activation marker
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2.3.9 Reverse transcriptase assay
2.3.9.1 Principle of reverse transcriptase assay
Reverse transcriptase (RT) is essential for retroviral replication and present in all replication 
competent retrovirus virions (Baltimore 1970, Temin and Mizutani 1970) (Section 1.2.3). An 
assay based on detection of RT activity can be used as a general technique for revealing the 
presence of retroviruses. RT assays are based on incorporation of nucleosides into DNA 
using RNA as a template by utilising the RNA-dependent DNA polymerase activity of viral 
RTs. The gold standard is the conventional RT assay based on incorporation of radioactive 
nucleosides into the cDNA product and measurement of radioactivity (Kacian 1977). The 
inclusion of Mg^  ^or Mn®^  as cofactors in the assay is used to determine the relative Mg^  ^or 
Mn^^-dependence of any RT activity present. Use of MAbs and biotinylated or digoxigenin- 
labelled nucleosides has allowed enzyme-linked immunosorbent assay (ELISA)-based 
assays for RT activity to be developed, increasing sensitivity (Eberle and SeibI 1992, Suzuki 
et al 1993). Sensitivity has been further increased with PCR-based RT assays that allow 
exponential amplification of cDNA produced from an RNA template, with detection of product 
by Southern blot (SB) hybridisation or ELISA (Silver et al 1993, Pyra et al 1994). RNA 
viruses are used as templates in these assays because they do not have a DNA phase that 
could contaminate the RT-PCR reaction and are utilised less efficiently than synthetic 
templates for reverse transcription by cellular DNA polymerases, reducing non-specific 
reactivity (Robert et al 1972).
2.3.9.2 Conventional reverse transcriptase assay
The conventional reverse transcriptase assay was performed according to the method of 
Klement and Nicolson (1977). Supernatants collected from cell cultures and stored at -20°C 
(Section 2.3.3.6) were thawed and clarified by centrifugation at 10,000 g (13,000 rpm) for 20 
min in a J2-21 centrifuge (Beckman) with a JA-20 fixed angle rotor. Clarified supernatants 
were transferred to 10 ml plastic centrifuge tubes (Ultra-Clear, 14 mm x 89 mm, Beckman) in 
SW41 Ti buckets. The tubes were filled to within 0.5 cm of the top with Tris-NaCI-EDTA 
(TNE) 1x and opposing buckets were balanced to within 50 mg. The samples were 
centrifuged at 210,000 g (35,000 rpm) in an L8-60M ultracentrifuge (Beckman) with an 
SW41 Ti swinging bucket rotor at 4°C for 1 hour. Alternatively, they were centrifuged at 
274,000 g (40,000 rpm) for 30 min. Retrovirus virions would be expected to form part of a 
pellet including some cellular debris at the bottom of the tubes. The supernatants were 
removed, the tubes were allowed to drain and the inside surfaces were dried, taking care not 
to dislodge the pellet. Virus disruption buffer, containing 20 mM dithiothreitol (DTT), 0.1% 
Nonidet P-40 (NP-40), 40 mM Tris pH 8.1 and 50m M KCI (Appendix 4: A4.4.2), was added 
with a pipette (170 pi for each 10 ml of original supernatant volume) and the bottom of each 
tube was scraped with the pipette tip to dislodge adherent debris and virus particles. The 
tubes were placed on ice for 10 to 15 min to allow virions to be disrupted by the buffer. The 
solution was assayed for RT activity immediately or stored at -80°C.
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Reaction solutions (labelled X, Y and Z) were prepared for testing for and Mn" 
dependent RT activity (Table 2.8). In the presence of RT responsive to either cofactor, 
tritiated thymidine triphosphate (®H-TTP) (Appendix 4: A4.4.3) would be Incorporated by 
reverse transcription into radiolabelled poly-thymidine deoxyribonucleic acid (poly-dT) that 
could be quantified in a scintillation counter. Solution X contained poly-adenosine ribonucleic 
acid (poly-rA) and oligo-thymidine deoxyribonucleic acid (oligo-dT) (Poiy(rA).p(dT)i2-i8. 
Pharmacia): the poly-rA acted as a template and the oligo-dT acted as a primer for RNA- 
dependent DNA polymerase (RT) activity in the presence of Mg^  ^or Mn^ .^ Solution Y 
contained poly-adenosine deoxyribonucleic acid (poly-dA) and oligo-dT (Poly(dA).p(dT)i2-i8, 
Pharmacia); the poly-dA acted as a template for DNA-dependent DNA polymerase activity 
and the oligo-dT similarly acted as a primer. Since DNA polymerases of cellular origin may 
have a degree of RNA-dependent DNA polymerase activity, the quantification of DNA- 
dependent DNA polymerase activity in a sample gives an indication as to whether RT activity 
In a sample is likely to be due to the presence of a retrovirus or to contamination by cellular 
material (Goodman and Speigelman 1971). Solution Z did not contain either synthetic 
oligonucleotide reagent and acted as a negative control for ®H-TTP retention within the 
assay system.
In each assay, samples of supernatant were labelled 1, 2, 3 ... n. Assays for both Mn®^  and 
Mg^^-dependent RT activities were performed in duplicate. For each cofactor, 25 pi of 
reaction solution X, Y or Z were added to duplicate 15 ml screw-top polypropylene tubes 
labelled Xi, Yi, Zi; X2, Y2, Z2; X3, Y3, Z3; ... Xn, Yn, Zn (Table 2.9). Disrupted virus (25 pi) was 
added to each of these volumes and the mixtures were incubated in a water bath at 37°C for 
1 hour. The tubes were placed on ice and mixed with approximately 10 ml of an aqueous 
solution containing 10% trichloroacetic acid (TCA) and 1% w/v sodium pyrophosphate 
(NaPPi) that had been cooled to 4°C. This mixture was placed on ice for 10 to 20 min to 
precipitate DNA, including ®H-TTP-labelled products of the RT reaction.
A 1225 sampling manifold (Millipore) was used to collect precipitated DNA onto filters (GF/C 
glass microfibre filters, 2.5 cm, Whatman) by vacuum filtration (OM109 vacuum/pressure 
pump, Millipore). The top plate had 12 cups, each holding up to 15 ml. It was screwed onto a 
unit in which 12 glass microfibre filters were placed over polypropylene support screens on a 
support plate. Fluid passed through the filters under vacuum and was collected into a 
reservoir. The glass microfibre filters were moistened with a few ml of 10% TCA, 1% NaPP, 
before the RT assay samples (approximately 10 ml) were poured into the cups and vacuum 
filtration commenced. The RT assay reaction tubes were rinsed with approximately 10 ml of 
10% TCA, 1% NaPPii this was poured into the cups on the sampling manifold top plate and 
the vacuum filtration repeated. The filters were rinsed twice with 10 to 15 ml 5% TCA under 
vacuum, then with 10 ml 98% ethanol (absolute alcohol) under vacuum. The glass microfibre 
filters were removed from the apparatus with plastic forceps and allowed to dry on blotting 
paper at room temperature. The sampling manifold was dismantled and soaked in 
decontaminating solution (Decon) overnight, then rinsed thoroughly with water and allowed 
to dry.
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Table 2.8; Reaction solutions for reverse transcriptase assay.
Reagent X Y Z
(W) (Ml) (Ml)
Mn^^-dependent reverse transcriptase assay
0.8 M Tris pH 8.1 2 0 2 0 2 0
Tris pH 8.1, 0.15 M NaCI - - 160
1 M KCI 2 0 2 0 2 0
20 mM MnCl2 40 40 40
5  U/ml Poly(rA).p(dT)i2-i8 160 - -
5 U/ml Poly(dA).p(dT)i2-i8 - 160 -
®H TTP 40 40 40
Ultrapure water 120 120 120
Total 400 400 400
Mg^^-dependent reverse transcriptase assay
0.8 M Tris pH 8.1 20 20 20
Tris pH 8.1, 0.15 M NaCI - - 160
1 M KCI 20 20 20
0.1 M MgClz 80 80 80
5 U/ml Poly(rA).p(dT)i2-i8 160 - -
5 U/ml Poly(dA).p(dT)i2-i8 — 160 -
®HTTP 40 40 40
Ultrapure water 80 80 80
Total 400 400 400
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Table 2.9: Preparation of samples for reverse transcriptase assay.
Cofactor Sample
code
RNA
activity
(rA)
DNA
activity
(dA)
Negative
activity
(N)
X Y Z
Mn^^ 1 Xi Yi Zi
2 Xg Y2 Za
3 X3 Ys Z3
n Xn Yn Zn
Mg"" 1 Xi Yi Zi
2 X2 Yg Za
3 X3 Y3 Z3
n Xn Yn Zn
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The dry glass microfibre filters containing RT assay products were placed in 18 ml Type II 
polyethylene scintillation vials (Poly-Q vials, Beckman) with 5 ml scintillation liquid (Ecoscint 
A, National Diagnostics). Vials were loaded onto racks in a scintillation counter (LSI 701 
Liquid Scintillation System, Beckman) and the ®H counts per minute (cpm) were determined 
by exposure of the detector for 10 min per vial. After use, scintillation vials, fluid and filters 
were place in sealed plastic bags and sent for disposal through the same system as for other 
radioisotopes in use in the Department of Veterinary Pathology.
The RNA-dependent DNA polymerase (RT) activity (rA) in each sample, determined by 
quantification of ®H-TTP-labelled product transcribed from the poly-rA template, was 
compared to the DNA-dependent DNA polymerase activity (dA) in the same sample, 
determined by quantification of ®H-TTP-labelled product transcribed from the poly-dA 
template, after correction for background ®H-TTP activity with no template (N). Evidence for 
RT activity was an elevated value of rA divided by N (rA/N) with either Mn"" or Mg"", while 
the values of dA divided by N (dA/N) in the same sample remained low.
2.3.9.3 Positive and negative control samples
Positive control samples for testing in the RT assay were supernatants obtained from known 
retrovirus-infected cell lines that are productive for retrovirus virions. Supernatants from the 
BLV-infected fibroblast cell line BLV-FLK grown at the LRF Virus Centre were used as 
positive controls for Mg""-dependent RT activity (Section 2.3.4.6). Supernatants from FL4, 
an IL2-dependent feline cell line infected with the Petaluma strain of feline immunodeficiency 
virus (FIV) were used as an additional positive control for Mg""-dependent RT activity 
(Yamamoto et al 1991 ). Supernatants from this cell line were provided by Dr M Hosie, 
Department of Veterinary Pathology. SSN-1 is a fish cell line derived from the striped 
snakehead {Channa striatus) and persistently infected with snakehead fish retrovirus (SnRV) 
(Frerichs et al 1991, Hart et al 1996). Supernatants from this cell line, used as a positive 
control for Mn""-dependent RT activity, were kindly provided by Dr D Hart, Department of 
Veterinary Pathology.
2.3.9.4 Product-enhanced reverse transcriptase (PERT) assay
The product-enhanced RT (PERT) assay is a PCR-based method for detection of RT activity 
that uses brome mosaic virus as the RNA template (Pyra et a l 1994). PERT allows detection 
of 1 X 10'® U (2.1 X 10" molecules) of murine leukaemia virus (MuLV) RT, equivalent to the 
activity present in 3 to 11 MuLV virions. This is 1 x 10® to 1 x 10  ^times more sensitive than 
conventional RT assays. Samples of supernatants from cell cultures of selected patients with 
CTCL were submitted to Dr J Schüpbach, Swiss National Center for Retroviruses, University 
of Zurich, Switzerland, for testing in the PERT assay for RT activity, with detection and 
quantification by ELISA. Positive and negative controls were as described by Pyra et al 
(1994).
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2.4 Results
Whole blood, skin and lymph nodes submitted to the LRF Virus Centre from patients with 
cutaneous lymphoid infiltrates during the period 1992 to 1995 were processed for cultivation 
of T cells and for molecular analyses (Sections 2.2.1 and 2.4.1). Samples received at the 
LRF Virus Centre from 1987 to 1992 had been cultivated mainly by Shauna Crae and 
resulted in the establishment of one continuous CD4" T cell line, L-726A (Section 2.1.3.1). 
Cells derived from skin and PBMCs during this period had been treated with PHA, IL2, CM, 
polybrene, 12-o-tetradecanoyl phorbol-13 acetate (TPA, phorbol-12-myristate 13-acetate), 
anti-CD3 and anti-IFNa. Cells had also been cocultivated with UCMCs and depleted of CD8" 
T cells. Serum samples had tested negative for HTLV-I by ELISA and WB ELISA, except for 
a few patients who had seroindeterminate bands by WB ELISA.
Results of investigations prior to 1992 will not be presented. However, samples stored from 
this period were used in molecular analyses described in Chapter 3 (Table 2.3). Cell pellets 
for PCR and DNA extraction, as well as some viable cells, had been stored from samples 
submitted from patients with LGL leukaemia and butchers from Cardiff with ALL in 1991 
(Sections 2.2.2 and 2.2.3). These included PHA-stimuiated PBMCs that had been cultured 
from one patient with LGL leukaemia. Samples from these patients were processed for 
molecular analyses (Chapter 3) (Tables 2.4 and 2.5). The results of cell biology studies are 
described here.
2.4.1 Cultivation of lymphocytes from patients with cutaneous lymphoid infiltrates
PBMCs and cells derived from skin and lymph nodes were cultivated from 15 patients with 
CTCL and three patients with CBCL (Table 2.10). Most samples of PBMCs were stimulated 
with PHA or ConA then IL2, IL2 alone or were unstimulated (Table 2.11). PBMCs were also 
cultivated with IL2 + SAF CM, IL2 + GMCSF, IL2 + IL4, IL2 + IL7, IL7 alone or UCMC CM. 
PBMCs from eight patients were cocultivated with UCMCs. Skin samples were cultivated 
with PHA or ConA then 1L2, IL2 alone, IL2 + GMCSF, IL2 + IL7 or IL7 alone or were 
unstimulated. Lymph node samples from two patients were cultivated with ConA then IL2,
IL2 alone, IL2 + SAF CM, IL2 + GMCSF, IL2 + IL4, IL7, UCMC CM or with no stimulants and 
were also cocultivated with UCMCs.
Within 1 week of stimulation with PHA, ConA, IL2 alone or in combination with other 
cytokines and UCMC CM, lymphocytes in culture formed dense clumps of proliferating cells, 
between which were many single cells exhibiting morphological changes suggestive of 
activation. These proliferating cells were larger than non-proliferating cells and had 
protrusions from the cell membrane. The clumps of proliferating cells dispersed within a few 
weeks and most cells died within 1 to 2 months of initiation of cultures. The use of cytokines 
did not appear to result in extended survival of most cultured lymphocytes.
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Four long-term T cell cultures (greater than 6 months duration in culture) were established 
from skin samples of patients with MF (patients 2531, 2600 and 2862) following stimulation 
with PHA then IL2, IL2 alone or 1L2 + IL4 (Table 2.12). These cultures were maintained for 6 
to 8 months and remained dependent on IL2 for the duration of cultivation. No viruses were 
detected by EM in any of these iong-term cuitures (Section 2.4.2) and supernatants were 
negative for RT activity (Section 2.4.3). All four long-term cultures were immunophenotyped 
as CD8* T cell populations by fiow cytometry. Since the source neoplasms comprised 
cutaneous infiltrations of CD4* T cells, as is typical for MF, the proliferating CD8^ T ceiis in 
these cultures were thought to represent long-lived IL2-driven cytotoxic T ceii clones derived 
from non-neoplastic infiltrates (TILs) in the skin.
One EBV-infected B-LCL was cultivated for 5 months from a skin sample from patient 2132 
who had CBCL (Table 2.12). This culture had been stimulated with PHA then IL2. EBV 
infection was demonstrated by staining for LMP-1 (Section 2.3.3.7).
in skin cuitures from patients 2116, 2132, 2552 and 2578, adherent fibroblasts grew out from 
pieces of tissue, forming monolayers that could be grown for more than 6 months. In several 
cultures, lymphocytes and other mononuclear cells appeared to have enhanced survival 
when cultivated in suspension above the fibroblast monolayers, remaining viable for 2 to 4 
months.
Testing for mycoplasma revealed infection with Mycoplasma arginini in the CD8^ T ceil line 
established from patient 2600, as well as in short-term cultures from patients 2116, 2560 and 
2669.
2.4.2 Electron microscopy
Cells were submitted for EM examination from four CD8* T ceii cultures that had been grown 
from three patients with MF for 6 to 8 months, as well as selected cultures from skin and 
PBMCs of five other patients with MF or SS that had been maintained for 21 to 50 days. EM 
examinations did not reveal any evidence of retrovirus-like particles (Table 2.12). 
Representative electron micrographs are shown In Figures 2.1 and 2.2.
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Table 2.10: Clinical diagnoses of cutaneous T cell lymphoma cases 
from which viable cells were submitted for culture 1992 to 1995.
Clinical diagnosis Number of patients
Mycosis fungoides 11
Sézary syndrome 3
Cutaneous T ceii iymphoma 1
Cutaneous B cell lymphoma 3
Total 18
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Table 2.11: Methods used for cultivating T cells from patients 
with cutaneous T cell lymphoma.
Protocol Number of
PBMC samples
Number of 
skin samples
Number of lymph 
node samples
PHA IL2 13 8 0
Con A -> IL2 11 5 2
IL2 18 10 2
IL2 + SAP CM 8 0 2
IL2 + GMCSF 9 2 2
IL2 + IL4 8 0 2
IL2 + IL7 2 1 0
IL7 8 2 2
UCMC CM 7 0 2
Cocultivation with UCMCs 8 0 2
Unstimulated 13 7 2
CM Conditioned medium
ConA Concanavalin A
IL2 Interleukin 2
IL4 Interleukin 4
IL7 Interleukin 7
GMCSF Granulocyte macrophage colony stimulating factor
PHA Phytohaemagglutinin
SAP Sézary T cell activating factor
UCMC Umbiiical cord blood mononuclear cell
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Figure 2.1: Electron micrograph of lymphocytes from a CD8* T cell line 
cultivated from a patient with mycosis fungoides.
Culture derived from the skin of patient 2600 following stimulation with IL2. Photograph 
taken after 49 days in culture. One large lymphocyte (25 pm x 40 pm) exhibits features of 
activation, including dispersed chromatin and a prominent nucleolus in a slightly indented 
nucleus. There is abundant cytoplasm with moderately abundant rough endoplasmic 
reticulum, numerous mitochondria and multiple processes of up to 5 pm length protruding 
from the cell membrane. One small lymphocyte (10 pm x 12 pm) appears to be relatively 
inactive, with a small, condensed, indented nucleus and a narrow rim of cytoplasm 
containing few mitochondria. There are only a few relatively blunt protrusions from the cell 
membrane. 3,000x. Bar =10 pm. Courtesy of Ross Blackley.
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Figure 2.2: Electron micrograph of lymphocytes cultivated from 
peripheral blood mononuclear cells of a patient with Sézary syndrome.
Culture derived from PBMCs of patient 2669 following stimulation with IL2 and IL4. 
Photograph taken after 28 days in culture. One medium-sized lymphocyte (20 pm x 20 pm) 
has moderately condensed chromatin in a lobulated nucleus, relatively inconspicuous 
endoplasmic reticulum and few mitochondria in the cytoplasm. There are multiple processes 
up to 3 pm in length protruding from the cell membrane. 4,400x. Bar = 5 pm. Courtesy of 
Ross Blackley.
108
2.4.3 Reverse transcriptase assay
2.4.3.1 Standard reverse transcriptase assay
Results of RT assays are shown in Tables 2.13 to 2.15. All scintillation counts were taken 
from the average of two readings. RT assays were performed on 88 cell culture 
supernatants in 29 pools from 15 patients. Most samples were negative for RNA-dependent 
DNA poiymerase (RT) activity (rA:N <10) with Mn^ "" and Mg^ as cofactors and aiso had 
negiigible DNA-dependent DNA polymerase activity (dA:N <10) (Table 2.13). A pool of three 
supernatants collected 23 days after initiation of cultures of PBMCs and skin from patient 
436 had an elevated rA:N value of 87.9 with Mg^ as a cofactor. However, cultured cells from 
this patient did not survive ionger than 1 month, the positive supernatants were derived from 
cuitures containing mostly necrotic cells and no RT activity was detected in fresh cultures of 
PBMCs inoculated with the positive supernatants.
Supernatants from positive controi cuitures exhibited Mn^ "" or Mg^ '*’-dependent RT activity 
corresponding to the known properties of the retroviruses with which they were infected 
(Table 2.14). Consistently high Mn^'^-dependent RT activity was detected in SSN-1 
supernatants (rA/N >200), whereas this cell line exhibited low Mg^'*'-dependent RT activity 
(rA/N <10). A wide variation in Mn^^-dependent and Mg^’^ -dependent RT activity was 
detected in BLV-FLK supernatants among assays, even using supernatants coliected on the 
same date, but the level of Mg^'^-dependent RT activity was ai ways at least five times the 
level of Mn^^-dependent RT activity. There was an increased level of DNA-dependent DNA 
polymerase activity in some BLV-FLK supernatants with Mn^  ^as a cofactor and this 
correiated with increased rA/N values in the same samples tested on the same date. The 
FIV-infected cell line FL4 exhibited high Mg^^-dependent RT activity (rA/N 1,601.4), 
consistent with the known properties of lentivirus RTs.
The non-productive HTLV-l-infected CD4^ T ceii line C8166, as well as three continuous T 
cell lines not known to be infected with HTLV-I or other exogenous retroviruses (J.JHAN, L- 
726A, HH and My-La MC), had low Mn^'"-dependent and Mg^'"-dependent RT activity (rA:N 
<10) (Table 2.15). Normal tissue culture medium (RPMI 1640 + 20% hi-FBS + 2-ME) did not 
exhibit RT activity with either Mg^ '*' or Mn^ as cofactors (rA/N <10).
2.4.3.2 Product-enhanced reverse transcriptase (PERT) assay
All of five sampies of supernatants from cell cultures of patients with CTCL had negligible 
reactivity for Mg^^-dependent RT activity and low Mn^^-dependent RT activity by ELISA 
(optical densities at 405 nm and 630 nm, OD405/630 <2.0) in the PERT assay (Boni and 
Schüpbach 1993, Pyra et al 1994) (Table 2.16).
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Table 2.16: Results of product-enhanced reverse transcriptase (PERT) assay.
Patient Clinical
diagnosis
Source of 
supernatant
Optical density
(O D 4 05 /6 30 )
Mn^^ Mg""
1198 SS Skin 1.7 0.0
2522 CTCL PBMCs 1.9 0.1
2531 MF PBMCs 0.0 0.0
2600 MF Skin 1.7 0.2
2669 SS PBMCs 1.7 0.0
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2.5 Discussion
In the cell biology studies conducted at the LRF Virus Centre from 1992 to 1995, attempts 
were made to establish continuous CD4" T cell lines from patients with cutaneous iymphoid 
infiltrates, particularly MF and SS. The rationale for this approach was that HTLV-I had been 
isolated from continuous CD4" T cell lines established from patients with ATL and other 
diseases associated with HTLV-I (Poiesz et al 1980a, b, Miyoshi et a l 1980, HInuma et al 
1981, Poiesz et al 1981, Jacobson et al 1988). T cell lines from patients with other forms of 
CD4" T ceii neoplasia, particularly MF and SS, might also propagate HTLV-I or related 
retroviruses, aiiowing a viral aetiology to be established for these conditions. However, in this 
study no CD4" T cell lines were established from 158 cultures initiated from PBMCs, skin 
and iymph nodes of 18 patients (Tables 2.10 and 2.11). Most cells from clinical samples of 
patients with MF/SS, as well as cells from patients with other cutaneous lymphoid infiltrates, 
died within 3 months of initiation of cultures. This relatively short duration of survival is 
consistent with the findings of several other groups studying MF/SS (Capésius et al 1991, 
Bazarbachi et al 1997) (Section 1.11.1.4). The observation that the longevity of some 
lymphocyte cultures in vitro is increased in the presence of fibroblasts is also consistent with 
the findings of other groups (Scott et a l 1990).
In contrast to the findings in this study, Abrams et a/ (1991b) established 25 T ceil lines from 
patients with SS using SAF CM. GMCSF and IL2 were used as growth stimulants by Zucker- 
Franklin et al (1991) to establish 18 cell lines from patients with MF/SS but the 
immunophenotype of these cell lines was not reported. Few studies that have Identified 
HTLV-reiated retroviruses in cell cultures from patients with CTCL have confirmed that the 
propagated cells are of T cell lineage (Kaltoft et al 1987, 1988); most of the cell lines from 
CTCL patients in which there is evidence for infection with a retrovirus are B cell lines 
(Manzari et al 1987, Hall et al 1991) or are uncharacterised (Zucker-Franklin et al 1991, 
1992). In an HTLV-Il-infected cell line established by Zucker-Franklin et a /(1992) from a 
patient with MF, 80% of cells were CD2" and only 50% were CD4" after 71 days in culture, 
so this culture may contain a mixed population of ceils.
HTLV-I I has been isolated from CD8" T cell lines established from patients with T cell 
variants of HCL, but its role as an aetiological agent in T cell or other neoplasia has not been 
confirmed (Kaiyanaraman et a/ 1982b) (Section 1.7.1). The techniques used in this study 
were also suitable for cultivating CD8" T cells and four long-term CD8" T cell cultures were 
established from skin samples of three patients with MF. However, these cultures were not 
derived from neoplastic cells, which in all MF/SS cases consisted of CD4" T cells. Instead, 
the CD8" T cells would have expanded from TILs accompanying the neoplastic infiltrate. 
Other studies have found that most T cell clones cultured from MF lesions are not derived 
from neopiastic MF/Sezary cells but originate from TILs (Ho et a /1990, Harwix et al 2001 ). 
Depletion of CD8" T cells (TILs) may permit the outgrowth of neopiastic CD4" T cell clones 
from MF lesions (Kaltoft et al 1984). This approach was used frequentiy at the LRF Virus 
Centre from 1987 to 1991 but did not result in the estabiishment of any continuous CD4" T 
cell lines.
115
EM, RT assays and PCR were used for detection of retroviruses in cultured cells in this 
study. No retroviruses were detected by EM in four continuous CD8" T cell lines established 
from three patients with MF or in short term cell cultures from five other patients with MF or 
SS. RT activity was detected in one pooi of supernatants from degenerating cells of one 
patient, but this result could not be reproduced because all cultured cells from this patient 
died within one month. The resuits of PCR analyses conducted on cultured cells are 
presented in Chapter 3.
In this study one EBV-infected B-LCL was estabiished from the skin of a patient with CBCL, 
consistent with the in vitro transforming properties of EBV (Pattengaie et ai 1973). The B- 
LCL is more ilkeiy to be derived by EBV infection of bystander iymphocytes than from 
neoplastic B cells, since most primary CBCLs are not associated with EBV, except in 
immunocompromised patients (Dupin et ai 1997, Beylot-Barry et al 1999, Nagore et al 2000). 
However, detailed molecular genetic, viral and immunophenotypic analyses were not 
undertaken on the B-LCL or CBCL in this case.
Mycoplasma infection was detected in several cell cuitures established from clinical samples 
and was though to be derived from infected source material rather than from contamination 
in the laboratory.
The results of these studies and the use of cell culture for isolation of novel retroviruses are 
discussed further in Chapter 5.
Chapter 3
Use of Molecular Techniques to Detect 
Human I  Lymphotropic Virus-Related Retroviruses 
in Human T Cell Leukaemias and Lymphomas
3.1 Introduction
3.1.1 Molecular approach to detection o f human T lymphotropic viruses in T cell 
neoplasms
The aim of the molecular biology part of this project was to detect proviral sequences of 
human T lymphotropic virus type I (HTLV-I), HTLV-I I or related retroviruses in human T cell 
neoplasms using the polymerase chain reaction (PCR) in combination with Southern blot 
(SB) hybridisation. HTLV-I causes adult T cell leukaemia/lymphoma (ATL) (Section 1.6.1), 
whereas HTLV-I I has not been confirmed as the cause of neoplasia (Section 1.7.1). The 
hypothesis tested in this study was that HTLV-I, HTLV-I I or related retroviruses are 
associated with other T cell leukaemias and lymphomas, particularly mycosis fungoides (MF) 
and Sézary syndrome (SS), in the United Kingdom (UK). These neoplasms have similar 
clinicopathological features to some forms of ATL (Section 1.11.1). However, the prevalence 
of HTLV-I and HTLV-I I infection in the UK is low, except in populations derived from endemic 
regions (Section 1.5.2.1). Cases of large granular lymphocytic (LGL) leukaemia were also 
studied because HTLV-I and HTLV-I I have been identified in a small proportion of cases of 
this disease (Section 1.11.2).
Bovine leukaemia virus (BLV) causes B cell leukaemia and lymphoma in cattle and is 
endemic in the UK (Chasey et a! 1978) (Section 1.9.2.1). Although BLV is not known to be a 
zoonosis, samples from cases of acute lymphoblastic leukaemia (ALL) in butchers from 
Cardiff were examined for this virus because of their occupational exposure to cattle 
(Whittaker 1991) (Section 1.10.5). Samples were also tested for HTLV-I and HTLV-I I 
because these viruses are related to BLV.
The molecular techniques used in attempts to identify HTLV-I and related retroviruses in 
samples from patients with cutaneous T cell lymphoma (CTCL), LGL leukaemia and adult 
ALL at the Leukaemia Research Fund (LRF) Virus Centre are described in this chapter. 
PCRs were designed to amplify HTLV-I, HTLV-I/I! and BLV proviral DNA sequences from 
clinical samples and cultured cells from these patients. PCR products were hybridized to 
HTLV-I or BLV-specific nucleotide probes and products of interest were cloned and 
sequenced. Results of these studies were used to assess the role of HTLV/BLV group 
viruses in selected cases of CTCL, LGL leukaemia and adult ALL in the UK.
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3.1.2 Detection o f retroviral sequences in T cell neoplasms by the polymerase chain 
reaction
PCR is a method for amplifying specific DNA sequences from target DNA using primer 
extension and a thermostable DNA polymerase (Saiki et al 1985, Mullis and Faloona 1987, 
Saiki et a l 1988). Successive cycies of template dénaturation, primer annealing and 
extension result in exponential amplification of target sequences depending on the efficiency 
of reaction conditions. The technique is highly sensitive and can detect low copy numbers of 
target DNA sequences. Thus, it Is the tool of choice for detecting integrated proviruses in 
samples in which infected ceiis may be rare. The frequency of infected peripheral blood 
mononuclear cells (PBMCs) in HTLV-I carriers may be low (Section 1.6.3.3). Skin lesions 
from patients with MF/SS and other CTCLs often have low densities of neoplastic 
lymphocytes, which form part of a population including non-neoplastic tumour infiltrating 
lymphocytes (TILs) and other inflammatory cells, as well as kératinocytes, fibroblasts, 
endothelial cells, melanocytes and other cutaneous cell populations.
The sensitivity of detection can be increased by nested PCR, in which a second round of 
reactions is performed using primer sets specific for sequences within the first round PCR 
product. SB hybridisation using sequence-specific nucleotide probes that bind to products 
amplified by PCR can also be used to increase the sensitivity of detection. The stringency of 
hybridisation can be adjusted to allow detection of sequences with high or low similarity to 
that of the probe. Hybridisation under conditions of high stringency provides a measure of 
confirmation of the specificity of product amplification. Hybridisation under conditions of low 
stringency can be used to detect target sequences that are similar but not identical to the 
sequence of the probe and could allow detection of novel retroviruses. PCR is also a 
potentially useful tool for detecting novel retroviral sequences, since primers can be seiected 
from conserved regions of known viruses (Section 3.1.2.3).
In this study, careful attention was paid to preparation of clinical samples, design of PCR 
primers, standardisation and optimisation of PCRs, determining the sensitivity of detection of 
target sequences and preventing PCR contamination.
3.2 Sources of clinical samples
Details of patients from whom clinical samples were obtained are given in Section 2.2. The 
methods for processing clinical samples and cultured cells are described in Chapter 2.
3,2.1 Cutaneous T cell lymphomas and other cutaneous lymphoid infiltrates
Samples of cultured and uncultured PBMCs and skin from 36 patients with cutaneous 
lymphoid infiltrates, predominantly MF and SS, were examined by PCR for HTLV-I and 
HTLV-I/I I sequences (Tables 2.3 and 3.1).
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Table 3.1: Clinical diagnoses of patients with cutaneous lymphoid infiltrates 
from whom samples were analysed by the polymerase chain reaction.
Clinical diagnosis Number of patients
Mycosis fungoides 21
Sézary syndrome 5
Cutaneous T cell lymphoma 1
Angiocentric T cell lymphoma 3
Small plaque parapsoriasis 1
Langerhan’s cell histiocytosis 1
Cutaneous B cell lymphoma 4
Total 36
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3.2.2 Large granular lymphocytic leukaemia
Cultured and uncultured PBMCs from six patients with CD3" CD8" LGL leukaemia were 
tested for HTLV-I and HTLV-I/I I sequences by PCR (Table 2.4).
3.2.3 Adult acute lymphoblastic leukaemia in butchers from Cardiff
PBMCs and bone marrow from six patients with ALL, all male butchers from Cardiff, were 
tested for HTLV-I, HTLV-I/I I and BLV sequences by PCR (Table 2.5).
3.3 Materials and methods
3.3.1 Molecular biology facilities
The molecular biology laboratory in the LRF Virus Centre was used for gel electrophoresis of 
PCR products and restriction endonuclease (RE)-digested DNA, Southern blotting and 
electroblotting, molecular cloning, purification of plasmids and most other molecular work. A 
separate room was used for bacterial culture work and a dark room was used for ultraviolet 
(UV) transilluminaton, photography and exposing autoradiographic film. Radioisotopes were 
handled in a dedicated radioactivity room in the Department of Veterinary Pathology.
3.3.2 Materials
The sources of frequently used materials are listed in Appendix 3 and the compositions of 
routinely used stock solutions and buffers for molecular biology are listed in Appendix 5. 
Additional materials and chemicals are specified elsewhere in the text of individual sections. 
Ali chemicals used were of Analytical (Analar) or Molecular Biology grade and, unless 
otherwise stated, were obtained from Sigma or BDH. Most restriction and DNA modifying 
enzymes were obtained from Life Technologies. Taq polymerase (Amplitaq) and other PCR 
reagents were obtained from Perkin-Elmer. Ultrapure deionised water obtained from a 
reverse osmosis filtration system (Millipore) was used in enzymatic manipulations and to 
dissolve DNA. PCR grade sterile ultrapure water (Sigma) was used for PCRs, Deionised 
water (Miilipore) was used in other general laboratory solutions.
3.3.3 Extraction of high molecular weight DNA from tissues and cells
3.3.3.1 Enzymatic digestion of tissues and cells
High molecular weight (HMW) DNA was extracted in class II microbiological safety cabinetes 
(MSCs) in the level II containment facility (Section 2.3.1). Cells for DNA extraction were 
collected from established cell lines (Section 2.3.4), cultured clinical samples (Section 2.3.6) 
and uncultured PBMCs and lymph node cells. Purification of uncultured PBMCs from blood 
by metrizoate-Ficoll density gradient centrifugation is described in Section 2.3.5.1, The 
densities of cells in suspension were determined by counting using an haemocytometer 
(Section 2.3.3.3). Aiiquots containing 1 x 10® to 1 x 10® cells were transferred to 15 ml screw-
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top polypropylene tubes and centrifuged at 1,500 g (2,700 rpm) in a GPR bench centrifuge 
(Beckman) with a GH 3.7 swinging bucket rotor for 5 min at room temperature. The 
supernatant was discarded, cells were resuspended in phosphate-buffered saline (PBS) 1x 
and the centrifugation was repeated. Ceii pellets were stored at -80°C until processed for 
PCR. Pellets of fresh PBMCs and cultured cells were resuspended in Tris-NaCI-EDTA (TNE) 
1x then centrifuged at 270 g for 5 min. The supernatant from each peiiet was discarded and 
the cells were resuspended in 5 ml TNE 1x containing 100 pg/ml proteinase K, 0.2 M NaCI 
and 0.5% sodium dodecyl sulphate (SDS). The mixture was incubated at 55°C for 1 hour or 
at 37°C overnight (16 to 20 hours).
Preparation of tissues for DNA extraction Is described in Section 2.3.5.2. Frozen tissue was 
cut into small pieces with sterile scissors, placed in steriie plastic bags with 5 to 25 ml of TNE 
1x and mechanically disrupted using a Stomacher 80 (Colworth). The contents were 
transferred to 15 or 50 ml screw-top polypropylene centrifuge tubes and incubated with 
proteinase K, NaCI and SDS as above.
3.3.3.2 Phenol-chloroform extraction
After SDS-proteinase K digestion, protein and lipids were separated from dissolved DNA by 
phenol-chloroform extraction. An equai volume of phenol equilibrated with Tris pH 8.0 
(Rathburn Chemical Company) was added to each tube at room temperature and the tube 
was gently inverted to mix the aqueous and organic phases. Tubes were centrifuged at 484 
g  (2,000 rpm) for 10 min in a JS-21 centrifuge (Beckman) using a JA-20 fixed angle rotor to 
separate the aqueous and organic phases. The upper aqueous phase containing dissolved 
DNA was transferred to a fresh tube using a wide-bore polypropylene bulb pastette to 
prevent shearing. Phenol extraction was performed twice then foilowed by extraction with 
chloroform or isoamyl alcohohchloroform (24:1) by the same method.
3.3.3.3 Precipitation and dissolution of DNA
After chloroform extraction, the aqueous phase was transferred by pastette into 
approximateiy 2.5 times the volume of 99.7% ethanol (absolute alcohol) to precipitate DNA. 
HMW DNA, which formed a flocculent suspension, was spooled onto a polypropylene 
pastette or sealed glass pipette and transferred to a sterile 1.5 ml screw-top prolypropylene 
microcentrifuge tube. If the concentration was too low for the precipitate to be visualised, the 
ethanol solution was transferred to a 30 ml glass centrifuge tube (Corex, Sarstedt) and 
centrifuged at 12,100 g (10,000 rpm) for 30 min in the JS-21 centrifuge using a JA-20 rotor. 
DNA pellets were washed in 1 ml 70% ethanol and air dried at room temperature. The DNA 
was dissolved in an appropriate volume of ultrapure water or Tris-EDTA (TE) 1x by 
incubating at 37°C overnight on a roller mixer.
3.3.3.4 Quantification of genomic DNA
The concentration of double-stranded genomic DNA was determined by measuring the 
optical densities at 260 nm (ODzeo) and 280 nm (OD280) in a spectrophotometer
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(GeneQuant). Calculations were made on the basis that 50 pg/mi of double-stranded DNA 
has an OD260 of approximately 1.0. The ratio of the readings at 260 nm and 280 nm 
(OD260/OD280) was used to estimate the purity of the nucleic acid; pure preparations of DNA 
have an OD260/OD280 ratio of 1.6 to 1.8 (Sambrook et al 1989).
3.3.3.5 Restriction endonuclease digestion of genomic DNA
Genomic DNA was digested with restriction endonucleases (REs) for gel electrophoresis and 
Southern blot hybridisation (Section 3.3.10). RE digests were performed with 10 pg HMW 
DNA incubated with 30 U of the appropriate enzyme (Life Technologies) in a 50 pi volume 
containing proprietary buffer at 1x concentration and 3 mM spermidine (GeneBloc, 
International Laboratory Services). To prevent inhibition by glycerol in RE storage buffers, 
the volume of RE solutions added was kept below 10% of the total reaction volume. 
Reactions were incubated at 37°C overnight. DNA from the C8166 cell line was digested 
with HcoRI, Pst\, Sst\, Sst\/Hindi\\\, Sst\lXho\ and Sst\/BamH\ for assessment of proviral 
integrations by SB hybridisation (Section 3.3.11.2).
3.3.4 Processing o f cells for the polymerase chain reaction
3.3.4.1 Preparation of cells for PCR
Cell pellets for PCR were prepared by diluting cultured and uncultured cells to 1 x 10® 
cells/ml in PBS 1x in the level II containment facility (Sections 2.3.3.3 and 2.3.5.1). An 
appropriate number of 0.5 ml aliquots containing 1x10® cells were transferred to 0.6 ml flip- 
top PCR tubes and centrifuged at 10,500 g (13,000 rpm) for 5 min in a bench 
microcentrifuge (MicroCentaur, MSE). Supernatants were discarded, leaving the pelleted 
cells in the bottom of each tube. These cell pellets were stored frozen at -80°C until used for 
PCR analysis. Some cryopreserved cells were prepared for PCR by thawing as described in 
Section 2.3.3.5. After centrifuging and washing cells with PBS 1x, the density of viable cells 
was determined (Section 2.3.3.3) and pellets of 1 x 10® cells for PCR were prepared as 
above. Serial dilutions of positive and negative controi ceiis for use in determining PCR 
sensitivity are described in Section 3.3.8.2.
3.3.4.2 Non-ionic detergent lysis and proteinase K digestion of ceiis for PCR
To disrupt cells and inactivate proteins in preparation for PCR, 25 pi of non-ionic detergent 
buffer (NIB) consisting of 1.5 mM MgCb, 50 mM KCI, 10 mM Tris pH 8.2, 100 pg/ml gelatin, 
0.45% Nonidet P-40 (NP-40), 0.45% Tween-20 and 60 ng/pl proteinase K were added to 
pellets of 1 X 10® cells in PCR tubes in the LRF Virus Centre levei II containment facility 
(Appendix 5: A5.6). The buffer was overlain with two drops (approximately 25 pi) of mineral 
oil (Sigma) using a polypropylene pastette. Tubes were sealed with parafilm (Nesco sealing 
film, Bando) or placed in a locking rack (Treff) and incubated at 55°C for 1 hour in a heated 
water bath (Techne). The proteinase K was inactivated by heating at 95°C in a thermal block 
(Techne) or boiling for 10 min. Tubes containing lysed cells were then placed on ice and 25 
pi of PCR master mix were added in preparation for thermal cycling.
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3.3.5 Design o f oligonucleotide primers for the polymerase chain reaction
3.3.5.1 Principles of primer selection
Sets of oligonucleotide primers for PCR were designed for annealing to specific sequences 
of target DNA to act as primers for incorporation of oiigonucieotides by Taq DNA 
polymerase. Forward (sense) primers allowed extension from 5’ to 3’ on the negative strand 
of DNA, while complementary reverse (antisense) primers ai lowed extension from 5’ to 3’ on 
the positive strand. The size of the intervening sequence for efficient amplification by PCR 
was between 100 and 400 base pairs (bp). Primer sets for PCR were selected with a 
preference for oligonucleotides of iength 17 to 21 bases with similar melting temperatures 
(Tm) within the range 55 to 65°C. Strings of identical nucleotides were avoided, as were 
excesses of G and C residues. The sequence at the 3’ end of each primer was considered 
most important for specificity of annealing and a G or C was selected for the 3’ terminal 
residue. Primers were checked for the absence of complementary sequences that might 
permit self-annealing and amplification of non-specific products.
Theoretical values for annealing temperatures of oligonucieotide primers can be determined 
using formulae for calculating the Tm of double-stranded DNA. The following formula is 
applicable to oligonucleotides of 11 to 23 bases, which Includes most PCR primers used in 
this study (Suggs et al 1981 ):
Formula 3.1: Tm = 4 (G+C) + 2(A+T) °C
Where: A, C, G and T are the number of bases of each nucleotide in the primer. Primers 
with degenerate bases such as K, M, R or Y were assumed to have been synthesised with 
an equal proportion of purine and pyrimidine residues and their number was multipiied by 
three (Appendix 2).
This formula was used to compare the values of forward and reverse primers in a set, 
with the aim to select primers with similar annealing temperatures. Formula 3.2 was used to 
calculate the Tm of the 29 base primer 3 (Section 3.3.12.1):
Formula 3.2: Tm = 81.5 + 16.6 logio[M"] + 0.41 (%G+C) -  500/L -  P-0.63(%Formamide) °C
[Nal
Where: [M"] = Adjusted molar Monovalent cation concentration: --------------1 +0.7 INa1
%G+C = Percentage of G and 0  nucleotides in the DNA 
L = Length of the DNA:DNA duplex in bp 
P = Percentage base mismatch
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However, such theoretical values do not reliably predict the compatibility of any pair of 
primers. Similarly, although an annealing temperature 5°C below the calculated Tm of the 
primers is often used as a guide to selecting PCR thermal cycling conditions, it is usuaiiy 
necessary to determine the optimal annealing temperature empirically (Section 3.3.7.3).
3.3.5.2 Design of primers for amplification of HTLV-I, HTLV-I I and BLV by PCR
Primer sets for ampiification of HTLV-I, HTLV-I/I I and BLV sequences by PCR were 
designed at the LRF Virus Centre based on alignments of viral sequences and on previously 
published information (Appendices 6 to 8). Incomplete proviruses with preferential retention 
of the p X  region are frequent in neoplastic cells of patients with ATL (Section 1.6.1.4) and 
have been suspected in patients with MF/SS (Section 1.11.1.6). The possibility that 
proviruses with deletions are involved in the aetiology of CTCLs was addressed by selecting 
PCR primers from the LTR, gag, pol, env and pX  regions of the HTLV-I genome (Section 
1.3.3). Use of the full panel of primer sets on any infected sample would allow detection of 
some viral sequences by PCR even if other regions of the proviral genome were absent due 
to deletions. The use of primer sets with different sensitivities could lead to false deductions 
that incomplete proviruses are present and therefore it was important to optimise and 
quantify the sensitivity of PCR reactions.
Published sets of primers for PCR that reliably amplified HTLV-I pol and HTLV-I/I I pX  
sequences were used as standards for detection of HTLV-I and HTLV-I I (Kwok et al 1988). 
LTR, gag and pX  primers that had been used to detect defective HTLV-I proviruses in 
patients with MF were adopted from Hall et al (1991). Additional HTLV-I gag primers were 
those used to detect variant (Melanesian strain) HTLV-I in Papua New Guinea (Sherman et 
al 1992). Primers for env had previously been used in attempts to detect HTLV-I sequences 
by PCR in patients with multiple sclerosis (MS) (Greenberg et al 1989a) (Section 1.6.4.6). 
Two additional sets of unpublished HTLV-I pol and pX  PCR primers that had been used at 
the LRF Virus Centre previously were also included in the study (primer sets 3 & 4 and 67 & 
68). Primers for amplification of BLV gag sequences were adapted from a published study 
(Murtaugh et al 1991).
Amplification of a sequence of p-globin was used as a test for the integrity of DNA (Saiki et 
al 1988) (Appendix 9). These PCR primer sets are shown in Figure 3.1. Accepted letter 
codes for nucleotides and amino acids, including nomenclature for incompletely specified 
bases, are iisted in Appendix 2.
3.3.5.3 Design of consensus retroviral PCR primers
There is a high degree of sequence divergence over most of the genome of known 
retroviruses and thus few regions are available with a high degree of similarity from which 
consensus PCR primers can be selected. However, regions of nucleotide conservation in the 
retroviral pol gene and amino acid conservation In the translated product of this gene, 
reverse transcriptase (RT), offer potential for the design of consensus primers that can be 
used for detection of novel retroviruses. Consensus PCR primers with generic specificity for 
the HTLV/BLV (Deltaretrovirus) group were derived by alignment of regions of similarity
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among the HTLV-I, HTLV-I I and BLV virus LTR and gag nucleotide sequences (Figure 3.2). 
Alignments of sequences in the GenEMBL database were made using the Genetics 
Computer Group (GCG) programmes on the University of Glasgow VAX and UNIX 
mainframe computers. Consensus primers were selected from these regions of homology on 
the assumption that they are conserved in other, as yet unidentified, HTLV-reiated viruses. 
Where regions of homology did not provide for a perfect match of bases among the viruses, 
degenerate primers were used. This resulted in the identification of one LTR sense primer 
(174) that could be used in conjunction with either of two antisense primers to yield PCR 
products of 491 to 522 bp (LTR primer 175) or 1823 to 1858 bp {gag primer 176) from 
HTLV/BLV group viruses (Figure 3.2).
Consensus primers with potential to detect a wide range of retroviruses and hepadnaviruses 
were aiso designed by alignment and reverse translation of Pol amino acid sequences (Mack 
and Sninsky et al 1988, Donehawer et al 1990). Two regions of conservation in the retroviral 
RT protein have been identified that are sufficiently close together for amplification of a 
product of suitable size by PCR (Appendix 10: A10.1). The number of permutations of 
nucleotide codons for the invariant amino acids in these regions is relatively small, facilitating 
design of degenerate primers. The 5' conserved region contains the motif LPQG, which is 
consistent among exogenous retroviruses except for the substitution of R for G in simian 
retrovirus 1 (SRV-1). Group-specific 5' primers can be derived from a 9 amino acid segment 
in this region with consistent LPQ and SP residues. The 3' conserved amino acid sequence 
contains the motifs YMDD or YVDD. The regions between these primer sequences differ 
among the retroviruses and can be used for specific identification by hybridisation, nested 
PCR or sequencing.
A potential problem with retroviral consensus primers is that they will bind to endogenous 
retroviral sequences, resulting in the generation of PCR products that are difficult to 
distinguish from those of exogenous retroviruses. This can be overcome by the use of RT- 
PCR to detect viral genomic RNA in purified virions or mRNA transcripts in infected cells. 
Donehawer et al (1990) used RT-PCR with two degenerate oligonucleotide primers to 
amplify a 117 bp pol fragment from genomic RNA of all retroviruses examined.
Consensus primers adapted from Mack and Sninsky (1988), Donehawer et al (1990) and 
designed by aligning retroviral sequences selected from the GenEMBL database using the 
GCG programmes are shown in Figure 3.3. These primers (296 & 297) have the potential to 
amplify a retroviral pol sequence of approximately 113 bp. BglW restriction sites for cloning 
were added at the ends of both of these primers, resulting in a potential PCR product of 
approximately 133 bp.
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Figure 3.1: Oligonucleotide primers for amplification of HTLV-I, HTLV-I I, 
bovine leukaemia virus (BLV) and p-globin sequences 
by the polymerase chain reaction.
Letter codes for nucleotides, including nomenclature for incompletely specified bases, are 
listed in Appendix 2.
LRF
oligonucieotide
number
Primer sequence 5’ to 3’ with 
HTLV-I nucleotide position 
(HTLV-II nucleotide 
positions in brackets)
Length Tm
(b) r c )
Size of 
PCR 
product 
(bp)
Reference
HTLV-I LTR
118 Sense
119 Antisense
HTLV-I gag
120 Sense
121 Antisense
122 Sense
123 Antisense
HTLV-I pol
1 Sense
2 Antisense
67 Sense
68 Antisense
HTLV-I env
124 Sense
125 Antisense
HTLV-I/II pX
50 Sense
51 Antisense
Sense
Antisense
126 Sense
127 Antisense
BLV gag
194 Sense
195 Antisense
P-globin
5 82 TGACCCTGCTTGCTCAACTCTA 603 
764 TCTCTCCTGAGAGTGCTATAG 744
1388 CTGCAGTACCTTTGCTCCTCCCTC 1411 
1660 TTCTACGAAGGCGTGGTAAG 1641
1423 CCATCACCAGCAGCTAGATAGC 1444 
1556 GCTGGTATTCTCGCCTTAATCC 1535
33 66 CTTCACAGTCTCTACTGTGC 3 3 85 
3484 CGGCAGTTCTGTGACAGGG 3466
4 75 8 CCMTACAAYCCMACCAGCTCAG 4779 
4 943 GTGGTGRAKYTGCCATCGGGTT 4 922
5800 CTCGAGCCCTCTATACCATG 5 819 
612 6 GGATCCTAGGGTGGGAACAG 6107
(7248) (7267)
73 59 CGGATACCCAGTCTACGTGT 73 78 
7517 GAGCCGATAACGCGTCCATCG 74 97(7406) (7386)
(7370) (7398)
74 81 TCACCTGGGACCCCATCGATGGACGCGTT 7509
75 92 GTAAGGACCTTGAGGGTC 7575 (7481) (7464)
7597 CCAATCACTCATACAACCCCCA 7618 
7723 CTGGAAAAGACAGGGTTGGGA 7703
110 9 CTGACCTAGAACAACTTTGC 1128 
13 55 GACGAGTAGGGAGATTTTTCC 1315
22 66 183
21 62
22 68 134
22 64
20
19
22
22
29
18
22
21
60 119
62
69 185
69
20 62 159
21 68
68 112 
56
66 127
64
{Hail et a /1991)
24 76 273 (Sherman et a /1992)
20 60
(Hall et al 1991)
(Kwok et al 1988) 
Unpublished
20 62 327 (Greenberg e ta /1989)
20 60
(Kwok et al 1988)
Unpublished
(Hall et a /1991)
2 0 58 247 (Murtaugh et a /1991)
21 62
(Saiki e ta /1988)Sense
Antisense
9114 ACACAACTGTGTTCACTAGC 33 
123 CAACTTCATCCACGTTCACC 104
20
20
58
60
126
Figure 3.2: Consensus oligonucleotide primers for amplification of 
human T cell lymphotropic/bovine leukaemia virus group viral 
LTR sequences by the polymerase chain reaction.
Letter codes for nucleotides, including nomenclature for incompletely specified bases, are 
listed in Appendix 2.
HTLV/BLV 
group viruses
Sequence
alignment
Length
(b)
Tm
(°C)
Sense
HTLV-IHTLV-IIBLV
Consensus sense LTR primer 174
Antisense
779 TTGGGGGCTCGTCCGGGAT 797 765 TTGGGGGCTCGTCCGGGAT 783 532 TTGGGGGCTCGTCCGGGAT 550 
* * * * * * * * * * * * * * * * * * *
5' > TTGGGGGCTCGTCCGGGAT < 3 19 61
HTLV-IHTLV-IIBLV
Consensus sequence
Consensus antisense LTR primer 175
1267 AGACCTACAGGCCATTAA 12841268 AGACTTACAGGCCATCAA 1286 1005 AGAATTACAAGATATCAA 1022
*  *  *  * * * *  *  *  *  *  *
5' > AGAMYTACARGMYATYAA < 3' 
5' > TTRATRKCYTGTARKTCT < 3' 18 48
HTLV-IHTLV-IIBLV
Consensus sequence
Consensus antisense 
g a g primer 176
2611 CCTTTAAACCAGAACGCCTCCAGGCC 263 6 2585 CCTTTAAACCTGAGCGCCTCCAGGCC 2610 233 0 CCTTTAAACTAGAACGCCTCCAGGCC 2355 *********  * * ************
5' > CCTTTAAACYWGARCGCCTCCAGGCC < 3' 
5' > GGCCTGGAGGCGYTCWRGTTTAAAGG < 3' 26 54
Expected PCR product sizes 174 & 175 HTLV-1 HTLV-11 BLV
506 bp522491
174 & 176 HTLV-1 HTLV-11 BLV
1858 bp18461823
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Figure 3.3: Consensus reverse transcriptase (po/) primers for ampiification of 
retrovirai sequences by the poiymerase chain reaction.
Letter codes for nucleotides, including nomenclature for incompletely specified bases, are 
listed in Appendix 2.
LRF
oligonucleotide
number
Primer sequence 5’ to 3' 
with HTLV-1 nucleotide 
position
Length
(b)
Tm
(°C)
Size of PGR 
product 
(bp)
Consensus retrovirai pol Bgrlll
296 Sense 2976 GCCGAGATCTYTNCCNCARVG 2986 21 51 -133
297 Antisense 3088 GCCGAGATCTTCRTCNAYRTA 3078 
B g l l J
21 46
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3.3.6 Preparation of oligonucleotides
3.3.6.1 Oligonucleotide synthesis and purification
Oligonucleotides for use as PGR primers were manufactured on an automated synthesiser 
and cartridge-purified (Alta Bioscience or Genosys). They were dissolved in ultrapure water 
and stored external to the Department of Veterinary Pathology to reduce the risk of PGR 
contamination (Section 3,3.8). An aliquot from each solution was quantified (Section 3.3.6.2) 
and the remaining volume was diluted to an appropriate concentration (usually 10 pM) after 
optimisation for PGR (Section 3.3.7.3).
Selected oligonucleotides were produced within the Department of Veterinary Pathology 
using an automated synthesiser (Model 381 A, Applied Biosystems). These were used as 
primers for PGRs not involving clinical samples, for example for cloning, and for use as 
probes for hybridisation to PGR products. They were cleaved from the synthesis cartridge by 
flushing with 2 ml of 30% ammonia over a 2 hour period and then deprotected by incubating 
at 55°G in the ammonia solution overnight. The solution was divided into aliquots and 
desiccated by centrifugation under vacuum (Speedvac SGI GO, Savant) to remove the 
ammonia before being dissolved in ultrapure water.
3.3.6.2 Quantification of oligonucleotides
Goncentrations of oligonucleotides were determined by measuring ODgeo and ODggo in a 
spectrophotometer (Section 3.3.3.4). Galculations were made on the basis that 30 pg/ml 
single-stranded DNA has an OD260 of approximately 1.0. Pure preparations of single 
stranded DNA have an OD260/OD280 ratio of 1.6 to 1.8 (Sambrook et al 1989). The molar 
concentration was calculated on the basis that 1 pmol of a single-strand of the 4.3 kb 
plasmid pBR322 contains 1.4 pg DNA.
3.3.7 Polymerase chain reaction
3.3.7.1 Standard PGR master mixes
Standard PGRs were performed in 0.6 ml PGR tubes in 50 pi volumes containing target 
DNA, 200 pM each deoxynucleoside triphosphates (dATP, dCTP, dGTP and dUTP or 
dTTP), 50 mM KGI, 10 mM Tris pH 8.2, 0.05% Nonidet P-40 (NP-40), 0.02 U/pl Tag 
thermostable DNA polymerase (Amplitaq DNA Polymerase, Perkin-Elmer) and PGR grade 
sterile ultrapure water with optimised concentrations of MgGL and oligonucleotide primers. 
Most oligonucleotides were used at a final concentration of 0.5 or 1.0 mM after optimisation 
(Section 3.3.7.3). The range of MgGb concentrations used in PGRs was 1.0 to 3.0 mM, with
1.5 mM being optimal for most primer sets (Section 3.3.7.3). To prevent evaporation during 
thermal cycling, the reaction was overlaid with two drops (approximately 25 pi) of mineral oil.
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PCR master mixes were prepared with concentrations of reagents allowing for the final 
addition of the DNA template to a total volume of 50 pi. Usually 10 pi of a 100 ng/pl solution 
of purified DNA (1 pg) were mixed with 40 pi of PCR master mix. In PGRs using cell pellets, 
25 pi of PGR master mix with constituents at appropriate concentrations were added to PGR 
tubes in which 1x10^ cells had been lysed with 25 pi NIB-proteinase K (Section 3.3.4.2).
3.3.7.2 Standard PGR thermal cycling protocol
PGRs were performed by placing tubes containing reaction mixes in a thermal cycling 
machine (DNA Thermal Cycler, Perkin-Elmer Getus) using the following protocol: initial 
denaturing at 94°G for 7 min; then 40 cycles comprising dénaturation at 94°G for 10 sec, 
cooling at 19.5°G/min over 2 min, annealing at an optimised temperature (usually 55°G) for 
10 sec, heating at 17°G/min over 1 min, extension at 72°G for 30 sec, then heating at 
22°G/min over 1 min to start the next cycle at 94°G; followed by a final extension at 72°G for 
7 min. The reaction was then cooled to 6°G. Samples were stored at 4°G in the molecular 
biology laboratory unless processed immediately.
3.3.7.3 Optimisation of polymerase chain reaction conditions
Optimal concentrations of oligonucleotide primers and MgGl2 were determined for each 
primer set using the standard PGR thermal cycling protocol with annealing at 55°G and a 
standard quantity (1 pg) of positive control DNA template. G8166 DNA was the positive 
control for HTLV-I PGRs and BLV-FLK DNA was the positive control for BLV PGRs. Serial 
two-fold dilutions of primers were prepared to give a range of final concentrations of each 
primer in PGRs from 4.0 to 0.125 mM. The concentration of MgGla used in standard PGRs 
was 1.5 mM but some primer sets required different Mg^  ^concentrations for optimal results. 
PCR optimisations for Mg^  ^were performed with 0.5 to 3.0 mM final concentrations of MgGIg 
in grades of 0.5 mM. The composition of other constituents was held constant when varying 
the primer or MgGL concentrations. Amplified products were separated by electrophoresis 
on 8% polyacrylamide gels, stained with ethidium bromide and examined by UV 
transillumination (Section 3.3.9).
Using optimised concentrations of primers and MgGb, with all other constituents as 
standard, PGRs were then performed with a range of annealing temperatures from 50 to 
70°G to allow the optimal annealing temperature to be selected. The quantity of template 
used was 1 pg positive control DNA. Optimal conditions were considered to be those that 
yielded large amounts of PGR product at the highest possible annealing temperature with a 
preference for final concentrations of 1.0 to 2.5 mM MgGb and 0.5 to 1.0 pM of each primer 
in a set. An attempt was also made to select PGR conditions that were relatively robust, for 
example by not using annealing temperatures or concentrations of MgGla or primers that 
would lead to a loss of sensitivity if altered only slightly.
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The reproducibility of PCR results was confirmed by preparing uniform batches of PCR 
master mixes containing 08166 DNA with primers for amplification of p-globin and HTLV-I 
sequences. These PCR master mixes were prepared on the same day and frozen at -20°C. 
PCR thermal cycling was then performed on different days in the same week using reagents 
thawed on the day of use. The uniformity of amplification in each well of the thermal cycler 
was also tested by placing an array of PCR tubes containing aliquots from a common master 
mix across the thermal cycling block and comparing PGR products by gel electrophoresis. 
The efficacy of amplification was compared using 200 pM dTTP, 200 pM dUTP or 400 pM 
dUTP and found to be similar.
3.3.7.4 Sensitivity of polymerase chain reactions
The sensitivity of each PGR primer set was determined by preparing PGR master mixes 
containing graded concentrations of template. All other reaction constituents, including 
optimised concentrations of primers and MgGla, were held constant for each sensitivity assay 
(Section 3.3.7.1). A standard PGR programme of 40 thermal cycles was then performed 
using the optimised annealing temperature for each primer set.
Serial ten-fold dilutions of positive control DNA in negative control DNA were prepared in the 
molecular biology laboratory to determine the sensitivity of PGRs for detecting template in 
DNA samples from tissues. G8166 DNA was diluted in DNA extracted from human placenta, 
reactive lymph node, PBMGs or J.JHAN cells to assess the sensitivity of PGRs for detecting 
HTLV-I. Serial dilutions of BLV-FLK DNA in FLK DNA were used to determine the sensitivity 
of BLV PGRs. In a standard serial dilution, 50 pi of 100 ng/pl G8166 DNA were added with a 
direct displacement pipette to 450 pi of 100 ng/pl J.JHAN DNA in a 1.5 ml tube to give 10% 
G8166 DNA. This mixture was vortexed thoroughly for 1 min, then 50 pi was transferred to 
another tube containing 450 pi of 100 ng/pl J.JHAN DNA to give 1% G8166 DNA. The 
process was repeated to give a series of dilutions containing 10 to 0.001% positive control 
DNA in negative control DNA. Tubes containing 1 ml 100% G8166 DNA and 1 ml 100% 
J.JHAN DNA were included in the set. Each PGR tube in the sensitivity assay for a particular 
set of primers contained 1 pg total DNA in a 50 pi reaction volume, with 1 pg, 100 ng, 1 ng, 
0.1 ng, 0.01 ng, 0.001 ng, 0.0001 ng or nil positive control DNA. Sets of tubes prepared in a 
similar way for each primer set allowed the sensitivities of HTLV-I and BLV PGRs to be 
determined for DNA templates such as DNA extracted from skin and lymph nodes.
To assess the sensitivity of PGRs for detecting HTLV-I and HTLV-I/II in PBMGs from 
patients or In cultured cells, tubes containing pellets of 1 x lOf  cells were prepared with 
decreasing proportions of HTLV-l-infected G8166 cells diluted in HTLV-I/II negative PBMGs, 
UGMGs or J.JHAN cells (Section 2.3.4). Gells were prepared and diluted in the level II 
containment facility (Section 2.3.1). In a standard serial dilution, 1 ml of G8166 cells at 1 x 
10  ^cells/ml was added to 9 ml of PBMGs at 1 x 10® cells/ml in a 15 ml tube to give 10% 
G8166 cells. After thorough mixing by inversion, a 1 ml aliquot was removed from the tube 
and added to a second tube containing 9 ml of PBMGs at 1 x 10® cells/ml to give 1% G8166 
cells. This process was repeated to give a panel of seven tubes containing 10, 1, 0.1, 0.01 
and 0.001% G8166 cells diluted in PBMGs. Tubes were inverted gently at all stages of
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dilution to maintain even suspensions of cells. Two aliquots of 0.5 ml, each containing 0.5 x 
10® cells, from each mixture were successively transferred to 0.6 ml PCR tubes, centrifuged 
at 10,500 g for 10 min in a bench microcentrifuge and the supernatants discarded to 
produce cell pellets of 1 x 10® cells. In addition, two 0.5 ml aliquots of pure suspensions of 1 
X 10® cells/ml 08166 and 1x10® cells/ml PBMCs were centrifuged In 0.6 ml PCR tubes to 
produce pellets of 1 x 10® cells representing 100% 08166 and 100% PBMCs, respectively. 
These tubes were centrifuged at 10,500 g for 10 min in a bench microcentrifuge and the 
supernatants were discarded. The cell pellets were stored at -80^0 until processed for PCR.
3.3.7.5 Nested polymerase chain reaction
Nested PGRs were performed on some samples to increase sensitivity or to re-amplify PGR 
products for cloning. Nested primers were designed for annealing to sequences internal to 
primers 50 & 51 for amplification of first round PGR products of HTLV-I (282 & 283) and 
HTLV-I/II (288 & 289) (Figure 3.4). The HTLV-I inner primer set was optimised as a single 
round PGR on G8166 DNA and amplified the expected product of 136 bp. Even though no 
HTLV-I I positive control was available for the HTLV-I I inner primer set, primers 288 & 289 
also amplified a product of similar size from G8166, due to sufficient sequence similarity 
between the two viral sequences. Second round PGRs were performed using the inner sets 
of primers at 0.5 pM each and 1.5 mM MgGIg in a standard PGR reaction with 10 pi of a 1 in 
100 dilution of first round product amplified from clinical samples using primers 50 &51.
3.3.7.6 Consensus retroviral PGR
The consensus HTLV/BLV LTR oligonucleotide primers 174 & 175 and 174 & 176 (Figure 
3.2) and consensus retroviral primers 296 & 297 (Figure 3.3) were used in PGRs with 
standard master mixes and thermal cycling conditions (DNA Thermal Cycler, Perkin-Elmer 
Getus) in an attempt to amplify HTLV-I PGR products from pMT2 (Section 3.3.11.2), G8166 
and BLV-FLK DNA, with DNA from human placenta and the FLK cell line as negative 
controls. Serial two-fold dilutions of each primer were made to yield final concentrations of 
4.0 to 0.125 pM and this titration was tested with 1 pg G8166 DNA in standard PGR mixes 
using 1.5 or 2.5 mM MgGl2 . Thermal cycling protocols with annealing temperatures of 55, 60 
and 65°G were compared.
Primer sets were also used in a touchdown PGR protocol in which the annealing 
temperature is changed decrementally with each cycle to increase the likelihood of 
amplifying sequences with the highest similarity to the oligonucleotide primers (Don et al 
1991). The following protocol was used on a 9600 GeneAmp PGR System thermal cycler 
(Perkin-Elmer): initial denaturing at 94°G (5 min); then 26 cycles with dénaturation at 94°G (1 
min), annealing initially at 68°G then decreasing by 0.5°G per cycle (2 min) and extension at 
72^G (1 min); followed by 14 cycles of dénaturation at 94°G (1 min), annealing at 55°G (2 
min) and extension at 72°G (1 min); final extension at 72°G for 7 min then the reaction was 
held at 4°G. Primers 174 & 175 were used at 0.5 pM each with 1.5 and 2.5 mM MgGL.
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Figure 3.4: Nested oligonucleotide primers for amplification of 
HTLV-I and HTLV-II p X  sequences.
LRF
oligonucleotide
number
Primer sequence 5' to 3’ with 
HTLV-I nucleotide position
Length
(b)
Tm
(°C)
Size of PCR 
product 
(bp)
HTLV-I pX
282 Sense 73 68 AGTCTACGTGTTTGGAGACT 73 8 7 20 58 136
283 Antisense 75 03 TCCATCGATGGGGTCCCAGGT 74 83 21 68
HTLV-II pX
288 Sense 72 61 TACGTGTTTGGCGATTGTGT 7280 20 58 131
289 Antisense 7391 CCATCGATGGGGTCCCAGGT 7371 20 66
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3.3.8 Prevention of PCR contamination
3.3.8.1 Preparation of PCR reagents
Since PCR is highly sensitive, contamination of reagents with positive control DNA samples, 
plasmids containing target sequences and previously amplified PCR products can be a 
source of false positive results. Stringent precautions were taken at the LRF Virus Centre to 
minimise the possibility of contamination of PGRs during the preparation and analysis of 
samples. Reagents for PGR were ordered from sources outside the Department of 
Veterinary Pathology and divided into aliquots of the required volume at an external location 
by a person who did not work in the Department. These reagents were delivered as required 
and temporarily stored at -20°G in a dedicated freezer in a room separate from both the level 
II containment facility and the molecular biology laboratory.
PGR master mixes for use with clinical samples were prepared in a designated room 
separate from other buildings in the Department of Veterinary Pathology and not used for 
any other purpose. Pipettes, pipette tips, PGR tubes, gloves and other equipment were 
dedicated to this room. PGR master mixes were prepared at the start of the day before all 
other laboratory work. A new disposable surgical gown, face mask, surgical cap and two 
pairs of gloves were worn while handling reagents and tubes. Positive (direct) displacement 
pipettes or air displacement pipettes (Gilson) with plugged tips were used during the 
preparation of solutions. Gloves were changed between each sample. Reagents and tubes 
were placed on ice in disposable foam buckets during the preparation of PGR master mixes. 
Master mixes were then transported on ice to the level II containment facility.
3.3.8.2 Preparation of clinical samples for PGR
The level II containment facility was used for handling all clinical samples, including 
processing of PBMGs and tissues, cultivation of cells, extraction of DNA and preparation of 
cell pellets for PGR. PGR master mixes were combined with DNA samples or added to tubes 
containing NIB-proteinase K-disrupted cell pellets in this laboratory (Section 3.3.4.2). Gell 
cultures infected with HTLV-I (G8166) or BLV (BLV-FLK) for use as positive controls were 
grown in the level II containment facility but were always handled in a separate class II MSG 
(Section 2.3.1.2). Aliquots of cells from these cell lines, including serial dilutions of positive 
control cells, were prepared in the same MSG (MSG 1). The use of bench centrifuges was 
common to all cell culture work in the laboratory. Extractions of DNA from positive control 
cells were performed in the molecular biology laboratory.
3.3.8.3 Positive and negative controls
PGR tubes containing water in place of DNA or disrupted cells were processed in parallel 
with all clinical samples to act as negative controls. Gontrol tubes were opened and closed at 
the same time as their matching sample tubes but care was taken to ensure that the clinical 
sample was not itself a source of contamination.
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DNA from virus negative cell lines and cell pellets containing PBMCs from people in the 
Department of Veterinary Pathology were included in each batch of PGRs as additional 
negative controls.
Sealed PGR sample and control tubes were transferred a room adjacent to the level II 
containment facility for thermal cycling. Positive control samples were added to PGR master 
mixes in the molecular biology laboratory and placed in the thermal cycler after all tubes 
containing clinical samples had been handled. After completion of the PGR thermal cycle, 
tubes were transferred to the molecular biology laboratory to be opened for gel 
electrophoresis, electroblotting and hybridisation of PGR products.
3.3.8.4 Substitution of dUTP for dTTP in PGR reactions
Deoxyuridine triphosphate (dUTP) was substituted for deoxythymldine triphosphate (dTTP) 
in PGR nucleotide mixes as a further precaution against contamination. Uracil (U) was thus 
incorporated into PGR products instead of thymidine (T) and contamination could be reduced 
or eliminated by adding the enzyme uracil N-glycosylase (UNO) (Gambio or Life 
Technologies) to PGR master mixes to eliminate carry-over PGR products (Longo et al 
1990). The protocol for prevention of PGR contamination using UNG was to add 0.25 U of 
enzyme per 100 pi reaction volume of selected PGR mixes prior to amplification. The mixture 
was incubated at 37°C for 1 hour to break down any U-containing products. The initial 94'^G 
dénaturation step in the standard PGR (Section 3.3.7.2) was increased from 7 to 10 min to 
inactivate the enzyme. Trials using UNG in the molecular biology laboratory showed that it 
eliminated most potential contamination unless large quantities of PGR products were used.
3.3.9 Polyacrylamide gel electrophoresis and electroblotting of polymerase chain 
reaction products
3.3.9.1 Polyacrylamide gel electrophoresis
PGR products less than 500 bp were analysed by polyacrylamide gel electrophoresis 
(PAGE). After removal from the thermal cycling machine, PGR tubes were opened in the 
molecular biology laboratory and 8 pi of PGR product from each tube were mixed with 2 pi of 
gel loading buffer/dye 5x. Glycerol in the buffer acted as a carrier for the DNA. Xylene 
cyanole and bromophenol blue dyes were indicators of electrophoretic migration. Fine 
pipette tips were used to load the 10 pi mixture into wells of 8% polyacrylamide gels 
(Appendix 5: A5.6.1) that had been prepared between 10.0 cm x 7.2 cm x 0.1 cm glass 
plates with a comb inserted at the top to create the wells. A DNA molecular weight (MW) 
marker, 400 ng ())X174/Haelll (Life Technologies), was loaded on each gel as a size 
reference. PGR products were separated by gel electrophoresis using a Mini-Protean II gel 
electrophoresis apparatus (Bio-Rad) for 1 hour at 120 mV (17 mV/cm) with power supplied 
by a standard electrophoresis unit (Pharmacia). Double-stranded DNA PGR products, as 
well as single-stranded DNA such as unused oligonucleotide primers, which carry a net 
negative charge, migrated towards the anode. TBE 1x was used as the buffer in the gel 
electrophoresis tank.
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After electrophoresis, gels were removed from between the glass plates and stained with 0.5 
mg/ml ethidium bromide in deionised water for 6 min. Ethidium bromide is a fluorescent 
agent that intercalates double-stranded DNA. PCR products were viewed using a UV 
transilluminator (TC-254A, Spectroline or 3-3504 Foto/Prep I, Fotodyne) while wearing a 
face shield and photographed with a Polaroid MP4 Land camera using Polaroid Type 57 
high speed (3,000 ASA/36 DIN) film (Genetic Research Instrumentation).
3.3.9.2 Electroblotting of PCR products
PCR products separated by PAGE were transferred to 0.45 pm nylon membrane (Hybond-N, 
Amersham) by electroblotting in preparation for hybridisation to sequence-specific probes. 
Polyacrylamide gels were immersed in alkali buffer for 8 min to denature double-stranded 
DNA, neutralising buffer (pH 8.0) for 8 min, then TAE 1x for 5 min (Appendix 5: A5.7). Each 
gel was positioned onto a sheet of nylon membrane moistened with TAE 1x, then 
sandwiched between two sheets of moistened blotting paper (No. 3, Whatman or GB003, 
Schleicher & Schuell) and placed in a rack between two gauze pads to maintain apposition. 
The rack was Inserted Into the electrode unit of a mini-electroblotting apparatus (Transblot 
cell, Bio-Rad), the tank was part-filled with TAE 1x and a frozen ice container was added to 
keep the buffer cool. Applying 15 V for 1 hour from an electrophoresis power unit transferred 
DNA from the gel to the nylon membrane, while a magnetic stirrer was used to circulate the 
buffer and prevent overheating. After electroblotting, the apparatus was dismantled and the 
nylon membrane exposed to 120 J/cm^ UV light for 48 sec (Stratalinker 1800, Stratagene) to 
fix the DNA to the substrate by cross-linking.
3.3.9.3 Purification of PCR products from polyacrylamide gels
PCR products to be cloned were purified from polyacrylamide gels by excising ethidium 
bromide-stained fluorescent bands with a clean scalpel blade while examining gels on a UV 
transilluminator. Excess polyacrylamide was trimmed and the gel slice was cut into small 
pieces, then placed in a 1.5 ml tube containing an appropriate volume of elution buffer 
(usually 50 pi) containing 0.5 M ammonium acetate and 1 mM EDTA (Appendix 5: A5.6.1). 
The tube was Incubated at 37°C for 1 hour then centrifuged at 11,600 g (13,000 rpm) in a 
microcentrifuge. The supernatant was transferred to a fresh 1.5 ml tube and the eluted DNA 
was precipitated by adding 2.5 volumes (125 pi) of absolute alcohol and holding at -20^C for 
2 hours. A carrier such as glycogen (Boehringer Mannheim) was sometimes added to the 
solution at 20 ng/ml to enhance precipitation of DNA present at low concentration.
After centrifugation, the precipitated DNA was washed in 70% ethanol and air dried, then 
dissolved in a small volume (10 to 20 pi) of ultrapure water or TE 1x. The concentration of 
DNA was estimated by electrophoresis of 2 to 5 pi on a 1 or 2% agarose gel next to a MW 
marker or another DNA sample of known concentration.
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3.3.10 Agarose gel electrophoresis and Southern blotting
3.3.10.1 Agarose gel electrophoresis
Electrophoresis of DNA in 1 or 2% agarose gels was used for visualisation of PCR products 
of 500 bp or more, visualisation of plasmids and products of RE digestion and purification of 
DNA bands for cloning. Agarose was dissolved in TBE 1x by boiling, allowed to cool to 50 to 
60°C, then poured into a Perspex tray and allowed to set at room temperature with a comb 
to form wells. Ethidium bromide was added to the gel during preparation at a concentration 
of 5 to 10 pg/ml. The gel was immersed in TBE 1x in an electrophoresis tank (BRL) and the 
comb was removed. An appropriate volume of gel loading buffer/dye 5x was added to each 
DNA sample and the mixture was pipetted into the wells. A voltage of 1 V/cm was applied 
across the electrodes from an electophoresis power unit. XHIndlW (Life Technologies) or 
(|)X174//-/aelll were used as molecular weight markers. The DNA was visualised on a UV 
transilluminator and gels were photographed as required.
HMW DNA samples that had been digested with REs for SB hybridisation (Section 3.3.3.5) 
were separated by electrophoresis In a 0.8% agarose gel overnight at 1 V/cm. The gel was 
immersed in 0.5 mg/ml ethidium bromide on a rocking tray for 30 to 60 min to stain the DNA 
and then placed in deionised water for 30 to 60 min to destain the background. A photograph 
of the gel was taken under UV transillumination with a ruler adjacent to the MW marker. This 
photograph provided a reference for estimating the sizes of positive bands that might be 
revealed following SB hybridisation (Sections 3.3.12). Test samples included C8166 DNA 
and DNA from patients with neoplasia. Since negative control tissues were not available 
from the same patients, placental DNA samples digested with the same REs were usually 
electrophoresed in parallel with each test sample to provide a reference for hybridisation.
3.3.10.2 Southern blotting
RE-digested DNA for hybridisation was transferred to 0.45 pm nylon membrane (Hybond-N, 
Amersham) using a modified Southern blotting procedure (Southern 1975). After 0.8% 
agarose gel electrophoresis, the DNA was denatured by immersing the gel in alkali buffer for 
1 hour at room temperature. The gel was then submerged in neutralising buffer for 1 hour 
and finally placed in sodium saline citrate (SSC 10x) transfer buffer for 30 min (Appendix 5: 
A5.7). Layers of absorbent paper towels were placed in the bottom of a tray and covered 
with several layers of thick blotting paper (No. 3, Whatman or GB003, Schleicher & Schuell) 
followed by thin blotting paper (No. 1, Whatman). A piece of nylon membrane that had been 
cut to the same size as the gel and rinsed with SSC 10x was placed on the blotting paper. 
The denatured and neutralised gel was laid on top of this membrane and covered with 
several layers of thin blotting paper that had been moistened with SSC 10x. Care was taken 
to exclude bubbles. A sponge soaked with SSC lOx was placed over the top layer of blotting 
paper. The tray and its contents were sealed inside a plastic bag to reduce evaporation 
during blotting. This system used gravity-assisted capillary action to transfer the DNA 
downwards onto the nylon membrane.
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After overnight blotting, the nylon membrane was rinsed with SSC 3x and exposed to UV 
light to cross-link the DNA to the substrate (Section 3.3.9.2).
3.3.10.3 Purification of DNA from agarose gels
PCR products to be cloned and inserts to be excised from plasmids by RE digestion for 
subcloning were purified from agarose gels using diethylaminoethyl (DEAE) membrane 
(Schleicher & Schuell) or a liquefactive enzyme (Gelase, Cambio). Migrating fragments were 
visualised by UV transillumination following gel electrophoresis. Where possible, bands were 
illuminated using a long wavelength (356 nm) hand-held UV light source (UVGL-58 
Mineralight Lamp, UVP) or a UV transilluminator set to preparative mode (3-3504 Foto/Prep 
I, Fotodyne). Purification with DEAE membrane was performed by placing a piece of 
membrane into a slit cut in the agarose gel on the anode side of a DNA fragment of interest, 
then the gel was returned to the electrophoresis tank and 1 V/cm was applied for 10 min. 
When the DNA had migrated onto the DEAE membrane, the membrane was removed, 
trimmed, placed in 50 pi of elution buffer in a 1.5 ml tube and incubated at 65°C for 1 hour 
(Appendix 5: A5.6.1 ). The tube was centrifuged at 11,600 g for 10 min in a microcentrifuge 
and the supernatant transferred to a fresh tube. After adding 2.5 volumes (125 pi) of 
absolute alcohol, the tube was held at -20°C for 2 hours to precipitate the eluted DNA. A 
carrier such as transfer RNA (tRNA) was sometimes added. After centrifugation, the 
precipitated DNA was washed in 70% ethanol and air dried, then dissolved in a small volume 
of ultrapure water or TE 1x. The concentration of DNA was estimated by electrophoresis of 
an aliquot from this volume in parallel with a DNA sample of known concentration (usually 
serial dilutions of the 3.0 kb plasmid pUC8).
DNA to be purified from agarose gels using Gelase was separated by electrophoresis on a 
1% low melting point agarose gel in TAE 1x. The fragment of interest was excised from the 
gel with a scalpel blade, placed in a 1.5 ml tube and weighed. The Gelase enzyme solution 
(1 U/ml) was added to the gel slice at 1 U (1 ml) per 100 g agarose. The tube was incubated 
at 70°C for 20 min or 45°C for 1 hour until the agarose was liquefied, then the liquid was 
transferred to a 30 ml glass centrifuge tube (Corex). DNA was precipitated by adding a 0.1 
times volume of 5 M ammonium acetate, holding at room temperature for 30 min, then 
centrifuging at 12,100 g for 30 min at room temperature in a JS-21 centrifuge using a JA-20 
rotor. After washing with 70% ethanol and drying, the DNA was dissolved in ultrapure water 
or TE 1x and the concentration was estimated by electrophoresis.
3.3.11 Preparation of radioiabetied probes
3.3.11.1 Applications of radiolabelled probes
Hybridisation using radiolabelled probes was employed as a method of increasing the 
sensitivity of detection and confirming the specificity of PGRs for HTLV-I and BLV. The 
stringency of hybridisation was adjusted according to the requirements for sensitivity and 
specificity. Radiolabelled probes were hybridised to DNA that had been separated by gel 
electrophoresis, blotted onto nylon membranes and cross-linked (Sections 3.3.9 and 3.3.10).
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Probes were either linear double-stranded plasmid inserts radiolabelled with a ®^P dCTP by 
random priming (Section 3.3.11.4) or synthetic oligonucleotides that had been 5’ end- 
labelled with y ®^P ATP (Section 3.3.11.5) and purified by Sephadex column filtration (Section 
3.3.11.6).
3.3.11.2 Selection and design of probes
The 11.7 kb plasmid pMT2 contains a full-length molecular clone of the HTLV-I provirus from 
the cell line MT2 cloned into the 2.7 kb vector pUC (Miyoshi et al 1981a, b, Seiki et al 1982) 
(Section 2.1.2.1). pMT2 was grown in Escherichia co li{E  coll) DH5a. A 9 kb viral insert, 
designated pMT2i, was excised from purified plasmid by RE digestion using Sst\ (Section
3.3.13.4). Ssfl cuts pMT2 In the HTLV-I LTR and the 9 kb insert is nearly full-length. pMT2j 
was labelled with a  ®^P dCTP by random priming (Section 3.3.11.4) and used as a probe for 
hybridisation to HTLV-I and HTLV-I/II PCR products and to SBs of RE-digested genomic 
DNA from C8166 cells. The same probe was also used for hybridisation to RNA blots 
(Section 4.2.3.2). HTLV-I and HTLV-II have 60% sequence similarity and pMT2j has been 
used as a probe for detection of HTLV-II sequences amplified by PCR (Shaw et al 1984) 
(Section 1.5.3.1); in this study primers were used that amplified HTLV-I and HTLV-II 
sequences from the pX  region, which is more highly conserved (Figure 3.1).
Three plasmids containing 2.4, 1.1 and 1.9 kb Fsfl fragments from pMT2 ligated into the 4.3 
kb vector pBR322 were also used as probes for hybridisation to SBs of RE-digested 
genomic DNA from C8166 cells. These plasmids were designated pMT2-1 (6.7 kb), pMT2-2 
(5.4 kb) and pMT2-3 (6.2 kb) and were specific for the pol-env, pol, and gag-env regions, 
respectively. Hybridisation studies with these probes were used to verify the HTLV-I provirus 
pattern in C8166, consistent with the findings of Bhat et a /(1993) (Section 2.3.4.1). The 
probe used for hybridisation to BLV PCR products was a y ®^P ATP 5' end-labelled synthetic 
oligonucleotide (Section 3.3.11.5) (Figure 3.5).
3.3.11.3 Procedures for handling radioactive substances
Radioisotopes for labelling probes for hybridisation were handled in the radioactivity room in 
the Department of Veterinary Pathology with precautions to prevent radioactive 
contamination. A radioactivity badge was worn and all surfaces and equipment were 
checked with a Geiger counter before, during and after handling radioisotopes. All 
manipulations were made behind a Perspex shield wearing double gloves. Tubes containing 
radioactive solutions were stored in containers with appropriate shielding and were held in 
Perspex blocks during manipulations. Direct displacement or plugged pipettes were used for 
transfer of radioactive solutions. Absorbent blotting paper with a plastic under-surface 
(Bench-cote) was used In case of spillage of radioactive material. Reusable equipment that 
had been in contact with radioactive substances was soaked in decontaminating solution 
(Decon). Surfaces suspected of being contaminated with radioactivity were also cleaned with 
this solution. Radioactive waste was placed in designated containers for disposal and 
solutions were flushed down a dedicated sink for containment in a holding tank. The 
disposition of all radioisotopes was recorded.
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Figure 3.5; Oligonucleotide probe for hybridisation to poiymerase chain reaction
products generated using bovine leukaemia virus primers.
LRF oligonucleotide Oligonucleotide sequence Length Tm
number 5' to 3' with nucleotide position (b) (°C)
BLV gag
301 2 7 3 6 AGCACTACAGGAACCTCTTCGCCAAGTTTC 2 76 5 30 48
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3.3.11.4 Radiolabelling of linear double-stranded plasmid inserts by random priming
Linear double-stranded DNA inserts purified from plasmids following RE digestion (Section
3.3.13.4) were radiolabelled with a dCTP by random priming to produce radioactive 
oligonucleotide probes for hybridisation. Double-stranded inserts were denatured by boiling 
25 ng linear DNA in 25 \i\ water for 5 min in a 1.5 ml tube then cooling the tube on ice to 
maintain separation of DNA strands. Solutions added to this volume for random priming 
were 10 pi of buffer containing dATP, dGTP and dTTP, 5 pi of primer solution containing 
random hexanucleotides, 2 pi of enzyme solution containing 1 U/pl DNA polymerase I 
Klenow fragment (Multiprime Kit, Amersham) and 8 pi (2.96 MBq) of a  ^^ P dCTP with a 
specific activity of 30 TBq/mmol (R82075, Amersham or Redivue, Amersham) (Appendix 5: 
A5.8.1). The random priming reaction was allowed to proceed for 4 hours at room 
temperature (R82075, Amersham) or 30 min at 37°C (Redivue, Amersham). The 
radiolabelled probe was purified by Sephadex column filtration (Section 3.3.11.6).
3.3.11.5 Radiolabelling of oligonucleotide probes by 5' end-labelling
The oligonucleotide probe for hybridisation to BLV PCR products was synthesised in the 
Department of Veterinary Pathology (Section 3.3.6.1). The 5’ end-labelling reaction mix 
contained 70 pmol synthetic oligonucleotide, 20 U T4 polynucleotide kinase, T4 kinase buffer 
1x (50 mM Tris pH 7.5, 10 mM MgCIa, 5 mM dithiothreitol (DTT), 100 pM spermidine, 100 pM 
EDTA pH 8.0), and 70 pmol y ^^P ATP (ION) (specific activity 111 MBq/mmol) in a total 
volume of 100 pi (Appendix 5: A5.8.2). The reaction mix was incubated at 37°C for 1 hour 
then the radiolabelled probe was purified by Sephadex column filtration (Section 3.3.11.6).
3.3.11.6 Purification of radiolabelled probes by Sephadex column filtration
Radioactive oligonucleotide probes generated by random priming and 5’ end-labelling were 
purified from unincorporated nucleotides by column filtration. Washed Sephadex beads 
(Sephadex-G50, Pharmacia) were pipetted into a glass column and the column was 
equilibrated with TE 1x. Pre-packed disposable Sephadex columns (Sephadex G-50 NICK 
column, Pharmacia) were also used. The 50 pi solutions containing products of random 
priming or 100 pi solutions containing products of 5’ end-labelling were pipetted into the top 
of the equilibrated column and flushed into the Sephadex with TE 1x. Orange-G dye was 
added as a marker for elution of unincorporated nucleotides.
The descent of radioactivity was monitored with a Geiger counter. The first peak of 
radioactivity eluted from the column contained the ^^P-labelled DNA probe. This was 
collected into a 1.5 ml tube for addition to hybridisation solutions. Unincorporated nucleotides 
were eluted as a second peak of radioactivity and discarded by flushing down the liquid 
radioactive waste sink.
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3.3.12 Hybridisation of radioiabeiied probes to membrane-bound DNA
3.3.12.1 Principles of hybridisation
Pairing of complementary bases in single-stranded DNA molecules results in the formation 
of DNA;DNA duplexes with a strength of association that depends on the degree of 
sequence similarity (percentage base mismatch), nucleotide composition, length of 
sequence, temperature and chemical properties of the solution in which hybridisation takes 
place. The temperature of hybridisation, composition of hybridisation solutions and 
stringency of washing can be adjusted according to the predicted properties of probes used 
for hybridisation. The melting temperature (Tm) is a measure of the stability of nucleotide 
association and for DNA:DNA duplexes can be calculated using formula 3.2 (McConaughy et 
a /1969, Wetmur 1991) (Section 3.3.5.1). The Tm for hybridisation of DNA probes in solution 
to target DNA immobilised on nylon membranes is usually slightly lower than the calculated 
value (Beltz et al 1983). Hybridisations are performed at 20 to 25°C below the calculated Tm 
to maximise the rate of DNA:DNA association and for aqueous solutions this is usually 60 to 
70°C. Washing of blots in aqueous solutions to remove unbound and weakly bound probes 
is usually conducted at 5 to 25°C below the calculated Tm. The effective Tm can be 
manipulated by adding formamide to the hybridisation solution; Tm decreases by 0.63% for 
every 1% increase in formamide (Howley et a /1979).
In this study, hybridisations using pMT2| were carried out in standard hybridisation solution 
containing 50% formamide with SSC 3x ([Na^ = 0.59 M, thus [M""] = 0.42) (Appendix 5:
A5.9). Probes produced by random priming have an average length of 100 bp and thus a 
value L = 100 was used for pMT2| (Section 3.3.11.4). The full-length 9,068 bp HTLV-I 
sequence has 53.8% G+C (2,093 A, 3,165 0, 1,720 G, 2,090 T) (Appendix 6). Assuming a 
100% match with a PCR product with a similar %G+C, the calculated Tm for randomly primed 
pMT2j is 61 °C. Hybridisation using pMT2i was routinely performed at 37°C, which is 24°C 
below the calculated Tm. Hybridisations with oligonucleotide probes are usually performed at 
5 to 10°C below the calculated Tm, since the empirically determined Tm is often up to 10°C 
higher. The synthetic oligonucleotide (301) used as a BLV probe in this study had 30 bases 
and 50% G+C (Figure 3.5). This probe was hybridised in standard hybridisation solution 
containing SSC 3x with 50% formamide (Appendix 5: A5.9) at 37°C; the calculated Tm was 
48°C.
3.3.12.2 Prehybridisation
Prehybridisation reduces non-specific binding of radiolabelled probes to nylon membranes 
during hybridisation. Hybridisation solution was prepared with 50% formamide and SSC 3x to 
achieve an effective Tm 5 to 10°C below the calculated Tm of the probe, as discussed above 
(Section 3.3.12.1). This solution was used for both prehybridisation and, following addition of 
radiolabelled probe, for hybridisation. Nylon membranes with bound DNA were moistened 
with SSC 3x, 0.1% SDS and inserted into 50 ml screw-top polypropylene tubes with care 
taken to prevent the formation of bubbles.
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Membranes were prehybridised with 2.5 ml hybridisation solution by continuous rotation at 
37°C in a hybridisation oven (Hybridiser HB-1, Techne) for at least 4 hours. Alternatively, 
nylon membranes were placed in glass hybridisation tubes (Techne) with a larger volume of 
hybridisation solution (10 to 20 ml) depending on the size of the tube and surface area of 
membrane.
3.3.12.3 Hybridisation
The randomly primed a dCTP radiolabelled probe pMT2j (Section 3.3.11.4) was boiled 
for 5 min and cooled on ice to denature any DNA duplexes. Usually 25 pi of radiolabelled 
probe was added to 2.5 ml of the 50% formamide, SSC 3x hybridisation solution that had 
been used for prehybridisation to yield approximately 1x10® counts per ml. Nylon 
membranes were then hybridised with this buffer by rotating the hybridisation tubes in an 
oven at 37°C overnight. The oligonucleotide probe for BLV was added to a hybridisation 
solution of the same composition to approximately 1x10® counts per ml and hybridised 
overnight at 37°C.
3.3.12.4 Washing blots to remove unbound probe
After overnight hybridisation, the hybridisation solution was removed and disposed of 
according to normal radioactivity procedures. The nylon membranes were initially washed 
twice at low stringency by filling the tubes with SSC 2x, 0.1% SDS and rotating in the 
hybridisation oven at room temperature for five min per wash. Subsequent washes were 
carried out under high stringency conditions. Usually, this consisted of Immersing 
membranes in SSC 0.5x, 0.1% SDS in a sealed plastic container and washing twice at 65°C 
for 30 min per wash on an oscillating tray in a heated water bath (Techne). When a SB 
hybridisation was to be repeated, the nylon membrane was stripped of probe by agitating in 
0.1% SDS at 85°C for 30 min then changing the solution and continuing for a further 10 min.
3.3.12.5 Autoradiography
After the final high stringency wash, each nylon membrane was wrapped in plastic (Saran 
Wrap, Dow, Genetic Research Instrumentation) and exposed to X-ray film (Hyperfilm-MP, 
Amersham) in an autoradiograph cassette with an intensifying screen under dark room 
conditions. Cassettes were held at -80°C during exposure and autoradiographs were 
developed in an automatic processor in the Department of Veterinary Pathology after 
exposures of 1 to 21 days.
3.3.13 Manipulation of bacteria
3.3.13.1 Growth and storage of bacteria
Strains of bacteria used for most molecular biology purposes were E coli HB101 or DH5a. 
These were grown at 37°C on Luria-Bertani (LB) agar in Petri dishes in a standard incubator 
or in flasks containing LB broth in an orbital incubator (Fisons) at 225 rpm (Appendix 5:
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A5.1Û.1). Antibiotics were added according to the resistance genes expressed by plasmids 
within the bacteria. Ampicillin (50 pg/ml) was used for growth of E co//containing pMT2 and 
TA cloning vectors (Section 3.3.16.2) (Appendix 5: A5.10.2). Tetracycline (12 pg/ml) was 
used for growth of E coli containing pMT2-1, pMT2-2 and pMT2-3 (Section 3.3.11.2).
Stocks of viable bacteria were prepared by mixing 1 ml of bacteria in suspension from 
overnight LB broth cultures with 500 \x\ sterile 80% glycerol in cryopreservation tubes 
(Cryotubes, Nunc). Cryotubes were frozen in liquid nitrogen (liqN2) or a mixture of dry ice 
and absolute alcohol then transferred to a freezer for long-term storage at -80°C. Unwanted 
bacterial cultures and supernatants were sterilised by autoclaving or inactivated with 
disinfectant solutions (sodium dichloroisocyanurate, Presept, Surgikos).
3.3.13.2 Transformation of chemically competent bacteria with plasmid DNA
Plasmids are circular double-stranded DNA molecules that replicate in bacteria and are 
widely used for manipulation of DNA. Plasmids with antibiotic resistance genes can be used 
for selection of cloned DNA inserts. Transformation is the method by which plasmid DNA is 
introduced into bacteria. Competent bacteria (Life Technologies) were stored at -80°C and 
thawed on ice when required for transformation. Volumes of 50 pi were placed in 15 ml 
polypropylene tubes (2059, Falcon) on ice and 10 to 100 ng of plasmid DNA was added to 
each tube. The mixture was held on ice for 10 min, then the tubes were placed in a 42°C 
water bath for 45 sec to induce passage of plasmid DNA across the bacterial cell wall. After 
the addition of 900 pi of LB broth or SOC, tubes were incubated in an orbital incubator at 
37°C for 1 hour to allow expression of plasmid-encoded antibiotic resistance genes. Aliquots 
of 50 to 200 pi bacteria were spread onto LB agar plates containing the appropriate 
antibiotic. These plates were incubated at 37°C overnight to allow the selective growth of 
transformed bacteria.
3.3.13.3 Transformation of bacteria by electroporation
Bacteria were grown at 37°C in 200 ml LB broth containing antibiotics for approximately 6 
hours to an ODeoo of 0.5 to 0.7 (Hanahan 1983). The cultures were centrifuged at 3,740 g  
(4,500 rpm) for 10 min in the JS-21 centrifuge using a JS-7.5 rotor at 4°C, After removing 
the supernatant, bacteria were centrifuged and resuspended four times in decreasing 
volumes (400, 200, 20 and 1 ml) of sterile 10% glycerol in water. Aliquots of 100 pi were 
stored at -80°C. Bacteria were thawed at room temperature, placed on ice and 40 pi of 
chilled bacterial suspension was mixed with 1 to 2 pi (5 to 10 ng) plasmid DNA in a 1.5 ml 
tube on ice. This volume was transferred to an ice cold sterile 0.2 cm electroporation cuvette 
(Bio-Rad), placed in a chilled Teflon block and electroporated with a voltage of 2.5 kV, 
charge transfer of 2.4 C (25 pF), resistance of 200 D. and time constant between 4 and 5 sec 
(Gene Puiser and Pulse Controller, Bio-Rad). Following electroporation, 1 ml of LB broth was 
added to the cuvette and transferred to a 15 ml tube (2059) for incubation at 37°C for 1 hour 
at 225 rpm in an orbital incubator. Bacteria were then spread on LB agar containing the 
appropriate antibiotic and incubated at 37°C overnight.
144
3.3.13.4 Selection and growth of transformed bacteria
A sterile flamed loop was used to pick single colonies of transformed bacteria that had grown 
on selective agar plates after overnight incubation. Colonies were inoculated into 15 ml tubes 
(2059) containing 5 ml LB broth with an appropriate antibiotic and incubated at 37°C in an 
orbital incubator at 225 rpm overnight. Small scale preparations of plasmids were made from 
these cultures (Section 3.3.14.1). Large scale plasmid preparations (Sections 3.3.14.2 and 
3.3.14.3) were made by transferring 5 ml of overnight broth culture into flasks containing 500 
ml of LB broth and an appropriate antibiotic. These flasks were incubated overnight in an 
orbital incubator at 37°C. Chloramphenicol (25 pg/ml) was added to overnight cultures 
containing tetracycline (12 pg/ml) to maximise expression of pMT2, pMT2-1, pMT2-2 and 
pMT2-3 in E coli DH5a for large scale plasmid purification.
3.3.14 Purification of plasmid DNA
3.3.14.1 Small scale purification of plasmid DNA
Small scale preparations of plasmid DNA for RE digestion and screening for inserts by gel 
electrophoresis were prepared by modified alkaline lysis or boiling methods or by column 
purification. One or two 1.5 ml aliquots of overnight cultures of bacteria in LB broth 
containing antibiotics were centrifuged in 1.5 ml tubes at 11,600 g in a microcentrifuge for 5 
min. Supernatants were removed, leaving a pellet of bacteria in the bottom of each tube.
Bacteria to be disrupted by alkaline lysis were resuspended by vortexing with 100 \x\ of 
Solution I (Birnboim and Doly 1979) (Appendix 5: A5.11.1). This suspension was mixed with 
200 \i\ Solution II, which contained 0.2 M NaOH and 1% SDS to lyse cells, then was vortexed 
with 150 pi Solution III, containing 3 M potassium acetate to precipitate bacterial proteins and 
genomic DNA. The tubes were centrifuged at 11,600 g for 5 min in a microcentrifuge and the 
supernatants, containing plasmid DNA, were transferred to fresh tubes. Extractions with 1 ml 
phenol and 1 ml chloroform were each followed by centrifugation and transfer of 
supernatants to fresh tubes. Plasmid DNA was precipitated by the addition of 2.5 volumes of 
absolute alcohol followed by centrifugation and washing in 70% ethanol. The DNA pellet was 
allowed to dry then dissolved in 30 to 50 pi ultrapure water or TE 1x. Plasmid DNA was 
visualised by electrophoresis of 10 pi on an agarose gel (Section 3.3.10.1 ) and RE digests 
were prepared to check for the presence of inserts by gel electrophoresis (Section 3.3.14.4).
Bacteria were harvested from LB broth cultures by centrifugation in 1.5 mi tubes for 
extraction of plasmid DNA by the boiling method. After removing the supernatant, pelleted 
bacteria were vortexed with 150 pi sucrose-Triton X-100-EDTA-Tris (STET) solution and 10 
pi 10 pg/ml lysozyme (Boehringer Mannheim) to disrupt cell walls (Appendix 5: A5.11.2). 
Tubes were boiled for 40 sec, placed on ice for 5 min and then centrifuged at 11,600 g for 10 
min. The glutinous pellet that formed in each tube was removed by pipetting with a wide-bore 
micropipette tip and discarded. The plasmid DNA was precipitated by adding 100 pi of 
isopropanol and placing the tubes at -20°C for 15 to 30 min. Tubes were centrifuged at 
11,600 g for 5 min, the supernatant was removed and the precipitated DNA was washed with
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1 ml 70% ethanol. The tubes were allowed to dry and the plasmid DNA was dissolved in 30 
to 50 pi ultrapure water or TE 1x as above. RNase A was added at a final concentration of 
50 pg/ml in preparation for gel electrophoresis.
Plasmids were column purified for RE digestion and for sequencing using resin columns 
(Wizard minipreps DNA purification system, Promega). LB broth cultures of bacteria were 
centrifuged (1.5 ml twice) in 1.5 ml microcentrifuge tubes at 11,600 g for 5 min and the 
bacterial pellet was resuspended in 200 pi cell suspension solution. Bacteria were disrupted 
with 200 pi cell lysis solution then treated with 200 pi neutralisation solution. After 
centrifuging at 11,600 g for 10 min the supernatant was transferred to a fresh tube and 
mixed with 1 ml DNA purification resin. This volume was pipetted into a 5 ml syringe 
attached to a column inserted into a vacuum manifold. A vacuum was applied to filter the 
liquid through the column then 2 ml column wash solution was added and drawn through 
under vacuum. The columns were dried by continued vacuum for 2 min then centrifugation 
for 1 min. DNA was dissolved by adding 50 pi water at 70°C for 5 to 15 min then eluted from 
the column by centrifuging at 11,600 g for 1 min.
3.3.14.2 Large scale crude extraction of plasmid DNA
Flasks containing 500 ml overnight bacterial cultures were cooled on ice and the contents 
transferred to 250 ml screw-top centrifuge tubes (Beckman) on ice. The cultures were 
centrifuged at 9,060 g (7,000 rpm) in the JS-21 centrifuge using a JS-7.5 rotor (Beckman) 
for 10 min at 4°C. The supernatant was discarded, the bacteria were resuspended in 100 ml 
TNE 1x and the centrifugation was repeated. The bacterial pellet was resuspended in 4 ml 
0,5% lysozyme solution and allowed to stand at room temperature for 5 min to disrupt 
bacterial cell walls. The DNA was denatured by adding 16 ml of alkaline lysis solution, 
vortexing and holding on ice for 10 min. The solution was neutralised with 12 ml of 
potassium acetate solution pH 4.8 and placed on ice for a further 10 min to allow plasmid 
strands to re-anneal. The lysed bacteria were centrifuged at 43,700 g (19,000 rpm) for 30 
min at room temperature in the JS-21 centrifuge using a JA-20 rotor. The supernatant was 
divided between two 30 ml glass centrifuge tubes (Corex). Plasmid DNA was precipitated by 
adding 0.6 volumes of isopropanol followed by thorough mixing. The precipitate was 
centrifuged at 12,100 g (10,000 rpm) for 30 min at room temperature in the JS-21 centrifuge 
using a JA-20 rotor. The supernatant was removed and 5 ml of 70% ethanol was added to 
the pellet to remove salt from the precipitated plasmid DNA. This solution was centrifuged at 
12,100 g for 15 min at room temperature. The pellet was allowed to dry for a maximum of 10 
min and then dissolved in 5 ml of TE 1x buffer.
3.3.14.3 Large scale purification of plasmid DNA by caesium chloride density gradient 
centrifugation
The crude extract of plasmid DNA in 5 ml TE 1x (Section 3.3.13.2) was prepared for density 
gradient centrifugation by adding 1 g/ml CsCl and 740 mg/ml ethidium bromide. The mixture 
was transferred to 5 ml ultracentrifuge tubes (Quick-Seal, Beckman), which were balanced, 
heat sealed and centrifuged overnight at 49,000 rpm in an L-8 60M ultracentrifuge
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(Beckman) using a Vti 65.2 rotor at 20°C. The lower band of supercoiled plasmid DNA was 
visualised using a hand-held ultraviolet lamp (UVGL-58, UVP) in the dark room. This band 
was removed using a needle and syringe and was diluted with TE 1 x to a volume of 5 ml. 
Ethidium bromide was removed from the solution by repeated mixing with water-saturated 
isobutanol. When the aqueous phase was colourless, the plasmid DNA was precipitated by 
adding 2.5 volumes of absolute alcohol and holding the solution at -20°G for 2 hours. The 
tubes were centrifuged at 12,100 g for 30 min in the JS-21 centrifuge using a JA-20 rotor at 
4*^0. Salt was removed by washing with 70% ethanol then the DNA pellet was allowed to dry 
before being dissolved in 50 to 200 pi ultrapure water or TE 1x.
3.3.14.4 Restriction endonuclease digestion of plasmid DNA
Plasmids were digested with 5 U of the appropriate RE per mg of plasmid DNA in a solution 
containing proprietary buffer (Life Technologies) at 1x concentration. The most frequently 
used REs were SamHI, EcoRI, H/ndlll, Pst\, Sst\ and Xba\ (Appendix 5: A5.3.1). Reactions 
were incubated at 37°C for 1 to 3 hours. If two REs were required to excise a plasmid insert, 
both enzymes were added to the same solution if they had similar activities in the same 
buffer. If buffer requirements were substantially different, the enzymes were used in 
succession and the plasmid DNA was precipitated with ethanol and washed with 70% 
ethanol to remove salts between each digest. RNase A was sometimes added to RE digests 
at a final concentration of 50 pg/ml to remove RNA contamination. Inserts were separated 
from RE-digested plasmids by agarose gel electrophoresis (Section 3.3.10.1) and bands 
were purified using DEAE membrane or Gelase (Section 3.3.10.3).
3.3.15 Subcloning plasmid inserts
Subcloning was used to transfer a double-stranded segment of insert DNA from one plasmid 
to another. Plasmid DNA was purified by agarose gel electrophoresis using DEAE 
membrane (Section 3.3.10.3). Supercoiled plasmid DNA migrated most rapidly, followed by 
linear and nicked forms. Inserts were excised from plasmids by digestion with one or two 
REs followed by gel electrophoresis and gel purification (Section 3.3.14.4). A recipient 
plasmid vector was prepared by digestion with the same REs and gel-purified similarly. The 
insert and recipient plasmid were mixed at an appropriate molar ratio (usually insert:plasmid 
3:1) and ligated in a solution containing T4 DNA ligase and ligation buffer 1x in a total 
volume of 10 to 40 pi. Purified plasmid or other DNA that had been dissolved in solutions 
with a low concentration of salt was concentrated by mixing an aqueous solution with 0.1 
volumes of 3 M sodium acetate and 2.5 volumes of absolute alcohol. The mixture was held 
at -20°C for 1 to 2 hours, centrifuged at 11,600 g in a microcentrifuge, then washed in 70% 
ethanol. The DNA was then dissolved in an appropriate volume of ultrapure water or TE 1x.
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3.3.16 Cloning and sequencing PCR products
3.3.16.1 Re-amplification of PCR products
Selected PCR products were cloned into plasmid vectors for sequencing. When dUTP was 
substituted for dTTP in PCRs, products of amplification could not be readily cloned because 
UNGs present in standard laboratory strains of bacteria degrade plasmids containing inserts 
with U residues. Therefore, PCR products for cloning were re-amplified by PCR using dTTP 
in the dNTP mix with the same primers as those used for the original PCR reaction. An 
alternative approach would have been to use strains of bacteria that were defective for UNG 
activity (UNG' strains) for transformation.
3.3.16.2 TA cloning of PCR products
Non-proof reading DNA polymerases, such as the Taq polymerase (Amplitaq DNA 
Polymerase) used in standard PCRs (Section 3.3.7.1), add single dA residues to the 3’ ends 
of duplex DNA molecules generated by PCR. These PCR products can be cloned by ligation 
into vectors with single 3’ dT residues. The vector used for this purpose was pCRII (TA 
Cloning System, Invitrogen). PCR products were cloned directly from unpurified reaction 
mixes or were gel-purified and dissolved in ultrapure water before ligation. The reaction mix 
for TA cloning using PCRII contained 1 pi of PCR product, 4 U T4 DNA ligase, commercial 
ligation buffer 1x and 50 ng plasmid vector in a total volume of 10 pi. E coli DH5a was 
transformed with the ligation reaction mix (Sections 3.3.13.2) and plated on LB agar 
containing 50 pg/ml ampicillin and spread with 1 mg 5-bromo-4-chloro-3-indolyl-p-D- 
galactoside (X-gal). Blue-white screening was used for selection of plasmids containing 
inserts. X-gal is a substrate for p-galactosidase, which turns blue when cleaved by active 
enzyme produced in plasmids that lack inserts. Bacteria transformed with plasmids 
containing inserts do not produce active enzyme and colonies remain white. LB agar plates 
spread with transformed bacteria were incubated at 37°C overnight. White colonies were 
picked and inoculated into 5 ml LB broth containing 50 mg/ml ampicillin. These cultures were 
grown overnight at 37°C in an orbital incubator at 225 rpm and small scale preparations of 
plasmids made using the boiling method (Section 3.3.14.1). The plasmids were digested with 
REs and separated by agarose gel electrophoresis. Plasmids containing inserts of the 
expected size were identified and the source broth cultures were regrown. Small scale 
preparations of plasmids were then made using the alkaline lysis method followed by phenol- 
chloroform extraction or column purified (Wizard minipreps DNA purification system, 
Promega) (Section 3.3.14.1). The purified plasmids were quantified by spectrophotometry 
and submitted for sequencing.
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3.3.16.3 Sequencing of plasmid inserts
Some plasmids were sequenced at the University of Birmingham (Alta Bioscience) using 
standard primer sequences (T3 and T7) present in the cloning vector pCRII (Appendix 5: 
A5.12.1). Other plasmids were sequenced with the ^^Sequencing Kit (Pharmacia), which 
uses the dideoxy sequencing method in which primer extension by T7 DNA polymerase is 
terminated in reactions specific for A, C, G and T bases (Sanger et al 1977, Tabor and 
Richardson 1987) (Appendix 5: A5.12.2).
Plasmids that had been purified for sequencing (2 pg) were denatured in 0.4 M NaOH for 10 
min at room temperature In 1.5 ml microcentrifuge tubes. The DNA was precipitated with 0.1 
volumes of 3 M sodium acetate and 2.5 volumes absolute alcohol at -20°G for 30 min. The 
tubes were centrifuged at 11,600 g for 15 min then the precipitated DNA was washed with 
70% ethanol, vacuum desiccated and dissolved in 10 pi ultrapure water. This volume was 
mixed with 2 pi (10 pmol) universal primer (Ml 3) and 2 pi annealing buffer and incubated at 
65°C for 10 min then 37°C for 10 min. The sequencing enzyme T7 DNA polymerase (2 pi) 
was mixed with 8 pi enzyme dilution buffer on ice. Each of four labelling reactions consisted 
of 14 pi annealed template and primer, 3 pi labelling mix (dATP), 1 pi (9.25 MBq) a  ®®S dATP 
(Amersham) (Appendix 5: A5.12.3) and 2 pi of diluted T7 DNA polymerase in a total volume 
of 20 pi. The labelling reactions were incubated at room temperature for 5 min then 4.5 pi 
was added to each of four 1.5 ml microcentrifuge tubes containing 2.5 pi of one of four 
sequencing mixes (‘A’, 'C, 'G' or T  mix-short) that had been incubated at 37°C for 2 min. 
The termination reaction was allowed to proceed for 5 min at 37°C then stopped by the 
addition of 5 pi of a proprietary solution containing formamide, EDTA, bromophenol blue and 
xylene cyanole.
Aliquots (3 pi) of each reaction were incubated at 80°C for 3 min and placed on ice then 2.5 
pi was loaded into one of four adjacent wells of a 5% polyacrylamide sequencing gel (Long 
Ranger DNA sequencing gel solution Hydro-Link, AT Biochem) (Appendix 5: A5.12.4). The 
glass sequencing plates had been coated with silicon (Sigmacote SL-2, Sigma) prior to 
pouring the polyacrylamide gel. The samples were separated by electrophoresis in a 
sequencing cell (Sequi-Gen II System, 21 cm x 50 cm, Bio-Rad) at 1,500 V for 90 min with 
power supplied by an electrophoresis unit (ECPS 3000/150, Pharmacia). After dismantling 
the apparatus and separating the glass plates, the gel was transferred to blotting paper 
(Number 3, Whatman) and dried at 80^0 for 2 hours in a gel-drier (Bio-Rad). Autoradiograph 
film was exposed for 4 hours then developed. The A, G, G, T sequence was read manually 
from the pattern of bands in each lane.
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3.4 Results
3,4.1 Sensitivity of detection of HTLV-i and BLV by PCR
The primer sets for amplification of HTLV-I, HTLV-I/II and BLV sequences by PCR are 
shown in Figure 3.1. The sensitivities of these primer sets for detecting HTLV-I and BLV 
positive control DNA using optimised PCR conditions are indicated in Table 3.2 and depicted 
in Figures 3.6 to 3.23. Most primer sets were able to detect 0.1 to 1.0 ng positive control 
DNA in a total quantity of 1 |.ig DNA when 8 pi from 50 pi of PCR products were 
electrophoresed on a polyacrylamide gel and stained with ethidium bromide. The sensitivity 
was increased to 0.01 to 0.1 ng when these PCR products were electroblotted and 
hybridised to HTLV-I or BLV-specific probes. Some primer sets were less sensitive. Specific 
PCR products could be detected in not less than 10 ng C8166 DNA on polyacrylamide gels 
using primers 120 & 121. Primers 67 & 68 also had relatively low sensitivity (10 ng C8166 
DNA): both had degenerate bases, increasing the probability of binding to non-specific DNA 
sequences. Primers 3 & 4 had different calculated 7m values because primer 3 was 
substantially larger (29 bases) than primer 4(18 bases), but this primer set retained good 
sensitivity (1.0 ng C8166 DNA). The primer set used for amplification of BLV sequences 
(194 & 195) also had relatively low sensitivity (10 ng BLV-FLK DNA). Another set of primers 
and oligonucleotide probe used for BLV PCRs was found to lack specificity (Agresti ef al 
1993).
The sensitivities of PCRs for detection of HTLV-I and BLV in serial dilutions of positive 
control cells in PBMCs or other negative control cells are shown in Table 3.3. On ethidium 
bromide-stained polyacrylamide gels, PCR product could be detected with most primer sets 
when 100 to 1,000 positive control cells were present in a total quantity of 100,000 cells. 
Some primer sets could detect 10 positive cells in this quantity. Hybridisation to HTLV-I- 
specific probes increased the sensitivity to 1 to 100 positive cells.
Serial dilutions of positive control DNA or cells were included with each batch of clinical 
samples tested by PCR to ensure that sensitivity was maintained. Sensitivities of most 
primer sets were highly repeatable. If the titration of positive controls in any batch of PCRs 
with clinical samples did not show acceptable sensitivity, the PCRs were repeated on the 
same samples. In interpretation of these sensitivity assays, it is important to note that C8166 
cells contain three copies of each LTR and of the p X  region of HTLV-I, but only one copy of 
gag, po/and er?v sequences (Section 2.3.4.1). BLV-FLK cells contain one copy of complete 
provirus (2.3.4.6).
The p-globin primers 18 & 52 were used with concentrations of 0.5 pM each primer and a 
concentration of 1.5 mM MgCL in each PCR. Serial dilutions showed that p-globin 
sequences could be detected in 0.01 ng DNA using these primers when PCR products were 
visualised on polyacrylamide gels (Figure 3.24).
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Table 3.2: Optimised conditions and sensitivity of polymerase chain reactions.
The listed concentrations of oligonucleotide primers and MgCL were used in PCRs for 
amplification of HTLV-I, HTLV-I/II and BLV sequences following optimisation. The sensitivity 
of each PCR primer set is given for detection of template (C8166 DNA for HTLV-I/II PCRs 
and BLV-FLK DNA for BLV PCRs) in a total of 1 pg DNA. In most cases, hybridisation of the 
HTLV-I probe pMT2j to electroblots increased the sensitivity of detection by 10-fold relative 
to examination of ethidium bromide-stained polyacrylamide gels by UV transillumination.
LRF primer 
number
Optimum 
concentration 
of each primer 
(pM)
Optimum 
concentration 
of MgCL 
(mM)
Quantity of positive control DNA detected 
in a total quantity of 1 pg DNA (ng)
Ethidium-bromide- Hybridisation 
stained polyacrylamide gels using probe pMT2i
HTLV-I LTR
118& 119 0.5 2.5 0.1 0.01
HTLV-I gag
120 & 121 1.0 1.5 10 0.1
122 & 123 1.0 1.5 1.0 0.1
HTLV-I pol
1 &2 1.0 1.5 1.0 0.1
67& 68 0.5 2.0 10 1.0
HTLV-I env
124 & 125 1.0 1.5 1.0 0.01
HTLV-I/II pX
50&51 1.0 1.5 0.1 0.01
3 & 4 0.5 2.5 1.0 0.1
126 & 127 1.0 1.5 1.0 0.1
BLV gag
194 & 195 0.5 1.5 10 1.0
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Table 3.3: Sensitivity of poiymerase chain reactions for detection 
of HTLV-I, HTLV-I/II and BLV sequences in cell pellets.
The sensitivity of each PCR primer set is given for detection of template (C8166 DNA for 
HTLV-I and HTLV-I/II PCRs and BLV-FLK DNA for BLV PCRs) in pellets of 1 x 10® cells 
digested with non-ionic detergent buffer and proteinase K. In most cases, hybridisation of the 
HTLV-I probe pMT2i to electroblots increased the sensitivity of detection by 10-fold relative 
to examination of ethidium bromide-stained polyacrylamide gels by UV transillumination.
LRF primer 
number
Number of positive cells detected 
in a total of 1 x 10® cells
Ethidium-bromide- Hybridisation 
stained polyacrylamide gels using probe pMT2i
HTLV-1 LTR
118 & 119 1 X 10^ 1 x1Qi
HTLV-1 gag
120 & 121 1 xIO^ 1 x1Qi
122 & 123 1 xIO^ 1 x10°
HTLV-1 po/
1 & 2 1 x1Qi 1 x10°
HTLV-I env
124 & 125 1 X 10^ 1 X 10°
HTLV-I/II pX
5 0 & 5 1 1 X 10^ 1 x 1 0°
126 & 127 1x10^ 1 x 1 0°
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Figure 3.6: Sensitivity of PCR for detection of HTLV-I LTR
sequences using primers 118 & 119.
PCR for HTLV-I LTR sequences using primers 118 & 119 was performed on serial dilutions 
of 08166 DMA in placental DMA (total quantity 1 pg DMA) and products were examined on 
an ethidium bromide-stained polyacrylamide gel following electrophoresis. The expected 
PCR product size is 183 bp. Additional bands at approximately 300 bp represent migration of 
single-stranded PCR product. M = (j)X174//-/aelll molecular weight marker, bp = base pairs.
Quantity of C8166 DNA (ng) 
in total 1 pg DNA
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Figure 3.7: Hybridisation of probe pMT2j to HTLV-i LTR PCR products
amplified using primers 118 & 119.
HTLV-I LTR PCR products from Figure 3.6 amplified using primers 118 & 119 were 
electroblotted onto nylon membrane and hybridised to probe pMT2i radiolabelled by random 
priming. PCR products of 183 bp were positive on hybridisation, as were PCR products that 
migrated as single-stranded bands at approximately 300 bp. M = Molecular weight marker 
lane, bp = base pairs.
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Figure 3.8: Sensitivity of PCR for detection of HTLV-i gag sequences
using primers 120 & 121.
PCR for HTLV-I gag sequences using primers 120 & 121 was performed on serial dilutions 
of C8166 DNA in placental DNA (total quantity 1 pg DNA) and products were examined on 
an ethidium bromide-stained polyacrylamide gel following electrophoresis. The expected 
PCR product size is 273 bp. Additional larger bands at approximately 400 and 850 bp may 
represent migration of single-stranded PCR products. M = (|)X174//-/aelll molecular weight 
marker, bp = base pairs.
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Figure 3.9: Hybridisation of probe pMT2i to HTLV-I gag PCR products
amplified using primers 120 & 121.
HTLV-I gag PCR products from Figure 3.8 amplified using primers 120 & 121 were 
electroblotted onto nylon membrane and hybridised to probe pMT2j radiolabelled by random 
priming. PCR products of 273 bp, as well as larger bands including probable single-stranded 
PCR products, were positive on hybridisation. M = Molecular weight marker lane, bp = base 
pairs.
Quantity of C8166 DNA (ng) 
in total 1 pg DNA
o
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Figure 3.10: Sensitivity of PCR for detection of HTLV-I gag sequences
using primers 122 & 123.
The sensitivity of PCR for detecting HTLV-I gag sequences using primers 122 & 123 was 
determined using serial dilutions of C8166 DNA in placental DNA (total quantity 1 pg DNA). 
In conjunction with the sensitivity assay, PCRs were performed on 1 pg skin DNA from three 
patients with cutaneous lymphoid infiltrates, along with water controls. PCR products were 
separated by polyacrylamide gel electrophoresis and stained with ethidium bromide. The 
expected PCR product size is 134 bp. M = (j)X174/Haelll molecular weight marker.
P = Patient number. CBCL = Cutaneous B cell lymphoma. MF = Mycosis fungoides. SS = 
Sèzary syndrome, bp = base pairs.
Clinical
samples
Quantity of 
C8166 DNA (ng) 
in total 1 pg DNA
(0 (/) Ü
(0 (0 DQ so> O) o> o
(O (O lO o><o O (O o CO o h -M a! ry (N (N CMX Û . X 0 . X Q.
og I s
1,353
134 bp
157
Figure 3.11: Hybridisation of probe pMT2| to HTLV-I gag PCR products
amplified using primers 122 & 123.
HTLV-I gag PCR products from Figure 3.10 amplified using primers 122 & 123 were 
electroblotted onto nylon membrane and hybridised to probe pMT2| radiolabelled by random 
priming. PCR products of 134 bp were positive on hybridisation and there was hybridisation 
to products that migrated as single strands at higher molecular weight. M = Molecular weight 
marker lane. P = Patient number. CBCL = Cutaneous B cell lymphoma. MF = Mycosis 
fungoides. SS = Sèzary syndrome, bp = base pairs.
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Figure 3.12: Sensitivity of PCR for detection of HTLV-I pol
sequences using primers 1 & 2.
PCR for HTLV-I pol sequences using primers 1 & 2 was performed on serial dilutions of 
C8166 DNA in placental DNA (total quantity 1 pg DNA) and products were examined on an 
ethidium bromide-stained polyacrylamide gel following electrophoresis. The expected PCR 
product size is 119 bp. Additional bands at approximately 150 bp represent migration of 
single-stranded PCR product. M = <j)X174//-/aelll molecular weight marker, bp = base pairs.
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Figure 3.13: Hybridisation of probe piVIT2, to HTLV-I pol PCR products
amplified using primers 1 & 2.
HTLV-I pol PCR products from Figure 3.12 amplified using primers 1 & 2 were electroblotted 
onto nylon membrane and hybridised to probe pMT2j radiolabelled by random priming. PCR 
products of 119 bp were strongly positive on hybridisation. PCR product that migrated as 
single stranded bands at approximately 150 bp was also hybridisation positive and there was 
weak hybridisation to unincorporated PCR primers. . A faint band visible by eye in the lane 
with 0.1 ng C8166 DNA is not reproduced in the photograph. M = Molecular weight marker 
lane, bp = base pairs.
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Figure 3.14: Sensitivity of PCR for detection of HTLV-I pol sequences
using primers 67 & 68.
The sensitivity of PCR for detecting HTLV-I pol sequences using primers 67 & 68 was 
determined using serial dilutions of C8166 DNA in placental DNA (total quantity 1 pg DNA). 
In conjunction with the sensitivity assay, PCRs were performed on 1 pg skin DNA from three 
patients with cutaneous lymphoid infiltrates, along with water controls. PCR products were 
separated by polyacrylamide gel electrophoresis and stained with ethidium bromide. The 
expected PCR product size is 186 bp. Several bands migrating at larger sizes represent 
single-stranded PCR products. M = 4)X174//-/aelll molecular weight marker. P = Patient 
number. CBCL = Cutaneous B cell lymphoma. MF = Mycosis fungoides. SS = Sèzary 
syndrome, bp = base pairs.
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Figure 3.15: Hybridisation of probe pMT2| to HTLV-I pol PCR products
amplified using primers 67 & 68.
HTLV-I pol PCR products from Figure 3.14 amplified using primers 67 & 68 were 
electroblotted onto nylon membrane and hybridised to probe pMT2i radiolabelled by random 
priming. PCR products of 186 bp were positive on hybridisation and there was hybridisation 
to products that migrated at higher molecular weight. Faint bands visible by eye in the lanes 
with 10 and 1 ng C8166 DNA are not reproduced in the photograph. M = Molecular weight 
marker lane. P = Patient number. CBCL = Cutaneous B cell lymphoma. MF = Mycosis 
fungoides. SS = Sèzary syndrome, bp = base pairs.
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Figure 3.16: Sensitivity of PCR for detection of HTLV-i env sequences
using primers 124 & 125.
PCR for HTLV-I env sequences using primers 124 & 125 was performed on serial dilutions 
of C8166 DNA in placental DNA (total quantity 1 pg DNA) and products were examined on 
an ethidium bromide-stained polyacrylamide gel following electrophoresis. The expected 
PCR product size is 327 bp. Specific PCR products from C8166 were detected as a doublet, 
probably reflecting amplification from different integrated proviruses in the DNA. Additional 
bands migrating at approximately 1,200 and 900 bp represent migration of corresponding 
single-stranded PCR product. M = (})X174/Haelll molecular weight marker, bp = base pairs.
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Figure 3.17: Hybridisation of probe pMT2| to HTLV-I env PCR products
amplified using primers 124 & 125.
HTLV-I env PCR products from Figure 3.16 amplified using primers 124 & 125 were 
electroblotted onto nylon membrane and hybridised to probe pMT2| radiolabelled by random 
priming. PCR products of 327 bp were strongly positive on hybridisation, as were products of 
other sizes with decreasing intensity as the quantity of positive control template decreased.
A faint band visible by eye in the lane with 0.01 ng C8166 DNA is not reproduced in the 
photograph, bp = base pairs.
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Figure 3.18: Sensitivity of PCR for detection of HTLV-I pX  sequences
using primers 50 & 51.
PCR for HTLV-I pX  sequences using primers 50 & 51 was performed on serial dilutions of 
C8166 DNA in placental DNA (total quantity 1 pg DNA) and products were examined on an 
ethidium bromide-stained polyacrylamide gel following electrophoresis. The expected PCR 
product size is 159 bp. Bands at approximately 400 bp represent PCR product that has 
migrated as single-stranded DNA. Non-specific PCR products increase as the proportion of 
C8166 DNA decreases. M = (|)X174//-/aelll molecular weight marker, bp = base pairs.
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Figure 3.19: Hybridisation of probe pMT2| to HTLV-I pX  PCR products
amplified using primers 50 & 51.
HTLV-I pXPGR products from Figure 3.18 amplified using primers 50 & 51 were 
electroblotted onto nylon membrane and hybridised to probe pMT2j radiolabelled by random 
priming. PCR products of 159 bp were positive on hybridisation and there was hybridisation 
to bands that migrated at approximately 400 bp and represent single-stranded PCR product. 
Hybridisation to several non-specific bands is visible in the lane containing product from the 
PCR with no C8166 DNA template (1 pg placental DNA only). A faint band visible by eye in 
the lane with 0.01 ng C8166 DNA is not reproduced in the photograph. M = Molecular weight 
marker lane, bp = base pairs.
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Figure 3.20: Sensitivity of PCR for detection of HTLV-I pX  sequences
using primers 126 & 127.
PCR for HTLV-I pX  sequences using primers 126 & 127 was performed on serial dilutions of 
C8166 DNA in placental DNA (total quantity 1 pg DNA) and products were examined on an 
ethidium bromide-stained polyacrylamide gel following electrophoresis. The expected PCR 
product size is 127 bp. A slightly larger band at approximately 150 bp in some lanes 
probably represents an alternative product from one of three proviruses in C8166 DNA. 
Bands at approximately 275 bp are due to migration of single-stranded PCR products. M = 
4>X174//-/aelll molecular weight marker, bp = base pairs.
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Figure 3.21: Hybridisation of probe plVIT2, to HTLV-I pXPCR products
amplified using primers 126 & 127.
HTLV-I pXPCR products from Figure 3.20 amplified using primers 126 & 127 were 
electroblotted onto nylon membrane and hybridised to probe pMT2j radiolabelled by random 
priming. PCR products of 127 bp, as well as larger single-stranded PCR products migrating 
at approximately 275 bp, were positive on hybridisation. A faint band visible by eye in the 
lane with 0.1 ng C8166 DNA is not reproduced in the photograph. M = Molecular weight 
marker lane, bp = base pairs.
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Figure 3.22: Sensitivity of PCR for detection of bovine leukaemia virus
gag sequences using primers 194 & 195.
The sensitivity of PCR for detecting bovine leukaemia virus gag sequences with primers 194 
& 195 was determined using serial dilutions of BLV-FLK DNA in FLK DNA (total quantity 1 
pg DNA). In conjunction with the sensitivity assay, PCRs were performed on three samples 
of 1 x lO f  peripheral blood mononuclear cells (PBMCs) from two patients with T cell acute 
lymphoblastic leukaemia (ALL) (patient 1130) and common ALL (patient 1131), along with 
water controls. PCR products were separated by polyacrylamide gel electrophoresis and 
stained with ethidium bromide. The expected PCR product size is 247 bp. M = (j)X174//-/aelll 
molecular weight marker. P = Patient number. T-ALL = T cell acute lymphoblastic leukaemia. 
C-ALL = Common acute lymphoblastic leukaemia. BLV-FLK = Bovine leukaemia virus- 
infected foetal lamb kidney cells, bp = base pairs.
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Figure 3.23: Hybridisation of a bovine leukaemia virus probe to gag PCR products
amplified from BLV-FLK DNA using primers 194 & 195.
Bovine leukaemia virus (BLV) gag PCR products from Figure 3.22 amplified using primers 
194 & 195 were electroblotted onto nylon membrane and hybridised to the BLV 
oligonucleotide probe 301 radiolabelled by 5’ end-labelling. PCR products of 247 bp were 
positive on hybridisation and there was hybridisation to single-stranded PCR products that 
migrated at higher molecular weight. A faint band visible by eye in the lane with 1 ng C8166 
DNA is not reproduced in the photograph. M = Molecular weight marker lane. P = Patient 
number. T-ALL = T cell acute lymphoblastic leukaemia. C-ALL = Common acute 
lymphoblastic leukaemia. BLV-FLK = Bovine leukaemia virus-infected foetal lamb kidney 
cells, bp = base pairs.
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Figure 3.24: Sensitivity of PCR for detection of (3-globin sequences in
genomic DNA using primers 18 & 52.
PCR for p-globin sequences using primers 18 & 52 was performed on serial dilutions of 
C8166 DNA in water and products were examined on an ethidium bromide-stained 
polyacrylamide gel following electrophoresis. The expected PCR product size is 91 bp. 
M = (j)X174//-/aelll molecular weight marker, bp = base pairs.
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3.4.2 Cutaneous T cell lymphomas
Samples from 36 patients with cutaneous lymphoid infiltrates were examined by PCR for 
HTLV-I sequences. Clinical diagnoses in these patients were 21 cases of MF, five cases of 
SS, four cases of CBCL, three cases of angiocentric T cell lymphoma (ATCL) and one case 
each of CTCL (peripheral T cell lymphoma), small plaque parapsoriasis (SPP) and 
Langerhan’s cell histiocytosis (LCH) (Table 3.1). Samples from all patients were positive with 
primers 18 & 52 for p globin by PCR, indicating the presence of amplifiable DNA (Tables 3.4, 
3.5 and 3.6).
Three samples of PBMCs from two patients, one with SS (patient 1198) and one with CBCL 
(patient 1359), had faintly positive bands of approximately 159 bp on hybridisation for HTLV- 
i/ll tax sequences amplified using primers 50 & 51 (Table 3.7) (Figures 3.25 and 3.26). 
Attempts were made to clone and sequence the 159 bp first round PCR products after gel 
purification, but the quantity of amplified material was too small to yield clonable DNA. The 
PCR products were re-amplified using nested primers that annealed to sequences internal to 
primers 50 & 51 (Section 3.3.7.5). Bands of 136 bp were obtained using the HTLV-l-specific 
primer set 282 & 283, whereas multiple non-specific bands, as well as bands of the 
approximate expected size, were obtained using the HTLV-Il-specific primers 288 & 289.
This suggested that HTLV-l-specific product was present.
The second round (nested) PCR products amplified using primers 282 & 283 from two 
submissions of PBMCs from patient 1198 (1198-1 and 1198-3) were successfully TA cloned 
and sequenced (Section 3.3.16.2), along with PCR products cloned from C8166 DNA 
following a single round amplification using the outer set of primers (50 & 51). The 
sequences amplified from these two samples from patient 1198 were identical and matched 
the sequence from C8166, but differed at four bases from the sequence of the same region 
of prototypical HTLV-I (Seiki et a! 1983) (Figure 3.27). The first round PCR product from 
patient 1198 had been handled in the potentially contaminated molecular biology laboratory 
before the nested PCR was performed.
One sample of skin from a patient with MF (patient 436) had a faintly positive band of 
approximately 127 bp on hybridisation for HTLV-I fax sequences amplified using primers 126 
& 127 (Table 3.7) (Figures 3.28 and 3.29). The first round PCR product from this sample 
was cloned after gel purification of the 127 bp band. The sequence of this PCR product was 
identical to that expected from the prototypical HTLV-I sequence, as well as the sequence 
amplified from positive control C8166 DNA using the same primers (Figure 3.30).
All other samples were negative by PCR using primers specific for HTLV-I LTR, gag, pol, 
env and pX  regions.
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3.4.3 Large granular lymphocytic leukaemia
Fresh and cultured PBMCs were tested from six patients with CD3* CD8* LGL leukaemia 
(Table 2.4). All samples were positive for (3 globin, indicating the presence of amplifiable 
DNA, although the signal from one patient was weak (Table 3.8).
Of six samples tested for HTLV-l/ll tax using primers 50 & 51 and four samples tested for 
HTLV-I pol using primers 1 & 2, all were negative by PCR. Faint bands with sizes of 
approximately 119 and 180 bp were observed on ethidium bromide-stained gels in one 
patient following amplification with primers 1 & 2 but neither of these bands hybridised to the 
specific HTLV-I probe. No BLV gag PCR products were detected in two PBMC samples from 
two patients tested using primers 194 & 195.
3.4.4 Acute lymphoblastic leukaemia cases
PBMCs and bone marrow were tested from six patients with ALL of common, pre-B cell or T 
cell type (Table 2.5). All patients were male butchers from Cardiff. Seven samples of PBMCs 
and three of four bone marrow samples were positive for (3 globin, indicating the presence of 
amplifiable DNA (Table 3.8).
PBMCs and bone marrow samples from four patients tested for HTLV-l/ll tax using primers 
50 & 51 and HTLV-I pol using primers 1 & 2 were negative by PCR. Following amplification 
with primers 50 & 51, a faint band with a size of approximately 118 bp was detected in one 
sample, but this was negative on hybridisation. Using primers 1 & 2, faint bands with a size 
of approximately 120 bp were observed on ethidium bromide-stained gels in four samples 
from three patients. Additional bands also observed on ethidium bromide-stained gels were 
90 and 230 bp in one sample, 350 bp in a second sample from the same patient and 170 bp 
in a sample from another patient. Faint bands of approximately 119 bp were detected in 
samples from two of these patients when amplification with primers 1 & 2 was repeated, 
whereas no PCR product was detected in another sample from one of these patients. These 
additional bands were negative on hybridisation to the specific HTLV-I probe.
No BLV gag PCR products were detected in six PBMC and four bone marrow samples from 
five patients tested using primers 194 & 195 (Table 3.9).
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3.4.5 Polymerase chain reaction for detection of HTLV-I and HTLV-II in cultured cells
PCR was used to test for HTLV-I and HTLV-l/ll sequences in four long-term T cell cultures 
established from skin samples of three patients with MF (patients 2531, 2600 and 2862) and 
one Epstein-Barr virus (EBV)-infected B-LCL established from a skin sample from a patient 
with CBCL (patient 2132) (Section 2.4.1) (Table 2.12). Established T cell lines grown in the 
laboratory were also tested for HTLV-I, HTLV-l/ll and BLV sequences by PCR. These cell 
lines were J.JHAN, L-726A, HH, My-La and My-La MC, none of which is known to be 
infected with HTLV-I or HTLV-II (Sections 2.1.3.1 and 2.3.4). C8166 cells were used as 
positive controls. Pellets of 1 x 10® cells and 1 pg DNA extracted from cultured cells were 
tested by PCR with the complete panel of HTLV-I, HTLV-l/ll and BLV primers using 
optimised conditions for each primer set. Parallel samples were also tested for (3-globin 
sequences using primers 18 & 52. C8166 was positive with all HTLV-I and HTLV-l/ll primer 
sets but was negative with the BLV primer sets. All other cultured cells tested by PCR were 
negative for HTLV-I, HTLV-l/ll and BLV sequences.
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Table 3.4: Polymerase chain reaction results from skin samples of patients
with cutaneous lymphoid infiltrates.
Primer
set
PCR
product
Number
tested
Number
positive
18&52 p globin 37 37
118& 119 HTLV-I LTR 26 0
120 & 121 HTLV-I gag 25 0
122 & 123 HTLV-I gag 24 0
1 &2 HTLV-I pol 34 0
67&68 HTLV-I pol 29 0
124 & 125 HTLV-I env 28 0
3 &4 HTLV-I tax 29 0
50&51 HTLV-I tax 34 0
126 & 127 HTLV-I tax 28 1
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Table 3.5: Polymerase chain reaction results
from peripheral blood mononuclear cells of patients
with cutaneous lymphoid infiltrates.
Primer
set
PCR
product
Number
tested
Number
positive
18&52 P globin 16 16
118& 119 HTLV-I LTR 14 0
120 & 121 HTLV-I gag 11 0
1 &2 HTLV-I pol 15 0
124 & 125 HTLV-I env 12 0
50&51 HTLV-I tax 15 3
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Table 3.6: Polymerase chain reaction results from lymph node samples
of cutaneous T cell lymphoma patients.
Primer
set
PCR
product
Number
tested
Number
positive
18&52 p globin 5 5
118& 119 HTLV-I LTR 5 0
120 & 121 HTLV-I gag 5 0
1 &2 HTLV-I pol 5 0
124 & 125 HTLV-I env 5 0
50&51 HTLV-I tax 5 0
126 & 127 HTLV-I tax 4 0
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Table 3.7: Details of polymerase chain reaction positive 
cutaneous T cell lymphoma cases.
Patient
number
Age
(years)
Sex Clinical
diagnosis
Sample
number
Sample
type
Primer
set
PGR
product
436 64 M MF 15757 8kin 126 & 127 HTLV-I tax
1198 81 M 88 13702
13944
PBMGs
PBMGs
50&51
50&51
HTLV-I tax 
HTLV-I tax
1359 NA M BCL 15644 PBMGs 50&51 HTLV-I tax
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Figure 3.25: Amplification of HTLV-I p X  sequences from clinical 
samples of patients 1198 and 1359 using primers 50 & 51.
Peripheral blood mononuclear cells (PBMCs) from a patient with Sèzary syndrome (patient 
1198) and a patient with cutaneous B cell lymphoma (patient 1359) were positive for HTLV-I 
pX  sequences when tested by PCR using primers 50 & 51. Samples are shown on a 
polyacrylamide gel stained with ethidium bromide. Water controls were run next to each 
sample. C8166 cells (1 x 10^) were used as a positive control. Sensitivity was determined by 
electrophoresis of PCR products amplified from serial dilutions of 08166 cells in PBMCs on 
a different polyacrylamide gel (sensitivity 10 C8166 cells). Bands of the expected size (159 
bp) could not be distinguished from non-specific bands on the polyacrylamide gel, but bands 
representing single-stranded DMA migrated at approximately 400 bp in lanes containing two 
samples from patient 1198 and one sample from patient 1359. These bands hybridised to a 
probe for HTLV-I (Figure 3.26). M = (j)X174/Haelll molecular weight marker. P = Patient 
number. SS = Sèzary syndrome. MF = Mycosis fungoides. CBCL = Cutaneous B cell 
lymphoma, bp = base pairs.
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Figure 3.26: Hybridisation of probe pMT2j to HTLV-I pX  PCR products amplified
from clinical samples of patients 1198 and 1359 using primers 50 & 51.
HTLV-I pXPGR products from Figure 3.25 amplified using primers 50 & 51 were 
electroblotted onto nylon membrane and hybridised to probe pMT2j radiolabelled by random 
priming. PCR products of 159 bp from two samples of PBMCs from patient 1198 (Sèzary 
syndrome) and one sample of PBMCs from patient 1359 (cutaneous B cell lymphoma) were 
faintly positive on hybridisation. Positive control cells from the C8166 cell line were strongly 
positive on hybridisation. Bands that migrated at approximately 400 bp, representing single­
stranded PCR products, were also positive on hybridisation. M = Molecular weight marker 
lane. P = Patient number. SS = Sèzary syndrome. MF = Mycosis fungoides. CBCL = 
Cutaneous B cell lymphoma, bp = base pairs.
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Figure 3.27: Sequences of nested HTLV-I pXPCR products
amplified using primers 282 & 283 from patient 1198.
First round PCR products were amplified from peripheral blood mononuclear cells of patient 
1198, who had SS, using primers 50 & 51. Second round (nested) PCR products were 
amplified using primers 282 & 283, then TA cloned and sequenced. The 136 bp sequence is 
aligned with prototypical HTLV-I (Seiki et al 1983) and sequences amplified from positive 
control DMA (C8166) using primers 50 & 51 in the same laboratory. Primers are underlined. 
The sequences from patient 1198 and C8166 are identical but differ at four bases from the 
prototypical HTLV-I sequence.
HTLV-I AGTCTACGTGTTTGGAGACTGTGTACTiAGGCGACTGGTGGCCCATCTCTGGGGGACTATGTTCGGCCC 
C 816 6 AGTCTACGTGTTTGGNGACTGTTTACAAGGCGACTGGTGCCCCACCTNTGGGGGACTATATCCGGCCC 
1198-1 AGTCTACGTGTTTGGAGACTGTTTACAAGGCGACNGGTGCCCCAÇCTCTGGGGGACTATÂTCCGGCCC 
1198-3 AGTCTACGTGTTTGGAGACTGTTTACAAGGCGACTGGTGCCCCACCTCTGGGGNACTATATCCGGCCC 
P r i m e r  2 8 2
HTLV-I GCCTACATCGTCACGCCCTACTGGCCACCTGTCCAGAGCATCAGATCACCTGGGACCCCATCGATGGA 
C816 6 GCCTACATCGTCACGCCCTACTGGCCACCTGTCCAGAGCATCAGATCACCTGGGACCCCATCGATGGA 
1198-1 GGCTACATCGTCNCGCCCTACTGGCCACCTGTCCAGAGCATCAGATCACCTGGGACCCCATCGATGGA 
1198-3 GCCTACATCGTCACGCCCTACTGGCCACCTGTCCAGAGCATCAGATCACCTGGGACCCCATCGATGGA
P r i m e r  2 8 3
HTLV-I Prototypical HTLV-I sequence
C8166 Positive control HTLV-l-infected T cell line
1198-1 Second round PCR product from PBMCs of patient 1198, sample number 13702
1198-3 Second round PCR product from PBMCs of patient 1198, sample number 13944
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Figure 3.28: Amplification of HTLV-I pX  sequences
from skin DMA of patient 436 using primers 126 & 127.
DMA samples (1 pg) from involved skin of five patients with mycosis fungoides (MF) and one 
patient with angiocentric T cell lymphoma were tested for HTLV-I pX  sequences by PCR 
using primers 126 & 127. Water control PCRs were performed along with each sample. 
C8166 DMA (1 pg) was used as a positive control. Sensitivity was determined by 
electrophoresis of PCR products amplified from serial dilutions of C8166 DMA in placental 
DMA on a different polyacrylamide gel (sensitivity 1 ng positive control DMA). Bands of the 
expected size (127 bp) were detected in PCR products from lesional skin of patient 436, who 
had MF, as well as in positive control DMA. These bands hybridised to a probe for HTLV-I 
(Figure 3.29). Multiple non-specific bands were also amplified from clinical samples but did 
not hybridise to the HTLV-I probe. Polyacrylamide gel electrophoresis and ethidium bromide 
staining. M = (j)X174//-/aelll molecular weight marker. P = Patient number. MF = Mycosis 
fungoides. ATCL = Angiocentric T cell lymphoma, bp = base pairs.
Clinical
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Figure 3.29: Hybridisation of probe pMT2j to HTLV-I pX PCR products amplified
from skin DMA of patient 436 using primers 126 & 127.
HTLV-I pX PCR products from Figure 3.28 amplified using primers 126 & 127 were 
electroblotted onto nylon membrane and hybridised to probe pMT2j radiolabelled by random 
priming. PCR products of 127 bp from skin DNA of patient 436 and positive control DMA 
(C8166) were positive on hybridisation, whereas there was no hybridisation to non-specific 
PCR products. M = Molecular weight marker lane. P = Patient number. MF = Mycosis 
fungoides. ATCL = Angiocentric T cell lymphoma, bp = base pairs.
Clinical
samples
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Figure 3.30: Sequences of polymerase chain reaction products
ampiified using primers 126 & 127 from patient 436.
PCR products were amplified by PCR using primers 126 & 127 from a skin sample of patient 
436, who had mycosis fungoides, then cloned and sequenced. The 127 bp sequence is 
aligned with prototypical HTLV-I (Seiki e ta l 1983) and sequences amplified from positive 
control DNA (08166) in the same laboratory. Primers are underlined.
HTLV-I
C8166
305-1-2
305-5-2
305-6-3
HTLV-I 
C8166 
305-1-2 
305-5-2 
305-6-3
CCAATCACTCATACAACCCCCAACATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCC 
CCAATCACTCATACAACCCCCAACATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCC 
CCAATCACTCATAGAACCCCCAACATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCC 
CCAATCACTCATACAACCCCCAACATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCC 
CCAATCACTCATACAACCCCCAACATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCC 
Primer 126
CCTTCCGAAATGGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTGTCTTTTCCAG
CCTTCCGAAATGGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTGTCTTTTCCAG
CCTTCCGAAATGGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTGTCTTTTCCAG
CCTTCCGAAATGGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTGTCTTTTCCAG
CCTTCCGAAATQGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTQTCTTTTCCAG
Primer 127
HTLV-I Prototypical HTLV-I sequence 
C8166 Positive control HTLV-l-infected T cell line 
305-1-2 First round amplification product 
305-5-2 Second round amplification product 
305-6-3 Second round amplification product
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Table 3.8: Polymerase chain reaction results from peripheral blood mononuclear cells
of cases of large granular lymphocytic leukaemia.
Primer
set
PCR
product
Number
tested
Number
positive
18&52 p globin 6 6
1 &2 HTLV-I pol 4 0
50&51 HTLV-I tax 6 0
194 & 195 BLV gag 2 0
185
Table 3.9: Polymerase chain reaction results from peripheral blood mononuclear cells 
of acute lymphoblastic leukaemia cases in butchers from Cardiff.
Primer
set
PCR
product
Number
tested
Number
positive
18&52 P globin 11 10
1 &2 HTLV-I pol 6 0
50&51 HTLV-I tax 10 0
194 & 195 BLV gag 10 0
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3.4.6 Consensus retroviral polymerase chain reaction
The expected size of HTLV-I PCR products amplified using the consensus HTLV/BLV LTR 
primers 174 & 175 was 506 bp (Figure 3.2). Products of approximately 550 bp that 
hybridised to the HTLV-I probe pMT2[ were amplified from pMT2 when these primers were 
used in a standard PCR (annealing temperature 55°C) at concentrations of 1.0 pM with 1.5 
mM MgCl2 (Section 3.3.7.6). Bands of approximately 600 bp were amplified from C8166 
DNA and human placental DNA under the same PCR conditions but did not hybridise to the 
HTLV-I probe. PCR products of a variety of different sizes were amplified from pMT2, C8166 
and placental DNA at different annealing temperatures, but only the products from pMT2 
hybridised to pMT2|. Specific PCR products could be amplified from pMT2 using 1.0 to 2.5 
mM MgClg. Touchdown PCR resulted in PCR products of approximately 400 bp from pMT2 
with 1.5 and 2.5 mM MgCl2 and 450 bp from C8166 with 2.5 mM MgClz only. Although 
smaller than the expected product size, both bands hybridised to pMT2j, suggesting that 
non-specific priming from plasmid and proviral sequences may have occurred.
PCR using 1.0 pM each of primers 174 & 176 and 1.5 mM MgCl2 resulted in variable, weak 
amplification of a specific 1,858 bp LTR-gag product from pMT2, as well as smaller bands 
that hybridised to pMT2|. Several bands of 100 to 250 bp amplified from C8166 also 
hybridised to pMT2j, whereas similar bands amplified from placental DNA were negative. In a 
MgCl2 titration using pMT2 as template, the number of non-specific PCR bands increased as 
the MgCl2 concentration increased from 1.0 to 3.0 mM. The specific 1,858 bp product was 
amplified from pMT2 only using touchdown PCR. This band, as well as several smaller 
bands amplified from pMT2 and C8166, hybridised to pMT2|.
The consensus retroviral primers 296 & 297 were used in an attempt to amplify HTLV-I pol 
sequences from pMT2, C8166 and BLV-FLK DNA using human placental DNA and FLK 
DNA as controls. Titrations of C8166 DNA in human placental DNA from 1 pg to 0.01 ng in a 
total of 1 pg DNA were tested, as were titrations of C8166 DNA in water. The primers were 
used at 1.0 to 4.0 pM each with MgCL concentrations of 1.5, 2.5 and 3.5 mM in standard 
PCR reactions with annealing temperatures of 55, 60 and 65°C. A touchdown PCR protocol 
with the same compositions of PCR reaction mixes was also applied. A band of 
approximately 130 bp consistent with the expected product size of 133 bp was amplified 
from pMT2 using 1.0 pM of each primer and 3.5 mM MgC^. A band of moderately high 
intensity that migrated at approximately 180 bp was frequently amplified from both C8166 
and human placental DNA using 3.5 or 2.5 and sometimes 1.5 mM MgCb. However, at 2.5 
and 1.5 mM MgCl2 there were many additional bands in all samples. Only PCR products 
from pMT2 hybridised to pMT2|. The 180 bp PCR product from C8166 was gel-purified, TA 
cloned and sequenced. Excluding the primers, the sequence had 98% identity over 137 
bases to a sequence on human chromosome 4 using the BLAST programme but had no 
significant matches with retroviral sequences. The specific PCR product amplified from 
pMT2 was also sequenced and shown to contain the expected 133 bp HTLV-I retroviral pol 
sequence. Bands of approximately 160 and 130 bp were amplified from both BLV-FLK and 
FLK DNA using 3.5, 2.5 and 1.5 mM MgCb.
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3.5 Discussion
HTLV-I, HTLV-I I and related sequences have previously been detected in HTLV-I/II 
seronegative or indeterminately seroreactive patients with MF and SS by PCR, SB 
hybridisation and sequencing (Kaplanski e ta l 1986, Hall ef a /1991, Zucker-Franklin et al 
1991, D'Incan et al 1992, Kiss et al 1992, Srivastava et al 1992, Chan et ai 1993, Kiss et al 
1993, Whittaker and Luzzato 1993, Bazarbachi et al 1994, Manca et al 1994) (Section 
1.11.1.5). In a number of cases, molecular analysis has indicated clonal integration of 
incomplete or variant HTLV-I provirus in neoplastic cells, with preferential retention of HTLV- 
I/II tax sequences (Kaplanski et ai 1986, Hall et al 1991, Zucker-Franklin et a /1992, Pancake 
and Zucker-Franklin 1993, Manca et al 1994). Other patients with CTCL have no evidence of 
HTLV-I infection (Capésius et a /1991, Lisby et a l 1992, Bazarbachi et al 1994).
The amplification of HTLV-I/II tax sequences from two patients with CTCL (one SS, one MF) 
in this study would have been of significance if these results were verified as genuine 
evidence of infection with HTLV-I. To eliminate the possibility of contamination with PCR 
products, probes or positive control DNA, attempts were made to clone and sequence PCR 
products from the hybridisation-positive samples. The PCR products amplified from two 
different samples from a patient with SS were identical and matched the sequence from the 
positive control DNA used in the laboratory, but differed at four bases from the sequence of 
prototypical HTLV-I. It was concluded that these PCR products were the result of 
contamination from positive control (C8166) DNA. The first round PCR products from these 
samples had been handled in the molecular biology laboratory before the nested PCR was 
performed and therefore contamination could have resulted during either the first or second 
round PCRs.
The first round PCR product amplified from a patient with MF using a different set of primers 
also had an identical sequence to that amplified from positive control DNA, as well as 
prototypical HTLV-I. Therefore, it cannot be determined whether this PCR product was the 
result of contamination. It would be necessary to amplify HTLV-I sequences from these 
same clinical samples using other sets of tax primers and identify unique sequence 
signatures to confirm that the patients were infected with HTLV-I or a related virus. An 
alternative approach would be to have another sample of the same type collected from the 
same patient at the same time tested by PCR for HTLV-I tax sequences in a different 
laboratory. Sequence errors introduced by Tag polymerase could also be resolved by 
replicating the amplification, cloning and sequencing of PCR products from samples. 
However, in the cases in which false positive results were suspected in this study there was 
insufficient DNA available to retest all samples.
HTLV-I/II tax PCR products were also detected in one patient with CBCL, but it was not 
possible to re-amplify, clone and sequence these products. Therefore, this result cannot be 
verified. The detection of HTLV-I/II sequences in patients with cutaneous BCL has not 
previously been reported, but HTLV-I has been associated with B cell CLL (Mann et al 
1987).
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HTLV-I I sequences have also been detected by PCR in patients with CTCL (Zucker-Franklin 
et a /1992) and LGL leukaemia (Loughran et al 1992, Martin et al 1993, Heneine et al 1994, 
Loughran et al 1994). In this study, no HTLV-I, HTLV-I I or related sequences were detected 
in six patients with LGL leukaemia. Similarly, no HTLV-I, HTLV-I I or BLV sequences were 
detected in six butchers from Cardiff with ALL.
Differences in sensitivities of primer sets used for amplification of HTLV-I and HTLV-I I 
sequences were noted in this study, despite careful optimisation (Section 3.4.1) (Table 3.3). 
This means that it might be possible to detect sequences from one portion of a provirus by 
PCR using a highly sensitive set of primers, whereas other proviral regions are negative by 
PCR because the specific sets of primers for those regions are less sensitive. In addition, 
highly sensitive primer sets are more likely to yield false positive results if there is 
contamination from PCR products, plasmids or positive control DNA. The implications of 
these results are discussed further in Chapter 5.
The use of two sets of consensus oligonucleotide primers based on alignment of HTLV/BLV 
group virus LTR and gag sequences showed limited potential for a group-specific PCR 
assay. Specific PCR products of the appropriate sizes could be amplified from purified 
plasmid (pMT2) containing the full-length HTLV-I sequence, but not from the HTLV-l-infected 
cell line C8166. Similar non-specific bands were frequently amplified from C8166 and 
placental DNA.
While consensus primers can be designed for amplification ot po l sequences of most known 
retroviruses, they lack specificity when used on complex (genomic) DNA, resulting in 
amplification of many endogenous sequences. Preferential amplification of endogenous 
viruses, retrotransposons or non-specific cellular sequences reduces the sensitivity of PGR 
for detection of accompanying proviral DNA using consensus primers. This can be overcome 
by reverse transcribing purified viral RNA to cDNA before amplification by PCR but for this 
approach it is necessary to isolate the uncharacterised virus to ensure adequate quantities 
of template (Donehawer et al 1990).
In this study most samples from patients with CTCL, LGL leukaemia and ALL were negative 
for HTLV-I, HTLV-II and BLV sequences where tested by PCR in combination with Southern 
blot hybridisation. Positive results could be accounted for by contamination. Therefore, no 
unequivocal evidence for infection with HTLV/BLV group retroviruses was demonstrated. 
Molecular approaches to the detection of HTLV-l-related retroviruses in patients with CTCL 
are discussed further in Chapter 5.
Chapter 4 
The Role of Human T Lymphotropic Virus Type I 
pX  Gene Products In Apoptosis
4.1 Introduction
4.1.1 Role of apoptosis in HTLV-I leukaemogenesis
4.1.1.1 Oncogenic properties of HTLV-I pX proteins
The Tax protein of human T lymphotropic virus type I (HTLV-I) is the main regulator of viral 
transcription and has transforming properties in a number of experimental systems (Section
1.8.3). Established rodent fibroblast cell lines can be transformed by Tax (Tanaka et ai 1990, 
Smith and Greene 1991). Primary rat embryo fibroblasts (REFs) can be immortalised by Tax 
alone or transformed by Tax in cooperation with oncogenes such as Ras (Pozzatti et al 
1990, Matsumoto et al 1994). Oncogenic features of the HTLV-I p i2* protein have also been 
demonstrated (Section 1.8.4). pi 2' enhances transformation of C l 27 fibroblasts by the 
bovine papillomavirus type 1 (BPV-1) E5 protein (Schlege! et a /1986, Franchini et al 1993). 
The contribution of other HTLV-I pX  gene products to leukaemogenesis is unknown. Rex 
acts as a post-transcriptional regulator of HTLV-I gene expression (Inoue et al 1987, Hidaka 
et al 1988, Nosaka et al 1989) (Section 1.3.5.2). The presence of a nuclear export signal 
(NES) in p2 l"‘ and a nucleolar localisation signal (NLS) in p30" (Tof) suggest that these 
proteins could have a regulatory function. However, there is insufficient information available 
to attribute roles to p2 l"‘, Tof, pi 3" and pi 2*.
4.1.1.2 Induction of apoptosis by Tax
Rodent fibroblasts expressing Tax, including transformed Rati fibroblasts and non­
transformed REFs and 3Y1 rat fibroblasts, undergo apoptosis when deprived of serum and 
this effect is inhibited by Bcl-2 (Sakurai et al 1992b, Yamada et al 1994, Fujita and Shiku 
1995) (Section 1.8.7.4). Tax appears to promote cell cycle progression in the absence of 
external growth factors (Yamada et al 1994) and thus the response of cells expressing Tax 
to withdrawal of growth factors is similar to that of cells expressing c-Myc (Evan et al 1992) 
(Sections 1.8.6 and 1.8.7). This has led to the hypothesis that Tax activates pathways 
leading either to proliferation or cell death, depending on the availability of survival factors. 
Tax might exert this effect directly or indirectly through up-regulation of c-myc or fos (Fujita 
and Shiku 1993, Smeyne et al 1993). Since several oncogenic viruses produce proteins that 
induce proliferation and inhibit apoptosis (Section 4.1.3), it is possible that HTLV-I p X  region 
gene products with currently unknown function could oppose the pro-apoptotic properties of 
Tax and thus cooperate with Tax in oncogenesis.
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4.1.2 c-Myc-model o f proliferation and apoptosis
4.1.2.1 Differential responses of rodent fibroblasts to c-Myc expression
The oncogene c-Myc appears to prime cells for either proliferation or apoptosis, depending 
on whether they are permissive for survival (Evan et al 1992) (Section 1.8.6). Rati cells 
constitutively expressing c-Myc undergo transformation and have a high rate of proliferation 
when grown in medium containing normal concentrations of serum (Small et al 1987). Eilers 
et al (1989) transfected Rati cells with a gene encoding a chimaeric c-Myc-murine 
oestrogen receptor (c-Myc-ER) protein, allowing translocation of functional c-Myc to the 
nucleus when the cells were exposed to oestrogen. Transient expression of c-Myc in the 
presence of oestrogen resulted in reversible proliferation (conditional transformation) in the 
absence of other mitogenic stimuli (Eilers et al 1989). Evan et a/ (1992) demonstrated that 
these Rati cells undergo apoptosis when c-Myc expression induced by oestrogen occurs 
under conditions of serum deprivation. Cells with deregulated expression of c-Myc are 
unable to withdraw from the cell cycle and arrest growth, but when grown in medium with a 
low concentration of serum the rate of population increase is slowed due to an increase in 
the rate of apoptosis. Induction of apoptosis by c-Myc has also been demonstrated in REFs, 
rat vascular smooth muscle cells and Swiss 3T3 cells (Harrington et al 1994).
4.1.2.2 Chimaeric c-Myc-modified oestrogen receptor system
The system of c-Myc induction by oestrogen in Rat1-c-myc-ER cells (Section 4.1.2.1) has 
been improved by substitution of the oestrogen receptor (ER) with a modified receptor 
(ER™) that responds to 4-hydroxytamoxifen (4-HT) (Littlewood et al 1995). This removes the 
need for charcoal-dextran stripping of natural steroid hormones from foetal bovine serum 
(FBS), previously necessary to prevent constitutive activation of the ER. Cells transfected 
with chimaeric ER proteins could not be grown In phenol red, whereas this indicator can be 
included in the medium used to grow cells with the ER™. Therefore, Rati cells stably 
transfected with a chimaeric c-myc-ER™ gene (Rati -c-myc-ER™ cells) were used in this 
study (Littlewood et al 1995).
4.1.3 Inhibition of apoptosis by oncogenic DNA viruses
Several oncogenic viruses express proteins that inhibit apoptosis. These may cooperate with 
growth-promoting oncoproteins produced by the same viruses. This strategy allows cell 
proliferation to be switched on without activating pathways that lead to apoptosis. The E1B 
proteins of adenovirus type 5 block apoptosis induced by the viral oncoprotein El A; p55^^® 
binds to and inactivates p53 by promoting degradation through the ubiquitin system, 
whereas p i 9^ ^® inhibits apoptosis by a mechanism similar to that of Bcl-2 (Scheffner et al 
1990, Werness et a l 1990, Rao et al 1992, White et al 1992, Lowe and Ruley 1993, Lowe et 
al 1994). The simian virus 40 (SV40) large tumour (large T) antigen and the E6 proteins of 
highly oncogenic human papillomaviruses (HPVs) also bind to and inactivate or promote the 
degradation of p53 (Lane and Crawford 1979, Sa mow et a /1982, Mietz et al 1992).
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The Epstein-Barr virus (EBV) gene product BHRF1 is a Bcl-2 homologue that inhibits 
apoptosis and may cooperate with other EBV transforming genes (Henderson et al 1993, 
Marshall et al 1999). Other oncogenic herpesviruses, including human herpesvirus type 8 
(HHV-8, Kaposi’s sarcoma-associated virus) and Herpesvirus saimiri, also encode Bcl-2 
homologues (Cheng et al 1997, Nava et al 1997). SV40 large T and EBV BHRF1 inhibit c- 
Myc-induced apoptosis (Hermeking et a /1994, Fanidi et al 1998). Expression of anti- 
apoptotic proteins thus appears to be a common strategy in infection by oncogenic DNA 
viruses. HTLV-I could use a similar mechanism to maintain the survival of infected T cells in 
vivo.
4.1.4 Investigation of the role of HTLV-I pX genes in proliferation and apoptosis
In this study the hypothesis was tested that the HTLV-I p X gene products Tax, Rex, p2 l"‘, 
Tof, p i 3 " and pi 2' contribute to leukaemogenesis by modulating apoptosis. One model used 
to test this hypothesis was the ability of p X  gene products, in particular Tax, to induce 
apoptosis in Rati cells under conditions of serum deprivation, similar to c-Myc (Evan et al 
1992). The other model was the ability of Tax or other pX  gene products to prevent 
apoptosis induced by c-Myc in Rati cells under conditions of serum deprivation. At the start 
of the study it was not known that Tax induces apoptosis in rat fibroblasts deprived of serum. 
However, as this property became apparent, it was realised that Tax provided a parallel 
model in which to test for anti-apoptotic properties of other pX  proteins. The pX  genes tax, 
rex, p30'', p i3'' and p i2' were cloned into the eucaryotic expression vector 
pcDNAI/Neo and introduced into Rati-c-myc-ER™ cells (Section 4.1.2.2). When these cells 
are exposed to 4-HT, the chimaeric protein translocates to the nucleus, allowing expression 
of c-Myc transcriptional activity. c-Myc activates the cell cycle, inducing proliferation, but at 
the same time activates the apoptosis pathway, leading to programmed death when cells are 
deprived of survival factors present in serum (Evan et a /1992). HTLV-I p X  region gene 
products were tested for their ability to maintain the survival of cells deprived of serum that 
would otherwise die by apoptosis induced by c-Myc or Tax.
4.2 Methods
4.2.1 Cloning HTLV-I pX genes
4.2.1.1 Source of HTLV-I tax and rex plasmids
Plasmids containing p40'^ (fax) and p27"' {rex) were kindly provided by Dr Moyra Campbell, 
Leukaemia Research Fund (LRF) Virus Centre. Competent bacteria (E coll DH5a) were 
transformed with these plasmids and grown on LB agar containing 50 pg/ml ampicillin 
(Section 3.3.13.2). Large scale preparations of plasmids were purified by CsCI gradient 
centrifugation (Sections 3.3.14.2 and 3.3.14.3). The 6.6 kb plasmid LRF-MC-p27 contained a
1.6 kb tax insert cloned into pUC18 (2.7 kb) at SamHI and Xba\ sites (Appendix 1). An Sph\ 
site within the insert had been deleted to remove the rex  initiation codon. The tax insert was 
flanked by the 255 bp CD3e promoter and 2.0 kb CD3e enhancer (Hall et a /1998).
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The 4.8 kb plasmid LRF-MC-p33 contained a 2.1 kb rex insert cloned into plC20R (2.7 kb) at 
SamHI and H/ndlll restriction sites (Appendix 1). The rex insert had been subcloned from 
Hind\\\ sites in pKCR27x (Siomi et al 1988, Nosaka et al 1989). The insert expressed Rex 
but mutations prevented expression of p2l'" and allowed expression of an inactive, truncated 
protein comprising the N terminal 60 amino acids of Tax.
4.2.1.2 Amplification and cloning of p 2 l" '
The HTLV-I p 2 l'"  gene was amplified by PCR from pMT2, a full-length HTLV-I molecular 
clone in the vector pUC (Seiki et al 1982) (Section 3.3.11.2). Primers were designed with 
SamHI and Xba\ restriction sites (Figure 4.1) (Appendix 1) and the PCR was performed 
under standard conditions with an annealing temperature of 55°C (Section 3.3.7.1). The 
reaction mix contained dTTP, 1.0 pM each primer and 1.5 mM MgClg. The PCR product (356 
bp) was ligated into the TA cloning vector pCRII (Invitrogen) (Section 3.3.16.2), grown in E  
coll DH5a and the plasmid construct was purified by CsCI gradient centrifugation.
4.2.1.3 Source of HTLV-I p30^ pi 3^  ^and p i 2' plasmid constructs
Plasmids containing the HTLV-I p30^ p13 '^ and p i 2^  genes were kindly provided by Dr 
Genoveffa Franchini, Laboratory of Tumor Cell Biology, National Institutes of Health, 
Bethesda, Maryland, USA. These consisted of tagged pX inserts cloned into the 3.2 kb 
vector HCMV-HSpA: p30'-HA1, p13 '^-HA1 and p12^-AU1. HCMV-HSpA contains the pUC19 
polylinker cloned into H/ndlll/Smal sites of HCMV-SEAP (Schwartz et al 1990) (Appendix 1). 
Competent E coll DH5a were transformed with the p30'-HA1, p13'-HA1 and p i2 -AU 1- 
HCMV-HSpA constructs. Transformants were grown on LB agar containing 50 pg/ml 
ampicillin and the plasmids were purified by CsCI gradient centrifugation then quantified by 
spectrophotometry.
4.2.1.4 Subcloning HTLV-I pX  genes into pcDNAI/Neo
The 7.0 kb (6,969 bp) vector pcDNAI/Neo (Invitrogen) was used for expression of HTLV-I pX  
gene products in eucaryotic cells. Genes cloned into this vector are constitutively expressed 
from the human cytomegalovirus (HCMV) promoter. pcDNAI/Neo has a neomycin resistance 
gene, permitting selection in eucaryotic cells with Geneticin (G418, Life Technologies).
The HTLV-I pX inserts tax, rex, p 2 f'“ , p30", p13" and pi 2^  were subcloned from their source 
vectors into pcDNAI/Neo using RE sites that permitted directional cloning (Table 4.1). The 
tax, p2^"', p30'\ p i3 '^  and p i 2^  inserts were excised from their respective vectors using 
SamHI and Xbal and the rex insert was excised from LRF-MC-p27 by digestion with SamHI 
and EcoRV (Section 3.3.15). Inserts were separated from the vector backbone by agarose 
gel electrophoresis and gel purified (Gelase, Cambio) (Section 3.3.10.3). BamH\/Xba\ and 
SamHI/EcoRV restriction endonuclease (RE) digests of pcDNAI/Neo were prepared and gel- 
purified at the same time. Inserts were ligated into pcDNAI/Neo using T4 ligase (Section 
3.3.14).
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Figure 4.1: Specific oligonucleotide primers for amplification of the HTLV-I p21 
sequence by the polymerase chain reaction.
LRF
oligonucleotide
number
Primer sequence S' to 3’ with 
HTLV-I nucleotide position
Length
(b)
Tm
{°C)
Size of PCR 
product 
(bp)
HTLV-I p2T"
jBanjHI
190 Sense 74 99 GCCGGGATCCATGGACGCGTTATCGGTCCA 7518 30 38 356
191 Antisense 7834 GCCGTCTAGATCACGTGGGGCAGGAGGGGC 7815 
X b a l
30 38
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4.2.1.5 Transformation of MC1061/P3 with pcDNAI/Neo constructs
Competent bacteria of E coli strain MCI 061/P3 (Ultracomp E coli, Invitrogen) were 
transformed with pcDNAI/Neo alone or with pcDNAI/Neo containing ligated inserts according 
to a modification of the protocol outlined in Section 3.3.13.2. Bacteria that had been stored at 
-80°C were thawed on ice and 100 pi transferred to a 5 ml polypropylene tube (2097,
Falcon). A fresh solution of 2-mercaptoethanol (2-ME) was added to the bacteria to a final 
concentration of 25 mM. Ligation reaction products (5 pi) were mixed with the bacteria and 
held on ice for 30 min. The tubes were treated at 42°C in a water bath for 75 sec then placed 
on ice for 2 min. SOC medium (900 pi) (Appendix 5: A5.10.1) was added and the 
transformed bacteria were incubated at 37°C for 1 hour on an orbital incubator (225 rpm). 
After centrifuging at 400 g (1500 rpm) in a bench centrifuge (BR401, Denley), the 
supernatant was discarded and the bacteria were resuspended in 200 pi SOC medium.
Equal volumes were spread on LB agar plates containing 25 pg/ml ampicillin or 10 pg/ml 
tetracycline (Appendix 5: A5.10). Growth on LB agar containing ampicillin, with no growth on 
medium containing tetracycline, was an indication of successful transformation without 
reversion of MC1061/P3 from type.
4.2.1.6 Selection and purification of pcDNAI/Neo p X  constructs
Small scale preparations of plasmid DNA (Section 3.3.14.1) followed by RE digestion were 
used to select MG1061/P3 transformants that contained the desired pcDNAI/Neo constructs. 
A large scale preparation of each plasmid was made by alkaline lysis and CsCI density 
gradient centrifugation, then quantified by spectrophotometry (Sections 3.3.14.2 and
3.3.14.3). Inserts were sequenced in both directions at the University of Birmingham (Alta 
Bioscience) using T7 and SP6 sequencing primers (Appendix 5: A5.12.1). Each purified 
plasmid construct was diluted to 0.4 pg/pl in preparation for transfection of Rati cells.
4.2.2 Transfection of Rat1 cells
4.2.2.1 Culture of Rati and Rati-c-myc-ER™ cells
Rati and Rati-c-myc-ER™ cells were obtained from Dr Gerard Evan, Imperial Cancer 
Research Fund (ICRF), Lincoln’s Inn Fields, London (Littlewood e ta l 1995). Rati cells were 
cultivated in Duibecco’s Modified Eagle’s Medium (DMEM) (Life Technologies) containing 
10% heat-inactivated foetal bovine serum (hi-FBS), 400 mg/ml streptomycin, 400 U/mi 
penicillin and 2 mM L-glutamine (Appendix 4: A4.2.1.3). Rati-c-myc-ER™ cells were grown 
in the same medium containing 5 pg/ml puromycin to maintain selection for the transfected 
genotype. These cell lines formed adherent monolayers and were subcultured by 
trypsinisation with 1.5 to 3 ml 0.25% crude trypsin in 1 M EDTA (trypsin-EDTA) (Section
2.3.3.1). Cells cultured in sealed flasks were aerated with 5% CO2 and cells grown in tissue 
culture dishes (Nunclon, Nunc) were grown in a 5% CO2 incubator at 37'^C.
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4.2.2.2 Transfection of Rat1 cells with plasmid constructs
Rat1-c-myc-ER™ cells were transfected with 1 pg of each pcDNAI/Neo plasmid construct 
(Section 4.4.1). Rati cells without the c-myc-ER™ gene were also transfected with selected 
plasmids. Some cultures were transfected with two active plasmids, for example p12-AU1- 
pcDNAI/Neo and Tax-pcDNAI/Neo, in which case 1 pg of each plasmid was co-transfected.
Cells were grown to 50% confluence in 10 cm diameter tissue culture dishes, then the 
medium was withdrawn and replaced with 10 ml serum-free DMEM. Plasmid DNA (1 pg) was 
diluted In 50 pi sterile uitrapure water in a 1.5 ml sterile polypropylene microcentrifuge tube, 
in a separate 1.5 ml tube 20 pi liposomal transfectant reagent (LipofectAMINE, Life 
Technologies) was mixed with 30 pi sterile uitrapure water. The DNA and liposomes were 
combined in a 15 ml screw-top polypropylene centrifuge tube and held at room temperature 
for 30 min to allow complexes to form. The 100 pi volume containing DNA-liposome 
complexes was then poured gently into the tissue culture dish containing cells in serum-free 
medium, mixed by gentle swirling and incubated at 37°C for 5 hours in a COg incubator.
The serum-free medium was replaced with DMEM + 20% hi-FBS and the cells were grown in 
this medium with daily replacement for two days. The cells were trypsinised, serial two-fold 
dilutions prepared in DMEM + 10% hi-FBS and re-seeded into a series of six tissue culture 
dishes at 1 x 10^  to 1 x 10  ^cells/ml. After one day in culture, the medium was replaced with 
medium containing 5 pg/ml puromycin and 1 mg/ml Geneticin to select for transfectants 
while maintaining the c-myc-ER™ phenotype. This medium was replaced after 3 days.
4.2.2.3 Selection of transfected Rati clones
Clones were selected 7 days after cells had been reseeded at different densities on tissue 
culture dishes. Colonies derived from a single cell were identified, the medium was removed 
and piates were rinsed briefly with 1.5 ml trypsin-EDTA. Marked colonies were isolated using 
metal or plastic cloning rings affixed to the bottom of the tissue culture dishes with sterile 
Vaseline.
Trypsin-EDTA (200 pi) was pipetted into the well formed by each ring and the tissue culture 
dishes were incubated at 37°C for 10 min in 5% CO2 to dissociate the cells. The solution in 
each well was pipetted up and down to dislodge remaining adherent cells and the trypsinised 
cells were transferred to a flask containing 5 ml DMEM + 10% hi-FBS with puromycin and 
Geneticin at standard concentrations. Each transfectant was subjected to a second round of 
clonal selection. These cell lines were maintained in medium containing puromycin and 
Geneticin at 37°C in 5% CO2 and trypsinised for subculturing or to prepare cells for seeding 
of tissue culture dishes.
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4.2.3 Detection of pX mRNA expression
4.2.3.1 Isolation of RNA from Rat1 cells
RNA was extracted using the acid guanidinium thiocyanate method with phenol-chloroform 
extraction (Chomczynski and Sacchi 1987). Rati cells and Rati -c-myc-ER™ cells 
transfected with HTLV-I pX  plasmid constructs were grown to near-confluence in 75 cm^ 
tissue culture flasks. The medium was removed and 4 ml RNAzol B (Life Technologies) was 
added to lyse the cells (Appendix 5: A5.13.1 ). The lysate was pipetted up and down several 
times to dislodge adherent cells, then transferred to a 15 ml polypropylene centrifuge tube. 
The mixture was shaken vigorously with 200 pi chloroform for 15 sec, placed on ice for 5 min 
and centrifuged at 1,500 g  (2,700 rpm) in a GPR bench centrifuge (Beckman) with a GH 3.7 
swinging bucket rotor for 15 min at 4°C.
The upper aqueous phase containing dissolved RNA was transferred to one or more 1.5 ml 
microcentrifuge tubes and the RNA was precipitated by mixing with an equal volume of 
isopropanol and holding at 4°C for 15 min. Tubes were centrifuged at 10,500 g (13,000 rpm) 
for 5 min in a bench microcentrifuge (MicroCentaur) at 4°C, then the RNA pellet was washed 
with 70% ethanol in uitrapure water containing 0.05% diethyl pyrocarbonate (DEPC) and re­
centrifuged.
The tubes were desiccated under vacuum for 10 min then dissolved in uitrapure water 
containing 1 mM EDTA pH 7.0, 0.5% SDS and 0.05% DEPC. The concentration was 
determined by spectrophotometry with calculations made on the basis that 40 pg/ml of 
single-stranded RNA has an optical density at 260 nm (OD260) of approximately 1.0.
4.2.3.2 Northern blot hybridisation
Northern blot hybridisation to detect expression of HTLV-I p X  mRNA in transfected cells was 
performed by Dr Moyra Campbell in the LRF Virus Centre. A 10 pi volume containing 10 pg 
RNA was mixed with 20 pi formamide buffer (Appendix 5: A5.13.2), heated at 6 5 X  for 15 
min to denature the RNA, then placed on ice for 5 min. RNA loading buffer/dye (2 pi) was 
added and the samples were separated by gel electrophoresis (5 V/cm) on a 1% agarose 
gel in 3-(N-morpholino)-2-hydroxypropane sulphonic acid (MOPS) buffer 1x with 6% 
formaldehyde prepared using uitrapure water with 0.05% DEPC (Appendix 5: A5.13.2). 
XHindW] and <t>X174//-/aelll (Life Technologies) were used as size markers in combination 
with visualisation of 288 and 188 ribosomal RNA bands after staining with ethidium bromide.
The RNA was transferred to nylon membrane (Hybond-N, Amersham) by Northern blotting 
using 8SC 20x as the transfer buffer, rinsed in 88C 3x, then cross-linked with ultraviolet 
(UV) light (Section 3.3.10) (Appendix 5: A5.7). Blots were hybridised to the HTLV-I probe 
pMT2i labelled with a ^^P dCTP by random priming (Sections 3.3.11.2 and 3.3.11.4). The 
following formula was used for calculation of the for RNA:RNA hybridisations (Section
3.3.12.1):
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Formula 4.1: 7m = 67 + 16.6 logio[M’*‘] + 0.8(%G+C) -  500/L -  P -  0.5(%Formamide) °C
[N a l
Where: [M"^ ] = Adjusted molar Monovalent cation concentration: --------------
1 + 0.7 [N a l
%G+C = Percentage of G and C nucleotides in the DNA probe 
L = Length of the DNA:RNA duplex in bp 
P = Percentage base mismatch
The calculated Tm for pMT2j labelled with a ^^P dCTP by random priming was 74°G. 
Hybridisation was performed overnight at 37°C in standard hybridisation solution containing 
SSC 3x with 50% formamide, as for Southern blot (SB) hybridisation (Section 3.3.12) 
(Appendix 5: A5.9). The high stringency washes were performed with SSC 0.5x, 0.1% SDS. 
Autoradiographic film was exposed for 3 days.
4.2.4 Induction of apoptosis
4.2.4.1 Serum starvation of Rati and Rati-c-myc-ER™ cells
Rati cells. Rati-c-myc-ER™ cells (selected with puromycin) and cells transfected with 
HTLV-I p X  pcDNAI/Neo constructs (selected with puromycin and Geneticin) were trypsinised 
and resuspended in DMEM + 10% hi-FBS. Serial two-fold dilutions were prepared and 500 pi 
aliquots were pipetted into duplicate wells of an eight well chamber slide (ChamberSlide, 
Lab-Tek, Nunc). This resulted in a series of approximately 2 x 10®, 1 x 10®, 5 x lO'^  and 2.5 x 
10"^  cells in each of two duplicate rows.
The chamber slides were incubated at 37°C in 5% CO2 for 24 hours to allow cells to adhere 
to the substrate. The medium was aspirated from each well and replaced with 500 pi DMEM 
without serum. Cells were maintained in this medium for 48 hours to undergo cell cycle 
arrest.
4.2.4.2 Induction of c-Myc-ER™ expression
Nuclear expression of the c-Myc-ER™ protein was activated in Rati-c-myc-ER™ cells on 
day 2 of serum starvation by the addition of 4-HT to a final concentration of 0.1 pM. Cells in 
500 pi medium in each well of one row of a chamber slide were induced by adding 5 pi of 10 
pM 4-HT. Cells in the duplicate row remained uninduced as negative controls. Experiments 
were performed twice with duplicate cultures in each experiment.
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4.2.4.3. Microscopic examination
Cells were examined microscopically using an inverted light microscope (Labovert, Leitz) 6, 
24 and 48 hours following withdrawal of serum and 6 and 24 hours following induction of c- 
MyC"ER™ expression with 4-HT.
Morphological changes occurring in cells undergoing apoptosis include loss of cell-cell 
contact, cell shrinkage, condensation of chromatin in the nucleus and disintegration of the 
nucleolus and nuclear membrane (Kerr ef a /1972) (Section 1.8.7.1). As the dying cell 
disintegrates, the cell contents are fragmented to produce membrane-bound apoptotic 
bodies.
4.2.4.4 Staining with propidium iodide
Cells were stained with propidium iodide (PI) 24 or 48 hours following withdrawal of serum 
and 6 and 24 hours following induction with 4-HT. PI is a fluorescent vital dye that does not 
cross the plasma membrane of viable cells. In dying cells in the late stages of apoptosis, PI 
enters the cell and intercalates DNA. It also stains DNA within apoptotic bodies. The dye 
fluoresces in the orange range of the spectrum.
Medium was removed from the wells of chamber slides to be stained with PI and the cells 
were fixed with 200 pi acetic acid-alcohol fixative for 30 min at room temperature (Appendix 
4; A4.6). The fixative was aspirated and replaced with 200 pi 4 M HOI for 30 min at room 
temperature to denature the DNA. This solution was replaced with 0.1 M sodium borate for 5 
min to neutralise the cells. After aspiration, the chamber slides were air dried for 5 min. The 
cells were then incubated at 37°C for 30 min in 200 pi of a solution containing 5 pg/ml PI and 
100 pg/ml RNase A in PBS 1x. This solution was removed and the walls of the chambers 
were removed from the glass slide along with the gasket.
Approximately 100 pi of mounting solution was pipetted onto each slide, overlaid with a glass 
coverslip and sealed at the edges with clear nail varnish. The mounting solution 
(Vectashield, Vector Laboratories) contained glycerol and PBS 1x at a ratio of 9:1 with 1,4- 
diazobicylo(2,2,2)-octane (DABCO) as an antiquenching agent (Johnson ef al 1982). The 
slide was wrapped in aluminium foil to protect the cells from light and held at 4°C for 5 to 10 
min for the mounting solution to set. The slides were examined under oil immersion using a 
fluorescent microscope (Laborlux K, Leitz) with a 562 to 588 nm band pass (green) filter.
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4.3 Results 
4.3.1 Detection of HTLV-I pX expression in Rati cells
The HTLV-I p X genes tax, rex, p2^'", p30", p13" and p12' were cloned into pcDNAI/Neo and 
transfected into Rat1 and Rat1 -c-myc-ER^"^ cells. Each plasmid construct was transfected 
alone and the Tax-pcDNAI/Neo construct was also co-transfected with each of the other pX- 
pcDNAI/Neo plasmids. Cells transfected with pcDNAI/Neo without an insert were used as 
negative controls. Transfectants were selected by cultivation in medium containing Geneticin 
and puromycin. RNA extracted from transfected cell cultures was hybridised to the HTLV-I 
probe pMT2[ labelled with a dCTP by random priming. Positive hybridisation to bands of 
the appropriate size was detected in all transfected cell lines (Table 4.1), whereas non­
transfected Rati cells were negative. Cells co-transfected with pX-pcDNAI/Neo and one 
other pX plasmid had two bands corresponding to the respective inserts. The assay for pX 
mRNA expression was not quantitative but the strongest bands were detected with tax, rex 
and p2 lT
4.3.2 Induction of apoptosis by expression of c-Myc
Rati cells and Rati-c-myc-ER™ cells grew to confluence when cultivated in DMEM + 10% 
hi-FBS, forming adherent monolayers in tissue culture flasks and dishes. When serum was 
withdrawn, there was cessation of proliferation and spreading in non-confluent cultures. 
Confluent cultures, which had stopped proliferating due to contact inhibition in the presence 
of serum, exhibited no obvious morphological changes by light microscopy when serum was 
withdrawn (Figure 4.2). Addition of 4-HT to Rati-c-myc-ER™ cultures grown in the absence 
of serum resulted in cell death, with rounding up and detachment of fibroblasts, while cells 
that remained adherent had attenuated cytoplasmic extensions (Figure 4.3). Cell death was 
visible initially at 6 hours and more than 50% of cells had died and detached by 24 hours. 
These changes were also observed consistently in Rati-c-myc-ER™ cells transfected with 
the vector pcDNAI/Neo that did not contain an insert and acted as a negative control. 
Addition of 4-HT to confluent Rati-c-myc-ER™ cells in the presence of serum had no visible 
effect within the time frame of observations. Addition of 4-HT had no effect on Rati cells 
cultured with or without serum.
4.3.3 Induction of apoptosis by expression of Tax
Transfection of cells with Tax-pcDNAI/Neo would have resulted in constitutive expression of 
Tax from the HCMV promoter. Rati and Rati-c-myc-ER™ cells expressing Tax exhibited 
mild piling up (focus formation), suggestive of transformation, with occasional large 
multinucleate cells scattered through cultures (Figure 4.4). When serum was withdrawn from 
these cultures, cell death was visible initially at 24 hours and by 48 hours 50 to 90% of cells 
had died (Table 4.2) (Figure 4.5). It was not possible to perform experiments with induction 
of c-Myc expression by 4-HT In these cells according to the selected protocol. However, the 
addition of 4-HT at 24 or 48 hours following withdrawal of serum did not alter the fate of Rati 
and Rati-c-myc-ER™ cells transfected with Tax-pcDNAI/Neo (Table 4.2) (Figure 4.6).
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4.3.4 Effects o f Rex, p 2 l‘'^ , p3&', p13^' and p12! on c-Myc and Tax-induced apoptosis
Constitutive expression of Rex, p2 l"‘, Tof, p13" and p12' from the pcDNAI/Neo HCMV 
promoter had no effect on Rat1 or Rat1-c-myc-ER™ cells transfected with single plasmids 
containing any one of these genes (Tabie 4.2). In the presence of serum Rat1-c-myc-ER™ 
cells transfected with these genes continued to proliferate and spread until confluent, 
whereas withdrawal of serum resulted in cessation of growth, similar to non-transfected 
cells. When Rat 1-c-myc-ER™ cells expressing these genes were exposed to 4-HT under 
conditions of serum deprivation, the cells died in a temporal pattern that was similar to non- 
transfected cells (Figure 4.7). Thus, there was no inhibition of c-Myc-induced apoptosis by 
any HTLV-I pX  genes.
Rat1-c-myc-ER™ cells were co-transfected with Tax-pcDNAI/Neo and pcDNAI/Neo 
expressing Rex, p2l'", p30" (Tof) p13" or p12‘. No morphological changes were evident in 
these cultures that were different from cells transfected with Tax-pcDNAI/Neo alone. When 
serum was withdrawn, the cells died with a time course and morphological pattern similar to 
that of Rat1 and Rat1-c-myc-ER™ cells expressing Tax alone (Figure 4.8). Thus, Rex, p2l'", 
Tof, p13*' and p12‘ did not oppose the apoptotic effects of Tax (Table 4.2).
4.3.5 Staining with propidium iodide
Staining of nuclei with propidium iodide (PI) in detaching and degenerating cells was visible 
by fluorescence microscopy in only small numbers of Rat1-c-myc-ER™ cells from confluent 
monolayers grown in the presence of serum or 24 and 48 hours following withdrawal of 
serum (Figure 4.9). There was increased intranuclear staining in serum-deprived Rat1-c- 
myc-ER™ cells stained 6 hours after treatment with 4-HT, as well as staining of DNA in 
fragments of degenerating cells (apoptotic bodies) (Figure 4.10). Serum-deprived Rati -c- 
myc-ER™ cells stained with PI 48 hours after treatment with 4-HT exhibited extensive 
degeneration and detachment. Pl-stained DNA was visible in adherent debris and in many 
cells that remained attached. However, most degenerating cells were washed away during 
the staining procedure.
Rati-c-myc-ER™ cells transfected with Tax-pcDNAI/Neo had mild piling up and occasional 
multinucleate cells when grown in the presence of serum (Figure 4.11). Only a few 
degenerating cells with condensed nuclei or apoptotic bodies were visible. Rati-c-myc-ER™ 
cells transfected with Tax-pcDNAI/Neo exhibited extensive degeneration and detachment of 
cells when PI staining was performed 24 and 48 hours after withdrawal of serum. PI staining 
of DNA was visible in fragmented cells, as well as attenuated cells that remained adherent 
(Figure 4.12). Induced expression of c-Myc in serum-deprived cells resulted in extensive 
degeneration and detachment, with numerous apoptotic bodies visible in Pl-stained slides, c- 
Myc-induced apoptosis was not inhibited by Rex, p2 l'“, p30" (Tof) p i3" or p12‘ (Figure 4.13). 
Similarly, apoptosis induced by Tax in serum-deprived Rati-c-myc-ER™ cells was not 
inhibited by Rex, p2 l'“, p30" (Tof) p i 3" or p i 2* (Figure 4.14).
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Table 4.2 Effect of induced expression of c-Myc following withdrawal of serum  
on survival of Rat1 -c-myc-ER™ cells constitutively expressing 
HTLV-I p X  region genes.
HTLV-I p X  gene 
expression
Normal serum  
c-M yc-
Low
c-M yc-
serum
c-Myc+
pcDNAI/Neo + +
p12' + + „
pi 3" + + -
p30“ + -
p2l"' + + -
Rex + + -
Tax + -
Tax+ p12‘ + - ND
Tax + p13" + - ND
Tax + p30" + - ND
Tax + p2 l"‘ + — ND
Tax + Rex + — ND
c-Myc-
c-Myc+
+
ND
No c-Myc expression
c-Myc expression induced by 4-HT
Survival
Death by apoptosis
Many cells already dead at time of addition of 4-HT 
Not done
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Figure 4.2: Rat1 -c-myc-ER™ cells following withdrawal of serum.
Rat1-c-myc-ER™ cells grown in the presence of serum had multiplied and spread across the 
bottom of the tissue culture flask to form a confluent monolayer that had ceased proliferating 
due to contact inhibition. These cells remained stable following withdrawal of serum. A few 
rounded, detached cells are visible (arrow). Original 200x magnification.
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Figure 4.3: Apoptosis in serum-starved Rat1 -c-myc-ER cells following  
induction of c-Myc expression.
c-Myc expression was induced in Ratl-c-myc-ER^*^ cells by addition of 4-hydroxytamoxifen 
48 hours following withdrawal of serum. At 6 hours following c-Myc induction there is 
attenuation (arrows), rounding up (arrow heads) and detachment of fibroblasts dying by 
apoptosis. Original 200x magnification.
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Figure 4.4: Rat1 -c-myc-ER™ cells expressing Tax grown in serum.
Rat1-c-myc-ER™ cells transfected with Tax-pcDNAI/Neo were grown in the presence of 
serum. These cells proliferated to form a confluent monolayers with mild piling up (focus 
formation) (arrow) and occasional multinucleate cells (arrow head). A few rounded, detached 
cells are visible. Original 200x magnification.
206
Figure 4.5: Effect of withdrawal of serum on Rat1 -c-myc-ER '^  ^cells expressing Tax.
Rat1-c-myc-ER^'^ cells transfected with Tax-pcDNAI/Neo formed confluent monolayers when 
grown in the presence of serum. At 24 hours following withdrawal of serum there is extensive 
cell death characterised by attenuation (arrows), rounding up (arrow heads) and detachment. 
Original 200x magnification.
© r
- j
'1r <St
I
.©
'•A ' a  A  ■
1 »
207
Figure 4.6: Effect of induction of c-Myc expression in serum-starved
Rat1 -c-myc-ER^"'" cells expressing Tax.
Rat1-c-myc-ER™ cells transfected with Tax-pcDNAI/Neo experienced apoptosis following 
withdrawal of serum (Figure 4.5). When c-Myc was induced in these cells by addition of 4- 
hydroxytamoxifen 24 hours following withdrawal of serum, there was no alteration in the 
pattern of cell death. Cells exhibit attenuation (arrow), rounding up (arrow heads) and 
detachment. Original 200x magnification.
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Figure 4.7: Effect of induction of c-Myc expression on serum-starved 
Rat1-c-myc-ER^*^ cells expressing p12‘.
c-Myc expression was induced in Rat1-c-myc-ER™ cells transfected with p12-pcDNAI/Neo 
by addition of 4-hydroxytamoxifen 48 hours following withdrawal of serum. At 24 hours after 
induction of c-Myc dying cells have rounded up and detached from the substrate. Original 
200x magnification.
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Figure 4.8: Effect of serum starvation on Rat1 -c-myc-ER^"'" cells 
expressing HTLV-I Tax and p12‘.
Rat1-c-myc-ER™ cells co-transfected with Tax-pcDNAI/Neo and p12-pcDNAI/Neo were 
allowed to grow to near-confluence in the presence of serum. At 24 hours following 
withdrawal of serum, a substantial proportion of cells are dying, characterised by rounding up 
and detachment. Expression of p12‘ has not inhibited cell death induced by Tax in serum- 
starved cells. Original 200x magnification.
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Figure 4.9: Propidium iodide staining of Rat1 -c-myc-ER^"^ cells 
following withdrawal of serum.
Near-confluent monolayer of Rat1 -c-myc-ER^"^ cells grown in the presence of serum shows 
survival of most cells 48 hours after withdrawal of serum. Cells detached from two sites in 
the field have been washed away during the staining procedure (arrows). Propidium iodide 
staining. Fluorescence microscopy. Original 400x magnification.
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Figure 4.10: Propidium iodide staining of Rat1 -c-myc-ER^'^ cells following serum  
deprivation and induction of c-Myc expression.
c-Myc expression was induced in Rat1-c-myc-ER™ cells by addition of 4-hydroxytamoxifen 
48 hours following withdrawal of serum. At 6 hours following c-Myc induction there are 
fragmented nuclear bodies containing condensed DNA that have arisen from fibroblasts 
dying by apoptosis (arrows). Propidium iodide staining. Fluorescence microscopy. Original 
400x magnification.
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Figure 4.11: Propidium iodide staining of Rat^-c-myc-ER^** ceiis expressing
Tax grown in serum.
Rat1-c-myc-ER cells transfected with Tax-pcDNAI/Neo and grown in the presence of 
serum form a near-confluent monolayer with mild piling up and some multinucleate cells. A 
single rounded, condensed nucleus from a dead cell can be seen (arrow). A mitotic figure is 
visible in a dividing cell (arrow head). Propidium iodide staining. Fluorescence microscopy. 
Original 400x magnification.
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Figure 4.12: Propidium iodide staining of Ratl-c-myc-ER '^  ^cells expressing
Tax following withdrawal of serum.
Rat1-c-myc-ER™ cells transfected with Tax-pcDNAI/Neo photographed 24 hours following 
withdrawal of serum exhibit attenuation (arrows) and formation of apoptotic bodies in 
degenerating nuclei of dying cells (arrow heads). Detached cells have been washed away 
during the staining procedure. Propidium iodide staining. Fluorescence microscopy. Original 
400x magnification.
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Figure 4.13: Propidium iodide staining of Rati-c-myc-ER "^'" cells expressing p i2
with induced expression of c-Myc expression following deprivation of serum
c-Myc expression was induced in Rat1-c-myc-ER™ cells transfected with p12'-pcDNAI/Neo 
by addition of 4-hydroxytamoxifen 48 hours following withdrawal of serum. At 24 hours after 
induction of c-Myc there are multiple foci of cell loss with numerous degenerating cells and 
apoptotic bodies (arrows). Propidium iodide staining. Fluorescence microscopy. Original 
400x magnification.
215
Figure 4.14: Propidium iodide staining of R at^-c-m y cells 
expressing HTLV-I Tax and p i 2* following serum starvation.
Serum was withdrawn from near-confluent Rat1-c-myc-ER™ cells co-transfected with Tax- 
pcDNAI/Neo and p12-pcDNAI/Neo. At 24 hours following serum deprivation there are 
multiple foci of cell loss and formation of apoptotic bodies in degenerating cells (arrows). 
Expression of p i 2* has not inhibited cell death induced by Tax in serum-starved cells. 
Propidium iodide staining. Fluorescence microscopy. Original 400x magnification.
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4.4 Discussion
In this study combinations of HTLV-I pXgenes were transfected into Rat1-c-myc-ER™ cells 
and tested for their ability to protect these cells from apoptosis following activation of c-Myc 
by 4-HT under conditions of serum deprivation. Rat1 and Rat1-c-myc-ER™ cells survived but 
ceased growing when serum was withdrawn. Activation of c-Myc in these cells under 
conditions of serum deprivation resulted in cell death due to apoptosis (Evan et a /1992). 
Constitutive expression of Tax induced cell death in Rati and Rati-c-myc-ER™ cells 
following withdrawal of serum, consistent with the observations of other groups using rodent 
fibroblasts in different experimental systems (Sakurai at al 1992b, Yamada et al 1994, Fujita 
and Shiku 1995). Within the constraints of the temporal pattern of cell death in serum- 
starved Rati-c-myc-ER™ cells expressing Tax, the fate of these cells was unaffected by 
Induced expression of c-Myc.
Constitutive expression of Rex, p2l'", Tof, p i3" and p i2' in Rati-c-myc-ER™ cells did not 
have any detectable effect on proliferation or survival when cells were cultivated in normal or 
reduced concentrations of serum. Co-expression of these gene products with Tax did not 
prevent Tax-induced apoptosis of serum-starved Rati-c-myc-ER™ cells. Similarly, 
constitutive expression of Rex, p 2 l‘", Tof, p i3" or p i2* did not prevent apoptosis induced in 
serum-starved Rati-c-myc-ER™ cells by activation of c-Myc. Therefore, no role in induction 
or inhibition of apoptosis by Rex, p2 l'“, Tof, p i 3" or p12' was demonstrated in this 
experimental system and these gene products did not appear to cooperate with Tax or c- 
Myc. It is uncertain whether prevention of apoptosis Is one of the oncogenic mechanisms 
used by HTLV-I.
In this study cell death due to apoptosis was demonstrated by visible changes in cells by 
standard light microscopy and by examination of Pl-stained cells by fluorescence light 
microscopy. These changes are largely qualitative. Quantification of apoptosis could be 
achieved by a variety of techniques, including the use of video time-lapse photography to 
follow the fate of individual cells (Evan et ai 1992), flow cytometry analysis of DNA strand 
breaks labelled with bromo-dUTP (Li and Darzynkiewicz 1995), detection of 
phosphatldylserine expression on apoptotic cells by flow cytometry using annexin V 
(Koopman et a! 1994) and staining of DNA strand breaks in cells on slides stained by the 
terminal deoxynucleotidyl transfer-mediated dUTP-biotin nick end labelling (TUNEL) (Kasagi 
et ai 1994). Use of these techniques could allow more subtle effects resulting from 
interactions between HTLV-I pXgene products to be detected.
HTLV-I pX mRNA expression was detected in transfected Rati-c-myc-ER™ cells in this 
study by Northern blot hybridisation. Expression of mRNA does not necessarily imply 
expression of a functional protein. The observed effects in Tax-pcDNAI/Neo-transfected cells 
deprived of serum indicate that functional Tax was expressed in these cells. However, it 
would be desirable to demonstrate expression of Rex, p2l'", Tof, p13" and p12' proteins by 
functional or Immunological assays to be confident that the apparent absence of effects due 
to these gene products was not due to lack of expression of active proteins. Monoclonal 
antibodies (MAbs) could be used to stain specific HTLV-I pX proteins or MAbs against amino 
acid tags such as AU1, HA1 and TSP in Tof, p13" and p12* (Table 4.1) could be used as
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markers for protein expression. In 2003 an attempt was made to revive 35 transfected cell 
lines that had been stored in liquid nitrogen to test for expression of HTLV-I pX  proteins but 
none of the cell lines were viable.
This study demonstrated that Tax induces apoptosis in Rat1 cells deprived of serum and that 
other HTLV-I p X gene products did not prevent apoptosis induced by either Tax or c-Myc 
under these conditions. The implications of these results and potential future studies are 
discussed further in Chapter 5.
Chapter 5 
General Discussion
5.1 Investigation of the role of retroviruses in human T cell leukaemias and 
lymphomas
The main aim of this project was to determine if human T iymphotropic virus type I (HTLV-I) 
or related retroviruses are associated with cutaneous T cell lymphomas (CTCLs), particularly 
mycosis fungoides (MF) and Sézary syndrome (SS). Additional aims were to determine if 
HTLV-l-related viruses are involved in large granular lymphocytic (LGL) leukaemia and if 
infection with bovine leukaemia virus (BLV) or other members of the HTLV/BLV group of 
viruses Is present In selected cases of adult acute lymphoblastic leukaemia (ALL). The 
possibility that undiscovered retroviruses might be involved in human T cell leukaemias and 
lymphomas was also considered. Identifying an association between a virus and a neoplasm 
is a first step in confirming the aetiology of virus-induced neoplasia. A final aim of the project 
was to determine if HTLV-I p X  region gene products are able to prevent apoptosis.
Identifying anti-apoptotic properties in p X  proteins with currently unknown function would 
contribute to an understanding of the mechanisms of HTLV-I leukaemogenesis.
MF is an epidermotropic CD4^ CTCL and SS is considered to be the leukaemic form of the 
same disease (Edelson 1980). These neoplasms were targeted for investigation because 
they have clinical and pathological similarities to some forms of adult T cell 
leukaemia/lymphoma (ATL), an aggressive CD4* T cell neoplasm that is caused by HTLV-I 
(Blattner et al 1982, Hinuma et al 1982b, Nagatani et al 1990). Infections with HTLV-I and 
HTLV-I I have been demonstrated in some patients with LGL leukaemia and therefore 
samples from cases of this lymphoproliferative disorder were included in the study (Loughran 
et a /1992, Martin et al 1993). Cases of acute ALL in butchers from the Cardiff area were 
examined for evidence of infection with BLV because of their occupational exposure to cattle 
(Whittaker 1991). A combination of cell culture and molecular biology techniques was used 
in an attempt to identify HTLV-I and related viruses in these neoplasms.
Many other groups have attempted to establish associations between HTLV-I, HTLV-II or 
related retroviruses and CTCLs (Hall 1994, Lessin et al 1994). Most cases of MF/SS can be 
distinguished from ATL on the basis of clinicopathologlcal features and the presence or 
absence of HTLV-I infection (Yamaguchi et a /1984, Nagatani et ai 1990, Levine et al 
1994a). Many cases initially diagnosed as MF/SS were reclassified as forms of ATL following 
the discovery of HTLV-I (Poiesz et al 1980a, 1981, Blattner et a /1982, Blayney et a/ 1983b). 
However, infection with HTLV-I or HTLV-II has been reported in a number of cases that 
conform to the case definition of MF/SS (Kaplanski et al 1986, Zucker-Franklin et al 1991, 
1992, Bazarbachi et al 1994, Manca et a l 1994). These results are part of a spectrum of 
evidence implicating HTLV-l-related retroviruses in T cell neoplasia distinct from ATL in 
HTLV-I non-endemic regions (Capésius et al 1991, D'Incan et al 1992, Lapis e ta l 1992,
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Lisby et al 1992, Bazarbachi et a /1993, Chan et al 1993, Whittaker and Luzatto 1993, 
Pancake et al 1995). However, the conflicting results of many of these studies indicate the 
need for stringent criteria to confirm that positive findings are genuine and have aetiological 
significance. Such criteria include establishing unequivocal case definitions for MF/SS and 
other CTCLs to enable them to be distinguished from ATL. The concept of HTLV-I positive 
MF/SS distinct from ATL remains controversial and may depend on strict pathological 
definitions.
Classification systems for T cell neoplasia are continually being updated and caution should 
be exercised in the Interpretation of studies that have used different criteria for definition of 
cases (Willemze et al 1997, 1999, Fink-Puches et al 2002). The classification of LGL 
leukaemia, which has T cell and natural killer (NK) cell forms, is still developing (Semenzato 
et a /1997). The relationship between clonal LGL leukaemia and lymphoproliferatlve disease 
of LGLs (LDLGLs) in which clonality cannot be demonstrated remains to be elucidated (Scott 
et al 1993, Richards et al 1995). Adult ALL is well-defined, but childhood ALL has received 
more attention in the search for an infectious aetiology because of temporal and spatial 
clustering (Alexander 1993, Harris et a /1994, Birch et al 2000).
Establishing an association between a virus and a defined clinicopathological entity depends 
on the acceptability of evidence that the virus is present. Gold standards for diagnosis of 
HTLV-I infection by serology in patients with ATL may not be applicable to MF/SS or LGL 
leukaemia if the serological response is altered in patients with these diseases. Variations in 
patterns of seroreactivity are difficult to interpret in this context, particularly as variant HTLVs 
have not so far been detected in seroindeterminate patients (Maruyama et al 1989, Ranki et 
a /1990, Srivastava et al 1990, Nerurkar et a l 1992, Madeleine et a /1993, Re et al 1993, 
Busch et al 2000). Therefore, serological testing was not performed in this study. Molecular 
techniques are increasingly being used for detection of viral sequences in blood and tissues 
but the most definitive evidence of retroviral infection remains isolation of infectious virus. In 
studies testing the hypothesis of a viral aetiology of MF/SS, a goal would be to isolate a new 
species of exogenous retrovirus or a distinct strain of HTLV-I or HTLV-II.
If the presence of infectious virus or viral sequences is confirmed in patients with T cell 
neoplasia, then further investigation is required to determine if the virus has an aetiological 
role in the disease (Evans 1976, Fredricks and Reiman 1996). The presence of a retrovirus 
in patients with CTCL, even if integrated in neoplastic cells, is not proof of a causal role in 
oncogenesis. Retroviruses may be carried as passengers in neoplastic cells, with infection 
representing tropism for proliferating T cells rather than an aetiological role. Early isolates of 
HTLV-II were obtained from T cell variants of hairy cell leukaemia (HCL) and CD8* T cell 
lymphocytosis in patients with B cell HCL, but HTLV-II does not appear to be aetiologically 
involved in HCL (Rosenblatt et al 1987, Hjelle et al 1991a). Similarly, cases of LGL 
leukaemia in which HTLV-I and HTLV-II have been demonstrated may reflect coincidental 
infection in patients from populations harbouring these viruses (Heneine et al 1994,
Loughran et al 1994b).
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5.2 Detection of retroviruses in human T cell leukaemias and lymphomas by cell 
culture
In the first part of this study attempts were made to isolate HTLV-I or other retroviruses in 
cell culture from patients with cutaneous lymphoid infiltrates. HTLV-I was first detected in a 
CD4* T cell line established from a patient with ATL (Poiesz et al 1980a, b) and HTLV-II was 
first identified In a CD8^ T cell line derived from a patient with a T cell variant of HCL 
(Kalyanaraman et al 1982b). HTLV-l-infected T cell lines can be readily established from 
ATL patients using mitogens, interleukin (IL) 2, conditioned medium (CM) and by 
cocultivation of peripheral blood mononuclear cells (PBMCs) with umbilical cord blood 
mononuclear cells (UCMCs) (Gazdar et al 1980, Miyoshi ef a/1981a, b, Markham et al 
1983). A number of CD4* T cell lines have been established from patients with MF and SS 
using IL2, IL4, IL7 and CM as growth stimulants (Kaltoft et al 1984, 1987, Abrams et ai 
1991a, b, Crae et al 1991, Starkebaum et al 1991, Kaltoft et al 1992). Although retrovirus- 
like particles have sometimes been demonstrated by electron microscopy (EM) and reverse 
transcriptase (RT) activity sometimes detected in cell culture supernatants in these cell lines, 
there is no definitive evidence of infection with exogenous retroviruses. Two groups have 
identified HTLV-I or HTLV-II sequences by the polymerase chain reaction (PCR) in 
lymphocytes cultivated from patients with MF/SS using IL2 and granulocyte-macrophage 
colony stimulating factor (GMCSF) as growth stimulants but infectious retroviruses have not 
been purified or propagated (Zucker-Franklin e ta l 1991, 1992, Ghosh et al 1994). Similar 
cell culture techniques were adopted in this study in an attempt to propagate T cell lines that 
might harbour T Iymphotropic viruses such as HTLV-I and HTLV-II. Cultivated cells were 
examined by EM for evidence of retrovirus infection and culture supernatants were assayed 
for RT activity. Cultivated cells were also tested for HTLV-I and HTLV-II by PCR.
PBMCs and lymphocytes derived from skin and lymph nodes were cultivated from 18 
patients with cutaneous lymphoid infiltrates. These were 11 patients with MF, three patients 
with SS, one patient with CTCL (peripheral T cell lymphoma) and three patients with 
cutaneous B cell lymphoma (CBCL). Four CD8^ T cell lines were cultivated for more than 6 
months from the skin of three patients with MF. Since these patients had CD4"^  T cell 
neoplasia, the cultivated cells probably arose from non-neoplastic CD8^ tumour Infiltrating 
lymphocytes (TILs). It has been shown that most T cell clones propagated from MF lesions 
are not derived from neoplastic MF/Sézary cells (Ho et al 1990, Harwix et al 2001). One 
Epstein-Barr virus (EBV)-infected B-lymphoblastoid cell line (B-LCL) was established from a 
patient with CBCL, consistent with the known B cell immortalising properties of this 
ubiquitous virus (Pattengale et al 1973). No evidence of retrovirus infection was found in 
cultured lymphocytes by EM or RT assay and no HTLV-I or HTLV-II sequences were 
demonstrated by PCR.
Reports of detection of retrovirus-like particles by EM and RT activity in cultured lymphocytes 
from patients with MF/SS (Kaltoft et a /1984, 1987, Saal et al 1989, Zucker-Franklin et al 
1991, Bazarbachi et al 1994) need to be verified by purification and characterisation of the 
putative virus, demonstration of infectivity and sequencing. None of the studies so far 
reported have been able to meet these criteria. It is necessary to exclude the possibility that 
putative virus Isolates are the result of expression of endogenous retroviruses in cultured
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cells (Lower et al 1993, Herbst et a /1996). Virus-like particles may be produced following 
activation of endogenous retrovirus-like elements in the altered environment of neoplastic 
tissue or In cell cultures. It is also necessary to ensure that propagated viruses have not 
been derived from laboratory contamination with exogenous or endogenous retroviruses, 
especially those of non-human primate origin (Reitz et a l 1976, Smith et al 1979, Popovic et 
al 1982). Contamination of cell cultures with non-human primate and murine retroviruses has 
been a frequent distraction during attempts to isolate retroviruses from human patients with 
neoplasia. Cell lines established from patients with CTCL should also be characterised by 
immunophenotyping, karyotyping and molecular analysis as necessary to determine if they 
are derived from the neoplastic clone. In many studies reporting HTLV-l-related viruses in 
cell cultures from patients with CTCL the propagated cells have not been confirmed to be of 
T cell origin (Manzari e ta l 1987, Hall ef a/1991, Zucker-Franklin e ta l  1991, 1992).
Human T cells infected with HTLV-I and HTLV-II can be immortalised (remaining IL2- 
dependent) or transformed (growing independently of IL2) in vitro (Miyoshi et a/ 1981c, Chen 
et al 1983). Normal human T cells are able to survive in standard cell cultures for 20 to 30 
days if unstimulated or 30 to 60 days if activated (Perillo et a /1989). Use of a variety of 
stimulants and cocultivation techniques can increase the longevity of T cells in culture and 
result in the selective outgrowth of specific T cell clones, such as the CD8* T cell lines 
established in this study. Success in establishing T cell lines could also be due to infection 
with immortalising viruses but extending the lifespan of propagated cells per se does not 
necessarily increase the chances of isolating new retroviruses. The cell culture approach to 
isolation of new viruses should therefore be directed at maintaining an environment in which 
the in vitro growth of cells is optimised for virus isolation without merely perpetuating the 
survival of normal T cells. This could be achieved by selective induction of specific T cell 
types and subtypes and stimulation of virion production from latent proviruses.
5.3 Use of molecular techniques to detect HTLV-reiated retroviruses in human T cell 
leukaemias and lymphomas
There is a wide range in reported frequencies of detection of HTLV-I and HTLV-II sequences 
by PCR in patients with MF/SS (Capésius ef a /1991, Hall ef a /1991, D'Incan ef al 1992, 
Lapis ef a /1992, Lisby ef a /1992, Bazarbachi ef al 1993, Chan ef a /1993, Manca ef al 1994, 
Pancake ef al 1995). A number of groups have provided molecular evidence that incomplete 
or defective genomes of HTLV-I, or possibly variant viruses, are present in some patients 
(Hall ef a /1991, Zucker-Franklin ef al 1991, Srivastava ef al 1992, Ghosh ef al 1994, 
Pancake ef al 1995). HTLV-I p X  sequences, especially tax sequences, are detected more 
frequently than other regions of the genome in these cases. Defective HTLV-I proviruses 
with preferential retention of the p X  region have been detected in a small proportion of 
patients with ATL (Konishi ef al 1984, Korber et al 1991, Ohshima ef al 1991, Kubota ef al
1995). Similarly, the p X  region is retained in defective BLV proviruses integrated in 
leukaemic B cells of cattle with enzootic bovine leucosis (EBL) (Kettmann ef al 1982). 
Therefore, the hypothesis was tested that incomplete or defective HTLV-I or HTLV-II 
proviruses are integrated in neoplastic cells of patients with MF/SS and that tax sequences 
are detected more frequently by PCR than other regions of the viral genome.
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In the second part of this study samples from 36 patients with cutaneous lymphoid infiltrates, 
six patients with LGL leukaemia and six patients with adult ALL were tested for the presence 
of HTLV-I and HTLV-I/II using PCR primer sets that amplified sequences from different 
regions of the HTLV-I proviral genome. Patients with LGL leukaemia and adult ALL were 
also tested for BLV gag sequences by PCR. An important feature of this study was the 
careful optimisation of PCR conditions for each primer set and the use of serial dilutions of 
positive control DNA and cells to quantify the sensitivity of each assay. Sensitivity was 
monitored in PCRs conducted on each batch of clinical samples to ensure that an adequate 
limit of detection was achieved. Precautions were taken to minimise PCR contamination.
PCR products were amplified from three patients (one MF, one 88 and one CBCL) using 
HTLV-I or HTLV-I/II tax primers. However, the sequences of cloned PCR products were 
identical to those amplified from C8166 cell line DNA used as a positive control. It was 
concluded that these PCR products were the result of contamination, despite the care taken 
in preparing PCR reagents and handling clinical samples.
False positive results due to PCR contamination have been a major problem in attempts to 
associate HTLV-I or HTLV-II with a number of diseases. HTLV-I sequences detected by 
PCR were reported in patients with multiple sclerosis (Koprowski et al 1985, Greenberg et al 
1989a, Reddy et a /1989) but extensive follow-up studies have been negative (Ehrlich et al 
1991 ). The use of PCR to detect viruses must be conducted with stringent precautions to 
eliminate contamination from PCR products, plasmids containing cloned viral sequences, 
positive control DNA samples and infected clinical samples. When there is controversy 
regarding the veracity of findings, for example when disparate results are obtained by 
different groups, positive findings must be subjected to high levels of scrutiny. Criteria for 
accepting a positive result as genuine need to take account of the precautions to prevent 
contamination at all stages of sample and reagent preparation and analysis.
In molecular studies of the involvement of HTLV-l-related viruses in T cell neoplasia, an 
acceptable level of proof in some circumstances would be to accept results only when 
sequences of PCR products differ significantly from reference strains of HTLV-I and HTLV-II, 
particularly those used as positive controls. It may be not be possible to resolve the issue of 
whether prototypical strains of HTLV-I are involved in the aetiology of CTCLs, since cases of 
MF/88 and T cell lymphomas (TCLs) that are HTLV-l-associated could be classified as 
variants, particularly cutaneous forms, of ATL. It may only be possible to identify a retrovirus 
as the cause of MF/88 by isolation of a distinct sequence variant of virus that can be 
classified as a new strain or new virus species. It would then be necessary to demonstrate 
that this virus is consistently associated with MF/88.
8ince this molecular investigation was conducted, several other PCR-based studies have 
been published that report no evidence of HTLV-I or HTLV-II infection In MF/88 patients 
(Boni ef a /1996, Wood ef al 1996b, Bazarbachi et al 1997, Fujihara ef al 1997, Wood et al 
1997, Daliani ef al 1998, Kim ef a /1998). The carefully controlled study of Wood ef al 
(1996a, b) provides a good model for future molecular studies attempting to identify viral 
sequences in lesions of patients with a variety of diseases. 8imilar to the molecular 
investigations described in this thesis, a PCR system for detection of HTLV-I in paraffin- 
embedded histological sections was carefully optimised, controlling for specificity by
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Southern blot (SB) hybridisation using an oligonucleotide probe and nucleotide sequencing 
(Wood et al 1996a). The integrity of total DNA was assessed by PCR for the nucleophosmin 
gene and the integrity of T cell DNA was assessed by PCR for the T cell receptor (TCR). 
Using PCR and SB hybridisation, HTLV-I pel sequences were initially detected in three (7%) 
of 42, env sequences in 2 (5%) of 37 and p X  sequences in 7 (17%) of 42 patients from the 
USA with MF/SS (Wood et al 1996b). However, after treatment of samples with ultraviolet 
(UV) light, only three of 12 previously positive cases remained positive, suggesting that the 
earlier positive results were due to trace contamination with PCR reagents or sample DNA. 
Furthermore, p X  and pel sequences cloned from one PCR-positive sample were identical to 
that of the positive control; the same sample was negative for HTLV-I by dot blot 
hybridisation of genomic DNA and new samples from the two remaining positive cases were 
negative by PCR. When material from 28 additional cases of MF/SS from the USA was 
subjected to PCR with the use of UV light to reduce contamination, all were negative for pX  
sequences. The conclusion from this study was that positive PCR results for HTLV-I in 
MF/SS patients were due to trace contamination with PCR products (Wood et a/ 1996b).
Measures to prevent contamination in many studies may not have been sufficiently stringent 
to prevent false positive results. Associations between diseases and viruses should be 
viewed with scepticism if they are based on PCR results without other supporting evidence.
If a retrovirus is involved in CTCL, it may not be related to HTLV-I or HTLV-II, it might be 
present in the skin in quantities below the detection limit of PCR or it might have been 
eliminated from the skin before clinical lesions develop (Lisby et al 1992). The best evidence 
to date, including the results described in this thesis, thus indicate that HTLV-I and HTLV-II 
are not involved in CTCL (Lessin et al 1996, Wood et al 1996b)
Supporting these observations, no HTLV-I sequences were detected by PCR in PBMCs or 
skin lesions of 127 patients with CTCL (108 with MF/SS) from Europe and the USA using 
HTLV-I and HTLV-II gag, pel, env, p X and LTR specific primers (Bazarbachi et al 1997). No 
HTLV-I sequences were detected by PCR in 50 Swiss and German patients with CTCL (Boni 
et al 1996) or 16 HTLV-I seronegative patients with MF/SS from north eastern USA (Fujihara 
et a l 1997). Similarly, PCR analyses conducted since this study have not shown any 
evidence of HTLV-I or HTLV-II in cases of LGL leukaemia and T prolymphocytic leukaemia 
in non-endemic regions (Pawson et al 1997).
However, some groups have continued to report detection of HTLV-I sequences by PCR in 
patients with CTCL (Zucker-Franklin 2001). Pancake and Zucker-Franklin (1996) detected 
HTLV-I tax sequences by in situ PCR in infiltrating lymphocytes, as well as keratinocyte-like 
cells, in the skin of 11 of 12 patients with MF. The skin PCR negative patient had HTLV-I 
sequences demonstrable by PCR and Southern blot (SB) hybridisation in PBMCs (Khan et a l
1996). HTLV-II tax and pel sequences were detected by PCR in tissues from one (5%) of 22 
patients with CTCL in the USA, although clonal HTLV-II integration could not be detected by 
SB hybridisation in PBMCs of this patient; all patients were negative for HTLV-I tax or pel 
sequences (Li et a l 1996). Kikuchi et a/ (1997a) reported that no HTLV-I sequences were 
detected in 50 HTLV-I seronegative Japanese patients with CTCL, then later reported that 
HTLV-I gag, pel, env and/or p X  sequences were detected by PCR in two HTLV-I 
seronegative patients with CTCL, although monoclonal integration of HTLV-I provirus could
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not be confirmed in these patients by SB hybridisation (Kikuchi et al 1997b). Similarly, HTLV- 
I gag, pol, env, p X  and LTR sequences were detected by PCR in PBMCs of an HTLV-I 
seronegative Japanese patient with SS, but no monoclonal integration of HTLV-I provirus 
could be detected by SB hybridisation (Miyoshi et al 1998). Twelve of 28 patients with CTCL 
(27 MF, one SS) had antibodies against HTLV-I by WB ELISA and HTLV-I sequences were 
amplified by PCR from PBMCs of six patients (Shohat et al 1999). An HTLV-II associated 
CTCL has been identified in an HIV-1-infected AIDS patient (Poiesz et al 2000).
Differences between studies in associating HTLV-I with MF/SS have been attributed to 
differences in the methods of processing samples for detection of HTLV-I sequences 
(Pancake and Zucker-Franklin 1996, Zucker-Franklin and Pancake 1998b). Zucker-Franklin 
and Pancake (1998b) showed that the use of whole-cell lysates instead of DNA extracts and 
the use of fresh instead of cultured cells for PCR increased the ability to detect HTLV-I tax 
sequences in samples from MF patients. They also observed that positive PCR products 
from clinical samples are more likely when tax primers are used than primers from other 
regions of the HTLV-I genome, when there are more than 30 cycles of amplification and 
when SB hybridisation is applied to PCR products (Ghosh et al 1994, Pancake et al 1995b, 
Pancake and Zucker-Franklin 1996). However, contamination is also more likely with 
extended PCR cycles using highly sensitive primer sets. Since it is difficult to assess 
precautions taken by other groups to prevent PCR contamination, independent studies are 
necessary to verify positive findings. The only study to have used a double blind method for 
confirmation of PCR results from the same patients at different times of collection reported 
positive results for HTLV-I pol and tax sequences in 10 (34%) of 29 patients with MF from 
Italy (Manca et al 1994). The need for carefully controlled independent studies will continue 
while ever there are claims of positive associations between HTLV-I or related viruses and 
CTCL.
In 50 MF patients positive for HTLV-I tax DNA and mRNA by PCR, 83% had antibodies 
against HTLV-I Tax, whereas only 5% had reactivity to structural proteins in standard HTLV-I 
serological assays (Pancake et a l 1996a). Although anti-Tax antibodies and tax sequences 
detected by PCR have been reported by some groups in 8 to 11% of normal blood donors 
and 4 to 33% of intravenous drug users (IVDUs) negative for HTLV-I in standard serological 
assays (Ehrlich et al 1989a, Pancake et al 1996a, b, Zucker-Franklin and Gorman 1997, 
Zucker-Franklin et al 1997, Zucker-Franklin and Pancake 1998a) these findings have not 
been supported in an independent, blind, multicentre study (Cowan et al 1999).
DNA extracted from skin samples of patients with MF usually contains only a small 
percentage of DNA from neoplastic T cells and therefore it is important to determine the 
sensitivity of detection of HTLV-I and HTLV-II sequences by PCR. The use of PCR to 
indicate the presence of incomplete HTLV-I or HTLV-II proviruses needs to be critically 
evaluated, since most studies have not adequately monitored the sensitivity of each primer 
set. A negative PCR result for some but not other regions of the HTLV genome could be due 
to poor sensitivity of particular primer sets in a panel. Alternatively, positive results could be 
due to contamination. It is notable that many tax primer sets appear to be more sensitive 
than primer sets used for PCR from other regions of the HTLV-I genome. The presence of 
HTLV-I or HTLV-II with variant sequences could also result in the failure to amplify products
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by PCR. The possibility of variant HTLV-I sequences was taken into account in this study by 
using primers covering multiple regions of prototypical HTLV-I and by use of consensus 
primers. Also, the pX  regions of HTLV-I and HTLV-II have sufficient similarity to cross- 
hybridise in SB hybridisation analyses, so the HTLV-I probe (pMT2j) used in these 
experiments would be expected to hybridise to PCR products amplified using HTLV-I/II 
primers (Shaw et al 1984).
To verify that a patient with CTCL is infected with HTLV-I or a related virus, it will be 
necessary to obtain a substantial length of sequence, preferably of the entire provirus, for 
comparative analysis. Sequencing of a fragment derived from a PCR reaction is inadequate 
unless the sequence can be shown to be substantially different from sequences of any 
known HTLV-I or HTLV-II strain and different from any positive control DNA used for the 
same study. Small differences in the sequences of PCR products could be due to errors 
introduced by Taq polymerase during amplification. This possibility could be excluded by 
sequencing PCR products from multiple independent reactions or by the use of proof 
reading enzymes with higher fidelity. Otherwise, even with the use of positive and negative 
controls, contamination cannot be excluded with the stringency required for declaration of a 
new virus or variant given the level of controversy in this field. The lack of adequate 
sequence data Is the major flaw of all studies so far reported that have attempted to 
associate HTLV-I, HTLV-II or related viruses with CTCL.
Regions of sequence similarity in the LTR and gag regions of HTLV-I, HTLV-II and BLV were 
used to design consensus PCR primers for the HTLV/BLV (Deltaretrovirus) group of viruses. 
However, these primers were shown to produce non-specific PCR products under a variety 
of conditions using HTLV-I and BLV DNA as templates. Further optimisation may improve 
the specificity of these primer sets or they may have specific applications in customised PCR 
systems. It would also be necessary to determine the sensitivity of these primer sets. 
Consensus retroviral PCR primers have been based on alignments of retroviral Pol region 
amino acid sequences and reverse translation to identify minimum degenerate codons 
(Mack and Sninsky et al 1988, Donehawer et al 1990). A major problem with these primers is 
that they will amplify homologous pol sequences from endogenous retroviral elements and 
therefore are only likely to be useful in PCR systems based on cDNA (Nelson et al 1999). 
Another approach is to use a modification of representational difference analysis (RDA) to 
preferentially amplify tester sequences that will not be present in driver DNA, thus limiting 
amplification of endogenous sequences (Lisitsyn et al 1993). This allows selective 
amplification of exogenous retroviruses from the tester DNA, which will not have partners in 
the driver DNA. RDA could also be applied to cDNA to search for retroviral RNA genomes 
(Hubank and Schatz 1994, Geng et al 1998).
A third HTLV-related retrovirus lineage, known as primate T Iymphotropic virus type L 
(PTLV-L or PTLV-3), has been identified in baboons {Papio hamadryas) (Goubau et a l 1994, 
Van Brussel et al 1997). There is sufficient similarity between fax sequences of PTLV-L and 
HTLV-I/II for this divergent group to be identified using generic tax primers (Busch et al 
2000). As discussed above, no variant PTLV-L tax sequences were detected by PCR in 269 
HTLV-I/II seroindeterminate blood donors in the USA (Busch ef a/2000).
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Although there Is little evidence for the involvement of EBV in most human primary CTCLs, 
including MF/SS (Kanavaros et al 1994, Anagnostopoulos ef al 1996, Angel ef a /1996), an 
EBV-related virus, HVmne, has been associated with MF in a pig-tailed macaque {Macaca 
nemestrina) (Rivadeneira ef a /1999). PCR using specific, degenerate and consensus 
primers for detection of herpesviruses could be applied to CTCLs (MacKenzie ef al 2001, 
Gallagher ef al 2002).
This project did not produce evidence that HTLV-I, HTLV-II or BLV are associated with 
MF/SS, LGL leukaemia or selected cases of adult ALL in the United Kingdom. The available 
reports attempting to implicate retroviruses in CTCLs similarly have failed to provide 
conclusive evidence for a primary aetiological role of HTLV-I or HTLV-II in MF/SS (Lessin et 
al 1994, Woods ef al 1996b). Therefore, it is concluded that HTLV-I and HTLV-II are not the 
cause of CTCLs in HTLV non-endemic regions.
5.4 The role of HTLV-I pX gene products In apoptosis
The third part of this project examined the ability of HTLV-I p X  gene products to inhibit 
apoptosis Induced by c-Myc in Rati fibroblasts. When cells proliferate in response to the 
activation of oncogenes such as c-Myc, the apoptosis pathway is switched on concurrently 
and these cells die when survival factors such as those present in serum are withdrawn 
(Evan ef al 1992). In models of oncogenesis there is a requirement for apoptosis to be 
blocked to enable proliferating cells to survive. Several oncogenic viruses produce proteins 
that inhibit apoptosis (Rao ef al 1992, White ef a /1992, Henderson ef a /1993).
In this study it was hypothesised that HTLV-I p X  region gene products with currently 
unknown functions might inhibit apoptosis. The system of c-Myc induction by 4- 
hydroxytamoxifen (4-HT) in Rati cells stably transfected with a chimaeric c-myc-modified 
receptor (ER™) gene provided an elegant model to test the anti-apoptotic properties of 
HTLV-I p X  proteins (Evan ef al 1992, Littlewood ef al 1995). However, expression of Rex, 
p 2 l‘", p30" (Tof), p i3" or p i2' did not inhibit c-Myc-induced apoptosis in Rati cells under 
conditions of serum deprivation. Furthermore, Rati cells expressing Tax underwent 
apoptosis when serum was withdrawn, indicating that Tax might trigger apoptotic pathways 
at the same time as it activates pathways leading to cell proliferation. Other workers similarly 
have demonstrated that Tax induces apoptosis in cells following withdrawal of cell survival 
signals (Sakurai et a l 1992b, Yamada ef al 1994, Fujita and Shiku 1995). Expression of Rex, 
p2l"*, Tof, p13" or p i2* alone had no effect on Rat1 cells in the absence of serum. Co­
expression of these p X  proteins with Tax did not inhibit Tax-induced apoptosis compared to 
expression of Tax alone and there was no evidence of a cooperative effect.
Although no inhibition of c-Myc or Tax-induced apoptosis by other HTLV-I p X  proteins was 
observed in this experimental system, further studies should be undertaken to explore the 
functions of HTLV-I pXgene products in other systems for detecting anti-apoptotic effects. It 
would be highly desirable to develop an inducible HTLV-I tax gene expression system such 
as a cell line stably transfected with a fax-ER™ plasmid construct. This would allow 
interactions between fax and other HTLV-I p X  proteins to be explored in a more tightly 
controlled system.
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5.5 Conclusions
The studies reported in this thesis have demonstrated no evidence for infection with HTLV-I 
or related viruses in patients with MF/SS or other CTCLs in Scotland using PGR and cell 
culture. PGR studies also showed no indication of HTLV-I, HTLV-II or BLV infection in cases 
of LGL leukaemia in the UK or in a cluster of ALL in butchers from the Gard iff region. The 
HTLV-I Tax protein was shown to induce apoptosis in rodent fibroblasts upon withdrawal of 
serum, whereas other HTLV-I pX  gene products failed to inhibit Tax or c-Myc-induced 
apoptosis.
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Appendix 1: Nucleotide and peptide sequences of HTLV-1 pX region gene products.
Tax
1 ATGGCCCACTTCCCAGGGTTTGGACAGAGTCTTCTTTTCGGATACCCAGT M A H F P G F G Q S L L F G Y P V
51 CTACGTGTTTGGAGACTGTGTACAAGGCGACTGGTGCCCCATCTCTGGGG Y V F G D C V Q G D W C P I S G
101 GACTATGTTCGGCCCGCCTACATCGTCACGCCCTACTGGCCACCTGTCCA G L C S A R L H R H A L L A T C P
151 GAGCATCAGATCACCTGGGACCCCATCGATGGACGCGTTATCGGCTCAGC E H Q I T W D P I D G R V I G S A
201 TCTACAGTTCCTTATCCCTCGACTCCCCTCCTTCCCCACCCAGAGAACCT L Q F L I P R L P S F P T Q R T
251 CTAAGACCCTCAAGGTCCTTACCCCGCCAATCACTCATACAACCCCCAAC S K T L K V L T P P I T H T T P N
301 ATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCCCCTTCCGAAA I P P S F L Q A M R K Y S P F R N
3 51 TGGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTGTCTTTTC G Y M E P T L G Q H L P T L S F
401 CAGACCCCGGACTCCGGCCCCAAAACCTGTACACCCTCTGGGGAGGCTCC P D P G L R P Q N L Y T L W G G S
451 GTTGTCTGCATGTACCTCTACCAGCTTTCCCCCCCCATCACCTGGCCCCT V V C M Y L Y Q L S P P I T W P L
501 CCTGCCCCACGTGATTTTTTGCCACCCCGGCCAGCTCGGGGCCTTCCTCA L P H V I F C H P G Q L G A F L
551 CCAATGTTCCCTACAAGCGAATAGAAGAACTCCTCTATAAAATTTCCCTC T N V P Y K R I E E L L Y K I S L
601 ACCACAGGGGCCCTAATAATTCTACCCGAAGACTGTTTGCCCACCACGCT T T G A L I I L P E D C L P T T L
651 TTTCCAGCCTGCTAGGGCACCCGTCACGCTAACAGCCTGGCAAAACGGCC F Q P A R A P V T L T A W Q N G
701 TCCTTCCGTTCCACTCAACCCTCACCACTCCAGGCCTTATTTGGACATTT L L P F H S T L T T P G L I W T F
751 ACCGATGGCACGCCTATGATTTCCGGGCCCTGCCCTAAAGATGGCCAGCC T D G T P M I S G P C P K D G Q P
801 ATCTTTAGTACTACAGTCCTCCTCCTTTATATTTCACAAATTTCAAACCA S L V L Q S S S F I F H K F Q T
851 AGGCCTACCACGCCTCATTTCTACTCTCACACGGGCTCATACAGTACTCT K A Y H P S F L L S H G L I Q Y S
901 TCCTTTCATAGTTTACATCTCCTGTTTGAAGAATACACCAACATCCCCAT S F H S L H L L F E E Y T N I P I
951 TTCTCTACTTTTTAACGAAAAAGAGGCAGATGACAATGACCATGAGCCCC S L L F N E K E A D D N D H E P
10 01 AAATATCCCCCGGGGGCTTAGAGCCTCCCAGTGAAAAACATTTCCGAGAA Q I S P G G L E P P S E K H F R E
1051 ACAGAAGTCTGA T E V *
Appendix 1: (continued).
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Rex
1 ATGCCCAAGACCCGTCGGAGGCCCCGCCGATCCCAAAGAAAAAGACCTCC 
M P K T R R R P R R S Q R K R P P
51 AACACCATGGCCCACTTCCCAGGGTTTGGACAGAGTCTTCTTTTCGGATA 
T P W P T S Q G L D R V F F S D
101 CCCAGTCTACGTGTTTGGAGACTGTGTACAAGGCGACTGGTGCCCCATCT 
T Q S T C L E T V Y K A T G A P S
151 CTGGGGGACTATGTTCGGCCCGCCTACATCGTCACGCCCTACTGGCCACC 
L G D Y V R P A Y I V T P Y W P P
201 TGTCCAGAGCATCAGATCACCTGGGACCCCATCGATGGACGCGTTATCGG 
V Q S  I R S P G T P S M D A L S
2 51 CTCAGCTCTACAGTTCCTTATCCCTCGACTCCCCTCCTTCCCCACCCAGA
A Q L Y S S L S L D S P P S P P R
3 01 GAACCTCTAAGACCCTCAAGGTCCTTACCCCGCCAATCACTCATACAACC
E P L R P S R S L P R Q S L I Q P
351 CCCAACATTCCACCCTCCTTCCTCCAGGCCATGCGCAAATACTCCCCCTT 
P T F H P P S S R P C A N T P P
401 CCGAAATGGATACATGGAACCCACCCTTGGGCAGCACCTCCCAACCCTGT 
S E M D T W N P P L G S T S Q P C
451 CTTTTCCAGACCCCGGACTCCGGCCCCAAAACCTGTACACCCTCTGGGGA 
L F Q T P D S G P K T C T P S G E :
501 GGCTCCGTTGTCTGCATGTACCTCTACCAGCTTTCCCCCCCCATCACCTG 
A P L S A C T S T S F P P P S P
551 GCCCCTCCTGCCCCACGTGA 
G P S C P T *
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p2l"
1 ATGGACGCGTTATCGGCTCAGCTCTACAGTTCCTTATCCCTCGACTCCCC 
M D A L S A Q L Y S S L S L D S P
51 TCCTTCCCCACCCAGAGAACCTCTAAGACCCTCAAGGTCCTTACCCCGCC 
P S P P R E P L R P S R S L P R
101 AATCACTCATACAACCCCCAACATTCCACCCTCCTTCCTCCAGGCCATGC 
Q S L I Q P P T F H P P S S R P G
151 GCAAATACTCCCCCTTCCGAAATGGATACATGGAACCCACCCTTGGGCAG 
A N T P P S E M D T W N P P L G S
201 CACCTCCCAACCCTGTCTTTTCCAGACCCCGGACTCCGGCCCCAAAACCT 
T S Q P C L F Q T P D S G P K T
251 GTACACCCTCTGGGGAGGCTCCGTTGTCTGCATGTACCTCTACCAGCTTT 
C T P S G E A P L S A C T S T S F
3 01 CCCCCCCCATCACCTGGCCCCTCCTGCCCCACGTGA 
P P P S P G P S C P T *
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p30" (Tof)
1 ATGGCACTATGCTGTTTCGCCTTCTCAGCCCCTTGTCTCCACTTGCGCTC 
M A L C C F A F S A P C L H L R S
51 ACGGCGCTCCTGCTCTTCCTGCTTTCTCCGGGCGACGTCAGCGGCCTTCT 
R R S C S S C F L R A T S A A F
101 TCTCCGCCCGCCTCCTGCGCCGTGCCTTCTCCTCTTCCTTCCTTTTCAAA 
F S A R L L R R A F S S S F L F K
151 TACTCAGCAATCTGCTTTTCCTCCTCTTTCTCCCGCTCTTTTTTTCGCTT 
Y S A I C F S S S F S R S F F R F
201 CCTCTTCTCCTCAGCCCGTCGCTGCCGCTCACGATGCGTTTCCCCGCGAG 
L F S S A R R C R S R C V S P R
251 GTGGCGCTTTCTCCCCTGGAAGGCCCCGTCGCAGCCGGCCGCGGCTTTCC 
G G A P S P G R P R R S R P R L S
301 TCTTCTAAGGATAGCAAACCGTCAAGCACAGCTTCCTCCTCCTCCTTGTC 
S S K D S K P S S T A S S S S L S
351 CTTTAACTCTTCCTCCAAGGATAATAGCCCGTCCACCAATTCCTCCACCA 
F N S S S K D N S P S T N S S T
401 GCAGGTCCTCCGGGCATGGCACAGGCAAGCATCGAAACAGCCCTACAGAT 
S R S S G H G T G K H R N S P T D
451 ACAAAGTTAACCATGCTTATTATCAGCCCACTTCCCAGGGTTTGGACAGA 
T K L T M L I  I S P L P R V W T E
501 GTCTTCTTTTCGGATACCCAGTCTACGTGTTTGGAGACTGTGTACAAGGC 
S S F R I P S L R V W R L C T R
551 GACTGGTGCCCCATCTCTGGGGGACTATGTTCGGCCCGCCTACATCGTCA 
R L V P H L W G T M F G P P T S S
601 CGCCCTACTGGCCACCTGTCCAGAGCATCAGATCACCTGGGACCCCATCG 
R P T G H L S R A S D H L G P H R
651 ATGGACGCGTTATCGGCTCAGCTCTACAGTTCCTTATCCCTCGACTCCCC 
W T R Y R L S S T V P Y P S T P
701 TCCTTCCCCACCCAGAGAACCTCTAA 
L L P H P E N L *
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p13'
1 ATGCTTATTATCAGCCCACTTCCCAGGGTTTGGACAGAGTCTTCTTTTCG 
M L I I S P L P R V W T E S S F R
51 GATACCCAGTCTACGTGTTTGGAGACTGTGTACAAGGCGACTGGTGCCCC 
I P S L R V W R L C T R R L V P
101 ATCTCTGGGGGACTATGTTCGGCCCGCCTACATCGTCACGCCCTACTGGC 
H L W G T M F G P P T S S R P T G
151 CACCTGTCCAGAGCATCAGATCACCTGGGACCCCATCGATGGACGCGTTA 
H L S R A S D H L G P H R W T R Y
201 TCGGCTCAGCTCTACAGTTCCTTATCCCTCGACTCCCCTCCTTCCCCACC 
R L S S T V P Y P S T P L L P H
251 CAGAGAACCTCTAA 
P E N L *
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p12'
1 ATGCTGTTTCGCCTTCTCAGCCCCTTGTCTCCACTTGCGCTCACGGCGCT 
M L F R L L S P L S P L A L T A L
51 CCTGCTCTTCCTGCTTTCTCCGGGCGACGTCAGCGGCCTTCTTCTCCGCC 
L L F L L S P G D V S G L L L R
101 CGCCTCCTGCGCCGTGCCTTCTCCTCTTCCTTCCTTTTCAAATACTCAGC 
P P P A P C L L L F L P F Q I L S
151 AATCTGCTTTTCCTCCTCTTTCTCCCGCTCTTTTTTTCGCTTCCTCTTCT 
N L L F L L F L P L F F S L P L L
201 CCTCAGCCCGTCGCTGCCGCTCACGATGCGTTTCCCCGCGAGGTGGCGCT 
L S P S L P L T M R P P A R W R
251 TTCTCCCCTGGAAGGCCCCGTCGCAGCCGGCCGCGGCTTTCCTCTTCTAA 
F L P W K A P S Q P A A A F L F *
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Appendix 2: International Union of Pure and Applied Chemistry (lUPAC) International 
Union of Biochemistry (IUB)/Genetics Computer Group (GCG) letter codes for 
nucleotide and amino acid sequences.
The nomenclature for incompletely specified bases in nucleic acid sequences Is also 
depicted. (Nomenclature Committee of the International Union of Biochemistry 1985).
Nucleotides
Purines A  Adenine
G Guanine
Pyrimidines C Cytosine
T/U Thymine/Uracil
lUB/GCG Meaning Complement
A A T
C C G
G G C
T / U T A
M A or C K
R A or G Y
W A or T W
s C or G S
Y C or T R
K G or T M
V A  or c .or G B
H A  or C 'or T D
D A  or G ,or T H
B C or G .or T V
X/N G or A or T or C X
not G or A  ,or T or C
Appendix 2: (continued).
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Amino acids
ÏUB
Ttlbol 3-letter Meaning Codons Depiction
A Al a Alanine GCT,GCC,GCA,GCG GCX
B
C
A s p ,Asn 
Cys
A spartic,
Asparagine
Cysteine
G A T ,G A C ,A A T ,AAC 
TGT,TGC
RAY
TGY
D Asp Aspartic GAT,GAC GAY
E Glu Glutamic GAA,GAG GAR
F Phe Phenylalanine TTT,TTC TTY
G Gly Glycine GGT,GGC,GGA,GGG GGX
H His Histidine CAT,CAC CAY
I Ile Isoleucine A T T ,A T C ,ATA ATH
K Lys Lysine AAA,AAG AAR
L Leu Leucine T T G ,TTA,CTT,C T C ,CT A ,CTG TTR,CTX,YTR;YTX
M Met Methionine ATG ATG
N Asn Asparagine AAT,AAC AAY
P Pro Proline CCT,CCC,CCA,CCG CCX
Q Gin Glutamine CAA,CAG CAR
R Arg Arginine C G T ,C G C ,C G A ,CG G ,A G A ,AGG CGX,AGR,MGR;MGX
S Ser Serine T C T ,T C C ,T C A ,T C G ,A G T ,AGC TCX,AGY;WSX
T Thr Threonine ACT, ACC, ACA,ACG ACX
V Val Valine GTT,GTC,GTA,GTG GTX
W Trp Tryptophan TGG TGG
X Xxx Unknown XXX
Y Tyr Tyrosine TAT, TAC TAY
Z
*
Glu,Gin 
End
Glutamic,
Glutamine
Terminator
GAA,GAG,CAA,CAG 
TAA, TAG, TGA
SAR
TAR,TRA;TRR
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Appendix 3: Sources of frequently used materials.
A & J Beveridge 
Alpha Labs, UK
Alta Bioscience, University of Birmingham
Amersham, Little Chalfont
Applied Biosystems, Warrington
AT Biochem, Malvern, Pennsylvania
BDH (Merck), Poole, Dorset
Beckman Instruments, High Wycombe
Becton Dickinson, Cowley
J Bibby, Stone
Bio-Rad, Hemel Hempstead
Boehringer Manheim, Lewes
British Biotechnology, Abingdon
BRL, Bethesda, Maryland
Cambio, Cambridge
Costar, High Wycombe
Coulter, Luton
Da ko, Glostrup, Denmark
Difco, East Molesey
Fisons Scientific Equipment, Loughborough
Fotodyne, New Berlin, Wisconsin
Genetic Research Instrumentation, Dunmow
Genosys, Cambridge
Greiner Labortechnik, Dursley
Hybaid, Teddington
ICN Biomedicals, Thame
International Laboratory Services, UK
Invitrogen, San Diego, California
J.Bio, Les Ulis Cedex, France
Leo Labs, UK
Life Technologies, Gibco BRL, Paisley 
Millipore, Watford
MSE, supplied by Philip Harris, Paisley
Bando Chemical Industries, Nippon Shoji Kaisha, Japan
Nunc, supplied by Philip Harris, Paisley
Unipath, Basingstoke
Perkin-Elmer, Beaconsfield
Pharmacia LKB Biotechnology, St Albans
Philip Harris Scientific, Clydebank
Polaroid, St Albans
Promega, Southampton
Qiagen, Chatsworth, California
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Rathburn Chemical Company, UK
Sarstedt, Beaumont Leys Schleicher & Schuell, West Germany
Scotlab Bioscience, Coatbridge
Sigma Chemical Company, Poole
Stratagene, Cambridge
Surgikos, Johnson & Johnson, Livingston
Techne, Cambridge
UVP, San Gabriel, California
Vector Laboratories, Burlingame, California
Whatman, Maidstone
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Appendix 4: List of commonly used reagents, stock solutions and buffers for cell 
culture, immunophenotyping and reverse transcriptase assay.
A4.1 Tissue culture disposable plastic-ware
50 cm^, 75 cm^ and 250 cm^ screw-top tissue culture flasks (Costar)
96-well microtitre tissue culture plate (Costar)
12-well tissue culture plate (Costar)
1, 5, 10 and 25 ml disposable filter-plugged polycarbonate pipettes (Costar)
5, 15 and 50 ml screw-top polypropylene centrifuge tubes (Falcon and Greiner)
0.6 and 1.5 ml flip-top and screw-top polypropylene microcentrifuge tubes (Elkay, Treff and 
Eppendorf, supplied by Scotlab)
20 ml screw-top polycarbonate Universal tube (Scotlab)
5 ml screw-top polycarbonate bijou (Scotlab)
1, 2.5, 5, 10 and 20 ml syringes (Scotlab)
0.2 and 0.45 pm sterile filters (Acrodisc, Gelman Sciences, supplied by Scotlab)
250 and 500 ml bottle filter systems with 0.2 or 0.45 pm cellulose acetate filter (Costar, 
Nalgene)
Cell scraper (Costar)
Sterile Petri dish, non-tissue culture grade (Scotlab)
Sterile Petri dish, tissue culture grade (Nunclon, Nunc)
Sterile plastic bulb pastettes (Scotlab)
Cryotubes (Nunc)
30 ml Corex glass centrifuge tubes (Sarstedt)
A4.2 Media for handling and culturing cells 
A4.2.1 Standard tissue culture medium
A4.2.1.1 RPMI 1640 + 10% hi-FBS + 2ME 
500 ml RPMI 1640 (Life Technologies)
50 ml heat-inactivated FBS (hi-FBS) (final concentration: nominal 10%; actual 8.7% FBS)
5 ml 200 mM (29.2 g/L) L-glutamine (final concentration: nominal 600 mg/L, 4 mM; actual 
296 mg/L, 2 mM)
20 ml 1 X lO'^  U/ml penicillin (final concentration: nominal 400 U/ml; actual 348 U/ml) and 1 x 
10"^  pg/ml streptomycin (final concentration: nominal 400 mg/ml; actual 348 pg/ml)
500 pL 5 X 10'  ^M 2 (P) mercaptoethanol (2ME) (final concentration: nominal: 5x10'® M; 
actual 4 X 10'® M)
Stored at 4°C
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A4.2.1.2 RPMI 1640 + 20% hi-FBS + 2ME 
500 ml RPMI 1640
100 ml hi-FBS (final concentration: nominal 20%; actual 16% FBS)
5 ml 200 mM L-glutamine (final concentration: nominal 4 mM; actual 3.2 mM)
20 ml 1 X 10"^  U/ml penicillin (final concentration: nominal 400 U/ml; actual 320 U/ml) and 1x 
10"^  pg/ml streptomycin (final concentration: nominal 400 mg/ml; actual 320 pg/ml)
500 pL 5 X 10'^ M 2 2ME (final concentration: nominal: 5 x10  ® M; actual 4x10® M)
Stored at 4°C
A4.2.1.3 Dulbecco’s Modified Eagle’s Medium (DMEM) + 10% hi-FBS + 2ME
Dulbecco's Modified Eagle Medium with sodium pyruvate and 1x10® mg/L glucose (Life 
Technologies)
50 ml charcoal-dextran-stripped (cds)-hi-FBS (final concentration: nominal 10%; actual 8.7% 
FBS)
5 ml 200 mM L-glutamine (final concentration: nominal 4 mM; actual 2 mM)
20 ml 1 X 10"^  U/ml penicillin (final concentration: nominal 400 U/ml; actual 348 U/ml) and 1 x 
lO'’ pg/ml streptomycin (final concentration: nominal 400 mg/ml; actual 348 pg/ml)
500 pL 5 X 10'  ^M 2ME (final concentration: nominal: 5x10'® M; actual 4 x 1 0  ® M)
Stored at 4°C
A4.2.2 Transport medium
500 ml RPMI 1640
100 ml hi-FBS (final concentration: nominal 20%; actual 15% FBS)
5 ml 200 mM L-glutamine (final concentration: nominal 4 mM; actual 1.5 mM)
20 ml 1 X 10'^  U/ml penicillin (final concentration: nominal 400 U/ml; actual 300 U/ml) and 1 x  
10"^  pg/ml streptomycin (final concentration: nominal 400 mg/ml; actual 300 pg/ml)
5 ml 250 pg/ml amphotericin B (final concentration: 2 pg/ml)
7.5 ml 10 mg/ml gentamicin (final concentration: 100 pg/ml)
12.5 ml 1 M N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES) buffer (final 
concentration: 20 mM)
500 pL 5 X 10'  ^M 2ME (final concentration: nominal: 5x10'® M; actual 4 x 10'® M)
300 pi 1x10® U/ml heparin (final concentration: 0.45 U/ml)
Stored at 4‘^ C
A4.2.3 Additives for tissue culture medium
Heat-Inactivated foetal bovine serum (hi-FBS) (Foetal calf serum, Life Technologies) 
Heat-inactivated at 56^C for 30 min 
Stored at -20°C
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200 mM L-glutamine 200 (Life Technologies)
292 mg in 10 ml ultrapure water 
Stored at -20°C
1 X 10"* U/ml penicillin (Life Technologies)
Stored at -20°C
1x10"^ pg/ml streptomycin (Life Technologies)
Stored at -20°C
10 mg/ml gentamicin (Life Technologies)
Stored at 4°C
250 pg/ml amphotericin B (Fungizone, Life Technologies)
2.5 g in 50 ml deionised water 
Filter sterilised 
Stored at -20°C
50 mM 2-(p)-mercaptoethanol (2-ME) (Sigma)
39 mg in 10 ml HBSS 
Stored at room temperature
1x10® U/ml preservative-free heparin (Leo Labs)
Stored at 4°C
1 M N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES) buffer (Life 
Technologies)
Stored at room temperature
100 mg/ml a  methylmannoside (methyl a-D-mannopyranoside) (Sigma)
1 g in 10 ml RPMI 1640 + 20% hi-FBS + 2ME 
Filter sterilised 
Stored at -20°C
Dimethyl sulphoxide (DMSO) (Sigma)
Stored at 4°C
0.2% w/v trypan blue (Sigma)
20 mg in 10 ml PBS 1x with 3 mM NaNs 
Stored at room temperature
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Tissue culture grade distilled water (Life Technologies)
Stored at room temperature
A4.2.4 Solutions for suspending viable cells
Phosphate-buffered saline (PBS) 1x (Dulbecco’s Phosphate-Buffered Saline without Mg^ or 
Ca^ ,^ Life Technologies)
Stored at room temperature
Phosphate-buffered saline (PBS) 10x (Dulbecco’s Phosphate-Buffered Saline pH 7.4 without 
Mg^  ^or Ca^ '*', Life Technologies)
Stored at room temperature
Hanks’ balanced saline solution (HBSS) + 2% hi-FBS 
500 ml Hanks’ balanced saline solution (Life Technologies)
10 ml hi-FBS (final concentration: 2%)
Stored at 4°C
Tris-NaCI-EDTA (TNE) 1x 
0.1 M NaCI 
10 mM Tris.Cl
1 mM ethylenediaminetetraacetic acid (EDTA)
Adjusted to pH 8.0 
Stored at room temperature
A4.2.5 Solutions for dissociating cells and tissues
Trypsin-EDTA
0.25% crude trypsin (Sigma)
1 M EDTA 
Stored at -20°C
100 U/ml dispase II (Boehringer Manheim)
0.5 g (250 U) in 10 ml PBS 1x without Ca^  ^or Mg^
Filter sterilised 
Stored at -20°C
A4.2.6 Mitogens and cytokines
0.5 mg/ml phytohaemagglutinin-P (PHA-P, Sigma)
Filter sterilised 
Stored at -20°C
328
Appendix 4: (continued).
0.5 mg/mi concanavalin A (ConA, Sigma or Boehringer Mannheim) 
5 mg in 10 ml RPMI 1640 + 20% hi-FBS + 2ME 
Filter sterilised 
Stored at -20°C
5 U/pl interleukin 2 (IL2, Interleukin-2, human recombinant, Amersham) 
50 |Ltg (1.5x10^
Stored at -20°C
.5 i c f u )  dissolved in 30 ml RPMI 1640 + 20% hi-FBS + 2ME
5 pg/ml interleukin 4 (IL4, hlL-4, recombinant Interleukin 4, human sequence, R & D 
Systems, British Biotechnology)
5 pg (2 X 10  ^to 5 X 10  ^U) dissolved in 1 ml PBS 1x containing 0.1% BSA 
Stored at -20°C
1 pg/ml interleukin 7 (IL7) (hlL-7, recombinant interleukin 7, human sequence, R & D 
Systems, British Biotechnology)
5 pg (2 X 10  ^to 5 X 10  ^U) dissolved in 5 ml PBS 1x containing 0.1% BSA 
Stored at -20°C
1x10^ U/ml granulocyte-macrophage colony stimulating factor (GMCSF, GM-CSF, human 
recombinant, Boehringer Mannheim) in PBS 1x containing 0.1% BSA 
Stored at -20°C
A4.3 Reagents for immunophenotyping cultured lymphocytes by flow cytometry 
A4.3.1 Stock solutions
10% sodium azide (Sigma)
10 g in 100 ml sterile ultrapure water 
Filter sterilised 
Stored at 4°C
PAB
100 ml PBS lOx (final concentration: PBS 1x)
10 ml 10% sodium azide (final concentration: 0.1%)
2 g bovine serum albumin (final concentration: 2% w/v)
Made up to 1 L with deionised water
Filter sterilised 
Stored at 4°C
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20% rabbit serum in PAB
100 )ul rabbit serum (Dako). Heat inactivated at 56° for 30 min. Filter sterilised. Stored at - 
20°C
400 pi PAB
1% paraformaldehyde in PBS 1x
10 g paraformaldehyde (BDH) in 450 ml deionised water (heated to 70°C)
Adjusted to pH 7.4 with 1 M NaOH 
50 ml PBS lOx 
Filter sterilised
20% paraformaldehyde in PBS 1x
10 g paraformaldehyde (BDH) in 20 ml deionised water (heated to 70°C)
Adjusted to pH 7.4 with 1 M NaOH 
5 ml PBS lOx 
Filter sterilised
A 4.3.2 Monoclonal antibodies
Mouse anW-Aspergillus n/gerglucose oxidase IgGI-FITC k  chain (X927, Dako)
100 pg/ml in 0.05 M Tris.HCI pH7.2, 15 mM NaNs and 1% BSA (negative control)
Mouse anti-A n/ger glucose oxidase IgGI-FITC + IgGI-RPE k  chain (X932, Dako) in 0.05 M 
Tris.HCI pH7.2, 15 mM NaNs and 1% BSA (negative control)
Mouse anti-CD2-FITC + anti-CD 19-RPE IgGI k  chain (FR894, Dako) in 0.05 M Tris.HCI 
pH7.2, 15 mM NaNs and 1% BSA
Mouse anti-CD8-FITC + anti-CD4-RPE IgGI k  chain (FR885, Dako) in 0.05 M Tris.HCI 
pH7.2, 15 mM NaNs and 1% BSA
Mouse anti-CD15-FITC IgM k  chain (F830, Dako)
75 pg/ml in 0.05 M Tris.HCI pH7.2, 15 mM NaNs and 1% BSA
Mouse anti-CD30-FITC IgGI k  chain (F849, Dako)
100 pg/mi in 0.05 M Tris.HCI pH7.2, 15 mM NaNs and 1% BSA
Mouse anti-CD33-FITC IgGI k  chain (F832, Dako)
100 pg/ml in 0.05 M Tris.HCi pH7.2, 15 mM NaNs and 1% BSA
Mouse anti-CD45 (LCA)-FITC IgGI k  chain (F796, Dako)
100 pg/ml in 0.05 M Tris.HCi pH7.2, 15 mM NaNs and 1% BSA
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A4.4 Reagents for conventional reverse transcriptase assay 
A4.4.1 Stock solutions
0.1 M Dithiothreitol (DTT) (Sigma)
1.54 g in 100 ml ultrapure water 
Stored at room temperature
2% Nonidet P-40 (NP-40) (Sigma)
2 ml plus 98 ml ultrapure water 
Stored at room temperature
0.8 M Tris pH 8.1 (Trizma-8.1, Sigma)
5.59 g in 50 ml ultrapure water 
Stored at room temperature
3 M NaCI (Sigma)
17.53 g in 100 ml ultrapure water 
Stored at room temperature
Tris pH 8.1, 0.15 M NaCI 
2.80 g Trizma-8.1
1.25 ml 3 M NaCI
Made up to 25 ml with ultrapure water 
Stored at room temperature
1 M KCI (Sigma)
7.46 g in 100 ml ultrapure water 
Stored at room temperature
20 mM MnCIs (Sigma)
396 mg in 100 ml ultrapure water 
Stored at room temperature
0.1 M MgCIs (Sigma)
952 mg in 100 ml ultrapure water 
Stored at room temperature
100% trichloroacetic acid (TCA) (BDH)
500 g in 500 ml ultrapure water 
Stored at room temperature
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10% TCA, 1% w/v sodium pyrophosphate (NaPPj)
50 ml 100% TCA 
5 g NaPPj (Fisons)
Made up to 500 ml with ultrapure water 
Stored at room temperature
5% TCA, 1% w/v tetrasodium pyrophosphate (NasPgOy, NaPP,)
25 ml 100% TCA 
5 g NaPPi (Fisons)
Made up to 500 mi with ultrapure water 
Stored at room temperature
5% TCA
50 ml 100% TCA
Made up to 1 L with ultrapure water on day of use 
Cooled to 4°C before use
5 U/ml Poly(rA).p(dT)i2-i8 (Pharmacia)
5 U precipitate (15.7 A260 units/mg) in 1 mi ultrapure water 
Stored at -20°C
5 U/ml Poiy(dA).p(dT)i2-i8 (Pharmacia)
5 U precipitate (16.0 A260 units/mg) in 1 ml ultrapure water 
Stored at -20°C
Ethanol 98% (Absolute alcohol, BDH)
A4.4.2 Virus disruption buffer
20 ml 0.1 M DTT 
5 ml 2% NP-40 
5 ml 0.8 M Tris pH 8.1 
5 ml 1 M KCI
Made up to 95 ml with ultrapure water 
Stored at -20°C
A4.4.3 Tritiated thymidine triphosphate
Tritlated thymidine triphosphate (^H-TTP) [methyl-^H] thymidine 5’-triphosphate, ammonium 
salt (Amersham) 37 MBq/ml (1 mC/ml) dissolved in 50% ethanol and 50% water 
Stored at 4°C
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A4.5 Reagents for eucaryotic expression
100 mg puromycin (P-7255, Sigma)
5 g geneticin (G-418 sulphate, Life Technologies)
1 mM 4-hydroxytamoxifen (Tamoxifen, T-5648, Sigma)
100 mg dissolved in 27 ml absolute alcohol 
Stored at -20°C
10 pM hydroxytamoxifen 
50 pi 1 mM hydroxytamoxifen 
450 pi absolute alcohol
A4.6 Reagents for propidium iodide staining
Acetic acid-alcohol fixative 
5 ml glacial acetic acid 
95 ml ethanol
Stored at room temperature 
4M  HCI
34.5 ml concentrated HCI (specific gravity 1.18)
Made up to 100 ml with ultrapure water
0.1 M sodium borate 
3.8 g sodium borate 
Made up to 100 ml with ultrapure water
500 pg/ml propidium iodide 
5 mg propidium iodide (Propidium I, Sigma)
Made up to 10 mi with PBS 1x
50 mg/ml RNase A (Sigma) in PBS 1x
Propidium iodide/RNase A staining solution
50 pi 500 pg/ml propidium iodide (final concentration: 5 pg/ml)
10 pi 50 mg/ml RNase A (final concentration: 100 pg/ml)
Made up to 5 ml with PBS 1x
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A4.7 Reagents for mycoplasma testing
Hoescht 33258 [2(4-hydroxyphenyl)-5[5-(4-methylpiperazine“1 -yl)- 
benzimidazol-2-yl]benzimidazole](bisbenzimide) (Sigma)
1 mg/ml in HBSS without phenol red or bicarbonate
Methanohglacial acetic acid (3:1)
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Appendix 5: List of commonly used reagents, stock solutions and buffers for 
molecular biology. 
A5.1 Disposable plastlcware
0.1-2 pi, 0.5-10 pi, 2-200 pi and 50-1,000 pi mi crop I pattes (Gilson, Sealpette)
2-25 pi and 10-50 pi positive (direct) displacement pipettes (Gilson)
0.1-2 pi, 0.5-10 pi, 2-200 pi and 50-1,000 pi micropipette tips (Greiner)
0.1-2 pi, 0.5-10 pi, 2-200 pi and 50-1,000 pi filter-plugged micropipette tips (Greiner)
2-25 pi and 10-50 pi positive (direct) displacement tips (Gilson)
5-50 pi fine gel-loading pipette tips (Greiner)
1,5, 10 and 25 ml disposable filter-plugged polycarbonate pipettes (Costar)
5, 15 and 50 ml screw-top polypropylene centrifuge tubes (Falcon and Greiner)
0.6 and 1.5 ml flip-top and screw-top polypropylene microcentrifuge tubes (Elkay and Treff) 
20 ml screw-top polycarbonate Universal tube (Scotlab)
5 ml screw-top polycarbonate bijou (Scotiab)
1, 2.5, 5, 10 and 20 ml syringes (Scotlab)
Narrow-bore polypropylene bulb pastette (Alpha Labs)
Wide-bore polypropylene bulb pastette (Alpha Labs)
14 ml (17 mm x 100 mm) polypropylene 2059 tubes (Falcon)
Petri dishes (Fisons)
A5.2 General laboratory solutions and buffers
Tris-EDTA (TE) 1x 
10 mM Tris.HCi pH 8.0
1 mM EDTA
Tris-boric acid-EDTA (TBE) 1x 
90 mM Tris.CI 
90 mM boric acid
2.25 mM EDTA 
Adjusted to pH 8.0
Tris-acetio acid-EDTA (TAE) 1x 
40 mM Tris.CI pH 8.0 
20 mM sodium acetate 
20 mM sodium chloride
2 mM EDTA 
Adjusted to pH 8.0
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Tris-NaCI-EDTA (TNE) 1x 
10 mM Tris.CI 
100 MM NaCI 
1 mM EDTA 
Adjusted to pH 8.0
20% sodium dodecyl sulphate (SDS)
A5.3 Reagents for restriction endonuclease digestion of DNA
A5.3.1 Restriction endonucleases
Restriction endonucleases (Life Technologies). 10 or 40 U/jul 
BamH\
EcoR\
EcoRV
Hind\\\
Pst\
Sst\
Xba\
Xho\
A5.3.2 Additives for restriction endonuclease digests
100 mM (5 mg/ml) Sonicated salmon sperm DNA, GeneBloc, International Laboratory 
Services)
Boiled for 5 min then placed on Ice before adding to RE digests 
Restriction buffers 10 x (Life Technologies)
50 mg/ml RNase A (Sigma) in PBS 1x
A5.4 Reagents for the polymerase chain reaction
10 X dNTPs
10 mM each deoxynucleoside triphosphates (dATP, dGTP, dCTP, dUTP or dTTP) (Cambio)
10 X PCR buffer (Perkin-Elmer)
15 mM MgCIa
500 mM KCi
100 mM Tris pH 8.2
0.5% Nonidet P-40 (NP-40)
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Taq polymerase
5 U/pl Thermus aquaticus (Taq) thermostable DNA polymerase (Amplitaq DNA polymerase, 
Perkin-Elmer)
25 mM MgCb (Perkin-Elmer)
A5.5 Reagents for processing cells and tissues for the polymerase chain reaction
Non-ionic detergent buffer (NIB)
PCR buffer 1x (1.5 mM MgCb, 50 mM KCI, 10 mM Tris pH 8.2, 100 pg/ml gelatin) (Perkin- 
Elmer)
0.45% Nonidet P-40 (NP-40) (Sigma)
0.45% Tween-20 (polyoxyethyiene (20)-sorbitan monolaurate, BDH)
1 pg/pl proteinase K (Sigma)
10 mg in 10 ml ultrapure water 
Stored at -20°C
10 pg/pl proteinase K (Sigma)
10 mg in 1 ml ultrapure water 
Stored at -20°C
A5.6 Reagents for gel electrophoresis
A5.6.1 DNA Size Markers
100 ng/pl PhlX174 bacteriophage DNA digested with Hae\i\ (0X174 RF DNA/Haelll Frag, 
Life Technologies) (1353, 872, 603, 310, 281, 271, 234, 194, 118, 72 bp)
Lambda bacteriophage DNA digested with Hind III {XHIndWl, Life Technologies) (23100, 
9400, 6600, 4400, 2300, 2000, 560 bp)
A5.6.2 Loading buffer/dye and ethidium bromide
Gel loading buffer/dye 5x 
0.42% bromophenol blue 
0.42% xylene cyanole 
50% glycerol
Made up to 100% with deionised water 
10 mg/ml ethidium bromide (Sigma)
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AS.6.1 Polyacrylamide gel electrophoresis
8% polyacrylamide gels
26 ml 30% acrylamide (Northumbria Biologicals)
13 ml 2% bis-acrylamide (Northumbria Biologicals)
10 ml TBElOx
2.2 ml 3% ammonium persulphate (APS)
30 pL N,N,N’,N’-tetramethylethylenediamine (TEMED)
Made up to 100 ml with water
Elution buffer
0.5 M ammonium acetate
1 mM EDTA
AS. 6.2 DNA agarose gel electrophoresis
Agarose (Sigma)
Low melting point agarose (Nusieve)
Diethylamlnoethyl (DEAE) membrane (Schleicher & Schuell) 
1 U/ml Gelase (Cambio)
5 M ammonium acetate
AS.7 Solutions for electroblotting and Southern blotting
Alkali (denaturing) buffer
438.3 g NaCI (final concentration: 1.5 M)
100 g NaOH (final concentration: 0.5 M)
Made up to 2 L with deionised water
Neutralising buffer pH 8.0
303.5 g Tris base
876.6 g NaCI 
165 ml HCI
Made up to 5 L with deionised water 
Adjusted to pH 8.0
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Sodium saline citrate (SSC) 20x 
3 M NaCI
0.3 M trisodium citrate
Adjusted to pH 7.0 with 10 M or 0.1 M NaOH
Transfer buffer SSC lOx 
500 ml SSC lOx 
Made up to 1 L with water
SSC 24x
1 kg NaCI (final concentration: 3.6 M)
500 g sodium citrate (final concentration: 0.36 M)
Made up to 4.7 L with water
Transfer buffer SSC lOx (9.6x)
400 ml SSC 24x 
Made up to 1 L with water
Rinse buffer SSC 3x 
250 ml SSC 24x 
Made up to 1 L with water
A5.8 Reagents for radiolabelling probes 
A 5.8.1 Random priming
Multiprime Kit (RPN.1601Y, Amersham)
Multiprime buffer solution/nucleotide mix. dATP, dGTP and dTTP in concentrated buffer 
solution containing Tris.HCi pH 7.8, MgCb and 2-mercaptoethanol (2ME)
Primer solution/primer-BSA containing random hexanucleotides and bovine serum albumin 
(BSA)
Enzyme solution/Klenow 1 U/pl containing 1 U/pl DNA poiymerase I “Klenow" fragment in 50 
mM potassium phosphate pH 6.5, 10 mM 2ME and 50% giycerol
a ^^P dCTP (R82075, Amersham)
370 MBq/ml (10 mCi/ml) a ^^P dCTP. Specific activity 30 TBq/mmol (800 Ci/mmol)
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AS. 8.2 S’ end-labelling
T4 kinase buffer 10x 
500 mM Tris.HCi pH 7.5 
100 mM MgClz 
50 mM dithiothreitol (DTT)
1 mM spermidine 
1 mM EDTA pH 8.0
10 U/pl T4 polynucleotide kinase
^32p a t p (R85132, ICN)
370 MBq/ml (10 mCi/ml) y ^^P ATP. Specific activity 111 MBq/mmoi (3000 Ci/mmol)
A5.9 Reagents for hybridisation 
AS.9.1 Hybridisation solution
Standard hybridisation soiution (50% formamide, SSC 3x)
500 ml 100% formamide (final concentratiobn: 50%)
50 ml Denhardt’s solution lOOx (final concentration: 5x)
5 ml 20% SDS (final concentration: 0.1%)
50 ml 1 M Tris pH 7.4 (final concentration: 50 mM)
20 ml 0.5 M EDTA (final concentration: 10 mM)
125 ml SSC 24x (final concentration: SSC 3x)
250 mg Sonicated salmon sperm DNA (GeneBloc, International Laboratory Services). Boiled
for 5 min then placed on ice
Made up to 1 L with deionised water
Denhardt's solution lOOx 
2% Ficoil
2% bovine serum albumin (Fraction V)
2% polyvinylpyrolidine
AS.9.2 Wash solutions
SSC3X, 0.1% SDS
30 ml SSC 24x
1.2 ml 20% SDS
Made up to 240 ml with water
340
Appendix 5: (continued).
SSC 2x, 0.1% SDS 
100 m is s e  20x 
5 ml 20% SDS 
Made up to 1 L with water
SSC0.5X, 0.1% SDS 
25 ml SSC 20x 
5 ml 20% SDS 
Made up to 1 L with water
A5.10 Media and reagents for cultivation of bacteria 
A5.10.1 Media
Luria-Bertani (LB) broth 
10 g tryptone (Unipath)
5 g yeast extract (Unipath)
10 g NaCI (BDH)
Made up to 1 L with water 
Sterilised by autoclaving
LB agar
10 g tryptone (Unipath)
5 g yeast extract (Unipath)
10 g NaCI (BDH)
15 g bacteriological agar (Number 1, Unipath)
Made up to 1 L with water 
Sterilised by autoclaving
SOC medium
20 g tryptone
5 g yeast extract
500 mg NaCI
200 mg KCI
10 ml 1 M MgCl2
10 ml 1 M MgS0 4
1 ml 2 M glucose
Made up to 1 L with water
Sterilised by autoclaving
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A5.10.2 Antibiotics
50 mg/ml ampicillln 
12 mg/ml tetracycline 
100 mg/ml chloramphenicol 
20 mg/ml kanamycin
AS. 10.3 Additives for blue-white screening
0.2 M isopropyl-1-thio-p-D-galactoside (IPTG)
40 mg/ml 5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-gal) 
100 mg dissolved in 2.5 ml dimethyl formamide 
Protected from light 
Stored at -20°C
AS.10.4 Additives for bacterial transformation
500 mM 2-(p)-mercaptoethanol (2-ME) (Sigma)
5 pi 1.12 g/ml (14.3 M) 2-ME stock solution 
138 pi sterile ultrapure water
A5.11 Reagents for extraction of plasmids from bacteria
AS. 11.1 Modified alkaline lysis
Solution I 
50 mM glucose 
25 mM Tris.CI pH 8.0 
10 mM EDTA pH 8.0
Solution II 
0.2 M NaOH 
1% SDS
Solution III
3 M potassium acetate
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3 M potassium acetate pH 4.8 
60 ml 5 M potassium acetate
11.5 ml glacial acetic acid 
Make up to 100 ml with water
AS. 11.2 Boiling method
Sucrose-Triton X-100-EDTA-Tris (STET)
8% sucrose 
0.5% Triton X-100 
50 mM EDTA pH 8.0 
10 mM Tris pH 8.0
AS.12 Reagents for sequencing
A5.12.1 Sequencing primers
M l3  5 '  > G T A A A A C G A C G G C C A G T  <  3 "
T3 5 "  > A A T T A A C C C T C A C T A A A G G G  <  3 "
T7 5 "  > G T A A T A C G A C T C A C T A T A G G G C  <  3 "
SP6 5 '  > A T T T A G G T G A C A C T A T A G A A T A T  <  3 "
A5.12.2 ^^Sequencing Kit (Pharmacia)
T7 DNA polymerase 8 U/pl in buffered glycerol
Sequencing mixes ('A', 'C, ‘G’ or T  mix-short) in 40 mM Tris.HCi pH 7.6 and 50 mM NaCI 
‘A’ mix-short: 840 pM each dCTP, dGTP and dTTP, 93.5 pM dATP, 14 pM ddATP 
‘C’ mix-short: 840 pM each dATP, dGTP and dTTP, 93.5 pM dCTP, 17 pM ddCTP 
‘G’ mix-short: 840 pM each dATP, dCTP and dTTP, 93.5 pM dGTP, 14 pM ddGTP 
'V  mix-short: 840 pM each dCTP, dGTP and dGTP, 93.5 pM dTTP, 14 pM ddTTP
Universal primer 
5 pM M13
Annealing buffer 
1 M Tris.HCi pH7.6 
100 mM MgCb 
160 mM DTT
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Enzyme dilution buffer 
20 mM Tris.HCi pH 7.5 
5 mM DTT
100 pg/ml bovine serum albumin (BSA)
5% glycerol
Labelling mix-dATP
1.375 pM each dCTP, dGTP and dTTP
333.5 mM NaCI
Stop solution 
97.5% formamide 
10 mM EDTA pH 7.5 
0.3% bromophenol blue 
0.3% xylene cyanole
A5.12.3 ^^S-labelled dATP radioisotope
a ^^ S dATP (SJ1304, Amersham)
9.25 MBq/pl (250 pCi/pl) a ^^ S dATP. Specific activity 37 TBq/mmol (1000 Ci/mmol)
A5.12.4 Polyacrylamide sequencing gel 
5% sequencing gel mix (non-setting)
10 ml Long Ranger DNA sequencing gel solution Hydro-Link (AT Biochem) 50% concentrate 
6 mi TBElOx 
42 g urea
Make up to 100 ml with deionised water
5% polyacrylamide gel mix (setting)
100 ml 5% sequencing gel mix 
500 pi 10% APS 
50 pi TEMED
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A5.13 Northern blot hybridisation 
AS. 13.1 Reagents for RNA extraction
0.05% diethyl pyrocarbonate (DEPC) in ultrapure water
EDTA-SDS-DEPC
1 mM EDTA pH 7.0 
0.5% SDS
Made with 0.05% DEPC in uitrapure water 
AS. 13.2 Reagents for RNA gel electrophoresis
3-(N-morpholino)-2-hydroxypropane sulphonic acid (MOPS) buffer 10x
41.8 g MOPS
6.8 g sodium acetate (final concentration: 0.05 M)
3.7 g EDTA (final concentration: 5 mM)
Made up to 1 L with water 
Adjusted to pH 7.0 with 10 M NaOH
1% agarose gel with MOPS 1x and 6% formaldehyde
2 g agarose dissolved in 147 mi water by boiling 
20 ml MOPS lOx
33 ml 37% formaldehyde (Analar). Warmed to 37°C
Formamide buffer 
500 pi MOPS lOx 
830 pi 37% formaldehyde
2.5 ml formamide
RNA loading buffer/dye 
50% glycerol 
1 mM EDTA 
0.4% bromophenol blue
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Appendix 6: Complete nucleotide sequence of human T lymphotropic virus type I
proviral DNA.
GenBank Accession number J02029 (9068 bp) (Seiki et al 1983). Oiigonucleotide primer 
sequences for PCR are underlined (overlined, shaded or emboldened where overlapping) 
and annotated at right.
1 ggaaaaactt ggagtgtagt tctgacaatg accatgagcc ccaaatatcc cccgggggct
61 tagagcctcc cagtgaaaaa catttccgag aaacagaagt ctgaaaaggt cagggcccag
121 actaaggctc tgacgfcctcc ccccggaggg cagctcagca ccggctcggg ctaggccctg
181 acgtgtcccc ctgaagacaa atcataagct cagacctccg ggaagccacc aagaaccacc
241 catttcctcc ccatgtttgt caagccgtcc tcaggcgttg acgacaaccc ctcacctcaa
3 01 aaaacttttc atggcacgca tatggctcaa taaactagca ggagtctata aaagcgtgga
361 gacagttcag gagggggctc gcatctctcc ttcacgcgcc cgccgcccta cctgaggccg
421 ccatccacgc cggttgagtc gcgttctgcc gcctcccgcc tgtggtgcct cctgaactgc
481 gtccgccgtc taggtaagtt taaagctcag gtcgagaccg ggcctttgtc cggcgctccc
541 ttggagccta cctagactca gccggctctc cacgctttgc ctgaccctgc ttqctcaact 118
601 ctacgtcttt gtttcgtttt ctgttctgcg ccgttacaga tcgaaagttc cacccctttc
661 cctttcattc acgactgact gccggcttgg cccacggcca agtaccggcg actccgttgg
721 ctcggagcca gcgacagccc atcctatagc actctcagga gagaaattta gtacacagtt 119, 174
781 gggqgctcgb ccgggatacg agcgcccctt tattccctag gcaatgggcc aaatcttttc
841 ccgtagcgct agccctattc cgcgaccgcc ccgggggctg gccgctcatc actggcttaa
901 cttcctccag gcggcatatc gcctagaacc cggtccctcc agttacgatt tccaccagtt
961 aaaaaaattt cttaaaatag ctttagaaac accggctcgg atctgtccca ttaactactc
1021 cctcctagcc agcctactcc caaaaggata ccccggccgg gtgaatgaaa ttttacacat
1081 actcatccaa acccaagccc agatcccgtc ccgtcccgcg ccaccgccgc cgtcatcccc
1141 cacccacgac cccccggatt ctgatccaca aatcccccct ccctatgttg agcctacggc
1201 cccccaagtc cttccagtca tgcatccaca tggtgctcct cctaaccatc gcccatggca
1261 aatgaaaqac ctacaggcca ttaagcaaga agtctcccaa gcagcccctg ggagccccca 175
1321 gtttatgcag accatccggc ttgcggtgca gcagtttgac ccoactgcca aagacctcca
13 81 agacctcctg cagbacctbt gctcctccct cqtggcttcc cbccabcacc agcagcbaga 120, 122
1441 bagccbbaba bcagaggccg aaacccgagg babbacaggb babaacccab bagccggbcc
1501 ccbccgbgbc caagccaaca atccacaaca acaaggabta aggcgagaab accagcaact 123
1561 cbggcbcgcc gccbbcgccg cccbgccggg gagbgccaaa gacccbbccb gggccbcbab
1621 cctccaaggc cbggaggagc cbbaccacgc cbbcgbagaa cgccbcaaca bagcbcbbga 121
1681 caabgggcbg ccagaaggca cgcccaaaga ccccabcbba cgbbccbbag ccbacbccaa
1741 tgcaaacaaa gaabgccaaa aabtactaca ggcccgagga cacacbaaba gccctctagg
1801 agababgbbg cgggcbbgbc agacctggac ccccaaagac aaaaccaaag tgttagbbgb
1861 ccagccbaaa aaaccccccc caaatcagcc gbgcbbccgg bgcgggaaag caggccacbg
1921 gagbcgggac bgcacbcagc cbcgbccccc ccccgggcca bgcccccbab gbcaagaccc
1981 aacbcacbgg aagcgagact gcccccgccb aaagcccacb abcccagaac cagagccaga
2041 ggaagabgcc cbccbattag accbccccgc bgacabccca cacccaaaaa acbbcabagg
2101 gggggaggbb baaccbcccc ccccacabba cagcaagtcc ttccbaacca agacccagca
2161 tctabtcbgc cagbbabacc gbbagabccc gcccgbcggc ccgbaabbaa agcccaggbb
2221 gacacccaga ccagccaccc aaagacbabc gaagcbbbac bagabacagg agcagacabg
2281 acagbccbtc cgabagccbb gbbcbcaagb aabacbcccc bcaaaaabac abccgbabba
2341 ggggcagggg gccaaaccca agabcacbbb aagcbcaccb cccbbccbgb gcbaabacgc
2401 cbcccbbbcc ggacaacgcc babbgbttba acabctbgcc bagbbgabac caaaaacaac
2461 baggccabca baggbcgbga bgccbbacaa caabgccaag gcgbcctgba ccbcccbgag
2521 gcaaaaaggc cgccbgbaab cbbgccaaba caggcgccag ccgbccbbgg gcbagaacac
2581 cbcccaaggc cccccgaaab cagccagbbc ccbbbaaacc agaacgccbc caggccbbgc 176
2641 aacactbggb ccggaaggcc cbggaggcag gccababcga acccbacacc gggccaggga
2701 ataacccagb abbcccagbb aaaaaggcca abggaaccbg gcgabbcabc cacgaccbgc
2761 gggccacbaa cbcbcbaacc abagatcbcb cabcabcbbc ccccgggccc ccbgacbbgb
2821 ccagccbgcc aaccacacba gcccacbbgc aaacbabaga ccbbagagac gccbbbbbcc
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2881 aaatcccctt acctaaacag ttccagccct actttgcttt cactgtccca cagcagtgta
2 941 actacggccc cggcactaga tacgcctgga aagtactacc ccaagggttt aaaaatagtc 2 96
3001 ccaccctgtt cgaaatgcag ctggcccata tcctgcagcc cattcggcaa gctttccccc
3061 aatgcactat tcttcagtac atggatgaca ttctcctagc aagcccctcc catgaggacc 2 97
3121 tactactact ctcagaggcc acaatggctt ccctaatctc ccatgggttg cctgtgtccg
3181 aaaacaaaac ccagcaaacc cctggaacaa ttaagttcct agggcagata atttcaccca
3241 atcacctcac ttatgatgca gtccccacgg tacctatacg gtcccgctgg gcgctacctg
3301 aacttcaagc cctacttggc gagattcagt gggtctccaa aggaactcct accttacgcc
3361 agccccttca cagtctctac tgtgcctbac aaaggcatac tgatccccga gaccaaatat 1
3421 atttaaatcc ttctcaagtt caatcattag tgcagctgcg gcaggccctg tcacagaact 2
3481 gccgcagbag actagtccaa accctgcccc tcctaggggc tattatgctg accctcactg
3541 gcaccactac tgtagtgttc cagtccaagg agcagtggcc acttgtctgg ctacatgccc
3601 ccctacccca cactagccag tgcccctggg ggcagctact tgcctcagct gtgttattac
3661 tcgacaaata caccttgcaa tcctatgggc tgctctgcca aaccatacat cataacatct
3721 ccacccaaac cttcaaccaa ttcattcaaa catctgacca ccccagtgtt cctatcttac
3781 tccaccacag tcaccgattc aaaaatttag gtgcccaaac tggagaactt tggaacactt
3841 ttcttaaaac agctgcccca ttggctcctg tgaaagccct catgccagtg tttactcttt
3 901 ccccggtgat tataaacacc gccccctgcc tgttttcaga cggatctacc tcccgggcag
3 961 cctatattct ctgggacaag caaatattgt cacaaagatc attccccctt ccgccaccgc
4021 acaagtcggc ccaacgggcc gaacttctcg gacttttgca tggcctctcc agcgcccgtt
4081 cgtggcgctg tctcaacata tttctagact ccaagtatct ttatcattac cttcggaccc
4141 ttgccctggg caccttccaa ggcaggtcct ctcaggcccc ctttcaggcc cttctgcccc
4201 gcttactatc gcgtaaggtc gtctatttgc accacgttcg cagccatacc aatctacctg
4261 atcccatctc caggctcaac gctctcacag atgccctact aatcacccct gtcctgcagc
4321 tctctcctgc agaactacac agtttcaccc attgcggaca gacggccctc acattgcaag
4381 gggcaaccac aactgaggct tccaatatcc tgcgctcttg ccacgcctgc cgcggaggca
4441 acccacaaca tcagatgcct cggggacaca tccgccgtgg cctacttcct aaccacatct
4501 ggcaaggcga cattacccat ttcaaatata aaaatacgct gtatcgcctt catgtatggg
4561 tagacacctt ttcaggagcc atctcagcta cccaaaagag aaaagaaaca agctcagaag
4621 ctatttcctc tttgcttcag gccattgccc atctaggcaa gcctagctac ataaacacag
4681 acaacggccc tgcctatatt tcccaagact tcctcaatat gtgtacctcc cttgctattc
4741 gccataccac ccatgtcccc tacaatccaa ccagctcagg acttgtagaa cgctctaatg 67
4801 gcattcttaa aaccctatta tataagtact ttactgacaa acccgaccta cccatggata
4861 atgctctatc catagcccta tggacaatca accacctgaa tgtgttaacc aactgccaca
4921 aaacccgatg gcagcttcac cactcccccc gactccagcc gatcccagag acacgttccc 68
4981 tcagcaataa acaaacccat tggtattatt tcaagcttcc tggtcttaat agccgccagt
5041 ggaaaggacc acaggaggct ctccaagaag ctgccggcgc tgctctcatc ccggtaagcg
5101 ctagttctgc ccagtggatc ccgtggagac tcctcaagcg agctgcatgc ccaagacccg
5161 tcggaggccc cgccgatccc aaagaaaaag acctccaaca ccatgggtaa gtttctcgcc
5221 actttgattt tattcttcca gttctgcccc ctcatcttcg gtgattacag ccccagctgc
5281 tgtactctca caattggagt ctcctcatac cactctaaac cctgcaatcc tgcccagcca
5341 gtttgttcgt ggaccctcga cctgctggcc ctttcagcag atcaggccct acagcccccc
5401 tgccctaacc tagtaagtta ctccagctac catgccacct attccctata tctattccct
5461 cattggacta agaagccaaa ccgaaatggc ggaggctatt attcagcctc ttattcagac
5521 ccttgttcct taaagtgccc atacctgggg tgccaatcat ggacctgccc ctatacagga
5581 gccgtctcca gcccctactg gaagtttcaa cacgatgtca attttactca agaagtttca
5641 cgcctcaata ttaatctcca tttttcaaaa tgcggttttc ccttctccct tctagtcgac
5 701 gctccaggat atgaccccat ctggttcctt aataccgaac ccagccaact gcctcccacc
5761 gcccctcctc tactccccca ctctaaccta gaccacatcc tcgagccctc tataccatgg 124
5 821 aaatcaaaac tcctgaccct tgtccagtta accctacaaa gcactaatta tacttgcatt
5881 gtctgtatcg atcgtgccag cctctccact tggcacgtcc tatactctcc caacgtctct
5941 gttccatcct cttcttctac ccccctcctt tacccatcgt tagcgcttcc agccccccac
6001 ctgacgttac catttaactg gacccactgc tttgaccccc agattcaagc tatagtctcc
6061 tccccctgtc ataactccct catcctgccc cccttttcct tgbcacctgt tcccacccta 125
6121 ggatcccgct cccgccgagc ggtaccggtg gcggtctggc ttgtctccgc cctggccatg
6181 ggagccggag tggctggcgg gattaccggc tccatgtccc tcgcctcagg aaagagcctc
6241 ctacatgagg tggacaaaga tatttcccag ttaactcaag caatagtcaa aaaccacaaa
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Appendix 6: (continued).
6301 aatctactca aaattgcgca gtatgctgcc cagaacagac gaggccttga tctcctgttc
6361 tgggagcaag gaggattatg caaagcatta caagaacagt gccgttttcc gaatattacc
6421 aattcccatg tcccaatact acaagaaaga cccccccttg agaatcgagt cctgactggc
6481 tggggcctta actgggacct tggcctctca cagtgggctc gagaggcctt acaaactgga
6541 atcacccttg ttgcgctact ccttcttgtt atccttgcag gaccatgcat cctccgtcag
6601 ctacgacacc tcccctcgcg cgtcagatac ccccattact ctcttataaa acctgagtca
6661 tccctgtaaa ccaagcacgc aattattgca accacatcgc ctccagcctc ccctgccaat
6721 aattaacctc tcccatcaaa tcctccttct cctgcagcaa cttcctccgt tcagcctcca
6781 aggactccac ctcgccttcc aactgtctag tatagccatc aatccccaac tcctgcattt
6841 tttctttcct agcactatgc tgtttcgcct tctcagcccc ttgtctccac ttgcgctcac
6 901 ggcgctcctg ctcttcctgc ttcctcctag cgacgtcagc ggccttcttc tccgcccgcc
6961 tcctgcgccg tgccttctcc tcttccttcc ttttcaaata ctcagcggtc tgcttttcct
7021 cctctttctc ccgctctttt tttcgcttcc tcttctcctc agcccgtcgc tgccgatcac
7081 gatgcgtttc cccgcgaggt ggcgctttct cccctggagg gccccgtcgc agccggccgc
7141 ggctttcctc ttctaaggat agcaaaccgt caagcacagc ttcctcctcc tccttgtcct
7201 ttaactcttc ctccaaggat aatagcccgt ccaccaattc ctccaccagc aggtcctccg
7261 ggcatgacac aggcaagcat cgaaacagcc ctgcagatac aaagttaacc atgcttatta
7321 tcagcccact tcccagggtt tggacagagt cttc ttttcg gatacccàqbl.ctatigffagt'tt  50, 282
73 81 gga^ actgbg tacaaggcga ctggtgcccc atctctgggg gactatgttc ggcccgccta
7441 catcgtcacg ccctactggc cacctgtcca gagcatcaga tcacctggga ccccabcgat 3, 51, 283
7501 ggacgdgGba' tcggctcagc tctacagttc cttatccctc gactcccctc cttccccacc 190
7561 cagagaacct ctaagaccct caaggtcctt accccgccaa tcactcatac aacccccaac 4, 126
7621 attccaccct ccttcctcca ggccatgcgc aaatactccc ccttccgaaa tggatacatg
7681 gaacccaccG ttgggcagca cctcccaacc ctgbcttttc cagaccccgg actccggccc 127
7741 caaaacctgt acaccctctg gggaggctcc gttgtctgca tgtacctcta ccagctttcc
7801 ccccccatca cctggcccctvccbgccccac:; gcgatttttt gccaccccgg ccagctcggg 191
7861 gccttcctca ccaatgttcc ctacaagcga atagaagaac tcctctataa aatttccctc
7921 accacagggg ccctaataat tctacccgaa gactgtttgc ccaccaccct tttccagcct
7981 gctagggcac ccgtcacgct aacagcctgg caaaacggcc tccttccgtt ccactcaacc
8041 ctcaccactc caggccttat ttggacattt accgatggca cgcctatgat ttccgggccc
8101 tgccctaaag atggccagcc atctttagta ctacagtcct cctcctttat atttcacaaa
8161 tttcaaacca aggcctacca cccctcattt ctactctcac acggcctcat acagtactct
8221 tcctttcata gtttacatct cctgtttgaa gaatacacca acatccccat ttctctactt
8281 tttaacgaaa aagaggcaga tgacaatgac catgagcccc aaatatcccc cgggggctta
8341 gagcctccca gtgaaaaaca tttccgagaa acagaagtct gaaaaggtca gggcccagac
84 01 taaggctctg acgtctcccc ccggagggca gctcagcacc ggctcgggct aggccctgac
84 61 gtgtccccct gaagacaaat cataagctca gacctccggg aagccaccaa gaaccaccca
8521 tttcctcccc atgtttgtca agccgtcctc aggcgttgac gacaacccct cacctcaaaa
8581 aacttttcat ggcacgcata tggctcaata aactagcagg agtctataaa agcgtggaga
8641 cagttcagga gggggctcgc atctctcctt cacgcgcccg ccgccctacc tgaggccgcc
87 01 atccacgccg gttgagtcgc gttctgccgc ctcccgcctg tggtgcctcc tgaactgcgt
8761 ccgccgtcta ggtaagttta aagctcaggt cgagaccggg cctttgtccg gcgctccctt
8821 ggagcctacc tagactcagc cggctctcca cgctttgcct gaccctgctt gctcaactct
8881 acgtctttgt ttcgttttct gttctgcgcc gttacagatc gaaagttcca cccctttccc
8941 tttcattcac gactgactgc cggcttggcc cacggccaag taccggcgac tccgttggct
9001 cggagccagc gacagcccat cctatagcac tctcaggaga gaaatttagt acacatagtt
9061 ggaggtag
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Appendix 7: Complete nucleotide sequence of human T lymphotropic virus type II
proviral DNA.
GenBank Accession number M10060 (8952 bp) (Shimotohno et al 1985). Oligonucleotide 
primer sequences for PCR are underlined (shaded or emboldened where overlapping) and 
annotated at right.
1 tgacaatggc gactagcctc ccaagccagc cacccagggc gagtcatcga cccaaaaggt
61 cagaccgtct cacacaaaca atcccaagta aaggctctga cgtctccccc tttttttagg
121 aactgaaacc acggccctga cgtccctccc ccctaggaac aggaacagct ctccagaaaa
181 aaatagacct cacccttacc cacttcccct agcgctgaaa aacaaggctc tgacgattac
241 cccctgcGca taaaatttgG ctagtcaaaa taaaagatgc cgagtctata aaagcgcaag
301 gacagttcag gaggtggctc gctccctcac cgaccctctg gtcacggaga ctcaccttgg
361 ggatccatcc tctccaagcg gcctcggttg agacgccttc cgtgggaccg tctcccggcc
421 tcggcacctc ctgaactgct cctcccaagg taagtctcct ctcaggtcga gctcggctgc
481 cccttaggta gtcgctcccc gagggtcttt agagacaccc gggtttccgc ctgcgctcgg
541 ctagactctg ccttaaactt cacttccgcg ttcttgtctc gttctttcct cttcgccgtc
601 actgaaaacg aaacctcaac gccgccctct tggcaggcgt cccggggcca acatacgccg
661 tggagcgcag caagggctag ggcttcctga acctctccgg gagaggtcta ttgctatagg
721 caggcccgcc ctaggagcat tgtcttcccg gggaagacaa acaattgggg gctcgtccgg 174
781 gatttgaatt cctccattct cacattatgg gacaaatcca cgggctttcc ccaactccaa
841 tacccaaagc ccccaggggg ctatcaaccc accactggct taactttctc caggctgctt
901 accgcttgca gcctaggccc tccgatttcg acttccagca gctacgacgc tttctaaaac
961 tagcccttaa aacgcccatt tggctaaatc ctattgacta ctcgctttta gctagcctta
1021 tccccaaggg atatccagga agggtggtag agattataaa tatccttgtc aaaaatcaag
1081 tctcccctag cgcccccgcc gccccagttc cgacacctat ctgccctact actactcctc
1141 cgccacctcG ccccccttcc ccggaggccc atgttccccc cccttacgtg gaacccacca
1201 ccacgcaatg cttccctatc ttacatcccc caggagcccc ctcagctcat aggccctggc
1261 agatgaaaga cttacaggcc atcaagcagg aggtcagctc ctctgctctt ggcagccccc 175
1321 agttcatgca gaccctccgg ctggcggtac aacagtttga ccccaccgcc aaggacttac
1381 aagatctcct ccagtaccta tgctcctccc tcgtagtttc cttacaccat cagcagctta
1441 acacactaat taccgaggct gagacccgcg ggatgacagg ctacaacccc atggcagggc
1501 ccctaagaat gcaggctaat aaccccgccc agcaaggtct tagacgggag taccagaatc
1561 tttggctggc tgctttctcc accctgccag gcaatacccg tgacccctct tgggcagcta
1621 tcctacaggg gctggaggaa ccctattgcg cgttcgtaga gcgccttaac gtggcccttg
1681 acaacggcct ccccgagggt acccccaaag agcccatctt acgttcccta gcgtactcaa
1741 acgccaacaa agaatgccaa aaaatcttac aagcccgcgg acacactaac agcccccttg
1801 gggagatgct ccggacatgt caggcgtgga cacccaagga caaaaccaag gtccttgtgg
1861 tccaaccacg gaggcccccc cccacacagc cctgctttcg ttgtggcaag gtaggacact
1921 ggagtcggga ctgtacccag ccacgccccc ctcctggccc ctgcccccta tgccaagatc
1981 cttctcactg gaaaagggac tgcccacaac tcaaaccccc tcaggaggaa ggggaacccc
2041 tcctgttgga tctcccttcc acctcaggca ctactgagga aaaaaactcc ttaagggggg
2101 agatctaatc tccccccatc ccgatcaaga catctcgata ctcccactca tccccctgcg
2161 gcagcaacag caaccaattc taggggtccg gatctccgtt atgggacaaa cacctcagcc
2221 tacccaagcg ctacttgaca caggagccga ccttacggtt ataccccaga cactcgtgcc
2281 cgggccggta aagctccacg acaccctgat cctaggcgcc agtgggcaaa ccaacaccca
2341 gttcaaactc ctccaaaccc ccctacacat attcttgccc ttccgaaggt cccccgttat
2401 Gctttcctcc tgcctcttag acacccacaa caaatggacc atcattggaa gggacgccct
2461 acaacaatgc caggggcttc tatacctccc agacgacccc agcccccacc aattgctgcc
2521 aatagccact ccaaacacca taggcctcga acaccttccc ccacctcccc aagtggacca
2581 atttcctbta aacctgagcg cctccaggcc ttaaatgacc tggtctccaa ggccctggag 176
2641 gctggtcaca ttgaaccata ctcaggacca ggcaataacc ccgtcttccc cgttaaaaaa
2701 ccaaatggta aatggaggtt cattcatgac ctaagagcca ccaatgccat tactaccacc
2761 ctcacctctc cttccccagg gccccccgat ctcactagcc taccgacagc cttaccccac
2821 ctacagacca tagatcttac tgacgccttt ttccaaatcc ccctccccaa gcagtaccag
2881 ccatacttcg ccttcaccat tccccagcca tgtaactatg gccccgggac cagatatgca
Appendix?: (continued).
2941
3001
3061
3121
3181
3241
3301
3361
3421
3481
3541
3601
3661
3721
3781
3841
3901
3961
4021
4081
4141
4201
4261
4321
4381
4441
4501
4561
4621
4681
4741
4801
4861
4921
4981
5041
5101
5161
5221
5281
5341
5401
5461
5521
5581
5641
5701
5761
5821
5881
5941
6001
6061
6121
6181
6241
6301
tggactgtcc
gccgtcctca
gacatacttt
caggcactga
caaatacgct
actattccca
cagtgggtct
cttcacgggt
ttacatgcca
cctctccttg
aagcaaaatt
tggggtcacc
ggccagctct
aggaactcGG
cttggcagcc
gaaccacgaG
tgcctttttt
cttcaacagg
G tG c ttg c a c
ttagactGta
acttccgcGC
taGctccacc
tacacagaGt
ctcacGcatt
tcccttgtac
gggtacattG
aagtacaaaa
tccgtctcGt
atttccctcc
caagaattGC
aacGCcaGGa
aaatatctac
actctcaatc
agtcctcGac
ttGtattata
caggaagcgg
cgattcctga
gcaacagacc
ttttccacta
cagcccctgt
aacggacGaa
gacttattcc
gtactactcg
agcatggaca
tgtaaatttc
ctcctGGatg
agaaccGact
tgtcctaacc
acagagcacc
tgtactGtac
tCCttCGCtt
acctcgccta
ttccctcgct
gtggcttgtc
atctctggct
ccaggccata
tagacgagga
ttccacaggg
accccatgag
tagGcagccG
ccaG gca tgg
tcttaggaca
taaaatccca
ctaaaggaac
acGgggaccc
ttcaacaagc
gcctGatGtc
ggcccGtggG
tactggcGtg
gccaatcttt
ctcatccaag
aaccgtctgg
tcctcaggcc
ccgatggctc
acatcactcc
ttatGtgtgg
aatatttaat
atcaaaccct
a tg tG c g c a g
CGGttatCtt
gcaatcaaag
agacttgcca
gcG ggggcct
aatacaaata
gtaaaaagaa
tagggaaacG
aggagttttg
gctcaggcGt
tagactgtcc
agctaaatgt
taccacccat
a a G tG G C G g g
Gcggggcagc
aaaaagctgc
accaacacca
gcccagcaga
agcccaaccc
Ggactacacc
ttatacttat
GGttcctaca
tc G g c a ta c a
acccaggaag
accctcctag
GagGctcGac
ccctccacgt
aattactcct
acccccaaGa
gcGGtgcGcg
caggcgataa
Gccgtacctc
tccgGCGtag
tccagtaaaa
gtcaaaaatc
ttagacctGC
gtttaaaaac
gaaaatgttt
G accaatgag
ccttccaatt
ggtcatctGC
atggacactc
acccatcctt
aagagcttgt
tctacaacat
gttaagtaca
t tg g c tG c a c
caccatGtta
ccaGcacaac
tgtcggcatG
tCGgtggaag
aattttcacG
ccctcaaaag
CGtgccctct
actacgtgct
caaataccta
ccaggcggGG
ccacaGGaac
agctcccGtt
ggctctagtG
tacctgtcaa
G ttgcccaac
c tg c c tG c a c
agaaaccagc
actccacatt
tacGtcctat
ggtcgagaga
t a a G c t t c c c
catgaaGGGG
tGGtgaagcc
c c t ta c G a a t
cttgctGtcc
atg ccG aag a
tgggtaatgt
gccgatgcac
aaGCcgtctg
ccccctgccc
tcGcacattg
atgaGCGttg
cgggccG cgt
tcagccaagt
tagatgGGCG
caacttctcc
cctggacgac
gcatggtttg
tctccattGG
CtCGtGCatC
caacagataa
ctccggcgaG
cggGGggaac
gccttctcct
atcaaaacat
tattGtggga
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agcGccaccG
Gccacatcga
gaattacaac
tcGcaggaaa
cctaatcaca
actgaattac
cgcaaacacc
atGaGcctca
aactgGGgtg
tctggtacaa
accccGcacc
actctagaca
a tg tG a a a g c
GtGattcacG
actctcttac
C t C t C G C G C g
gcagcgtacg
G aG gaaacac
gccaagccat
cattcGctcg
ttgccacGCG
c tcccG gacc
gttcGcctga
tcttttggcg
accatcaaGt
cacatatggc
gtctgggtag
tgtgagacta
aacacagata
cgGatcaagc
accaatggtg
Gtagacaatg
9-gtggtaaaa
tctacccctc
cagcggtgga
atagacggct
G cagacgG ca
tttGttGGta
actcacgatt
cacgtggaac
taaGctaatt
gataaaaaag
ctcgctacaa
c tC G a g tc ca
gtcGcttcga
tggatatgat
cccattggtc
caaaataGtG
cgtggataga
ccaacaaacc
ccaacccttc
ctgcaacaac
aagacgccgc
aggtatcgct
cgaggttgac
cctGGgggtt
acaagggggt
tcttcgaaca
ccattgtcca
aactctGGGa
aaacacaaca
ttacatatga
aagttatcct
taGaatccct
GGGcacaaGa
gGcgcGtcaa
catctgtcat
ctccgaccag
aatataGGGt
aagccctttg
acatgggtcg
acctcccaac
tcgtgcttga
ttctctggga
attccgcaca
ggcGttccct
ccattggggc
tactgcaggg
caatttccac
cgGcccaagg
GGacaccaag
cacaacatca
aaggtgatgt
aGaccttctc
tGagcgccgt
atgggccagc
attctaGcca
taatcaaaaa
CGattcacaa
cccgatggca
ccaaaccaGC
aaggtccatt
CGCGGGggtg
gGgaactcgc
cttttattca
ggtatctcct
ctcgacctta
acttactctg
Gcaaacagac
tgcccctaGt
tGctggaagt
GtacaGttct
cctttatggt
GatgaGtGcg
aaatttatcc
tccagcctct
tcctcccgaa
GcttggaGCG
tccattatcc
cgtgccgttc
ggtggagtaa
aaagacatct
gcacagtatg
ttgtgcaagg
acaattagca
atacatggat
gctaaccctc
aacGGcaggc
gagtacccct
aggagagatc
atattGtgGG
actccatgcg
Gcccgcccta
ctttcaacGC
tttatgtCGt
acaacattat
cgacttcctg
attccataac
c c t t c t c G a g
cacggccGGC
ccagactatc
aaagggggag
taacatGttt
cttcGtGggG
caagaGcatc
cttGaatgaa
GGtGGacggc
ggaagccaag
tatgcGtcga
aaGGGattat
cggtgcggtt
tcttcaggcG
cttcctatca
tataccataG
cttactaaat
agcGCtttgg
aatccaccaG
tcGcaaatgg
gcaatcGctc
gatcccgtgg
cgagcacgcc
gtctcacaGa
cctaccactc
attccctaaG
gcttccataa
agggcctagg
tgggctgcGa
ttcattcaga
Gtaagtgcgg
tcatcaGctG
accttgaaca
agctgacctt
catcctggca
CGatGCtGtt
a ttg c ta c G a
tGGCCCCttt
caatagcagt
c a g g c tc c G t
GGGaccttac
Gagcccaaaa
ccatacagga
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6361
6421
6481
6541
6601
6661
6721
6781
6841
6901
6961
7021
7081
7141
7201
7261
7321
7381
7441
7501
7561
7621
7681
7741
7801
7861
7921
7981
8041
8101
8161
8221
8281
8341
8401
8461
8521
8581
8641
8701
8761
8821
8881
8941
gcaatgttgc
tcttgaaaaa
ggcacgagaa
gtttggccGC
taaccagtat
gcaaatcccc
agtcgccccc
aacGCGcgct
cctgaagcaa
gcctttcttc
gctccGgctc
gtGtcGgacg
ttgGtgtcct
cctggtctcc
tgtctcGtct
taGgbgtfctg
acccgcctac
cccatcgatg
ttcGtcaaGa
cgtgtcatca
gccctccaga
tgtatcctcc
tGGGttatca
taggttcgtc
gatgtccagG
caGattCGtG
gtcacaaaac
G c tc tc c c g g
GtGaGgGtGC
agagtctcgc
tctcggttcc
taacggcaat
GagGGGattt
gGgattgtgt
atcgacatgc
gacgcgbtgt
ttccGcaccc
tc c c G c a a g g
ggatgGctgg
GtGGgtCGCG
cagctttccG
caattaggag
atgttGGtaG
ttccaacccg
cactccatct
tGGggccctt
ttcgaaaaat
caatactcct
tctattttat
acGGagggGg
aggctctgac
cctaggaaGa
gcgctgaaaa
aaaagatgGG
gaGcctGtgg
gacgccttGc
aagtctcctc
gagacaccGg
tcttgtctGg
ggGaggGgtG
Gctctccggg
ggaagacaaa
agagaacctc
ttccacGtgc
aaccaaGCGt
aaaacatcta
cacccatgac
CCttCGtGaG
acaGagggac
tgagggctcc
taacaacccc
acGGcaaagG
tcgaaaccaa
ccttcGataa
ttaataaaga
agtcatcgac
gtctccccct
ggaaGagctc
acaaggGtct
gagtGtataa
tcacggagac
gtgggaccgt
tcaggtcgag
ggtttCGgcc
ttGtttCGtC
ccggggccaa
agsggtctat
tGagtaaGac
ccggctgggg
caggcataaG
gGcaaatGca
acGcagaaaG
G c c c ta G c a t
G ctaaG tcg a
ccataggacc
ccatcaaaac
cgGttttgat
tgcagaagtt
acctgctcgc
tctcGagggg
GtcGtaaaat
ccGaggattt
aGaggccgat
cctGctggcG
cagctG tG ct
aaggaGCGtc
tcatgtatcc
actaaaGtgg
c a t t c t G g G t
ggcccttcca
catgctataa
tgacccatGG
ttGtgaataa
ttcttttccc
ccaggagtcc
GCttttGCGg
ttaagatctc
tgaGGgatcc
gaggGacacc
agtGtaaaaa
ggaGagagcG
tggtgtcccg
acGtgtccag
ctGcaataCG
aagqtcctta
cttGtttcaa
cggggatcag
caccacctgg
atggGcactt
caaggtgcct
agtcatagtc
ctgtatccag
a g g tc ta a ta
agggcagcca
agccttccat
GGttcacGtt
agaggcggat
Gcaaaaggtc
ttttttagga
tcG ag aaaaa
gacgattaGC
aagcgcaagg
tcaccttggg
ctcccggcct
ctcggctgG G
tgGgctGggG
ttGgGcgtca
catacgccgt
tgctataggG
tGaatgcgaa
CtCCGCtCGC
ggaaaaacGg
ataGGGGatg
Gtaaaacgat
GtcGcggagg
actgcctggt
tggaccttGa
tctttagtag
GCCtCCtatG
Gtattcgatg
gacaatggcg
agaccgtctc
actgaaaGGa
aatagacGtG
GcctgccGat
acagttcagg
gatccatcct
cggcacctcG
cGttaggtag
tagactctgc
ctgaaaaGga
ggagcgcagc
aggcccgGCG
gtcctccagg
gatcttggaG
G t a c t c c t c c
cagcggttac
tagacctgct
acagtcGtct
ttgcctcaaa
Gttcaggaaa
t a ta c a G tc c
GaggcgGtcG
ccgctgctcc
cgaGCGcaga
agatgtcaga
atcacacata
tcctatatqg
tctcaggtgg
agcaccaac^
ttatccctcg
^GGCtCCCaG
agcaGacccc
tcgcGttccc
tagtatgcct
tcatattctg
tagaagaact
acgacctaGC
gtaGaggaGt
atgacggctc
ttcagtcctc
taGtctGtGa
aatacaccaa
actagcctGC
acaG aaacaa
Gggccctgac
aGccttaccc
aaaatttgcG
aggtggctGg
ctccaagcgg
tgaaGtgctG
tcgctccGcg
cttaaacttc
aacctcaacg
aagggctagg
taggagcatt
aaGggccccc
tgtGGcaatg
tcgtcatatt
aaaaccgaca
agGttctgca
ataCGagatg
tagttcctct
tccacataac
aactgGtgat
tttctgcgcc
tccgccaaca
gggcgacctt
c t c g c c t c t G
a t t a c a a t c G
ataccccqtc 50
tGtatgttCG 288
cacctgggac 3, 289
CCtCGCCtGC 51
caGtcctgtc 4
ctaccgaaat
cgaacGtggG
atacGtatac
ccaccGcaga
tctatacaaa
caccacaatg
tCtCCGGtat
accaatgatt
cctattaatc
tcagcttata
catccctgtc
cgagccagG C
tcGGaagtaa
gtCGCtGCCC
acttccGcta
tagtcaaaat
GtCCCtGaCG
cctcggttga
GtGGGaaggt
agggtGttta
acttccgcgt
ccgccGtctt
g c ttcG tg aa
gtcttGGcgg
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Appendix 8: Complete nucleotide sequence of bovine leukaemia virus proviral DNA.
GenBank Accession number K02120 (8714 bp) (Sagata et al 1985). Oligonucleotide primer 
sequences for PCR are underlined and annotated at right.
1 tgtatgaaag atcatgccga cctaggagcc gccaccgccc cgtaaaccag acagagacgt
61 cagctgccag aaaagctggt gacggcagct ggtggctaga atccccgtac ctccccaact
121 tcccctttcc cgaaaaatcc acaccctgag ctgctgacct cacctgctga taaattaata
181 aaatgccggc cctgtcgagt tagcggcacc agaagcgttc ttctcctgag accctcgtgc
241 tcagctctcg gtcctgagct ctcttgctcc cgagaccttc tggtcggcta tccggcagcg
301 gtcaggtaag gcaagcacgg tttggagggt ggttctcggc tgagaccacc gcgagctcta
361 tctccggtcG tctgaGGgtG tccacgtgga ctGtctcctt tgcctGctga GGGcgGgGtc
421 caagggcgtG tggcttgGac ccgcgtttgt ttGCtgtGtt actttctgtt tctcgcggcc
481 cgcgctctct ccttcggcgc cctctagcgg GGaggagaga cGggcaaaca attgggggGt 174
541 cqtccgggat tgatcacccc ggaaGGGtaa caactGtctg gacccacccc ctcggGggca
601 ttttgggtct ctccttGaaa ttatatcatg ggaaattcGc cctcctataa ccccGGGgct
661 ggtatctCGG cctcagaGtg gctcaacctt Gtgcaaagcg cgGaaaggct caatGGgGga
721 ccGtGtccta gcgattttac Ggatttaaag aattaGatGc attggtttca taagaGccag
7 81 aaaaaaccat ggactttcac ttGtggtggc cccaGctGat gtccacccgg gagattcggc
841 cgggttCGGG tGgtGttggc GaGCctaaaG gaagtactct caaacgaagg gggGgcccGg
901 ggtgcatGgg Gcccagaaga aGaacccccc ccttatgacc cGCCGgGGat tttgccaatc
961 atatctgaag ggaatcgcaa GGgccatGgt gcttgggcac tccqagaatt acaagatatc 175
1021 aaaaaagaaa ttgaaaataa ggcacGgggt tcgcaagtat ggatacaaac actacgactt
1081 gGaatcctgc aggGcgaccG tactcGgqct qacctagaac aactttgGGa atatattgct 194
1141 tcGGGggtGg accaaaGggG ccatatgacc agcctaacgg Gagcaatagc cgGGgctgaa
1201 gcggcaacac cctccagggt tttaaccGGG aaaaGgggta Gcctaaccca aGaatcagct
1261 Gagcccaacg ccggggatGt tagaagtcaa tatcaaaacc tctggcttca ggGcggaaaa 195
1321 atGtGGGtac tcqtGcttGa gctacaacct tggtGcacca tGgtccaagg GGCGgccgaa
1381 agctctgtag agtttgtcaa ccggttaGaa atttGattag Gtgacaacct tGccgacgga
1441 gtcctaagga acccattatt gaGtGGCtta gttatgcaaa tgctaacaga gagtgtcagc
1501 aaattttgca ggggcgaggc cagtggGcgc ggtggggcaa aaactgGagg GttgcgGaca
1561 attgggcGcc Gaagaatgaa acagcctgca cttctcgtGG aGacGGGagg gcccaagatg
1621 GGcgggGctc ggcaaccggc ccccaaaagg GGtCGCGcag gaccatgcta tGgatgcctc
1681 aaagaaggcc attgggccGg ggattgtCGt accaaggcGa ccggccGacc tccgggacct
1741 tgcccGatat gtaaagatGc ttcGGattgg aaaGgagact gtccaaccct Gaaatcaaaa
1801 aactaataga ggggggaGtt agcgGGGCcc aaaccataac acctataacg gattctctta
1861 gtgaggccga attagaatgc ttactttcta ttcctctggG tcgcagGGgt ccctccgtgg
1921 ctgtatacct gtctggcGcc tggctgGagc cGtGtGagaa tcaagccctc atgcttgtgg
1981 acaccggggc tgaaaataGg gttGtGGcaG aaaattggct ggttcgagat taGccaGgga
2041 tcccGgccgc agtgGtcgga gcagggggag tctcccggaa cagatacaat tggctacaag
2101 gGGGtGtgac cGtggctGta aaaccagagg gtGCctttat GaccatGCGa aaaattttag
2161 ttgaGacttc cgacaaatgg caaattttag gaGgggaGgt ccctcGGgcc tacaggcttG
2221 tatctccata cctgaggaag taGgcGCGCG tgtggtaggc gtcttggata ccGccccgag
2281 ccacattgga ttagaaGatG tgGGCGCccc acGtgaggtg GctcaattGC ctttaaaGta 176
2341 gaacgGGtcG aggcccttca agaGctggtc catcgctctc tggaggGagg ttatatctcc
2401 CGCtgggacg ggccaggcaa taatccagtc ttGCGggtac ggaaaGGaaa tggcgcctgg
2461 aggtttgtgc atgacctacg agGtacaaat gGtcttacaa agcccattcc ggcaGtGtct
2521 cGcggaccgG GagacGttac GgGtatccct acgcaccctc cacatatcat ttgcGtagat
2581 Gtcaaagatg ccttGttGca gattccagtc gaagaccgct tccgcttcta cttgtctttt
2641 accGtGccat cccccggggg actcGaacct catagacgct ttgcctggcg ggtcctacct
2701 caaggcttca ttaacagcGC agGtGttttG gaacgagcac tacaggaacG tcttGgGcaa
2761 gtttGGgGcg GCttttGGca gtGtGttctg gtgtcctata tggaGgatat GctttacgGt
2821 tGgGctacag aagaacagcg gtcacaatgt tatGaagGGG tggctgcccg cctccgggac
28 81 ctagggtttc aggtggcatc cgaaaagaGt agGcagacgc cttcgcccgt cccctttttg
2941 ggacaaatgg tccatgagca gattgtGacc taGcagtccc tacctacctt gcagatctca
3001 tGGCcaattt GtcttGaGca attacaggcg gtcttaggag acctccaatg ggtctGtagg
3061 ggcacaccGa ctacccgccg gcccctgcaa GttctGtaGt Gttcccttaa aaggcatcat
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Appendix 8: (continued).
3121 gaccctaggg ccatcatcca gctttccccg gaacagctgc aaggcattgc agagcttcga
3181 caagccctgt cccacaacgc aagatctaga tataacgagc aagaacccct gctagcctac
3241 gtacacctaa cccgggcggg gtccaccctg gtactcttcc aaaagggcgc tcaatttccc
3301 ctggcctact ttcagacccc cttgactgac aaccaagcct caccttgggg cctccttctc
3361 ctgctgggat gccaatacct gcagactcag gccttaagct cgtatgccaa gcccatactt
3421 aaatattatc acaatcttcc taaaacctct ctagacaatt ggattcaatc atctgaggac
3481 cctcgagtcc aggagttgct gcaattgtgg ccccagattt cctctcaggg aatacagccc
3 541 ccgggccctt ggaagacctt aatcaccagg gcagaggttt ttttgacgcc ccagttctcc
3601 Gctgatccga ttcctgcggc cctttgcctc tttagtgacg gggctacagg acgaggagca
3661 tattgcttgt ggaaagacca ccttttagac tttcaggccg ttccggcccc agaatccgct
3721 caaaagggag aactagcagg tctcttggcg ggcttagcag ccgccccgcc tgaacctgta
3781 aatatatggg tagattccaa atacctgtac tctttgctca gaaccctagt tctgggagct
3841 tggcttcaac ctgaccccgt accctcctac gccctcctat ataaaagcct cctccgacat
3901 ccagcaatcg ttgttggtca tgtccggagc cactcttcag catcccaccc tattgcttcc
3961 ctgaacaatt atgtagatca actgcttccc ttagaaactc cagagcaatg gcataagctc
4021 acccactgca actctcgggc cttgtctcga tggccgaacc cacgtatctc tgcctgggac
4081 ccccgttccc ccgctacgct gtgtgaaacc tgccaaaagc ttaatccaac tggaggagga
4141 aagatgcgaa ctattcagag agggtgggcc ccgaatcata tttggcaggc cgatataacc
4201 cattataaat acaaacagtt cacctacgct ctgcatgtgt ttgtagatac ttactctgga
4261 gctactcatg cctcggcgaa gcgtgggctc accactcaaa cgaccattga gggccttctt
4321 gaggccatag tgcatctggg tcgcccaaaa aagctaaaca ctgaccaagg tgcaaactac
4381 acctccaaaa cctttgtcag gttttgccag cagttcggag tttccctttc tcatcatgtt
4441 ccctacaacc ccacaagttc ggggttagat gaacggacaa atggactgct caaacttctt
4501 ctatctaaat atcacctaga cgaaccccac cttcccatga ctcaggccct ttctcgagcc
4561 ctctggactc acaatcagat taacctccta ccaattctaa agaccagatg ggagctacac
4621 cattcacccc cacttgctgt catttcagag ggcggagaaa cacccaaggg ctctgataaa
4681 ctctttttgt acttgctccc cgggcaaaac aatcgtcggt ggctaggacc actcccggcc
4741 ctagtcgaag cctcgggagg cgctctcctg gctactgacc cccccgtgtg ggttccctgg
4801 cgtttgctga aagccttcaa atgcctaaag aacgacggtc ccgaagacgc ccacaaccga
4861 tcatcagatg ggtaagtctc actctcactc tcctcgctct ctgtcggccc atccagactt
4921 ggagatgctc cctgtcccta ggaaaccaac aatggatgac agcatataac caagaggcaa
4981 aattttccat ctccattgac caaatactag aggctcataa tcagtcacct ttctgtgcca
5041 agtctcccag atacaccttg gactctgtaa atggctatcc taagatctac tggccccccc
5101 cacaagggcg gcgccggttt ggagccaggg ccatggtcac atatgattgc gagccccgat
5161 gcccttatgt gggggcagat cggttcgact gcccccactg ggacaatgcc tcccaggctg
5221 atcaaggatc cttttatgtc aatcatcaga ttttattcct gcatctcaaa caatgtcatg
5281 gaattttcac tctaacctgg gagatatggg gatatgatcc cctgatcacc ttttctttac
5341 ataagatccc tgatccccct caacccgact ttccccagtt gaacagtgac tgggttccct
5401 ctgtcagatc atgggccctg cttttaaatc aaacagcacg ggccttccca gactgtgcta
5461 tatgttggga accttcccct ccctgggctc ccgaaatatt agtatataac aaaaccatct
5521 ccagctctgg acccggcctc gccctcccgg acgcccaaat cttctgggtc aactcgtcct
5581 cgtttaacac cacccaagga tggcaccacc cttcccagag gttgttgttc aatgtttctc
5641 aaggcaacgc cttgttatta cctcctatct ccctggttaa tctctctacg gcttcctccg
5701 cccctcctac ccgggtcaga cgtagtcccg tcgcggccct gaccttaggc ctagccctgt
5761 cagtggggct cactggcatt aatgtggccg tgtctgccct tagccatcag agactcacct
5821 ccctgatcca cgttctggag caagatcagc aacgcttgat cacagcaatt aatcagaccc
5881 actataattt gcttaatgtg gcctctgtgg ttgcccagaa ccgacggggg cttgattggt
5941 tgtacatccg gctgggtttt caaagcctat gtcccacaat taatgagcct tgctgtttcc
6001 tgcgcattca aaatgactcc attatcctcc gcggtgatct ccagcctctc tcgcaaagag
6061 tctctacaga ctggcagtgg ccctggaatt gggatctggg gctcactgcc tgggtgcgag
6121 aaaccattca ttctgttcta agcctgttcc tattagccct ttttttgctc ttcctggccc
6181 cctgcctgat aaaatgcttg acctctcgcc ttttaaagct cctccggcag gctccccact
6241 tccctgaaat ctccttaacc cctaaacccg attctgatta tcaggccttg ctaccatctg
6301 caccagagat ctactctcac ctctcccccg tcaaacccga ttacatcaac ctccgaccct
6361 gcccttgata cccccgcgtt tcacgcaccc ccaggctgtg gtggtgcact ggcttagtgg
6421 agtagtcagt gtaccatcac aagcctcttc ttgctgccag caccgagttc gaacacagct
64 81 ctacGCtgag cctGtGtgag tgGatgactg agtgtagGgG agagagattg tcgcttGtgc
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6541 gtgtcgctca gtcatttttt atagccgatt ggggttcgcg cccttccgtt gcctgtgaca
6601 cagataagac ctctctcact tctgcttcac catccccctg ccagcgttgg tctagtggaa
6661 agaactaacg ctgacggggg cgatttcttg cagctgtgct agcgggaggc tctggtgctg
6721 gggataagat gtggccctta gcaccacagt ctctgcgcct tttgggttcg aatcttcccc
6781 acgcagcttc cgctttttac gccctgttgc acaccctttc tagagatacc tgaaaatctc
6841 agctcgcacG ctgaggaagg ttgtggctca gaggttaaaa tagctGgagG GgcaacctcG
6901 Gtttcttttt attGGaGCGt cgcaaggccc cgggttctga gccccGtaaG ggaggttcaa
6961 aatttGGtGt acaaggggat gGtcgggtcG aagtgtgcaG aatatctctt GGaaaaggtG
7021 ctgatgaaGg tcttcccatg taacaagccG GagGagagac attccagcGa catccagGag
7081 catttgggGG gGGttttGta acagtgccGa taaagtccct tcGgtttGca GaaGggctgc
7141 ctctgGatct tctatttcca cctcggcaGc gaGtcccGcg cGgagccctt Ggagctcttc
7201 gggatccatt acctgataaG gacaaaatta tttcttgtct tttaagcaag tgttgttggt
7261 tgggggcGCG aGtGtctaGa tgcctgcccg gccctggttt tgtccaatga tgtcaGGatG
7321 gatgcctggt gGcccctctg cgggccccat gagGgaGtCG aattcgaaag gatcgacacc
73 81 acgctcacGt gcgagaGCGa ccgtatcaac tggaGcgGcg atggacgacc ttgcggcctc
7441 aatggaacgt tgttCGGtGg actgGatgtc tccgagaccc gcccccaagg gcGGGgacga
7501 ctctggatGa actgGCGGGt tccggccgtt cgGgctcagc ccggcccggt ttGaGtttcc
7561 GGCttcgagG ggtccGGctt ccagccctac GaatgcGaat tgccctGggG ctGtagcgac
7621 ggttgccGca ttatcgggca cggccttctt CGGtggaaca acttagtaac gcatcctgtc
7681 ctcggaaaag tccttatatt aaatcaaatg gccaattttt ccttactccc ctccttcgat
7741 acGctccttg tggacGGcct ccggctgtcc gtGtttgccc cagacaGGag gggagccata
7801 Ggttatctct ccaccGtttt gaGgctatgc Gcagctactt gtattGtacc Gctaggcgag
7861 cGCttctctc ctaatgtccc GatatgcGgG tttccccggg actccaatga accccccctt
7 921 tcagaattcg agctgcccGG GatccaaaGg cccggcctgt cttggtGtgt GGGGgGgatc
7981 gacGtattGG taaccggtcG cccttcccca tgtgacGggt taGaGgtatg gtccagtGCt
8 041 caggccttac agGgcttcct tGatgaccct aGgctaacct ggtGGgaatt ggttgctagG
8101 agaaaaataa gaGttgattc GGGcttaaaa ttacaactgG tagaaaatga atggctctGG
8161 Ggcctttttt gagggggagt catttgtatg aaagatcatg ccgaGctagg agccgccacG
8221 gccccgtaaa CGagacagag acgtcagctg ccagaaaagc tggtgacggc agctggtggc
8281 tagaatcccc gtaGCtcccG aacttccGGt ttcccgaaaa atccaGaccc tgagctgGtg
8341 acctcacctg ctgataaatt aataaaatgc cggccctgtc gagttagcgg GaccagaagG
8401 gttGttGtcc tgagaccctc gtgctcagct ctcggtGGtg agctctGttg Gtcccgagac
8461 cttctggtcg gGtatccggG agcggtcagg taaggcaagc acggtttgga gggtggttGt
8521 cggctgagac caGcgcgagc tGtatGtcGg gtcGtctgaG cgtctccacg tggactctGt
8581 GCtttgGctc ctgacGGGgG gctccaaggg cgtctggctt gcacccgGgt ttgtttcctg
8641 tcttaGtttc tgtttctcgc ggcccgcgct ctctccttcg gGgGcctGta gcggccagga
8701 gagaGGggca aaca
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Appendix 9: Human p-giobin partial sequence.
GenBank Accession number NM_000518 (626 bp) (Proudfoot and Brownlee 1976). 
Oligonucleotide primer sequences for PCR are underlined and annotated at right.
1 acatttgctt ctgacacaac tgtgttcact agcaacctca aacagacacc atggtgcacc 18
61 tgactcctga ggagaagtct gccgttactg ccctgtgggg caaggtgaac gtggatgaag 52
121 ttggtggtgd ggccctgggc aggctgctgg tggtctaccc ttggacccag aggttctttg
181 agtcctttgg ggatctgtcc actcctgatg ctgttatggg caaccctaag gtgaaggctc
241 atggcaagaa agtgctcggt gcctttagtg atggcctggc tcacctggac aacctcaagg
301 gcacctttgc cacactgagt gagctgcact gtgacaagct gcacgtggat cctgagaact
3 61 tcaggctcct gggcaacgtg ctggtctgtg tgctggccca tcactttggc aaagaattca
421 ccccaccagt gcaggctgcc tatcagaaag tggtggctgg tgtggctaat gccctggccc
481 acaagtatca ctaagctcgc tttcttgctg tccaatttct attaaaggtt cctttgttcc
541 ctaagtccaa ctactaaact gggggatatt atgaagggcc ttgagcatct ggattctgcc
601 taataaaaaa catttatttt cattgc
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Appendix 10: Alignments of conserved regions of retroviral and hepadnaviral Pol 
amino acid sequences and derived consensus oligonucleotides.
A10.1: Comparison of conserved regions of retroviral and hepadnaviral reverse transcriptase 
(Pol) amino acid sequences.
Alignments derived from GenEMBL database using Genetics Computer Group 1994 PileUp 
programme (Altschul et al 1997).
R e tro v iru s e s 1 46BIV WNVliPpGWVCSPAIYQTTTQKIIENIKKSHPDVMLYQYMDDLLIGSFIV WCSLPQGWILSPLIYQSTLDNIIQPFIRQNPQLDIYQYMDDIYIGSElAV WNCLPQGFVLSEYIYQKTLQEILQPFRERYPEVQLYQYMDDLFVGS
Visna WKVLPQGWKLSPAVYQFTMQKILRGWIEEHPMIQFGIYMDDIYIGSCAEV WKVLPQGWKLSPSVYQFTMQEILGEWIQEHPEIQFRIYMDDIYIRS
Sivagm FNCLPQQWKGSPTIFQNTASKILEEIKKELKQLTIVQYMDbLWVGSSIVmac YKVL^QdWKGSiPAIFQYTMRHVLEPFRKANPDVTLVQYMDDILrASSIVsm YKVLPQGWKGSPAIFQYTMRNILE PFRRANPDVTLIQYMDDILIASHIV-1 YNVLEQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSHIV-2 YKVLPQGWKGSf AIFQHTMRQVLEPFRKANKDVIIIQYMppiLIAS
BLV w r v l p q Gf i n's |a l f e r a l q e p l r q v s a a f s q s l l v s y m d d i l y a s
HTLV-II WTVLPQGFKNSETLFEQQIAAVLNPMRKMFPTSTIVQYMDDILLASHTLV-I WKVLPQGFKNSETLFEMQLAHILQPIRQAFPQCTILQYMDDILLASHTLV-I WRVLPQGFKNSgTLFEMQLAHILQPIRQAFPQCTILQYMDDILLAS
LPDV WTVLPQGMjKKSPYICQQWAEVIRPIRERFRDAVIIHYMDDILIAAMMTV WKyiPQ<3MKNSPTLCQKFVDKAILTVRDKYQDSYIVHYMDDILLAH
SRVl WKVLPQRMANSIBTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAG
SRV2 WKVLPgGMANSPTLCQKYVAAAIEPVRKSWAQMYIIHYMDDILIAGMPMV WKVLPQGMANSPTLCQKYVATAIHKVRHAWKQMYIIHYMDDILIAGSHIAP WKVLPQGMANSPTICQLYVQEALEPIRKQFTSLIVIHYMDDILICH
MuIAP WKVLPQGMSNSPTMCQLYVQEALLPVREQFPSLILLLYMDDILLCHpr-Rsv w k v l p q g m t c ||t i g q l v v g q v l e p l r l k h p s l c m l h y m d d l l l a a
Fr-MULV WTRLPQGFKNSETLFDEALHRDLADFRIQHPDLILLQYVDDLLLAAMo-MULV w t r Hp q g f k n s^ p-t l f d e a l h r d i a d f r i q h p d l i l i QYVDDLLLAABAEV WTR'LPQGFKNS PTLFDEALHRDLTDFRTQHPEVTLLQYVDDLLLAPlFELV WTRLPQGFKNSÜTLFDEALHSDLADFRVRYPALVLI QYVDDLLLAAGALV WTRLPQGFKNSETLFDEALHRDLAPFRALNPQWLLQYVDDLLVAA
MuRRS WMW*PQEFKNSPTLFDEALHRDLASFRAENSQVTLLQYVpDLLLAA Endogenous
HERV4 WTQLPQRFKNSPTIFGEALARDLQKFPTRDLGCVLLQYVpDLLLGH EndogenousHERVC WTQLPQRFKNSETIFGEALARDLQKFPTRDLGCVLLQYVPDLLLGH Endogenous
SFV3 WTRLPQGFLNSPALFTADWDLLKEVPN...... VQVYVDDIYISHSFVl WTRLPQGFLNjSPALFTADWDLLKEIPN...... VQAYVDDIYISHCFV w t r l p q g f l n S|a l f t a d a v d l l k e v p n  VQvfvbblYLSH
H e p a d n a v iru s e s
DHBV FRKAPMGVGLSEFLLHLFTTALGSEISRRF.NVWTFTYMDDFLLCHHeronHBV FRKAEMëVGLSPFLLHLFTTAIGAEIASRF.NVWTFSYMDDFLLCHHBV f r k i p m g v g l s e f l l a q f t s a i c s w r r a p p h c l a f s y m d d w l g aWHV FRKLPMGVGLbPFLLAQFTSALASMVRRNFPHCWI AYMDDLVLGAWHV FRKLPMGVGLS S SLLAQFTSALASMVRRNFPHCWFAYMDDLVLGAGSHV FRKIjPMGVGLSEFLLAQFTSALTSMVRRNFPHCLAFAYMDDLVLGA
A b b re v ia t io n s
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BAEV Baboon endogenous virus
BIV Bovine iratnunodeficiency virus
BLV Bovine leukaemia virus
CAEV Caprine arthritis-encephalitis virus
CFV Chimpanzee foamy virus
DHBV Duck hepatitis B virus
ElAV Equine infectious anaemia virus
FELV Feline leukaemia virus
FIV Feline immunodeficiency virus
Fr-MuLV Friend murine leukaemia virus
GALV Gibbon ape leukaemia virus
GSHV Ground squirrel hepatitis virus
HBV Hepatitis B virus
HeronHBV Heron hepatitis B virus
HERV4 Human endogenous retrovirus 4
HERVC Human endogenous retrovirus C
HIV-1 Human immunodeficiency virus type 1
HIV-2 Human immunodeficiency virus type 2
HTLV-I Human T lymphotropic virus type I
HTLV-II Human T lymphotropic virus type II
LPDV Lymphoproliferative disease virus of turkeys
MMTV Mouse mammary tumour virus
Mo-MuLV Moloney murine leukaemia virus
MPMV Mason-Pfizer monkey virus
Mu IAP Murine intracellular type A particles
MuRRS Murine retrovirus-like sequence
Pr-RSV Prague Rous sarcoma virus
SFVl Simian foamy virus 1
SFV3 Simian foamy virus 3
SHIAP Syrian hamster intracellular type A particles
SiVagm Simian immunodeficiency virus (African green monkey)
SIVmac Simian immunodeficiency virus (rhesus macaque)
SIVsm Simian immunodeficiency virus (sooty mangabey)
SRVl Simian retrovirus type 1
SRV2 Simian retrovirus type 2
Visna Maedi-visna virus
WHV Woodchuck hepatitis virus
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A I0.2 Comparison of nucleotide and amino acid sequences of conserved regions of retroviral 
reverse transcriptase (pol) genes (Donehawer et a /1990).
Nucleotides are designated by single letter codes (Appendix 5). The single letter code for each amino 
acid Is centred underneath the three nucleotides that encode It.
5' sequence
HTLV-I GTACTACCCCAAGGGTTTAAAV L P Q G F K
HTLV-II GTCCTTCCACAGGGGTTTAAAV L P Q G F K
BLV GTCCTAGCTCAAGGCTTCATTV L P Q G F I
HIV-1 GTGCTTCCACAGGGATGGAAAV L P Q G W K
ElAV TGTTTACCACAAGGATTCGTGC L P Q G F V
MO-MuLV AGACTCCCACAGGGTTTCAAAR L P Q G F K
Pr-RSV GTCTTGCCCCAAGGGATGACCV L P Q G M T
MMTV GTTTTGCCCCAGGGTATGAAAV L P Q G M K
3' sequence
CTTCAGTACATGGATGAC L Q Y M D D
GTCCAATACATGGATGACV Q Y M D D
GTGTCCTATATGGACGATV S Y M D D
TATCAATACATGGATGATV Q Y M D D
TATCAATATATGGATGATV Q Y M D D
CTACAGTACGTGGATGAC L Q Y V D D
TTGCATTATATGGATGAT L H Y M D D
GTGCATTACATGGATGACV H Y M D D
5' > GTNYTNCCNCARGG < 3 
5' consensus primer
5' > RTCRTCCATRTA < 3 
3' consensus primer
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A10.3 Comparison of 5’ conserved regions of retroviral and hepadnaviral reverse transcriptase 
(Pol) amino acid sequences and derivation of consensus sense (forward) oligonucleotide 
primers for PCR (Mack and Sninsky et a l 1988).
Amino acids and nucleotides are designated by single letter codes (Appendix 5). Potential three- 
nucleotide codons are listed under each amino acid alignment. Consensus nucleotide sequences 
derived from these reverse translations are shown using the standard nomenclature for incompletely 
specified bases.
Group 1 viruses
HTLV-I L P Q G F K N S p T L FHTLV-II L P Q G F K N S P T L FBLV L P Q G F I N S p A L FMuLV L P Q G F K N s p T L FPeLV L P Q G R K N s p T L F* * * *
TTGCCTCAAGGTTTTAAAAATTCTCCTACTTTGTTT TTACCCCAGGGCTTCAAGAACTCCCCCACCTTATTC CTTCCA GGACGTATT TCACCAACACTTCTCCCG GGGCGCATC TCGCCGACGCTCCTA CGAATA AGT GCTCTACTG CGG AGC GCCCTGAGA GCAAGG GCG
*  * *  * *  * *  *  *  *  * *  *  *  * *
5' > YTNCCNCARGGNHKNAWNAAYWSNCCNRCNYTNTTY < 3 
5' > YTNCCNCARGGNHKNAWNAA < 3'
5' > YTNCCNCARGG < 3'
Group 2 viruses 
MMTV L P Q G M K N S p T L C QSRV-1 L P Q R M A N S P T L C QMPMV L P Q G M A N s p T L c QSHIAP L P Q G M A N s p T I c QRSV L P Q G M T C s p T I c Q* *
TTGCCTCAAGGTATGAAAAATTCTCCTACTTTGTGTCAA TTACCCCAGGGC AAGAACTCCCCCACCTTATGCCAG CTTCCA GGA GCTTGTTCACCAACACTTCTCCCG GGG GCCTGCTCGCCGACGCTCCTA CGT GCA AGT CTACTG CGC CGA CGG AGA AGG 
*  *  *  *
GCGACTACCACAACG
AGC CTGATTATCATA
5' > YTNCCNCARVGNATGRMNWRYWSNCCNACNHTNTGYCAR < 3 
5' > YTNCCNCARVGNATG < 3'
5' > YWSNCCNACNHTNTGYCAR < 3
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Group 3 viruses 
HIV-l L P Q G N K G S pHIV-2 L P Q G W K G S PSIV-1 L P Q G W K G S pElAV L P Q G F V L s pCAEV L P Q G W K L s pVisna L P Q G W K L s p* *
TTGCCTCAAGGTAATAAAGGTTCTCCT TTACCCCAGGGCAACAAGGGCTCCCGC CTTCCA GGATGGGTTGGATCACCA CTCCCG GGGTTTGTCGGGTCGCCG CTA TTCGTATTGAGTCTG
*  *  *  *  *  *  *
GTGTTAAGCCTTCTCCTACTG
> YTNCCNCARGGÎSÏWDBRWNBKNWSNCCN < 3
Group 4 viruses
HBV I P M G V G L S P F L L A Q F TWHV L P M G V G L S p F L L A Q F TGSHV L P M G V G L S p F L L A Q F TDHBV A P M G V G L S p F L L H L F T* * * * * * *
TTGCCTATGGGTGTTGGTTTGTCTCCTTTTTTGTTGGCTCAATTTACT TTACCC GGCGTCGGCTTATCCCCCTTCTTATTAGCCCAGTTCACC GGAGTAGGACTTTCACCA CTTCTTGCATTG ACAGGGGTGGGGCTCTCGCCG CTCCTCGCGTTA ACGCTAAGT CTACTACATCTTCTGAGC CTGCTGCACCTCCTA CTG
CTTCCA CTCCCG CTA CTG GCT ATT ATC ATA
* *  * * * * *  *  *  *  *  *  * *  *  *  *  *  *  *  *  *
> NYNCCNATGGGNGTNGGNYTNWSNCCNTTYYTNYTNSMNYWNTTYYACN < 3
> CCNATGGGNGTNGGNYTNWSNCCNTT < 3
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A I0.4 Comparison of 3’ conserved regions of retroviral and hepadnaviral reverse transcriptase 
(Pol) amino acid sequences and derivation of consensus antisense (reverse) oligonucleotide 
primers for PCR (Mack and Sninsky ef al 1988).
Amino acids and nucleotides are designated by single letter codes (Appendix 5). Potential three- 
nucleotide codons are listed under each amino acid alignment. Consensus nucleotide sequences 
derived from these reverse translations are shown using the standard nomenclature for incompletely 
specified bases. The complementary sequences are used to derive antisense (reverse) oligonucleotide 
primers.
Group 1 viruses MuLVFeLV
Group 2 viruses
Group 3 viruses
Group 4 viruses
Group 5 viruses
Consensus :
TATGTTGATGAT TACGTCGACGAC GTA GTG 
*  *  *  *  *  *  *
5 ' > TAYGTNGAYGAY < 3
HTLV-I Q Y M D D IHTLV-II Q Y M D D IBLV S Y M D D I
k *
MMTV H Y M D D ISRV-1 H Y M D D IMPMV H Y M D D ISHIAP H Y M D D IRSV H Y M D D L* * •k *
HIV-1 Q Y M D D LHIV-2 Q Y M D D ISIV-1 Q Y M D D IElAV Q Y M D D LCAEV I Y M D D IVisna I Y M D D I
HBV S Y M D D VWHV A Y M D D LGSHV A Y M D D LDHBV T Y M D D F* * *
TATATGGATGAT TAG GACGAC 
* *  * * * * *  *  *
> TAYATGGAYGA < 3> ATRTACCTRCT < 5
5' > TCRTCCATRTA < 3'
TATGTTGATGAT TACGTCGACGAC GTA GTG ATG 
*  *  *  *  *  *  *
5' > TAYRTNGAYGA < 3'3' > ATRYANCTRCT < 5'
5' > TCRTCNAYRTA < 3'
